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Abstract 
Background: In July 2013, an oral live-attenuated monovalent human 
rotavirus G1P[8] vaccine, Rotarix
®
, was introduced into the United Kingdom’s 
national immunisation programme as a two-dose regime. This vaccine is used widely 
on a global scale. Data on vaccine take have been reported through clinical trials 
assessing shedding at specific timepoints and immunogenicity by seroconversion. 
However, the longitudinal dynamics of shedding and mucosal antibody IgA response 
had not been studied. Clinical trials have also evaluated vaccine safety, however, 
other than reports of vaccine-related genetic variants from single-timepoints captured 
through clinical admissions, there is an unanswered question about genome-wide 
genetic stability in vaccinees.  
Aims: The overarching hypothesis of this thesis was that immunisation with 
Rotarix
®
 would result in an evolving quasispecies through replication in vaccinees 
generating high-frequency variants and modulated by the mucosal secretory IgA 
response. To test this, the aims were i) to assess Rotarix
®
 shedding profiles in stool 
of a cohort of vaccinated infants, ii) to identify any vaccine and/or novel variants in 
shed virus and iii) to define the infants’ RV-specific copro-IgA levels.  
Methods: Stool samples from a cohort of vaccinated infants were collected 
longitudinally every other day throughout the vaccination period. Viral shedding was 
assessed through quantification of viral RNA extracted from faecal suspensions. 
Genetic variation was evaluated through next generation sequencing on an Illumina
®
 
platform, focusing on viral proteins with known function in viral entry or virulence: 
VP4, VP7, VP6 and NSP4. Total copro-IgA was measured using a commercial 
ELISA kit and RV-specific copro-IgA using an in-house ELISA.  
Results: All infants shed vaccine virus in faeces and patterns defined four 
profiles ranging from early control of vaccine virus in stool to delayed control with 
continued virus shedding. The maximum shedding of vaccine virus was comparable 
to natural infection. Some single nucleotide polymorphisms identified at low 
frequency in the vaccine were identified at higher frequencies in vaccine recipients, 
suggesting that these minority variants in cell culture were selected in infants. Novel 
vaccine-derived variant loci were identified from stool as a result of replication in the 
host, suggesting a possible effect in cell tropism, host range or immune evasion. 
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Mutations in the outer capsid proteins VP4 and VP7 impacted on residues involved 
in receptor binding, trypsin cleavage, membrane fusion and neutralisation; a 
mutation in VP6 highlighted the importance of structural conservation of the inner 
capsid and all novel mutations in NPS4 suggested they may be relevant in in vivo 
infection. Rotavirus-specific copro-IgA differed between infants ranging from 
continual high levels through sporadic to no detection. High pre-vaccination specific 
copro-IgA levels in three infants were likely to originate from maternal antibody, 
although this did not appear to affect vaccine virus shedding. Three of eight infants 
were positive for RV-specific copro-IgA a year after vaccination, suggesting they 
were late immune responders or had had a recent subclinical rotavirus infection. 
Infants with positive RV-specific copro-IgA presented viral load control and those 
with protracted shedding presented undetectable or weak RV-specific copro-IgA 
levels.  
Conclusions: Shedding of RV vaccine virus in vaccine recipients suggested 
active virus replication over several weeks and it fell within four broad profiles. 
Previously identified vaccine genetic variants increased in frequency and novel 
variants arose after replication in the gut. Infants who could not rapidly control 
shedding had a weak or undetectable RV-specific copro-IgA response and a higher 
number of high-frequency genetic variants detectable by the end of the vaccination 
period. By contrast, infants who controlled shedding and presented a strong RV-
specific copro-IgA response had vaccine virus variants that decreased in frequency 
by the end of the vaccination period, suggesting Rotarix
®
 is stable in vaccine 
recipients who present a robust and early RV-specific copro-IgA response.  
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Chapter 1: Introduction 
1.1 Thesis overview  
Wild-type (WT) rotavirus (RV) is transmitted via the faecal oral route and 
causes acute gastroenteritis (AGE) in children of less than five years of age; the only 
effective treatment is re-hydration therapy. Live-attenuated oral vaccines with high 
efficacy are available worldwide and rotavirus vaccination was incorporated into the 
UK national immunisation programme (NIP) in 2013. As a live virus replicating in 
infants, Rotarix
®
 is likely to be shed in stool of vaccinees and to accumulate changes 
in sequence. These may lead to variants in the vaccine virus population with 
potential to revert to WT virus. Virus replication will generate an immune response 
in the host, which may be affected by the quasispecies in the virus population.  
This thesis considers the profile of viral shedding of Rotarix
®
 in stool of 
vaccinated infants and genetic changes in the vaccine virus throughout the 
vaccination period. Mucosal responses in the cohort are reviewed as anti-rotavirus 
copro-IgA levels.  
1.2 Rotavirus  
The first rotaviruses were detected by electron microscopy (EM) of material 
isolated from faeces of mice (Pappenheimer and Enders, 1947), monkeys (Adams 
and Kraft, 1963; Malherbe and Harwin, 1963) and cattle in 1969 (Mebus et al., 
1969a, 1969b). Human rotavirus was discovered in 1973 (Bishop et al., 1973) in 
samples from diarrhoeic children, as the causative agent of AGE in infants (0-1 year-
old) and children under 5 years of age.  
1.2.1 Rotavirus structure 
Rotavirus is a non-enveloped, double-stranded RNA (dsRNA) virus. The 
fully infectious virion is approximately 75 nm in diameter and triple layered, 
containing two concentric icosahedral capsids and a core (Fig. 1.1; Estes, 2001). The 
viral proteins are encoded on 11 segments (section 1.2.3). The external capsid is 
formed by proteins VP7 and VP4, defining serotypes G (glycoprotein) and P 
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(protease-sensitive) respectively, with icosahedral symmetry and 780 molecules of 
VP7 as Ca
2+
-stabilised trimers and 180 molecules of VP4 as trimer spikes (Chen et 
al., 2009; Settembre et al., 2011). VP4 is composed of the subunits of VP5*, in 
contact with VP7 and VP6, and VP8*, known to interact with host cell receptors 
(Settembre et al., 2011; Liu et al., 2012). The internal capsid is formed by VP6, 
which presents T=13 icosahedral symmetry (each icosahedral asymmetric unit is 
composed of 13 proteins) and 780 molecules arranged as trimers, and defines groups 
or species A-J based on its antigenicity and accounts for 50% of the virion’s mass 
(Prasad and Chiu, 1994; Thouvenin et al., 2001; McClain et al., 2010; Mladenova et 
al., 2011; Settembre et al., 2011; Matthijnssens et al., 2012; Mihalov-Kovács et al., 
2015). VP6 interacts with VP4 and VP7 as well as with VP2 (Petitpas et al., 1998; 
Mathieu et al., 2001). The core is formed by VP2, with T=2 symmetry and 120 
molecules as dimers (Lawton et al., 1997). The non-structural proteins RNA-
polymerase VP1 and RNA-capping enzyme VP3, as well as the 11 dsRNA gene 
segments associated with them lay within the core (Estrozi et al., 2013; Periz et al., 
2013). 
 
 
Fig. 1.1. Rotavirus A triple-layered virion. Outer capsid proteins VP7 in orange 
and VP4 in red. Inner capsid protein VP6 in blue and core protein VP2 in dark green. 
Non-structural proteins and dsRNA (in pink) within the core (light green). Adapted 
from Angel, Franco and Greenberg, 2007.   
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1.2.2 Classification and nomenclature  
Rotaviruses belong to the Reoviridae family and comprise the genus 
Rotavirus within the family Sedoreovirinae.  
Antigenicity and genetic variability of VP6 define groups or species of 
rotavirus, from A to J. Groups A, B, and C infect humans and animals and group A 
rotaviruses (RVA) are responsible for 90% of these infections (Kapikian, Hoshino 
and Chanock, 2001). Group B rotaviruses have been associated with adult rotavirus 
infection originally in China (Hung et al., 1983, 1984) and subsequently in Asia 
(Kelkar and Zade, 2004; Lahon et al., 2013). Group C rotaviruses have been 
associated with outbreaks in humans across all ages worldwide (Rodger, Bishop and 
Holmes, 1982; Nilsson et al., 2002; Abid et al., 2007; Doan et al., 2016). The host 
range of groups D to J rotaviruses is restricted to non-human animals (Kapikian, 
Hoshino and Chanock, 2001) as seems the case for groups H to J (Wakuda et al., 
2011; Marthaler et al., 2014; Molinari et al., 2014; Mihalov-Kovács et al., 2015; 
Bányai et al., 2017) (see section 1.2.6).  
The different strains of rotavirus are defined by their types G (VP7) and P 
(VP4) sequences. For rotavirus A (RVA), there exist at least 36 G types and 51 P 
types (Matthijnssens, Ciarlet, Rahman, et al., 2008; Matthijnssens et al., 2011; 
RCWG, 2018). Serotypes and genotypes are equivalent for G types, while multiple P 
genotypes are associated with certain P serotypes. G types are designated by 
genotype/serotype as e.g. G1, G2, G3, etc., while P types are designated thus, 
P1A[8], representing serotype P1A and genotype [8]. Due to the vast sequence 
diversity among the 11 RVA genome segments, a new nomenclature has been 
recently agreed relating genotypes to nucleotide sequence differences and assigning 
cut-off values for each of the segments’s open reading frame (ORF). In summary, a 
one-letter code for each segment is followed by the number (x) of the corresponding 
genotype: Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx (Matthijnssens, Ciarlet, 
Rahman, et al., 2008; Matthijnssens et al., 2011). The gold-standard strains in the 
study of rotavirus that present homology in animals are human Wa-like (G1P[8]; 
porcine-like), human DS-1 (G2P[4]; bovine-like) and AU-1-like (G3P[9]; feline-like) 
(Nakagomi et al., 1990; Heiman et al., 2008; Matthijnssens, Ciarlet, Heiman, et al., 
2008; McDonald, Matthijnssens, et al., 2009). 
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1.2.3 Genome and proteins 
Rotavirus A has a linear genome of 18,550 base pairs (bp), comprising 11 
gene segments varying in size from 3,302 to 667 bp and encoding for six structural 
(VP1, VP2, VP3, VP4, VP6 and VP7) and six non-structural proteins (NSP1, NSP2, 
NSP3, NSP4, NSP5/6) (based on simian rotavirus A/strain SA11; Small et al., 2007) 
(Fig. 1.2; Table 1.1). Ten segments are monocistronic, with segment 11 subject to 
leaky scanning and encoding NSP5 plus NSP6 as a second out-of-frame protein 
(Mattion et al., 1991). The RVA gene segments contain 5′ and 3′ untranslated 
regions (UTRs) and a central ORF. The messenger ribonucleic acids (mRNAs) 
present a 5'-methylated cap structure, but no polyA tail at the 3' end, although there is 
a consensus sequence (5'-UGACC-3') conserved at the 3' end of all segments (Fig 
1.3A) (Chizhikov and Patton, 2000).  
   
 
Fig. 1.2. Rotavirus gene segments and proteins. Gene segment with encoded 
protein name boxed in the ORF and 5’ methyl cap in grey. ORF, open reading frame. 
Adapted from ViralZone, 2013.    
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Fig. 1.3. Rotavirus genome. (A) Linear genome map. General structure of 
rotavirus gene segments. Rotavirus genes do not present a polyadenylation signal, are 
A+U rich and contain conserved consensus sequences at their 5′ and 3′ ends. 
Variation in conserved ends shown. The cis-regulatory elements of RV mRNA 
required for transcript replication in cell-free replication system shown (Patton et al., 
1996; Wentz, Patton and Ramig, 1996; Kearney et al., 2004; Tortorici, Shapiro and 
Patton, 2006). The study of the 3′ variations indicated the minimal promoter as 
RN05CC (Kearney et al., 2004). The non-coding regions are predicted to interact and 
stably base-pair to form a panhandle structure maybe stabilised by VP1 (Imai et al., 
1983; Patton et al., 1996; Tortorici, Shapiro and Patton, 2006), and interactions 
between 3′ with NPS3 may promote viral mRNA translation (Vende et al., 2002). 5′-
GACC-3′ is a translation enhancer (Chizhikov and Patton, 2000). Reproduced from 
Estes, 2013, with permission from WK Health Book Copyright Clearance Center’s 
RightsLink
®
 order no. 4620900375548 (02/07/19). (B) Folded genome. Putative 
panhandle structure of one gene segment. The polymerase-capping enzyme complex 
(VP1-VP3) may be bound to the 3′- terminal sequence UGUGACC. A putative stem-
loop may be an assortment and/or packaging signal. Reproduced from McDonald et 
al., 2016, with permission from first author.  
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1.2.4 Rotavirus diversification 
RNA virus populations, mutant spectra or quasispecies (Lauring and Andino, 
2010) arise where an RNA polymerase lacking 3' exonuclease proofreading activity 
is encoded; such viruses undergo genetic drift at higher rates than do DNA viruses 
(Sanjuán et al., 2010). Quasispecies comprise a collection of genomic variants co-
evolving at the same time and within the same host, present at different relative 
frequencies, with a consensus sequence (or more than one) (Eigen and Schuster, 
1977) that behave almost like a single variant. The high mutation rate arising from 
the viral RNA polymerase generates diversity, and the accumulation of point 
mutations may result in antigenic changes that impact on infectivity, fitness, 
pathogenesis and viral dissemination, thereby contributing to viral adaptation and 
survival (Crotty, Cameron and Andino, 2001; Paul, 2002; Vignuzzi et al., 2006). 
Among the genetic variants that comprise the mutant spectra, minority variants may 
be selected throughout replication in the host (Moya, Holmes and González-
Candelas, 2004). Substitution rates depend on the rate of mutation and the rate of 
replication and for RNA viruses they have been estimated around 1 x 10
-3
 
substitutions per site and per year (Jenkins et al., 2002). Different mutation rates 
occur for each of the rotavirus genome segments and strains, ranging from 5 × 10
-5
 
bp/site/year for NSP5 (Blackhall, Fuentes and Magnusson, 1996), 
8.7 × 10
−4
 bp/site/year for NSP2 of N1 genotype (Donker and Kirkwood, 2012), 
5.8 × 10
−4
 bp/site/year for VP4 of human RV (Jenkins et al., 2002), 1.6-1.8 × 10
−3
 
bp/site/year for VP7 of G12 and G9 strains (Matthijnssens et al., 2010) to 1.01 × 10
-3
 
bp/site/year for NSP4 (Zeller et al., 2015).  
During recombination in non-segmented viruses, the polymerase copies the 
RNA template from one parental strain, switches template to use a different parental 
strain and generates a chimeric RNA molecule containing parts of sequence from 
each parent (McDonald et al., 2016). It usually occurs at points of conserved 
sequence. Although unusual for RV, intragenotype recombination has been reported 
in several studies for strains of the same genotype in VP7 (G4, G1, G3), NSP2, NSP4 
and NSP6 (Parra et al., 2004; Phan et al., 2007; Martínez-Laso et al., 2009; Donker, 
Boniface and Kirkwood, 2011; Jere et al., 2011). Rearrangements occur when there 
are partial duplications, deletions or insertions into coding or noncoding regions 
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(Pedley et al., 1983; Hundley et al., 1987; Tian et al., 1993; Taniguchi, Kojima and 
Urasawa, 1996; Kirkwood, 2010). 
Genetic reassortment of rotavirus occurs when segments from two parental 
viruses (from the same or different host species) are packaged together in new 
virions (in cells or in vivo), resulting in hybrid progeny (Fig. 1.4). It results in novel 
genetic and antigenic characteristics in the progeny, with theoretically up to 2
11
 
progeny viruses with novel characteristics generated after co-infection by two 
different RVs being generated (Ramig, 1997). Recombination cannot occur between 
viruses belonging to different RV species, as the replicase complex cannot be 
substituted by those of other groups and the crucial 3' ends are particular to each RV 
species (McDonald, Aguayo, et al., 2009; McDonald and Patton, 2011b). 
Compatibility between parental strains is determined by conserved packaging signals 
and the maintenance of RNA and protein interactions (McDonald et al., 2016). 
Reassortment contributes to maintenance of the segmented genomic structure and it 
is the main mechanism of evolution and zoonotic transmission of RV (Martella et al., 
2010). There may also be direct transmission of rotavirus strains from an animal into 
a human host, with potential impact on human RV diversity and human health 
(Martella et al., 2010).  
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Fig. 1.4. Rotavirus assortment and reassortment. (A) Rotavirus A assortment 
and packaging. Each of the (+) RNAs is bound by a polymerase-capping enzyme 
complex (VP1-VP3). They pair up and form a supramolecular complex that is 
encapsidated by a virion particle that is forming. During encapsidation or 
immediately after, the (+) RNAs are converted into dsRNA genome segments by the 
polymerase, which functions while tethered to the viral capsid (not shown in this 
figure, although shown in Fig. 1.5). Reproduced from McDonald et al., 2016, with 
permission from first author. (B) Rotavirus reassortment. Two different rotavirus 
strains infect the same enterocyte. The gene segments are mixed in replication in the 
cell, generating progeny viruses   with the same genome as the parental viruses and 
with different genome segments from the parental viruses, hence, different strains. 
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1.2.5 Rotavirus replication cycle 
Rotavirus is transmitted via the faecal-oral route, with as few as 10 virus 
particles required for transmission and an estimated infectious dose of 100-1000 
rotavirus particles (Ward et al., 1986). Rotavirus is shed in stool during infection and 
it can be transmitted via person-to person contact (Estes, 2001), as well as remain on 
fomites (Ansari, Springthorpe and Sattar, 1991; Butz et al., 1993). Once inside the 
host, rotavirus resists the stomach acid secreted by parietal cells in infants, transiting 
through to the small intestine, where it infects mature enterocytes and 
enteroendocrine cells of the villi in the duodenum (Greenberg and Estes, 2009).  
Trypsin in the gut lumen cleaves VP4 at amino acids 231, 241 and 247, as 
well as 259, 467 and 583, conserved in P serotypes of RVA, generating proteins 
VP5* and VP8* (Arias et al., 1996; Crawford et al., 2001). VP4 interacts with 
receptors containing N-acetylneuraminic acid (or sialic acid) and other glycans, such 
as those on histo-blood group antigens (HBGAs), via VP8* (López and Arias, 2004), 
which can perform the function of hemagglutinin (Weiner et al., 1978; Yeung et al., 
1987), and with other receptors concentrated in lipid rafts, such as integrins and heat-
shock protein 70 (Hsc70), via VP5* (Zárate et al., 2000). HBGA receptors have been 
shown to be used by RV for attachment, the interaction depending on a functional 
fucosyltransferase 2 (FUT2) enzyme generating fucose (Lee et al., 2018) and the 
FUT2 gene variant determining susceptibility to infection (Nordgren et al., 2014). 
Integrins α2β1, αvβ3, αxβ2, α4β1 and other receptors, such as Hsc70 can act as 
receptors post-attachment (Coulson, Londrigan and Lee, 1997; Hewish, Takada and 
Coulson, 2000; Zárate et al., 2004). Rotavirus also uses other hydrophobic 
domains/lipidic rafts to attach to the membrane. (López and Arias, 2004). The VP4 
spikes undergo conformational changes (Wolf, Vo and Greenberg, 2011), where key 
hydrophobic domains previously hidden in a “post-penetration umbrella” shape are 
exposed on VP5* (Fig. 1.6) (Trask, McDonald and Patton, 2012). This allows 
penetration through the cell membrane by an as yet unknown mechanism likely to be 
direct penetration or receptor-mediated endocytosis (Gutierrez et al., 2010). As 
calcium (Ca
2+
) levels are low in endosomes, the outer capsid solubilises, producing 
dual-layered particles (DLPs) (Jayaram, Estes and Prasad, 2004).  
Once in the cell, the DLPs remain in the cytoplasm, where the RNA 
undergoes transcription, translation and then replication in the viroplasm (a 
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specialised structure formed of cellular and viral proteins that recruit lipid droplet 
components for energy storage and transport in the cell) (Crawford et al., 2017). The 
RNA-dependent RNA polymerase VP1, tethered to the inner surface of the virus 
core, recognises the antisense strand of the genomic RNA by a sequence-specific 
interaction with seven nucleotides UGUGACC or UGUGGCU located at the 3′ end, 
and synthesises the sense strand ssRNA (~mRNA) (Lu et al., 2008). The mRNAs are 
capped at the 5′ end by VP3, a guanilyltransferase capping enzyme associated with 
the core, as a post-transcriptional modification that protects it from nuclease 
degradation (Figs. 1.3. B and 1.4. A) (Chen et al., 1999). The dsRNA genome is not 
completely uncoated, thereby preventing activation of an antiviral state triggered by 
toll-like receptor recognition of dsRNA (Greenberg and Estes, 2009). The capped 
mRNA is translated in the cytoplasm. NSP1 blocks the cellular type I interferon 
(INFγ) response and it has been observed that the proteasome of infected cells 
degrades signaling components required for IFN production, like interferon-
regulatory factor (IRF) and others necessary to respond to IFN secreted by 
neighbouring cells (Arnold, Barro and Patton, 2013). NSP3 binds to viral mRNAs in 
infected cells and impairs cellular protein synthesis by inactivating two translation 
initiation factors (Hu et al., 2012). NSP3 is also a translation enhancer for viral 
proteins. NSP3 ejects poly(A)-binding protein (PABP) from the translation initiation 
factor eIF4F. PABP is required for efficient translation of transcripts with a 3' 
poly(A) tail, which is found on most host cell transcripts. Moreover, NSP3 
inactivates eIF2 by stimulating its phosphorylation. Efficient translation of rotavirus 
mRNA, which lacks the 3' poly(A) tail, does not require either of these factors.  
The mRNA is later replicated into dsRNA and packaged in cytoplasmic 
inclusions called viroplasms (Crawford and Desselberger, 2016). NSP2 and NSP5 
are crucial in regulating translation and replication in the viroplasm (Hu et al., 2012). 
The dsRNA cannot be packaged directly due to its large size. There are 12 
transcription complexes available and it is not clear what role the extra complex 
plays in RV replication. The 11 different sense strand ssRNAs engage through cis-
acting RNA elements into a supramolecular complex, which is encapsidated by VP2 
during early viral assembly (McDonald and Patton, 2011a). Packaging/assortment 
signals are believed to be located within the 5' and 3' UTR sequences and are 
different for each of the segments and conserved in different strains of RVA (Trask, 
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McDonald and Patton, 2012). Rotavirus is believed to undergo an as yet unclear all-
or-none packaging mechanism, not as yet elucidated (McDonald and Patton, 2011a; 
Desselberger et al., 2013; Periz et al., 2013). The synthesised DLPs bind NSP4, 
which functions as a rough endoplasmic reticulum (RER) receptor, and bud into the 
RER acquiring a transient envelope (Desselberger, 2014). Rotavirus matures in the 
RER by losing that envelope and assembling VP7 and VP4, to be then released as 
infectious virions by lysis or by Golgi-independent non-classical vesicular transport 
(epithelial cells), infecting neighbouring cells and enabling spread (Estes and 
Greenberg, 2013).  
Viroplasms are formed within two hours post-infection and inclusion bodies 
within six to seven hours post-infection, with maximum yields at 10-12 h post-
infection in AGMK cells  (Ayala-Breton et al., 2009).  
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1.2.6 Rotavirus hosts 
Rotavirus group A severe disease is mostly limited to children <5 years of 
age but may affect adults and the elderly (section 1.8). Group B affects  mainly 
adults and it has been linked with water-borne outbreaks in East and South Asia 
(Hung et al., 1984; Nakata et al., 1987; Chitambar et al., 2011; Lahon et al., 2013). 
Group C affects all age groups as outbreaks or sporadic cases, with around half of the 
60-year-old population seropositive and a very low incidence in the infant population 
(<5% of AGE-associated hospitalisations) (Nilsson et al., 2002; Rahman, Banik, et 
al., 2005; Joshi, Jare and Gopalkrishna, 2017).  
In animals, group A rotaviruses have been identified in horses (first three 
months of life) (Collins et al., 2008), cattle (first four week of life) and pigs (first 
eight weeks of life) causing significant morbidity; and also in dogs and cats 
(Marshall et al., 1984, 1987). Group B has been identified in pigs, cattle, sheep, lamb 
and rats (Theil et al., 1985; Chasey and Banks, 1986; Parwani, Lucchelli and Saif, 
1987; Eiden et al., 1991; Tsunemitsu et al., 1991; Barman et al., 2004). Group C has 
been identified in pigs, ferrets, dogs and cattle (Saif et al., 1980; Torres-Medina, 
1987; Tsunemitsu et al., 1991; Chang et al., 1999; Otto, Schulze and Herbst, 1999; 
Collins, Martella and O’Shea, 2008; Tuanthap et al., 2018). Groups A, D, F, G have 
been identified in birds (Falcone et al., 2015; McCowan et al., 2018). Group E has 
been identified in pigs (Chasey, Bridger and McCrae, 1986; Martella et al., 2010). 
Group H has been identified in piglets (Wakuda et al., 2011; Marthaler et al., 2014; 
Molinari et al., 2014). Candidate group I infect dogs and candidate group J infect 
bats (Mihalov-Kovács et al., 2015; Bányai et al., 2017). Other animals susceptible to 
infection by rotavirus are monkeys, goats, cats, mice and rabbits (Martella et al., 
2010). Weaning and post-weaning piglets and young calves are those most affected 
by rotavirus diarrhoea (Rosen et al., 1994; Lanz Uhde et al., 2008).  
There is evidence for zoonotic transmission in rotavirus group A, and 
suspicion of zoonotic transmission in groups B and C (Cook et al., 2004; Luchs and 
Sampaio Tavares Timenetsky, 2016). Although exceptional zoonoses have occurred 
originating from rotaviruses in pigs and cattle jumping species into humans, 
rotaviruses in humans are usually transmitted human strains transmitted from person 
to person (Martella et al., 2010).  
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1.3 Systems to study rotavirus infection 
1.3.1 Animal models 
Although the neonatal mouse model can be used to study infection and 
disease, the short duration of diarrhoea in neonatal mice infected with RV 
(susceptible during the first two weeks of life) impairs the study of immunity (Franco 
and Greenberg, 1999). However, the adult mouse is susceptible to infection by 
certain RV murine strains, rendering it a useful model to study RV infection (Franco 
and Greenberg, 1999). In this model, it was found that B cells expressing the α4β7 
gut homing receptor are key for resolution of infection via non-neutralising anti-VP6 
IgA, which are protective in vivo. It was also found that J-chain deficient mice were 
not able to produce sIgA, suggesting transcytosis of IgA as a mechanism to produce 
protective antibodies (Desselberger and Huppertz, 2011). Moreover, it has been 
found that passive transfer of neutralising anti-VP4 and anti-VP7 antibodies 
contribute to infection resolution in a dose-dependent manner and that the 
neutralizing IgA was anti-VP4 IgA (Desselberger and Huppertz, 2011). Shedding 
patterns have been studied in this mouse model showing protection against shedding 
after reinfection (Eydelloth et al., 1984; Ward, McNeal and Sheridan, 1990; Burns et 
al., 1995). In vaccinated mice, local IgA has been shown to correlate with protection 
although not as the only effector (Ward, 2003).  
Rotaviruses have also been studied in the gnotobiotic piglet, susceptible to 
human and porcine RV strains and which present diarrhoea within the first six weeks 
of life (Saif et al., 1996; Yuan and Saif, 2002). The gnotobiotic piglet lacks 
microbiome, affecting mechanisms of mucosal immunity. In this model, it was found 
that specific anti-VP4 and anti-VP7 antibodies provided heterotypic protection 
against challenge and that anti-VP6 IgA was not protective (Desselberger and 
Huppertz, 2011). Serum and intestine RV-specific IgA were the main correlates of 
protection against human RV challenge and vaccination (Azevedo et al., 2004; 
Desselberger and Huppertz, 2011).  
Although there have been attempts at developing monkey models of human 
RVA infection (Chege et al., 2005), only very young monkeys are susceptible to 
diarrhoea (Leong and Awang, 1990) and the proportion of monkeys developing 
diarrhoea is low even in those infected with homologous simian RVA despite 
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shedding of virus in stool (McNeal et al., 2005; Bentes et al., 2018) or viremia (Yin 
et al., 2018).  
Although they have been useful models to understand RV biology, biological 
and experimental differences with respect to humans contribute to limited 
transferability as predictors of protection (Desselberger and Huppertz, 2011).  
1.3.2 Reverse genetics systems 
The functions of rotavirus proteins have been studied in spontaneous mutants 
and in several reverse genetics systems which depended on the use of a helper virus 
and strong selection conditions (Komoto and Taniguchi, 2013; Desselberger, 2014). 
Now, there is a plasmid-only based system that can yield rotavirus with specific 
changes, heterologous inserts in the genome, to study functionality of rotavirus 
proteins (Kanai et al., 2017). It is possible to study packaging signals of RV 
ss(+)RNAs (replication), to identify sequences of segments involved in genome 
reassortment (safety), to study compatibility of proteins from different species (e.g. 
RdRp, evolution), to study host restriction, pathogenicity, virulence and attenuation 
(therapy), to generate direct rotavirus mutants with GFP for imaging (pathogenesis) 
and to generate RV with highly cross-reactive epitopes (wide immunity, universal 
vaccine candidate) (Crawford et al., 2017; Kanai et al., 2017). For example, it was 
found that NSP6 is not essential for viral replication in cell culture (Komoto et al., 
2017) and that basal interferon limits RV replication and interferon treatment could 
inhibit RV replication (Hakim et al., 2018). This system will be useful in further 
studying the phenotype elicited by engineered mutations and in developing candidate 
vaccines and antivirals against RV.  
1.3.3 Human Intestinal Enteroids 
Previously, there had been a lack of models for the human small intestine. 
However, in the last few years, human stem cells from the crypts of small intestine 
have been differentiated into intestinal cell-like cultures as monolayers or in 3D a 
few years ago (Spence et al., 2011). It was observed that these cultures can be 
infected with lab strains and clinical isolates (Finkbeiner et al., 2012). These human 
intestinal organoids/enteroids (HIEs) are multicellular, containing cell types from the 
intestinal epithelium, such as enterocytes, goblet cells, enteroendocrine cells and 
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Paneth cells (Sato and Clevers, 2013; Saxena et al., 2016). These HIEs are used to 
study rotavirus replication (Kovbasnjuk et al., 2013), pathophysiology and epithelial 
cell restriction (Saxena et al., 2016), as well as the innate immune response to RV 
(Saxena et al., 2017). Human intestinal enteroids appear to be a robust and 
reproducible model to study human rotaviruses and may overcome the limitations of 
cell-based and animal models.  
1.4 Molecular pathogenesis  
1.4.1 Intestinal infection 
RV mainly infects mature enterocytes in the middle and upper part of the villi 
in the small intestine (Fig. 1.7; Lundgren and Svensson, 2001). When RV uncoats 
from the endocytic vesicles into the cytoplasm, it increases intracellular Ca
2+
 levels 
which in turn increase paracellular permeability, thereby disrupting tight junctions 
(Dickman et al., 2000; Lundgren and Svensson, 2001; Obert, Peiffer and Servin, 
2002). There is a resulting increase in epitelial turnover, loss of microvilli and 
atrophy of the villi (Davidson and Barnes, 1979; Tafazoli et al., 2002) and a decrease 
in absorptive function (Barnes and Townley, 1973; Holmes et al., 1975), leading to 
non-inflammatory osmotic diarrhoea. Viral progeny are released, spreading the 
infection and contributing to the non-inflammatory diarrhoea. 
NSP4, a viral enterotoxin (Horie et al., 1999) and viroporin, is responsible for 
interfering with Ca
2+
 balance and resulting in loss of plasma membrane integrity and 
altered epithelial homeostasis (Ball et al., 1996; Newton et al., 1997). This RER 
membrane protein acts on phospholipase C, activating Ca
2+
-dependent chloride 
channels and causing the exit of water into the lumen in parallel to chloride and 
resulting in secretory diarrhoea (Hyser et al., 2010). It also impairs the sodium-
glucose cotransporter 1 and prevents water reabsorption (Halaihel et al., 2002; 
Svensson et al., 2016). Moreover, NSP4 induces the release of peptides and amines 
that stimulate the enteric nervous system (ENS), such as 5-hydroxytryptamine (5-HT 
or serotonin) from enteroendocrine cells, increasing intestinal motility and 
contributing to secretory diarrhoea (Bialowas et al., 2016). NSP4 can activate the 
ENS directly (Weclewicz et al., 1993; Lundgren et al., 2000; Lundgren and 
Svensson, 2001). Another hallmark of RV disease is signalling for early vomiting via 
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the vagus nerve, after Ca
2+
-dependent secretion of 5-HT (Hagbom et al., 2011). 
Individuals with rotavirus disease also present with fever (Uhnoo, Olding-Stenkvist 
and Kreuger, 1986): higher levels of TNF and IL-6 have been detected in serum of 
infected infants (Jiang et al., 2003), although the mechanisms driving fever in 
rotavirus infection are currently unknown. NSP4 also binds to extracellular matrix 
proteins laminin-β3 and fibronectin (Boshuizen et al., 2004), which may allow 
further systemic infection.  
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1.4.2 Systemic and extraintestinal infection 
It has been reported that children with RV infection have infectious RV and 
viral antigens in blood (viraemia and antigenemia, respectively) and other sites up to 
5 days after onset of sypmtoms; those with antigenaemia present with more severe 
symptoms (Blutt et al., 2007). Further studies found that antigenaemia was more 
common among children with extraintestinal symptoms (Ramani, Paul, et al., 2010; 
Hemming et al., 2014). Individuals with systemic infection have been found to 
present more severe symptoms than those with only intestinal  infection (Hemming 
et al., 2014).  
Rotavirus-elicited extraintestinal symptoms have been previously observed in 
children  with neurological illness, seizures being the most frequent (Lloyd et al., 
2010; Rivero-Calle, Gómez-Rial and Martinón-Torres, 2016). Apart from the central 
nervous system, rotavirus has been found in liver, heart, bladder, lung, kidney and 
testes of children and animals (Blutt et al., 2007; Candy, 2007; Alfajaro and Cho, 
2014). Systemic infection may be due to direct spread of RV to the blood or the 
lymphatic system after reaching the lamina propria  or by infecting cells of the 
immune system (Boshuizen et al., 2004; Alfajaro and Cho, 2014; Mossel and Ramig, 
2016). Rotavirus may reach the central nervous system by attaching to specific 
receptors or using axon transport (Weclewicz, Svensson and Kristensson, 1998). 
Other extraintestinal manifestations are usually isolated cases (Rivero-Calle, Gómez-
Rial and Martinón-Torres, 2016). RV infection has also been associated with 
autoimmune diseases, such as diabetes mellitus type I or celiac disease (Honeyman et 
al., 2000, 2014; Stene et al., 2006; Ballotti and De Martino, 2007; Dolcino et al., 
2013; Pane, Webster and Coulson, 2014; Sarkar et al., 2014). Although there is no 
direct evidence of extraintestinal infection generated from systemic infection derived 
from intestinal infection (as opposed to direct extraintestinal infection by other 
mechanisms), the frequency of neurological illness and seizures indicate that RV is a 
systemic pathogen (Rivero-Calle, Gómez-Rial and Martinón-Torres, 2016; Gómez-
Rial et al., 2019a, 2019b; Salas et al., 2019). 
Chapter 1   Introduction 
22 
 
1.5 Symptoms, diagnosis and treatment  
Rotavirus infection can be asymptomatic or manifest as mild non-bloody 
diarrhoea of short duration, or it can manifest as severe diarrhoea accompanied by 
vomiting and fever and resulting in severe dehydration (Parashar, Nelson and Kang, 
2013). Rotavirus disease typically presents with cold-like symptoms, moderate fever 
and early vomiting, followed by secretory diarrhoea with frequent stools (Parashar, 
Nelson and Kang, 2013). The majority of infants with asymptomatic RV infection 
are under 2 years of age (Phillips et al., 2010). Nowadays, rotavirus is being 
considered a systemic disease by clinicians, with links to autoimmune disease and 
seizures appearing to be the most frequent and severe extraintestinal symptoms 
(section 1.4.2). 
Rotavirus diagnosis was originally performed by electron microscopy or latex 
agglutination tests (Pai, Shahrabadi and Ince, 1985). Then, polyacrylamide gel 
electrophoresis was used to identify the electrophoretic migration patterns of the 
rotavirus segments (Herring et al., 1982). Antigen detection assays are available, as 
well as reverse-transcription polymerase chain reaction (RT-PCR), which has greater 
sensitivity (Pang et al., 2004). Testing of stool and antigenemia are not routine 
diagnostic tools  as treatment remains the same  regardless of molecular diagnosis 
(Parashar, Nelson and Kang, 2013; Gómez-Rial et al., 2019b). 
The main treatment for rotavirus gastroenteritis (RVGE) in children with 
repeated vomiting and mild dehydration is oral rehydration therapy using a 
hyposmolar oral rehydration solution (ORS), composed of 75 mM sodium plus 
glucose, potassium, chloride and citrate (WHO, 2005), which aims to restore 
glucose-coupled sodium and water adsorption, based on rapid turnover of 
enterocytes. In severe dehydration cases or milder cases where vomiting impairs 
adequate ORS administration, intravenous rehydration therapy is used (Chow, Leung 
and Hon, 2010). In such cases, food intake is stopped until the patient has improved, 
whereupon breastfeeding or regular milk formulas are introduced, followed by solid 
food (WHO, 2005; Gregorio, Dans and Silvestre, 2011). Zinc supplementation is 
recommended by the WHO and United Nations International Children's Emergency 
Fund (UNICEF) for cases of diarrhoea in developing countries and has been found to 
reduce the duration of diarrhoea in children >6 months of age (Lazzerini and 
Ronfani, 2012). Although probiotics are not part of the standard treatment, they have 
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been shown to accelerate recovery from gastroenteritis symptoms and to reduce stool 
frequency (Allen et al., 2011). Bacteria that produce lactic acid, such as 
Lactobacillus and Bifidobacterium species,  in combination with prebiotics have 
shown an antiviral effect against rotavirus, as well as reduced duration and severity 
of disease (Gonzalez-Ochoa et al., 2017).  
Drugs that affect the nervous system, such as antiemetics and antisecretory 
drugs, are generally not recommended in children. However, in cases of vomiting 
impaired ORS or intravenous therapy, ENS inhibitors used in gastroenteritis 
treatment are serotonin or 5-HT3 receptor antagonists, which help reduce vomiting 
and water and electrolyte secretion, reduce intestinal motility, ultimately reducing 
dehydration. One such type of inhibitor, ondansetron, has proven effective at 
reducing vomiting and the need for intravenous therapy (Fedorowicz, Va and Carter, 
2011; Hagbom et al., 2017). Anti-viral drugs that selectively affect rotavirus 
receptors, polymerase, replication, viroplasm assembly, RNA assortment, packaging 
and maturation could be of great use. Nitazoxanide is an example of an anti-viral 
drug inhibiting RV replication, potentially by targeting cellular pathways of protein 
synthesis, that has been shown to reduce duration of rotavirus disease in hospitalised 
patients (Rossignol and El-Gohary, 2006; Rossignol et al., 2006). The use of 
antibodies has resulted in reduction of stool output and disease severity (Sarker et al., 
2013; Thu et al., 2017).  
1.5.1 Rotavirus faecal shedding 
Rotavirus shedding in stool has been observed in infected infants before the 
onset of diarrhoeal symptoms for up to 10 days (Nagavoshi et al., 1980; Vesikari, 
Sarkkinen and Mäki, 1981), and in hospitalised children from 4 to 57 days after the 
onset of symptoms (Richardson et al., 1998), with 70% of children ceasing shedding 
within 20 days of diarrhoea onset. Children who shed RV over an extended period of 
time appear to be less protected against rotavirus disease than those who do not shed 
continously (Richardson et al., 1998). Shedding may be longer in duration and to 
higher levels where symptoms are evident, as compared to asymptomatic children 
(onset of infection unknown), with intermittent shedding observed in symptomatic 
and asymptomatic children (Mukhopadhya et al., 2013). Rotavirus gastroenteritis 
severity correlated with RV viral loads (VLs) in infants in Southern India (Kang et 
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al., 2004). However, this correlation was not observed in neonates (Ramani, 
Sankaran, et al., 2010).  
1.6 Immune response  
1.6.1 Innate immune response 
In a primary infection, innate immune response mechanisms are triggered 
rapidly (Angel, Franco and Greenberg, 2012). Because RV dsRNA is not fully 
uncoated when entering enterocytes, macrophages, dendritic cells (DCs) or naïve B 
and T cells, recognition by pattern recognition receptors (PRRs) is prevented (Estrozi 
et al., 2013). However, sub-populations of uncapped and partially capped viral 
transcripts can activate the host innate immune response through (RIG-I)-like 
receptors (RLRs) and Toll-like receptors (TLRs) (Uzri and Greenberg, 2013), 
subsequently activating transcription factors of the IFN pathway involved in antiviral 
response (Fig. 1.8). These migrate to the nucleus and stimulate IFN and IFN 
stimulatory genes (ISG), to trigger types I, II and III responses. Secreted IFN binds to 
IFN receptors on cells in an autocrine and paracrine manner, stimulating the JAK-
STAT signalling cascade and activating a second wave of transcription. An ‘antiviral 
state’ is then established when a multitude of genes encoding antiviral proteins are 
expressed and a positive feedback for IFN expression ensures its amplification 
(Angel, Franco and Greenberg, 2012).  
However, the RV protein NPS1 interacts with cellular proteins involved in 
IFN production such as β-TrCP, degrades them –via the proteasome by NSP1´s 
suspected E3 ubiquiting-ligase activity (Barro and Patton, 2007; Graff, Ettayebi and 
Hardy, 2009; Morelli, Dennis and Patton, 2015; Davis and Patton, 2017)– and 
interacts with other proteins such as p53 to avoid early apoptosis, while VP3 inhibits 
the mitochondrial antiviral state and prevents dsRNA degradation (reviewed by 
Desselberger, 2014; reviewed by Arnold, 2016; Ding et al., 2018), resulting in low 
levels of IFN transcription or secretion. NSP1 has also been reported to antagonise 
the JACK-STAT pathway (Sen et al., 2014),  further preventing the establishment of 
an antiviral state. Although the NSP1 modulatory activity on the IFN response is 
conserved between strains, the molecular targets differ in a strain-dependent manner 
(Barro and Patton, 2007; Graff et al., 2007; Sen et al., 2009; Arnold and Patton, 
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2011). Recently, it was found in suckling mice that rotavirus re-programmes INF 
receptor signalling to reduce antiviral and anti-inflammatory functions (Sen et al., 
2019).  
 
 
Fig. 1.8. Rotavirus interference with the host immune system. Rotavirus enters 
the cells and the actively transcribing virus is recognised by the pattern recognition 
receptors ATP-dependent RNA helicase DDX58 (RIG-1) and interferon (IFN)-
induced helicase C domain-containing protein 1 (MDA5), which activate 
transcription factors IFN regulatory factor 3 (IRF3) and nuclear factor κB (NF-κB) 
through mitochondrial antiviral-state signalling protein (MAVS); inducing IFN type 
I, II and III responses. The viral protein NSP1 interacts with IRF3 and NF-κB-related 
proteins to inhibit IFN production, in some cases by degrading IRFs via the 
proteasome. When IFN is secreted in an autocrine manner, it interacts with IFN 
receptors and activates the signal transducer and activator of transcription 1 
(STAT1), 2 (STAT2) and IRF9 transcription factors, which stimulate IFN stimulated 
response element (ISRE), activating IFN stimulatory genes (ISG) and leading to 
amplification of IFN production and the so called ‘antiviral state’. NSP1 also 
interacts with STAT1 and IRF9 to prevent this state. BTRC, beta-transducin repeat 
containing E3 ubiquitin protein ligase; IFNAR1, IFN-α/β receptor; IκB, inhibitor of 
nuclear factor-κB; IKK-ε, inhibitor of NF-κB kinase subunit ε; ISRE, IFN-stimulated 
response element; JAK1, Janus kinase 1; TBK1, TANK(TRAF(TNF(tumour necrosis 
factor) receptor-associated factor)) family member-associated NF-κB activator)-
binding kinase 1; TYK2, non-receptor tyrosine kinase 2; VP3, Viral protein 3. 
Adapted and reproduced from Angel, Franco and Greenberg, 2012; Desselberger, 
2014; Crawford et al., 2017, with permission from Nature Reviews Disease Primers 
Copyright Clearance Center’s RightsLink® order no. 4620891497970 (02/07/19); 
and with added information from Ding et al., 2018. 
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1.6.2 Adaptive immune response  
The adaptive immune response is elicited after the innate immune response or 
is rapidly triggered in a secondary infection: it is mainly a mucosal response in the 
case of rotavirus (Uhnoo et al., 1988; Franco, Angel and Greenberg, 2006). 
Rotavirus-specific CD4
+
, CD8
+
 T cells and B cells express the gut homing receptor 
α4β7 (Gonzalez et al., 2003; Rojas et al., 2003), showing they are recruited to the 
gut-associated lymphoid tissue (GALT) in the event of an infection. In an 
immunocompetent host, rotaviral antigens are transported to mesenteric lymph nodes 
in the GALT, such as Peyer’s patches (pre-natal; the major induction sites of 
adaptive IgA responses) (Gonzalez et al., 2003) and mesenteric lymph nodes (Blutt 
et al., 2002). There, they undergo processing by antigen-presenting cells (APCs; B 
cells, plasmacytoid DCs or macrophages) and RV antigens are presented to T helper 
(Th) cells. Next, rotavirus-specific B cells are stimulated to produce antibody as 
plasma cells. The polymeric secretory IgA (sIgA), which binds the J chain covalently 
to stabilise the dimers, is generated by plasma cells in the lamina propria (LP) of the 
small intestine. Polymeric sIgA is transcytosed across epithelial cells towards the gut 
lumen by the polymeric Ig receptor (pIgR) through the secretory component (SC).  
Neutralising antibodies (NAbs) directed against VP4 and VP7 can prevent 
viral binding and penetration, inducing aggregation and viral immune exclusion and 
preventing damage to epithelium. Anti-VP4 and anti-VP7 sIgA secreted into the 
lumen have been shown to be neutralizing in vitro (Ball et al., 1996; Feng et al., 
2002; Franco, Angel and Greenberg, 2006). In a secondary infection, VP4 and VP7 
antibodies mediate heterotypic immunity (Nair et al., 2017). Anti-NSP4 antibodies 
may prevent disease but not infection (Ball et al., 1996; Angel et al., 1998). 
Moreover, both humoral and cellular immune responses to NSP4 have been reported, 
as well as increases in IL-2 and INFγ (Johansen et al., 1999). Viral replication in the 
cytosol can be inhibited by anti-VP6 sIgA during transcytosis across enterocytes. 
Anti-VP6 non-neutralizing sIgA binds intracellularly to VP6 in the viroplasm and 
prevents uncoating of the inner capsid as well as viral assembly (Burns et al., 1996), 
resulting in protection in vivo (Herrmann et al., 1996; Chen et al., 1997; O’Neal et 
al., 1997; Feng et al., 2002). The sIgA is believed to bind to a transcriptional pore to 
block viral transcription (Aiyegbo et al., 2013).  
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B cells, together with CD8
+
 T cells are believed to mediate rotavirus 
clearance (Blutt et al., 2002). Rotavirus-specific cytotoxic CD8
+
 T lymphocytes are 
believed to be the main cellular effectors in rotavirus clearance in mice (Franco, Tin 
and Greenberg, 1997). In infants with rotavirus infection, low levels of these have 
been detected (Rojas et al., 2003; Mesa et al., 2010). Another study detected 
significantly higher levels of CD8
+
 and CD4
+
 IFNγ-secreting cells in blood of 
symptomatic adults and faeces-exposed workers with respect to asymptomatic adults 
and children with severe RVGE (Jaimes et al., 2002).  
The main cytokines found in children with RVGE were IL-6, IL-10 and 
IFNγ, with patients with fever presenting higher IL-6 levels, and patients with fever 
and more diarrhoea episodes presenting higher levels of TNFα (Jiang et al., 2003). 
IL-2 was found at lower levels in children with a high number of stools passed and 
IFNγ was lower in those patients presenting vomiting. The Th1 response has been 
shown to be predominant in acute RVGE (Azim et al., 1999; Jiang et al., 2003) 
despite neonates being skewed to Th2 response (Wegmann et al., 1993; Sykes et al., 
2012). Cytokines in rotavirus infection appear to be linked to symptoms, such as in 
the case of fever (Jiang et al., 2003).  
Natural infection reduces the risk of subsequent severe disease and severity 
decreases with time. The first infection is usually more severe than the second or 
third infections (Velázquez et al., 1996), as acquired antibodies contribute to 
decreasing the acuteness of the disease. The G/P genotypes present in a second 
infection are likely to be different from those present in the primary infection 
(Hungerford et al., 2014) and protection against infection or disease is usually type-
specific. Subsequent infections with the same strain are less severe, although high 
protection against severe disease has been observed when infected by heterotypic 
strains. Most older children and adults (except when encountering a more virulent 
strain, when immune-supressed or depending on the type of gut microbiota and 
secretor status) are not susceptible to RV disease, as they present acquired immunity 
from childhood (Griffin et al., 2002; Mikami et al., 2004; Rodríguez-Díaz et al., 
2017).  
Immunocompromised individuals like children with severe-combined 
immunodeficiency (SCID) present prolonged viral shedding and systemic disease, 
thus highlighting the importance of the B and T cell response in clearing RV 
Chapter 1   Introduction 
28 
 
infection (N. C. Patel et al., 2012; Kaplon et al., 2015; Rosenfeld et al., 2017). 
Moreover, it has been observed that children with IgA-D deficiency overcompensate 
with specific anti-RV IgG (Istrate et al., 2008), suggesting that IgA is not crucial for 
resolution of RVGE in humans, in contrast to later studies in mice suggesting a key 
role for IgA in immunity against RV (Blutt et al., 2012).   
1.6.3 Correlates of protection  
Mechanisms underlying protection against rotavirus are not well understood, 
and antibody effector functions have been the most used predictors of protection so 
far.  
Maternal transplacental antibodies (IgG) may provide mild protection against 
rotavirus infection and diminish the need for the infant to mount a neutralizing 
immune response (Ramachandran et al., 1998; Ward et al., 2006; Appaiahgari et al., 
2014; Moon et al., 2016; Mwila et al., 2017). Breastfeeding may also provide 
maternal antibodies with neutralising capacity and other protective factors (Asensi, 
Martınez-Costa and Buesa, 2006; Chattha et al., 2013; Moon, Tate, et al., 2013). 
Some studies have found breastmilk maternal antibodies to be correlated with 
protection (Espinoza et al., 1997) and other studies have described mild protection 
(Glass et al., 1991) due to lactadherin (Newburg et al., 1998). The highest levels of 
antibodies in breastmilk are present in colostrum, with lower levels as breastfeeding 
continues (Chan et al., 2011; Tino De Franco et al., 2013).  
Correlates of protection against natural infection have been identified as 
neutralising and cross-reactive antibodies against various RV types in Japan and the 
United States of America (USA) (Chiba et al., 1986; Ward and Bernstein, 1994). 
They have also been identified as RV-specific IgA and IgG in serum, with IgA titre 
increases of >1:200 and IgG titre increases of >1:800 correlating with protection 
against infection and disease; with IgA titre increases of >1:800 presenting low risk 
of disease and protection against moderate/severe disease; and with IgG titre 
increases of >1:6400 presenting protection against infection and not illness (O’Ryan 
et al., 1994; Velázquez et al., 1996, 2000). RV-specific intestinal mucosal secretory 
IgA has also been identified as a natural correlate of protection, with a four-fold titre 
increase in infected with respect to uninfected children and higher copro-IgA 
associated with protection against infection and RV disease (Matson et al., 1993). In 
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an earlier study, it was found that there was a mild correlation between serotype-
specific neutralising IgA levels in serum and protection against severe disease and 
vomiting, as well as between older age (>1.5 years) and milder symptoms (Hjelt and 
Grauballe, 1990). These serum antibodies where thought to be polymeric IgA and 
originated from the intestine and spilled over into serum (Hjelt et al., 1987). Later, 
serum anti-RV IgA was observed to be related to clinical protection against infection 
(Ward, Knowlton, et al., 1997) and seropositivity for RV-specific IgA was defined as 
an increase in titre of >20 U/mL (Bernstein et al., 1999) In another study, individuals 
who did not generate serum NAbs were at higher risk of rotavirus disease than those 
who did (De Vos et al., 2004). The best correlate of protection in RV natural 
infection appeared to be NAbs in serum since they reflected intestinal anti-VP6, anti-
VP4 and anti-VP7 (Svensson, Sheshberadaran, Vene, et al., 1987; Franco, Angel and 
Greenberg, 2006). 
Regarding antibodies in stool, patterns of faecal IgA are not well understood 
either. Copro-IgA has been described as a good surrogate marker of duodenal 
secretory IgA (sIgA) (Grimwood et al., 1988; Coulson et al., 1992; Matson et al., 
1993). Anti-RV copro-IgA was associated with protection against infection and 
disease, and asymptomatic children presented higher levels at baseline (Matson et 
al., 1993). Frequent infection was seen to produce sustained copro-IgA, protecting 
against infection and disease, with copro-IgA persisting for a few weeks (Coulson et 
al., 1992). Low or no copro-IgA has been associated with risk of reinfection and 
copro-conversion was found to be more sensitive than seroconversion in secondary 
infection (Coulson et al., 1990). Continuous RV faecal shedding has been associated 
with copro-IgA boosts and with likelihood of mild diarrhoea during convalescence 
(Richardson et al., 1998). Copro-IgA is usually detected at <150 units/g of stool (or 
<50 total IgA index) (Coulson and Masendycz, 1990), ranging from 520 to 2040 
µg/mL (Martin, 2000). It was noted that rotavirus-specific copro-IgA (cIgA) 
concentrations peaked from 14 to 17 days after infection and persisted for longer 
than a year and up to two years, although at declining concentrations (from 2-4 
months after secondary infection (Coulson et al., 1992)) (Bernstein, McNeal, et al., 
1989). However, cIgA has sometimes not been detected or inconsistently detected 
(Offit, 1996). Children usually present copro-IgA for less time than serum IgA, 
maybe due to mounting of primary responses and a lack of boosting necessary to 
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generate long-life antibodies in stool (Franco, Angel and Greenberg, 2006). At high 
levels, copro-IgA has been observed to be correlated with protection (Coulson et al., 
1992; Matson et al., 1993). Copro-IgA is considered a marker of protection at a 
population level but it is not clearly indicative of protection at an individual level 
(Clarke and Desselberger, 2015). 
The correlates observed in challenge studies have been type-specific NAbs in 
serum (Kapikian et al., 1983), serum RV-specific IgG (Ward et al., 1986; Ward, 
Bernstein, et al., 1990), RV-VP7-epitope-specific antibodies in serum (Green and 
Kapikian, 1992) and intestinal NAbs (Ward et al., 1989). In animal studies in mice, 
adult mice have appeared to be protected by intestinal secretory IgA (Feng et al., 
1994; Burns et al., 1995). In non-human primates, serum IgG appeared to be 
responsible for mucosal immunity against RV (Westerman et al., 2005). 
1.7 Molecular epidemiology  
Despite rotavirus diversity and strain prevalence changing yearly (Patton, 
2012), a few rotavirus serotypes have been identified as the more common ones 
infecting humans globally in the recent decades: G1, G2, G3, G4 and G9 and G12 
strains in combination with P[4], P[6] or P[8] (Matthijnssens et al. 2009; Santos & 
Hoshino 2005). G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] strains have been the 
cause of >90% of human RVA infections worldwide, with G1P[8] being the most 
common circulating strain in Europe, North America and Australia and globally 
(Santos and Hoshino, 2005). Although G1P[8], G2P[4], G3P[8], G4P[8] were 
common in Europe (91.6%), North America (92%) and Australia (99.4%) from 1989 
to 2004, they were less common in South America and Asia (68%), and in Africa 
(50%). G9P[8] and G12P[8] have emerged since the 1990’s and 2000’s respectively, 
and have become major strains worldwide (Pongsuwanna et al., 2002; Rahman, 
Matthijnssens, et al., 2005; Ghosh et al., 2006; Rahman et al., 2007, 2008; 
Matthijnssens et al., 2009, 2010; Arana et al., 2019).  
These same strains were circulating in the UK prior to vaccine introduction in 
2013 (section 1.12), with G1P[8] being the most common circulating strain (Iturriza-
Gómara et al., 2000, 2008, 2011; Hungerford et al., 2016). Since rotavirus 
vaccination has been offered to all infants, the strain distribution has changed, with a 
vaccine-derived G1P[8] being the most common strain in <6 month-olds, likely 
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representing vaccine shedding post-vaccination; and G2P[4] followed by G9P[8] 
being the most frequently detected strains in >6 month-olds (Hungerford et al., 
2019), showing that there are strain differences in age distribution. 
1.8 Population epidemiology  
In temperate climates, rotavirus infection peaks annually in winter and spring 
(Kapikian et al., 1976; Cook et al., 1990). In contrast, in tropical climates, it is 
spread during the year and there is no defined peak, probably due to higher strain 
diversity and a lower transmission rate, maintaining infection levels in humans as 
reservoir (Cook et al., 1990). In the USA, around 10 years after vaccine introduction 
(section 1.10.3), biannual peaks in rotavirus cases have been observed due to 
accumulation of susceptible children (Payne, 2019).  
Most of the fatal disease caused by RV (>80%) affects children in developing 
countries due to their hygiene and sanitation, nutritional status, potential co-
infections and reduced access to rapid treatment (Parashar et al., 2003, 2006). 
Rotavirus infects almost every child by the age of 5, causing more severe disease in 
those younger than 2 years, except neonates (infants younger than one month), 
whose infections are less frequent and severe likely due to protection by maternal 
antibodies (Parashar et al., 2003). Children undergo sequential rotavirus infections in 
early infancy, with less severe symptoms after each infection (Velázquez et al., 1996; 
White et al., 2008; Gladstone et al., 2011). Although less of a public health burden, 
RVAs have also been associated with diarrhoea in adults and the elderly, which may 
go unreported or appear as sporadic cases or outbreaks (Anderson and Weber, 2004; 
Centers for Disease and Control (CDC), 2011; Anderson et al., 2012). Wild-type and 
vaccine derived RV chronic infections have been described in immunodeficient 
infants (Saulsbury, Winkelstein and Yolken, 1980; N. C. Patel et al., 2012; Kaplon et 
al., 2015; Rosenfeld et al., 2017), as well as adults (Mori et al., 2002); and RV 
diarrhoea has been observed in travelers to the Caribbean and surroundings (Bolivar 
et al., 1978; Steffen et al., 1999), as well as in healthcare settings (Cubitt and Holzel, 
1980; Abbas and Denton, 1987; Ryan et al., 1997).  
 Horizontal transmission of WT and vaccine-derived RV from infected 
children to older siblings, adults or the elderly in the household has been reported, 
showing that WT transmission leads to RV infection with a protective effect in the 
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newly infected individuals (Rodriguez et al., 1979; Grimwood et al., 1983; Rivera et 
al., 2011; Miura et al., 2017; Bennett et al., 2019). In other cases, the outcome for 
the household contacts of infected infants was unclear (Kaneko et al., 2017) or 
resulted in gastroenteritis (Payne et al., 2010; Wikswo et al., 2019). Vaccination of 
infants (sections 1.10 & 1.12) has also resulted in protection of other unvaccinated 
children and adults (Lopman et al., 2011; Paulke-Korinek et al., 2011; Gastañaduy et 
al., 2013; Pollard et al., 2015; Prelog et al., 2016). In developing countries, the 
indirect effects of vaccination are less clear (Bennett, Bar-Zeev and Cunliffe, 2016; 
Bennett et al., 2018). Herd protection may be due to a decrease in WT RV 
transmission among vaccinated infants, reducing the overall transmission in the 
population (Parashar, Nelson and Kang, 2013), including adults. In the UK, the herd 
effect in older children the year after vaccine introduction was large, likely due to 
vaccination starting in July (2013), well in advance of the rotavirus season in the 
country, and rapid high vaccine coverage (PHE, 2014; Marlow et al., 2015).  
1.9 Disease burden  
According to the World Health Organization (WHO) estimate for 2008, 
rotavirus was responsible for 453,000 deaths per year worldwide (Tate et al., 2012), 
most of them in developing countries (Figs. 1.9 & 1.10). Using data from 2013, after 
vaccine introduction in many countries, the WHO estimated that the annual RV-
associated mortality had dropped to 215,000 deaths/year (Angel, Steele and Franco, 
2014; Tate et al., 2016; WHO, 2016). Rotavirus hospitalization worldwide ranged 
from 30% to 50% of those infected, and 38% of diarrhoea cases in the under 5-year-
olds are due to rotavirus (Parashar et al., 2006; Lanata et al., 2013). After vaccine 
introduction, hospitalisation cases reduced by 16-99% in developed countries (Curns 
et al., 2010; Braeckman et al., 2012; David and Kirk, 2014; Shah et al., 2018) and by 
11-81% in developing countries (Molto et al., 2011; Quintanar-Solares et al., 2011; 
Yen, Armero Guardado, et al., 2011; Abeid et al., 2016; Bennett et al., 2018). 
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Fig. 1.9. Rotavirus diarrhoea deaths among children under 5 years of age 
worldwide, 2013. From www.rotacouncil.org, originally from Tate et al., 2016. 
With permission from Clinical Infectious Diseases Copyright Clearance Center’s 
RightsLink
®
 order no. 4625820118538 (11/07/19). 
 
 
Fig. 1.10. Rotavirus mortality rate per 100,000 among children under 5 years of 
age worldwide, 2013. From www.rotacouncil.org, originally from Tate et al., 2016. 
With permission from Clinical Infectious Diseases Copyright Clearance Center’s 
RightsLink
®
 order no. 4625820118538 (11/07/19). 
 
In the UK, the Department of Health estimated that RV infection prior to 
vaccination introduction accounted for 140,000 cases of diarrhoea each year in 
under-5s, of which around 10% result in hospitalizations due to dehydration Before 
vaccine introduction, it was estimated by modelling that RV was responsible for 45% 
Chapter 1   Introduction 
34 
 
of hospitalisations, 25% of GP consultations, 27% of national health service (NHS) 
calls and 20% of emergency attendances related to severe GE (Harris et al., 2007). 
Other reports estimated that there were 750,000 diarrhoea episodes and 80,000 
general practice consultations per year in the UK (Hungerford et al., 2014). Later, it 
was estimated that the economic cost of rotavirus disease in the UK in the period of 
2008 to 2009 was about £25 million (Tam and O’Brien, 2016). 
1.10 Rotavirus vaccines 
Rotavirus disease burden has led to extensive vaccine development, in order 
to protect against the high morbidity and mortality caused by severe RVGE. Animal 
rotavirus vaccines are available for cows (Rotavec
®
Corona, MSD), pigs 
(Prosystem
®
Rota, Merck, 2012) and horses (Equip Rotavirus Emulsion, Zoetis). 
Vaccines against RV for humans have been available as prophylaxes for >10 years 
and are the focus of this section.  
Since rotavirus replicates in the gut, oral, live-attenuated vaccines that 
mimicked the natural rotavirus infection and elicited a similar mucosal response to 
that against WT RV infection were the first to be designed. The two or three dose 
administration schedule is based on second and following infections being more 
effective at protecting against severe disease and different RV strains.  
1.10.1 History of rotavirus vaccines 
Based on the Jennerian approach that strains from animals are naturally 
attenuated in humans and generate an immune response, the first rotavirus vaccines 
were based on animal RV strains.  
1.10.1.1 RIT 4237 
RIT 4237 was an oral, live-attenuated, monovalent, bovine neonatal calf 
diarrhoea virus (NCDV) strain (G6P6[1]), manufactured by Smith Kline Beecham 
(Belgium), safe (Vesikari et al., 1983) and shown to be highly efficacious (>80%) 
against severe diarrhoea in Finland (Vesikari et al., 1985, 1986). However, it was 
discontinued later due to lack of efficacy and lack of cross-protection when tested in 
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developing countries (De Mol et al., 1986; Hanlon et al., 1987; Lanata et al., 1989; 
Santosham et al., 1991).  
1.10.1.2 Bovine WC3 (G6P7[5]) 
WC3 was an oral live-attenuated, monovalent bovine G6P[5] strain 
manufactured by Merck Research Laboratories (Merck & Co. Inc.; West Point, PA, 
USA) in Pennsylvania in 1981 at the Wistar Institute of Anatomy and Biology (Clark 
et al., 1986). It was generated from a bovine isolate from a calf at the veterinary 
school of the University of Pennsylvania, passaged 12 times in a Cercopithecus CV1 
cell line and tested in clinical trials (Clark et al., 1986, 1988; Bernstein, Kacica, et 
al., 1989). Although it presented good safety and immunogenicity, protection was 
inconsistent. There were no adverse effects, but it failed due to lack of protection 
against RVGE (Bernstein et al., 1990). Vaccination was protective against human 
RV in a small proportion of vaccinees, but did not modify the WT infection rate in 
vaccinees and did not prevent reinfection (Ward, Sander, et al., 1990). In a trial in 
central Africa, there was lower severity of RVGE in the vaccinated group, although 
the appearance of RV-specific antibodies did not guarantee protection (Georges-
Courbot et al., 1991).  
1.10.1.3 Rhesus rotavirus vaccine (RRV) 
RRV was an oral, live-attenuated, monovalent, simian strain MMU 18006 
(G3P5B[3]). It was generated by passaging a monkey isolate six times in primary 
megakaryoblastic cells (CMK) (Stuker, Oshiro and Schmidt, 1980). It was 
immunogenic and it protected vaccinated children against RVGE in North America, 
South America and Europe (Anderson et al., 1986; Losonsky et al., 1986; Vesikari et 
al., 1986; Wright et al., 1987; Flores, Daoud, et al., 1988; Flores et al., 1989; 
Gothefors et al., 1989; Madore et al., 1992), but was not as efficacious in certain 
populations in North America (Santosham et al., 1991, 1997). It failed due to 
secondary effects, such as fever and GE (Losonsky et al., 1986; Vesikari et al., 
1986).  
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1.10.1.4 RotaShield
®
 
RotaShield
®
 was an oral, live-attenuated, human-rhesus rotavirus tetravalent 
(RR-TV) reassortant manufactured by Wyeth Lederle Vaccines S.A. (Philadelphia, 
USA) and licensed in 1998 in the USA. It expressed RRV G3 and three human G 
serotypes RRV-based G1, G2 and G4 (Ward, 2008) and was administered in three 
doses. Its efficacy was higher for severe disease (>70%) than for all rotavirus disease 
(>49%) (Rennels et al., 1996; Joensuu et al., 1997; Santosham et al., 1997; Ward, 
Knowlton, et al., 1997).  
In 1999, RotaShield
®
 was found to correlate with intussusception in 1/10,000 
cases of vaccinated infants and was therefore withdrawn from the market a year later 
(Centres for Disease Control (CDC), 1999; Murphy et al., 2001, 2003; Peter et al., 
2002). Intussusception is a condition that causes part of the intestine to invaginate or 
fold into another section of the intestine and can lead to obstruction, necrosis, 
ischemia and sepsis (Poole and Penny, 2018).  It is the commonest cause of acute 
bowel obstruction in children younger than two years old (Bines et al., 2004; 
Waseem and Rosenberg, 2008), idiopathic in most of the cases, with a potential 
origin in viral infections by rotavirus, adenovirus and others. Ruling out such a risk 
has become critical for the licensure and universal use of any new rotavirus vaccine. 
There was a gap in availability of a global rotavirus vaccine when RotaShield
®
 was 
withdrawn from the market, as well as a need for large clinical trials (Phase III) 
designed to guarantee safety and reduce the risk of intussusception in future vaccines 
(Yung, Chong and Thoon, 2016).  
1.10.2 Current licensed vaccines used globally 
There are two live attenuated rotavirus vaccines available globally for public 
use since 2010: RotaTeq
®
 and Rotarix
®
. Such vaccines are highly effective at 
protecting individuals against infection. However, as they contain live virus, they 
may cause mild disease and the virus may acquire mutations that alter genetic 
stability. As G1P[8] was the most common strain of RVA circulating globally at the 
time, these VP7/VP4 serotypes have been included in both vaccines in order to 
provide wide protection.  
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1.10.2.1 RotaTeq
®
 
RotaTeq
®
 is an oral, live-attenuated, pentavalent human-bovine (strain WC3) 
reassortant manufactured by Merck Sharp & Dohme Corp. (MSD, White Station, NJ, 
USA) and licensed in 2006. Rotaviruses were reassorted in cell culture, with an 
animal rotavirus genetic background plus human rotavirus VP4 and VP7 genes 
representing common P and G types circulating globally. RotaTeq
®
 contains four 
human G types G1-G4 and one human P type P1A[8], plus bovine serotypes G6 and 
P[5] from strain WC3 (Midthun et al., 1985; Hoshino et al., 1997; Clark et al., 
2006). It was well tolerated and highly efficacious at protecting against severe 
RVGE, with neutralizing IgA generated in a proportion of vaccinees (Clark, Borian 
and Plotkin, 1990; Treanor et al., 1995; Clark et al., 2004; Vesikari, Matson, et al., 
2006; Ciarlet and Schödel, 2009; Vesikari et al., 2009; Staat et al., 2011; El Khoury 
et al., 2014). There was some correlation between protection and serotype-specific 
NAb levels, but none between efficacy and IgA levels in serum or stool (Ward et al., 
2004; Vesikari, Clark, et al., 2006). 
RotaTeq
®
 is recommended to be administered in three doses: Dose 1 at 6-12 
weeks of age followed by booster doses in a 4- to 10-week interval before 32 weeks 
of age (MerckVaccines.com, 2018). In the USA, it has been included since 2006 in 
the vaccination programme and administered at 2, 4 and 6 months of age (CDC, 
2018).   
1.10.2.2 Rotarix
®
 
Rotarix
®
 is an oral, live attenuated, monovalent human G1P[8] strain 
manufactured by Glaxo SmithKline Biologicals SA (GSK, Rixensart, Belgium) and 
licensed in 2008. It is administered in two doses at between 6 and 14 weeks of age 
for dose 1 with an interval between doses of at least 4 weeks (EMA, 2008). The 
second dose should be given preferably before 16 weeks of age and the last dose 
must be administered before 24 weeks of age (EMA, 2008) to prevent any 
association with age of incidence of intussusception, given the history of RotaShield® 
withdrawal from the market in 1998.  
Rotarix
®
 is derived from a single strain of human rotavirus RIX4414, 89-12 
strain from a child suffering from RV infection and diarrhoea in the 1988-89 season 
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(Bernstein et al., 1999). To attenuate the virus, it was passaged 26 times in primary 
African green monkey kidney (AGMK) cells and a further seven times in an AGMK 
cell line (Bernstein, 1998). This candidate RV vaccine virus was passaged 43 times 
in Vero cells, plaque-purified and lyophilised at GSK. Rotarix
®
 contains no less than 
10
6.0
 cell culture infectious dose 50 (CCID50) per dose (1.5 mL).  
The manufacturing process of Rotarix
®
 consists of an initial master viral seed 
G1P[8] RV strain, which is used to infect Vero cells, passaged multiple times 
(working seed) to attenuate the virus and an intermediate virus culture (inoculum) is 
used as  to produce the single harvest called vaccine bulk (Ruiz-Palacios et al., 2006; 
EMA, 2008). Harvests are pooled (bulk virus pool), clarified to discard Vero cell 
debris, DNAse-treated with benzonase and ultrafiltered (final bulk). Following sterile 
filtration, the final bulks are filled into sterile containers (final fill) (EMA, 2008) 
which are the biological medicine that is delivered to the vaccinee.  
Rotarix
®
 was tested in a randomised, double-blind, Phase III clinical trial in 
South America and Finland (Ruiz-Palacios et al., 2006). It was shown to be 85% 
effective at protecting against rotavirus AGE and rotavirus-associated hospitalisation, 
and 100% against most severe RVGE. During the trial, hospitalisations for diarrhoea 
decreased by 42%. Rotarix
®
 provided protection from the first dose and resulted 
cross-protective against other RV, such as G2P[4] (Vesikari et al., 2007; Yen, Tate, 
et al., 2011). Infection with monovalent G1P[8] vaccine virus has been shown to 
cross-protect against non-G1 rotaviruses (Ward et al., 2006), which supported the 
idea of heterotypic protection of this vaccine. Rotarix
® 
has been reported to be over 
85% effective at protecting against severe rotavirus infection in the first two years of 
life in countries with low mortality rates (Soares-Weiser et al., 2012). In a study 
comparing the safety and immunogenicity of Rotarix
® 
in 2005, vaccine ‘take’ for 
Rotarix
®
 was defined as serum RV-specific IgA seroconversion or vaccine RV 
shedding between the date of the first dose and two months after the second dose, as 
a measure to consider the vaccine had elicited a response in the vaccine recipient 
(Dennehy et al., 2005). 
1.10.3 Vaccines licensed for restricted markets 
Other RV vaccines are or have been available for use in more restricted 
capacities or geographical areas.  
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1.10.3.1 Lanzhou lamb rotavirus (LLR) 
LLR is an oral, live-attenuated, monovalent, lamb G10P[12] strain isolated in 
1984 in primary calf kidney cells, manufactured by the Lanzhou Institute of 
Biological Products (Lanzhou, China) and licensed for use in China since 2000 (Fu, 
Tate and Jiang, 2010). It was developed from the lamb strain LLR-85 (Chang et al., 
2010). Before its use, G10 was the main G type circulating, while currently G3, G1 
and G9 are filling the niche (Zhen et al., 2015). It is administered every year for three 
years between 2 and 35 months of age. LLR presented an efficacy of 44.3% in 
preventing hospitalisation (Fu et al., 2007) and a recent publication has confirmed 
vaccine efficacy of >30% against GE (Li et al., 2019).  
1.10.3.2 Rotavin-M1
®
 
Rotavin-M1
®
 is an oral, live-attenuated, monovalent, human G1P[8] strain 
(KH0118-2003) isolated in 2003 from a child in Vietnam (Le et al., 2009). It was 
developed by the Vietnamese Center for Research and Production of Vaccines 
(POLYVAC) and licensed in 2007. It is attenuated by serial passage in Vero cells. 
Rotavin-M1
®
 is administered in two doses at 10
6.3
 focus forming units (FFU)/dose, 
the first dose from 6 weeks of age and the second dose after 1-2 months (before 6 
months of age), with seroconversion of 73% and good safety and immunogenicity in 
Vietnamese infants (Clinicaltrials.gov, 2012, 2016c, 2016a; Dang et al., 2012). 
Another study to test the safety and immunogenicity of its liquid formulation is on-
going (Clinicaltrials.gov, 2018). A later trial will assess efficacy of Rotavin-M1
®
  
(Carey, 2017).  
1.10.3.3 ROTAVAC
®
 or 116E 
ROTAVAC
®
 is an oral, live-attenuated, monovalent, human G9P[11] strain 
116E isolated from asymptomatic neonates born during 1986-88 (Bhan et al., 1993; 
Das et al., 1994). It is manufactured at the All India Institute of Medical Sciences, 
New Delhi, in collaboration with Bharat Biotech International Ltd (Hyderabad, 
India) (Glass et al., 2005; Bhan et al., 2014) and was licensed in India in 2014. It was 
attenuated by serial passage in Vero cells and administered in three doses separated 
by a month each, starting at 6 weeks of age, containing 0.5 mL with not less than 
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10
5.0
 FFU of live rotavirus (BharatBiotech, 2018). It protects against subsequent 
disease and presents an efficacy of 53.6% against severe diarrhoea during the first 
year and 48.9% during the second year (Bhandari et al., 2014a; Bhandari et al., 
2014b). It was modelled to have a substantial impact on RV-related mortality and 
morbidity in India directly due to vaccination and not herd immunity, with 
introduction being cost-effectiveness (Rose et al., 2017). This vaccine has now 
received WHO prequalification status making it available for procurement by 
agencies such as UNICEF or GAVI for use in low and middle-income countries 
(LMIC) (PATH, 2018).  
1.10.3.4 RotaSIIL
®
 
This vaccine was co-developed by the Serum Institute of India and the USA 
National Institute of Allergy and Infectious Diseases and the Programme for 
Appropriate Technology in Health (PATH) as a pentavalent human-bovine 
reassortant. Several studies have shown an efficacy >60% at protecting against 
severe RVGE in infants in Niger and have deemed the vaccine safe (Isanaka et al., 
2017; Coldiron et al., 2018). Recently, it has shown safety and immunogenicity 
similar to Rotarix
® 
(Rathi et al., 2018). It has been licensed in India since 2016 and 
was granted WHO prequalification status in September 2018 (PATH, 2018b).   
1.10.4 Live-attenuated vaccines in development 
1.10.4.1 RV3-BB rotavirus vaccine  
RV3-BB is an oral, live-attenuated, monovalent human G3P2[6] strain 
isolated from an asymptomatic child in Australia, developed by PT Biofarma 
(Indonesia), Murdoch Children’s Research Institute (Australia) and DynCorp (USA). 
The vaccine is designed with a view of administration to neonates (Bishop et al., 
1983). It is a naturally-attenuated RV strain that replicates despite maternal sIgA 
present and provides heterotypic protection against severe disease by other human 
strains (Chen et al., 2017). It has been shown to be well tolerated and immunogenic 
(Danchin et al., 2013; Bines et al., 2015). RV3-BB has been shown to have an 
efficacy of up to 75% in neonates in Indonesia.  
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1.10.4.2 UK-based reassortants (UK-BRV) (NIH)  
UK-Compton bovine rotavirus vaccine (UK-BRV) is an oral, live-attenuated, 
quadrivalent, human-bovine reassortant developed by several manufacturers, such as 
Butantan, Brazil; Wuhan & Chengdu, China; SSI, India; Shanta, Biologicals E, 
Bharat, India. It originally contained the G6P[5] bovine backbone plus the human G 
types G1, G2, G3, G4, and later G types G8 and G9 were also added. The first UK-
BRV reassortants are well tolerated, safe, immunogenic and efficacious (Clements-
Mann et al., 1999, 2001; Kapikian et al., 2005; Vesikari, Karvonen, et al., 2006). 
The resassortant manufactured by the Serum Institute of India was safe, 
immunogenic and efficacious (Zade et al., 2014). The development of several 
candidate UK-BRV reassortants was stopped due to market competition from the 
oral rotavirus vaccines currently licensed.  
1.10.5 Non-replicating vaccines 
Non-replicating vaccines are developed to improve safety (e.g. 
intussusception related to early live attenuated rotavirus vaccines, reversion to 
virulence in the immunocompromised recipient or following transmission to 
immunocompromised or susceptible contacts or contamination with adventitious 
viruses), as well as efficacy and effectiveness (which are low in LIMCs). They may 
also be used in combination vaccines, be administered following a different dosing 
schedule and may be more cost-effective in LIMCs (cost of live-attenuated vaccines 
still high).  
1.10.5.1 P2-VP8* protein subunit vaccine 
P2-VP8* is a non-replicating RV vaccine (NRRV) that contains a 
recombinant VP8* subunit RV from G1P[8] (Wa) strain or human P types P[4] or 
P[6] fused to the tetanus toxin P2 CD4 epitope (Wen et al., 2012). It was developed 
by PATH and the USA National Institutes of Health (NIH). It was designed for 
parenteral administration. P2-VP8* was safe, highly immunogenic (homotypic and 
heterotypic immunity in guinea pigs) and highly efficacious against severe RVGE 
(Wen et al., 2012, 2015; Clinicaltrials.gov, 2013; Fix et al., 2015). In humans, it was 
well tolerated and immunogenic in healthy toddlers and infants (Clinicaltrials.gov, 
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2014, 2016b; Groome et al., 2017). A Phase III superiority trial against the 
comparator (Rotarix
®
) will commence soon in three African countries (Malawi, 
Ghana, Zambia) and India (Clinicaltrials.gov, 2019).  
1.10.5.2 Inactivated rotavirus vaccine (IRV)  
CDC-9 is a heat-inactivated monovalent strain G1P[8], generated by the USA 
Centers for Disease Control and Prevention. It was grown in Vero cells, heat-
inactivated and formulated with aluminium phosphate (Jiang, Gentsch and Glass, 
2008; Esona et al., 2010). Studies in mice, guinea pigs and gnotobiotic piglets 
indicated it was immunogenic when administered intramuscularly (Wang et al., 
2010; Jiang, Wang and Glass, 2013) and it can be administered intradermally (Moon, 
Wang, et al., 2013; Wang et al., 2016). This candidate vaccine induced mucosal 
immunity in mice (Resch et al., 2018) and it is still in pre-clinical stages with a Phase 
I trial set up yet to be established (Steele, Kirkwood and Ma, 2018).  
1.10.5.3 RV subunits and virus-like particles (VLPs) 
Mice immunised with chimeric VP6 and an adjuvant were protected against 
shedding and did not require intestinal IgA (Choi et al., 1999; McNeal et al., 2006). 
MBP:VP6 candidate was immunogenic and protective in mice (Ward and McNeal, 
2010). A combination of RV recombinant VP6 and norovirus VLPs have been shown 
to elicit immune responses able to inhibit viral replication both in vitro and in vivo in 
mice (Lappalainen et al., 2014) and RV nanostructures have been shown to act as 
local adjuvants in combination with norovirus VLPs (Malm et al., 2017). They have 
also been shown to induce heterogeneous CD4
+
 T cell subsets (Heinimäki et al., 
2018). 
VLPs have been designed as candidate vaccines as triple-layered or double-
layered and tested in mice for immunogenicity (Bertolotti-Ciarlet et al., 2003; 
Lappalainen et al., 2015). Human VLPs have been tested in the gnotobiotic pig 
model of human RV disease, generating immunogenicity and protection in 
combination with an oral attenuated human RV (Azevedo et al., 2013). Although in 
discovery phase, rotavirus VLPs may provide an advantage as next generation 
vaccine in terms of covering the genotypes by region and triggering both cellular and 
humoral immune responses (Changotra and Vij, 2017).  
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Rotavirus vaccines summary 
The rotavirus vaccines previously described are summarised in Table 1. 2. 
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1.11 Vaccine efficacy and effectiveness 
Rotavirus vaccines have had reduced impact in low-income countries (LICs) 
compared to developed countries with respect to vaccine efficacy (Ruiz-Palacios et 
al., 2006, 2007; Vesikari et al., 2007; Linhares et al., 2008; Madhi et al., 2010; 
Vesikari, 2012; Bhandari, Rongsen-Chandola, Bavdekar, John, Antony, Taneja, 
Goyal, Kawade, Kang, Rathore, Juvekar, Muliyil, Arya, Shaikh, Abraham, Vrati, 
Proschan, Kohberger, Thiry, Glass, Harry B Greenberg, et al., 2014; Liu et al., 2014; 
Jonesteller et al., 2017; Velázquez et al., 2017; Bar-Zeev et al., 2018) and rotavirus 
infection remains the main cause of severe infantile gastroenteritis, with the greatest 
impact on infant mortality and morbidity in LICs. Several factors related to the 
specific immune response to the vaccine, their induced global immune response and 
epidemiology of RV influence the reduction and prevention of disease in vaccinated 
individuals.  
1.11.1 Vaccine-specific host immune response 
The main factors related to rotavirus vaccine virus reaching the gut 
epithelium and being able to infect mature enterocytes are described below. It is 
believed that early vaccination may improve vaccine immunogenicity (Bhan et al., 
1993; Bines et al., 2015, 2018; Vesikari, 2015; Cowley et al., 2017).   
1.11.1.1 Maternal antibodies and breast milk 
Babies acquire antibodies from their mothers transplacentally, mainly IgG, 
that remain at similar titres to those in the mother’s serum for one to six months and 
may interfere with oral rotavirus vaccination (Becker-Dreps et al., 2015; Moon et al., 
2016; Parker, Ramani, et al., 2018). Although the placenta does not allow for IgA 
transfer, newborns can acquire IgA when breastfed (Patel et al., 2009; Parker, 
Ramani, et al., 2018). If maternally-acquired antibodies are neutralizing for rotavirus, 
they would likely target RV vaccine virus together with receptor analogues present in 
breast milk (lactadherin), inhibiting the vaccine virus replication (Morrow et al., 
2005; Patel et al., 2009; Moon et al., 2010; Parker, Ramani, et al., 2018). The effect 
of breastfeeding on vaccine efficacy and effectiveness is not well elucidated. While 
some studies had observed lower immunogenicity in breastfed infants (Pichichero, 
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1990; Glass et al., 1991; Rennels, 1996; Dennehy et al., 2005), others testing the 
effect of withdrawal of breastfeeding around vaccination observed no improvement 
on vaccine effectiveness (Groome et al., 2014; Rongsen-Chandola et al., 2014; Ali et 
al., 2015). The theory that breastfeeding inhibits vaccine virus is currently not 
supported because a reduction in immunogenicity has been observed at a 
group/population level but not at the individual level (Patel et al., 2009). Moreover, 
breastfeeding is important for regulatory T cell activation in infants (M’Rabet et al., 
2008), since breast milk contains factors that may buffer the virus from stomach acid 
and allow it to travel to the small intestine (Rennels, 1996) and it contains binding 
oligosaccharides and other immunoglobulins that are protective against different 
enteric pathogens (Bilenko et al., 2008; Cacho and Lawrence, 2017).  
1.11.1.2 Stomach acid  
Because low pH can inactivate rotavirus (Weiss and Clark, 1985), Rotarix
®
 
contains a buffer (calcium carbonate) to neutralise stomach acid (EMA, 2008; Lal 
and Jarrahian, 2017). However, stomach acid levels may vary in different 
populations (Patel et al., 2009) and so vaccination may be less effective in those 
populations with higher stomach pH levels, important for protection against 
salmonellosis, cholera and other bacterial infections.  
1.11.1.3 Microbiome 
At birth, the gastrointestinal tract is colonised by commensal bacteria that are 
different depending on mode of child delivery, subsequent feeding (breast milk, 
formula-fed; solid food diet) and any use of antibiotics (Dominguez-Bello et al., 
2010; Dzidic et al., 2018). The composition of the human microbiota changes with 
age; it stabilises and becomes differentiated around the age of 3-5 years, and this 
composition is strongly influenced by geographical location and diet (Dzidic et al., 
2018). In the case of rotavirus, susceptibility to infection may be partly influenced by 
certain gut bacteria (and viruses). For instance, in a small adult cohort in Spain, a 
negative correlation of Faecalibacterium and Ruminococcaceae with susceptibility 
to RV infection and a positive correlation of Akkermansia with susceptibility to RV 
infection were inferred from IgA titres in saliva (Rodríguez-Díaz et al., 2017). In a 
study in vaccinated adults, antibiotics did not alter absolute RV-specific IgA titres 
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but they were associated with an increase in RV-specific IgA boosting and RV faecal 
shedding at day 7 (Harris, Haak, et al., 2018). In a small study in Ghana, it was found 
by the same group that the infant Bacteroidetes phylum correlated positively and 
bacteria such as Streptococcus bovis correlated negatively with RV vaccine 
immunogenicity (Harris et al., 2017). In another small cohort study by that group, in 
Pakistan, it was found that infant Proteobacteria correlated with RV vaccine 
immunogenicity, although the control group were assumed to be high vaccine 
responders but had not been given the vaccine  (Harris, Ali, et al., 2018). In another 
study in infants in India, however, a modest correlation was found between 
microbiota richness and Rotarix
®
 shedding (Parker, Praharaj, et al., 2018).  
1.11.1.4 Oral poliovirus immunisation 
Co-administration of live-attenuated oral poliovirus vaccine (OPV) with 
Rotarix
®
 has been observed to lower seroconversion of rotavirus vaccination in 
developing settings such as South Africa and Bangladesh, where OPV was mainly 
used (Patel, Steele and Parashar, 2012). OPV is thought to outcompete rotavirus 
vaccine replication after the first dose, while after subsequent RV doses the 
interference is overcome. In other settings in Latin America, OPV presented no 
interference with Rotarix
® 
efficacy (Patel, Steele and Parashar, 2012). In Malawi, no 
interference with Rotarix
®
 shedding was observed and shedding of OPV showed 
common patterns with the response to Rotarix
®
 (Pollock, 2018). In 2012, the WHO 
recommended the inactivated poliovirus vaccine (IPV) to gradually substitute OPV 
due to the risk of vaccine-derived polio higher than the benefits of OPV vaccination 
(WHO, 2012), therefore potentially reducing the risk of OPV interference with 
rotavirus vaccination in those settings where IPV vaccination has been implemented.  
1.11.1.5 Host genetic polymorphism 
Common genetic polymorphisms determining RV susceptibility could 
contribute to population differences in vaccine efficacy as well as RV epidemiology. 
Genetic polymorphisms in HBGAs are encoded by fucosyltransferase genes such as 
FUT2 and FUT3, which define secretor status and Lewis antigen status respectively. 
Interactions of rotavirus with HBGA depend on the VP4 genotype, with binding 
depending on strain. Recently, it was found that the presence of fucosylated ligands 
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was related to susceptibility to RV-genotype-specific infection and that lack of 
fucosylated ligands on HBGAs was associated with resistance to GE caused by P[8] 
RVAs (Imbert-Marcille et al., 2014; Nordgren et al., 2014; Barbé et al., 2018). 
However, in LMICs such as Malawi, secretory and Lewis status did not predict 
vaccine (Rotarix
®
) uptake, although non-secretor phenotype was associated with a 
lower risk of vaccine failure (Pollock et al., 2018). This counterintuitive finding can 
be explained by G1P[8] strains being the most prevalent in Malawi, and non-
secretors having a degree of natural resistance to severe disease associated with this 
RV genotype. Non-secretors in Malawi were susceptible to infection by G1P[8] RV, 
shedding virus at lower levels than secretors and they were significantly resistant to 
severe GE (Pollock et al., 2018). In Nicaragua, it was found that a small proportion 
of Rotarix
®
 vaccinees of secretor phenotype remained susceptible to RVGE, while 
non-secretors completely resisted RVGE (Bucardo et al., 2018). Moreover, they 
recently found that non-secretors did not shed vaccine virus following Rotarix
®
 
vaccination (Bucardo et al., 2019).  
1.11.1.6 Gastrointestinal tract infection/inflammation 
Infants in developing countries may present a high proportion of 
enteroviruses at time of vaccination, which has been shown to influence OPV 
vaccine take and RV vaccine take slightly, potentially by binding to neighbouring 
receptors to the poliovirus receptor and prevent attachment and entry into target cells 
(Parker et al., 2014; Naylor et al., 2015; Taniuchi et al., 2016). Moreover, in these 
settings, environmental enteric dysfunction (EED) or ‘environmental enteropathy’ is 
a common subclinical condition that causes flattening of the villi, malabsorption and 
intestinal inflammation in infants, who then present with altered GI immunity 
(Parker, Ramani, et al., 2018). The immune response to rotavirus vaccination was 
found to be decreased under EED caused by enterovirus infection, likely due to the 
difficulty to replicate in a gut with an active antiviral state (Taniuchi et al., 2016).  
1.11.2 Global host immune response 
The factors related to the infant’s immune system state are described below. 
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1.11.2.1 Malnutrition 
The nutritional state affects susceptibility to RV (Colgate et al., 2016) and 
other enteric infections, having a large effect in morbidity in the under-5s in 
developing countries (Caulfield et al., 2004). Vitamin A and zinc supplementation 
have helped prognosis of diarrhoeal disease and prevented mortality (Ching et al., 
2000; Aggarwal, Sentz and Miller, 2007). In Bangladesh, a negative correlation was 
found between levels of malnutrition and rotavirus infection, although authors 
mention other factors may have influenced rotavirus transmission (Das et al., 2017). 
However, others have not found a correlation between malnutrition and rotavirus 
vaccine uptake (Parker, Ramani, et al., 2018).  
1.11.2.3 Co-infections (HIV, malaria, TBC)  
Susceptibility to RV infection may increase in the case of certain co-
infections. Mostly in developing countries, there may be concurrent enteric 
pathogens, viral (poliovirus, non-polio enteroviruses) or non-viral (Escherichia coli, 
Salmonella, Campylobacter, Helicobacter pylori, helminths), and other systemic 
pathogens, such as HIV, malaria or tuberculosis, affecting RV susceptibility and 
vaccine uptake (Patel et al., 2009; Parker, Ramani, et al., 2018).  
1.11.3 Viral epidemiology  
Vaccines that provide stronger homotypic than heterotypic protection will 
likely result in an increase of heterotypic strains and those which provide as strong 
heterotypic immunity will likely result in maintenance of the homotypic strain (Pitzer 
et al., 2011). In the first instance, vaccination may result in a greater reduction in 
vaccine efficacy against heterotypic strains over time, affecting LMICs where 
uncommon RV types circulate (Santos and Hoshino, 2005).  
Moreover, exposure to the vaccine target by undergoing a WT infection 
before vaccination may affect vaccine immunogenicity and prevent seroconversion 
(Groome et al., 2014; Becker-Dreps et al., 2015; Chilengi et al., 2016; Moon et al., 
2016). This would appear to be especially relevant in developing countries, where 
neonates are usually exposed to WT rotavirus prior to vaccination due to a RV strong 
force of infection (rate at which susceptible individuals acquire an infectious disease) 
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(Chilengi et al., 2016; Parker, Ramani, et al., 2018). The levels of its force of 
infection, as well as the viral loads, may affect vaccine efficacy if the threshold of 
immunity generated by the vaccine is overcome by the intensity of transmission or 
amounts of infectious virus (Parker, Ramani, et al., 2018).  
1.12 Rotavirus vaccine implementation worldwide 
In 2006, the WHO recommended the implementation of rotavirus vaccination 
in North and South America and in Europe (WHO, 2006). It was first introduced in 
Mexico (Rotarix
®
) and the USA (RotaTeq
®
) in 2006 (the USA introduced Rotarix
®
 
in 2008), followed by other countries in Latin America and Europe. Between 2006 
and 2010, 27 countries implemented rotavirus vaccination in their NIPs (Patel et al., 
2011). In 2009, the WHO extended recommendation to worldwide vaccination 
(WHO, 2009, 2013). While some of the countries that bear the highest disease 
burden have introduced vaccination, such as Afghanistan, Angola, Ethiopia, India, 
Kenya and Pakistan (Tate et al., 2012; RotaCouncil, 2018), others have yet to 
introduce the vaccine, including Chad, the Democratic Republic of Congo, Niger and 
Nigeria (Tate et al., 2016; RotaCouncil, 2018). These countries face difficulties in 
rolling out rotavirus vaccination due to large birth cohorts, financial challenges to 
commit to GAVI-funding if eligible, costs of purchasing the vaccine if GAVI-
funding-ineligible and suboptimal logistics of cold-chain storage and transport (Deen 
et al., 2017).  
To date, rotavirus vaccines have been introduced in 98 countries worldwide: 
92 NIPs, and 6 sub-national introductions (Figs. 1.11 & 1.12; RotaCouncil, 2018; 
ViewHubRV, 2018b). Worldwide coverage is <80% in 30 countries and >80% in 60 
countries (ViewHubRV, 2018c), with 70 million children lacking access to rotavirus 
vaccines (RotaCouncil, 2018; ViewHubRV, 2018a) due to vaccine costs and logistics 
(Abou-Nader et al., 2018). 
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Fig. 1.11. Rotavirus national vaccine introduction worldwide, by geographic 
region, May 2016. A total of 81 countries had introduced rotavirus vaccination, 
either GAVI-eligible (in indigo) or non-GAVI eligible (in green). GAVI, global 
alliance for vaccines and immunization; PATH, Programme for appropriate 
technology in health. From Vaccineresources.org, 2016.  
 
 
 
Fig. 1.12. Rotavirus vaccine introduction worldwide, August 2018. A total of 96 
countries have introduced rotavirus vaccination: 89 national introductions, three 
ongoing phased introductions and four pilot or sub-national introductions. From 
RotaCouncil&ViewHubRV, 2018.    
 
Following vaccine introduction, there was a large reduction in disease burden 
in many countries worldwide, with deaths from all causes of diarrhoea reduced by 
17-55% and rotavirus-related hospitalizations reduced by 49-92% (M. M. Patel et al., 
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2012; Tate and Parashar, 2014) and a decrease in nosocomial cases (Zlamy et al., 
2013). There has also been observed indirect protection of neonates, ineligible 
unvaccinated young infants, older children (two to five-year-old) and the elderly 
(Lopman et al., 2011; Prelog et al., 2016), as well as shortening of the rotavirus 
season and lower seasonal peaks (Tate et al., 2013).  
1.12.1 UK national vaccination programme 
The United Kingdom (UK) implemented a national vaccination programme 
in July 2013 for infants of 8 and 12 weeks of age using Rotarix
® 
(Iturriza-Gómara 
and Cunliffe, 2013; Gov.uk, 2014). Now, at 2 months old, as well as Rotarix
®
, all 
children concomitantly receive a licensed diphtheria, tetanus, pertussis, inactivated 
polio, Haemophilus influenzae type b conjugate vaccine (DTaP/IPV(polio)/Hib) 
(Pediacel
®
 or Infanrix IPV Hib
®
), a pneumococcal conjugate vaccine (PCV) 
(Prevenar 13
®
) and a meningitis B vaccine (Bexsero
®
), and depending on year, some 
also receive the meningococcal group B vaccine (Fig. 1.13). In the UK, IPV has been 
administered instead of OPV since 2004. At 3 months old, infants receive the second 
dose of Rotarix® and the second dose of DTaP/IPV/Hib and, depending on year, 
some also received the meningococcal group C vaccine and the hepatitis B vaccine. 
Rotarix® is the only oral vaccine in the current UK childhood NIP.   
Between 600,000 and 700,000 children were born every year between 2013 
and 2017 in the UK (ONS, 2018). Vaccination coverage was 87.5% for both doses in 
the first year after vaccination introduction (PHE, 2014), 88.1% in the second year 
after vaccine introduction (PHE, 2015) and 88.9-89.7% in the third year (PHE, 
2016a, 2016b), with more than half a million infants vaccinated per year in the UK.  
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Fig. 1.13. Routine childhood immunisation programme in the UK 2013-2018. 
(A) 2013-2014, (B) 2015-2016 and (C) 2017-2018. Vaccinations in grey if infants at 
risk. BCG, Bacille Calmette Guerin vaccine; DTaP, diphtheria, tetanus and pertussis 
vaccine; HBV, Hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; 
IPV, inactivated poliovirus vaccine; Men B, meningococcal group B vaccine; Men 
C, meningococcal group C vaccine; MMR, measles, mumps and rubella vaccine; 
PCV, pneumococcal conjugate vaccine. Constructed with data from Gov.uk, 2018a, 
2018b. 
 
A 77% reduction in cases of RV infection in the UK was recorded in the first 
year after vaccine implementation (Atchison et al., 2016). Concomitantly, there was 
also a reduction in cases in older children (63%), adults and elderly people (42% of 
all averted all-cause severe GE-associated hospital admissions) (Atchison et al., 
2016), probably due to herd immunity and/or reduced carriage and hence lower 
exposure to the virus. The implementation of the vaccination programme has been 
estimated to save the UK National Health Service around £12.5 million in the first 
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year after vaccination introduction through prevented primary care, emergency 
department visits and hospitalisations (Thomas et al., 2017).  
1.13 Adventitious agent in Rotarix
®
 
Rotarix
®
 and RotaTeq
®
 are live-attenuated vaccines grown in cell lines 
utilising trypsin derived from pig intestines (EMA, 2006, 2008) used to activavte 
rotavirus by generating a conformational change in the spike protein that allows cell 
penetration (section 1.2.5, Figs. 1.5 & 1.6). Victoria and colleagues identified DNA 
and viral particles of porcine circovirus 1 (PCV1) in Rotarix
®
 using next generation 
sequencing (NGS) (Victoria et al., 2010) and viral particles were confirmed soon 
after (Howe et al., 2010). Following these findings, DNA -but not infectious virus- 
from PCV1 and PCV2 was identified in the other globally licensed rotavirus vaccine 
RotaTeq
®
 (Ranucci, Tagmyer and Duncan, 2011). The use of trypsin points to the 
source of this contamination (Baylis et al., 2011; Ma et al., 2011; Dubin et al., 2013).  
PCV1 is an icosahedral, non-enveloped, single-stranded, circular DNA virus 
from the family of Circoviridae and genera Circovirus (Tischer, Rasch and 
Tochtermann, 1974; Mankertz et al., 1997) (Fig 1.14). Circoviruses are the smallest 
viruses that replicate in mammalian cells: the PCV1 virion is just 17 nm in diameter. 
PCV1 presents a circular genome that is 1,768 bp long and very compact: there is an 
intergenic region flanked by two open reading frames (Fig 1.15). The cap gene 
encodes the structural protein forming the capsid and the rep gene encodes two 
replicases, both required for DNA replication and able to initiate replication at the 
origin of replication of PCV2 (Mankertz and Hillenbrand, 2001; Mankertz et al., 
2004). Although circoviruses have been found in stool of adults and pork products in 
the USA (Li et al., 2010), PCV1 has not been found to be infectious in humans to 
date. PCV1 infects pigs, although no disease has been associated with infection.  
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Fig. 1.14. PCV1 virion. Capsid protein in green, core in blue and single-stranded 
DNA (ssDNA) in orange. Adapted from ViralZone, 2008.   
 
 
 
 
Fig. 1.15. PCV1 genome linear map. Open reading frames for capsid protein (cap) 
and replicase (rep) indicated in green and blue respectively, with transcription 
direction indicated by triangles. The intergenic region contains the origin of 
replication, with a stem loop and hexamer repeats. Bold letters indicate the binding 
site for replication initiator proteins Rep and Rep’. Reproduced from Mankertz et al., 
2004, with permission from first author.  
 
PCV2 is a closely related porcine circovirus, with 75% sequence identity 
(Meehan et al., 1998), but belonging to a different phylogenetic cluster from PCV1 
(Allan et al., 2012). PCV2 was identified in the 1990’s for the first time as the agent 
causing post weaning multi-systemic wasting syndrome (PMWS) in pigs (Meehan et 
al., 1997, 1998; Mankertz and Hillenbrand, 2002). The mechanism of PCV2 
pathogenicity is unknown to date (Mankertz, 2012). The genome of a new circovirus 
named PCV3 was recently identified in pigs with cardiac and systemic inflammation 
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(Phan et al., 2016). The replicase of PCV3 and capsid proteins is distantly to those of 
PCV1 and PCV2. 
Contamination of Rotarix
®
 with PCV1 is believed to have originated from the 
porcine-derived trypsin used to subculture cells and/or activate RV in order to infect 
the Vero cells in an early stage of vaccine production (Ma et al., 2011). PCV1 may 
have established chronic infection in Vero cells since the trypsin used in the master 
bank in 1983 was not irradiated (Dubin et al., 2013). When this unintended 
contaminant was identified, GSK tested the vaccine derived from all stages of the 
manufacturing process. Presence of PCV1 DNA and low levels of PCV1 viral 
particles were found up to the stage of vaccine final fill (Table 1.2, Howe et al., 
2010). Sequencing of the contaminant PCV1 viral genome revealed two mutations in 
the cap (viral capsid) gene region: mutation A222G results in a non-conserved amino 
acid substitution (I172T), while the T706G mutation is ‘silent’ (R11R) (McClenahan, 
Krause and Uhlenhaut, 2011; Gilliland et al., 2012; Dubin et al., 2013). These 
mutations may have occurred as a result of virus adaptation to the Vero cell line 
where the vaccine virus was generated, and their significance is currently unknown. 
To that point, PCV1 infection assays in human cell lines had not shown any 
infectious capability (Mankertz et al., 2003; Hattermann et al., 2004; Baylis et al., 
2011; Kumar et al., 2012; Mankertz, 2012). At the time, there was no immunological 
evidence of PCV1 infection in vaccinated infants. Therefore, GSK stated that PCV1 
was non-infectious in humans, a position which was supported by the USA Food and 
Drug Administration (FDA) (Kuehn, 2010), the WHO (WHO, 2010) and the 
European Medicines Agency (EMA) (EMA, 2010). Nevertheless, GSK initiated the 
development and manufacture of a PCV1-free Rotarix
®
 vaccine (Dubin et al., 2013; 
GSK personal communications to the NIBSC, 2018; GSK personal communications 
at the 8
th
 European Rotavirus Biology Meeting, 2019).  
 
Table 1.3. PCV1 DNA in Rotarix
®
 vaccine during manufacturing by GSK. 
Copies/mL were measured by qPCR in viral harvests, purified bulks and final 
containers (Howe, B., et al., 2010. Rotarix
®
 GSK’s PCV1 Investigation).  
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Since then, PCV1 viral loads in infants vaccinated with Rotarix
®
 have been 
measured by quantitative PCR (qPCR) in stool, with no increase in viral loads found 
for the period of shedding, suggesting there was no replication of PCV1 and only 
transient passage through the gastrointestinal tract (Mijatovic-Rustempasic et al., 
2017). PCV1 serologic response in infants vaccinated with Rotarix
®
 has been 
measured by ELISA in their serum with an antibody seropositivity rate very similar 
in vaccinees and placebo (Han et al., 2017). However, the current vaccine is 
administered to several hundred thousand infants every year in many countries and 
there is inconclusive evidence (Baylis et al., 2011; Beach et al., 2011) on whether 
PCV1 can replicate in humans. PCV1 might become infectious in humans if the 
changes it undergoes in cell culture adaptation alter its pathogenicity, with health 
issues potentially similar to those caused by PCV2. Therefore, further studies about 
PCV1 shedding in vaccinees and confirming the lack of replication in humans were 
required to respond to concerns regarding vaccination of children with weaker 
immune systems (undiagnosed at the time of vaccination).  
1.14 Rotarix
®
 vaccine faecal shedding  
Rotarix
®
 contains ≥106 CCID50/mL of RV (EMC, 2018) and approximately 
10
7
 genome copies/mL of vaccine dose (Mijatovic-Rustempasic et al., 2017). In 
clinical trials, several patterns of viral shedding after vaccination with Rotarix
®
 have 
been found (Table 1.3) and Rotarix
®
 shedding reported through clinical trials has 
been related to younger age (infants), lack of pre-existing rotavirus antibodies and a 
higher vaccine dose (Anderson, 2008). As indicated in Table 1.3, vaccine virus 
shedding is more common after dose 1 than after dose 2, perhaps owing to a level of 
immunity developing after the dose 1 and shedding after dose 2 appearing as a catch-
up effect in the absence of increased titres. While numbers vary between cohort 
studies, typically around 40-80% of vaccinated infants shed virus at day 7 after dose 
1 and up to approximately 25% shed at day 7 after dose 2. In some of the trials, 
horizontal transmission of Rotarix
®
 shed in stool has been reported, with a potential 
for herd immunity (vaccine virus transmitted) as well as for infection of 
immunocompromised individuals (vaccine-derived variant transmitted) (Anderson, 
2008). 
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1.15 Genetic stability of a live-attenuated RV vaccine  
Live-attenuated vaccines are inexpensive and generally safe, as well as highly 
effective against disease in individuals with a functional immune system (Minor, 
2015). However, they can acquire mutations during manufacture or during 
replication in vaccinated individuals (Hanley, 2011), with a potential to alter its 
phenotype, as well as the immune responses elicited in vaccinees. Examples of 
vaccines that became virulent causing disease after replicating in vaccine recipients 
are OPV reverting to wild type (Cann et al., 1984; Minor, 1993; Chumakov, 1999; 
Kew et al., 2005; Burns et al., 2014; Famulare et al., 2016) and genetically unstable 
live-attenuated HIV-1 strain deletants (Berkhout et al., 1999). Other examples are a 
study on a mumps vaccine that resulted in chronic encephalitis in an 
immunocompromised child (SCID-diagnosed after vaccination) after allogeneic 
transplantation (Morfopoulou et al., 2017) or a varicella zoster virus that became 
virulent in immunocompromised vaccine recipients (Willis et al., 2017).  
In the case of Rotarix
®
, despite clinical trials addressing vaccine safety and 
immunogenicity, the genetic changes that confer attenuation to the vaccine virus are 
not well characterised. It was suspected that amino acid substitutions in the VP4 
fusion domain (amino acid 385) and another amino acid substitution in NSP4 
(T45M) are probably correlated with a loss of virulence in humans (Tsugawa and 
Tsutsumi, 2016). Other studies have pointed at sites undergoing positive selection 
and sites differing from circulating G1P[8] RV in Belgium by Sanger sequencing, 
theoretical models and NGS (Zeller et al., 2012, 2015, 2017). However, it is 
unknown whether attenuation of Rotarix
®
 is due to a few mutations or an epistatic 
effect of several mutations. Rotavirus vaccination with a live-attenuated strain may 
allow for genetic variation of the vaccine through replication in vaccine recipients, 
potentially affecting immunogenicity, efficacy and virulence. On the other hand, the 
introduction of a live-attenuated vaccine may also impact on circulating WT RV 
dynamics, by exerting selective pressure on vaccine types and potentially leading to 
the emergence or re-emergence of novel or rare strains which could affect 
vaccination efficacy and/or lead to disease. Hence, it is of importance to monitor the 
stability and consistency of vaccine batches during manufacture as well as to monitor 
the vaccine shed by vaccine recipients in order to evaluate whether vaccine virus 
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may accumulate changes that would impact on infectivity, virulence or 
immunogenicity.  
Identification of single nucleotide polymorphisms (SNPs) at high and low 
frequencies has allowed the study of genetic diversity and minority variants in live-
attenuated vaccine populations (Peters et al., 2012; Bidzhieva et al., 2014; Depledge 
et al., 2014; Zapata et al., 2014; Majid et al., 2015; Jeon et al., 2016; Beck et al., 
2018; Riemersma et al., 2018). Because quasispecies appear usually at low 
frequency levels, they are difficult to detect by Sanger sequencing accurately if they 
are below 10-25% in an heterogeneous viral population (Leitner et al., 1993). 
However, high-throughput sequencing technologies allow the study of minority 
variants avoiding the time-consuming cloning followed by Sanger sequencing. Next 
generation sequencing is used to study intra-strain virus diversity and temporal 
evolution of variants, as well as the dynamics and emergence of escape mutants 
under different types of pressure. NGS has been used to identify minority variants 
and potential adventitious agents within live attenuated vaccines (Victoria et al., 
2010; Watson et al., 2013; Isakov et al., 2015).  
1.16 Rotarix
®
 vaccine correlates of protection 
Correlates of protection for current rotavirus vaccines are also not well 
defined. Differences in vaccine efficacy have been observed in developed (high) 
versus developing (low) countries and many factors may contribute to the difficulty 
in defining robust correlates (section 1.11). Currently, it is impractical to predict 
individual protection as a follow-up of 12 to 18 months is needed to determine 
protection (Coulson et al., 1990). 
Serum IgA as a correlate of protection has been investigated: heterotypic 
antibodies may be protective against common RV types (Green et al., 1990) and 
vaccine-induced serum Abs have appeared to be protective against WT infection 
(Jiang, Gentsch and Glass, 2002). Moreover, Rotarix
®
 seroconversion has been 
related to protection against RVGE (Vesikari, Karvonen, Puustinen, et al., 2004) and 
seroconversion rates have been observed to be >60% at two months after dose 2 
(Salinas et al., 2005). Serum IgA has been observed to correlate with vaccine 
efficacy at population level (Patel et al., 2013). Later, seropositivity of anti-RV IgA 
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after Rotarix
®
 vaccination was associated with a reduction in severe RVGE, although 
a proportion of the seronegative subjects were also protected (Cheuvart et al., 2014). 
In a recent study in Bangladesh, serum RV-specific IgA responses have appeared to 
correlate in a suboptimal manner with protection (Lee et al., 2018). In contrast, 
serum IgA was correlated with protection against disease in studies in Finland and 
Latin America (Ward, 1996; Velázquez et al., 2000; De Vos et al., 2004) and anti-
VP4 and anti-VP7 serum NAbs have been observed to generate heterotypic 
immunity (Johansen and Svensson, 1997). Specific anti-RV IgA seroconversion has 
shown no correlation with protection against severe RVGE in the first year after 
vaccination (Angel, Franco and Greenberg, 2012). Of note, Rotarix
®
 generates 
heterotypic immunity, protecting against other RV types (Angel, Franco and 
Greenberg, 2012). Apart from NAbs anti-VP7 and anti-VP4 homotypic protection, 
heterotypic protection is also induced by vaccination, similarly for Rotarix
®
 and 
RotaTeq
®
 and beyond strain variation worldwide (Clarke and Desselberger, 2015). 
Specific anti-RV IgA bound to secretory component has recently been correlated 
with protection against RVGE (Herrera et al., 2013). Specific, non-NAbs anti-VP6 
have been detected after vaccination in humans (Svensson, Sheshberadaran, 
Vesikari, et al., 1987; Lappalainen et al., 2017) and demonstrated protective effects 
in mice (Burns et al., 1996; Corthésy et al., 2006; Lappalainen et al., 2015). VP6 
might be transcytosed via the polymeric Ig receptor and may “expulse” RV into the 
gut lumen or it may inhibit transcription intracellularly (Thouvenin et al., 2001; Feng 
et al., 2002; Aiyegbo et al., 2013, 2014). Mucosal specific anti-VP6 IgA has been 
found to inhibit viral replication in vitro and in vivo (Lappalainen et al., 2014). 
Moreover, anti-VP6 antibody fragments have been found to be protective against 
infection and severe disease in the neonatal mouse model (Maffey et al., 2016). 
Specific anti-VP6 IgA are the most common antibodies produced by B cells  
(Weitkamp et al., 2003, 2014). Since most copro-IgA is composed of anti-VP6 non-
NAbs, anti-VP6 intracellular antibodies may be the most appropriate correlate of 
protection in infants. 
Research so far has shown that serum specific anti-RV IgA is the preferred 
marker of rotavirus vaccine immunogenicity, since it correlates with vaccine efficacy 
at a population level in developed countries (Patel et al., 2013). However, in studies 
of vaccine immunogenicity, specific anti-RV copro-IgA is a good correlate at high 
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levels and the most widely accepted for severe RVGE protection (Desselberger and 
Huppertz, 2011).  
1.17 Summary 
Rotavirus vaccination has been successful in reducing RV-associated 
mortality worldwide, however, questions remain around the extent of replication in 
vaccine recipients, the consequences (if any) of the presence of PCV1, the correlates 
of protection and the impact of genetic variation on vaccine kinetics and efficacy. 
Samples tested in clinical trials and clinical settings usually represent cross-sections, 
making investigation of the above issues challenging. However, access to a 
longitudinal set of samples would allow a much more focussed analysis.  
1.18 Hypothesis and aims 
The hypothesis for this study is that childhood rotavirus immunisation would 
result in high-frequency vaccine, revertant and/or novel variants while replicating 
within vaccine recipients. Mutations may appear because of biological immune 
pressure and assessment of the IgA response will contribute to understanding viral 
replication patterns and may indicate whether such changes alter the immune profile. 
The concomitant dispersal of the porcine circovirus found in the vaccine as an 
unintended contaminant could occur in parallel with rotavirus vaccine. We recruited 
a cohort of 12 vaccine recipients and obtained samples immediately before dose 1, 
after dose 1 at varying periods thereafter up until two to three months after dose 2 
and, for some vaccinees, at one year after dose 1.  
To test the hypothesis the work presented hereafter addresses the following 
aims: 
1. Define longitudinal Rotarix® faecal shedding patterns as a surrogate of 
Rotarix
®
 replication in vaccinees.  
2. Evaluate whether PCV1 is amplified in infants through rotavirus 
vaccination. 
3. Assess the genetic stability of faecal Rotarix® by identifying and/or 
quantifying minority variants/quasispecies in the population of vaccinees. 
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4. Assess the host immune response through faecal IgA as a correlate 
measure of protection.  
While cell lines, animal models and HIEs, are excellent systems for the 
dissection of specific mechanisms, the data from this unique cohort of vaccinated 
infants will provide novel insight in the most biologically relevant model: infants. 
Moreover, the analysis of longitudinal samples collected very frequently will provide 
a detailed picture of the kinetics and genetic polymorphisms of rotavirus vaccine in 
vaccinated infants and into their mucosal immune response to the vaccine virus.  
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Chapter 2: Materials and methods 
2.1 Materials 
2.1.1 Manufacturers 
Unless otherwise stated, reagents were of analytical grade and purchased as 
described in Table 2.1.  
 
Table 2.1. Manufacturers and location.  
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2.1.2 Chemicals and reagents 
Table 2.2. Chemicals and reagents, and corresponding manufacturer.  
 
2.1.3 Buffers and cell culture media 
Phosphate buffered saline (PBS) was prepared by the Scientific Support 
Services (SSS) Division at the National Institute for Biological Standards and 
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Control (NIBSC) at a final concentration of 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4 and 1.8 mM KH2PO4 in ultrapure distilled water and adjusted to pH 7.4 
with HCl.  
 
Table 2.3. Buffers used in enzyme-linked immunosorbent assays (ELISAs) and 
corresponding recipes. Reagents in grey tested during optimisation, reagents in 
black used in final testing.  
 
 
Table 2.4. Cell culture media and corresponding recipes. 
 
2.1.4 Kits 
Table 2.5. Kits and corresponding manufacturer.  
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2.1.5 Primers and probes 
Table 2.6. Rotavirus segment-specific cDNA synthesis and standard PCR full-
length primers. 
A 
Adapted from Cho et al. 2013 and 
B 
adapted from Matthijnssens 
et al. 2008 by J. Mitchell (NIBSC). Degenerate primers; R = A/G, W = A/T, Y = 
C/T. Full-length primers generated by J. Mitchell to be used for lamb, porcine and 
human rotavirus, extending before and after Rotarix
®
 coding region (Mitchell, Lui, 
et al., unpublished). *VP3: 38-17 bp before A of start codon; VP4: 64-43 bp before 
A of start codon; VP6: 23-3 bp before A of start codon; VP7: 48-27 bp before A of 
start codon; GENNSP2: 46-27 bp before A of start codon; NSP4: 41-20 bp before A 
of start codon. 
 
 
 
Table 2.7. Rotarix
®
 NSP2 standard PCR primers for TOPO TA cloning. 
Designed by C. Bronowski and M. Iturriza Gómara, the University of Liverpool.   
 
 
Table 2.8. Rotarix
®
 NSP2-specific quantitative PCR assay primers and probe. 
Aligned to Rotarix
®
 NSP2 reference number JX943605 (Gautam et al., 2014). 
 
 
Table 2.9. Pan-rotavirus VP6-specific quantitative PCR assay primers and 
probe. From Mukhopadhya et al., 2013. 
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Table 2.10. PCV1-specific quantitative PCR assay primers and probe. Called 
*PCV1fw and **PCV1rev in original paper (Gilliland et al., 2012).  
 
 
2.1.6 Antibodies 
Table 2.11. Antibodies used in ELISAs.  
 
2.1.7 Miscellaneous  
Table 2.12. Miscellaneous products and corresponding manufacturer. 
 
2.1.8 Vaccine material 
Archived Rotarix
®
 vaccine material was available at the NIBSC for control 
testing purposes and permission from the manufacturer was obtained to perform 
research related to Rotarix
®
 vaccine materials. Rotarix
®
 final fills were stored at 4ºC. 
Viral RNA (vRNA) and viral DNA (vDNA) extracted from the vaccine final fills 
were used as positive controls in RT-PCR or qPCR reactions.  
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2.1.9 Faecal sample collection 
Faecal samples were collected from a cohort of 12 infants born and 
vaccinated in around Hertfordshire, South East England, UK. The NIBSC Human 
Materials Advisory Committee (HuMAC) reviewed and approved the project 
(reference 13/009). The activities fall beyond the scope of the Human Tissue 
Authority. The scope of the project is to undertake research on faecal samples from 
infants pre- and post-Rotarix
®
 administration, including isolation of rotavirus genetic 
material to confirm viral shedding patterns, virus identity and stability (including 
post-one-year samples); isolation of PCV1 genetic material to determine viral 
shedding (excluding post-one-year samples); and measurement of faecal IgA levels 
(including post-one-year samples). Parents or guardians who agreed to participate in 
the study signed an informed consent form and completed a study questionnaire 
enquiring about age at time of vaccinations and type of feeding (breast milk, formula 
or mixed feeding). Infant sample collections were assigned a unique identifier 
number which was further anonymously randomised for data display. Sample 
collection and storage complied with the Human Tissue Act (HTA), 2004 (Human 
Tissue Act 2004, 2004) (license 12321-holder the NIBSC) and information was 
handled in line with the Caldicott Principles (‘The Caldicott Report.’, 1999) and the 
Data Protection Act 1998 (Data Protection Act 1998., 1998).  
Recruitment started in June 2014 and finalised in February 2017, with the last 
after-a-year sample collected in January 2018. Age at dose 1 was eight or nine weeks 
and at dose 2 it was 12 or 13 weeks. Six infants were breastfed, one infant was 
exclusively formula-fed and five infants were mixed-fed breastmilk; and faecal 
samples were collected throughout the two-month vaccination period or beyond 
(Table 2.13). Parents provided samples collected from 17 to 45 days along the 
vaccination period. Pre-vaccination samples were provided for eleven infants. After 
the first dose, samples were collected in most cases every other day up to one month 
or beyond after the second dose. Samples for individual M were provided for a week 
only after dose 2 (samples were provided for all other individuals for a month after 
dose 2). Post-one-year samples were provided for eight infants. The total number of 
samples collected, and the periodicity of collection varied across the cohort 
(Appendix I, Tables 8.1.1-8.1.12). Samples were collected non-invasively from 
nappies, placed in a 30 mL vial with a unique participant number and stored at -20°C 
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in home freezers until delivery to the NIBSC, frozen, by parents/guardians. 
Subsequently, samples were stored at -80°C until aliquoted and/or tested. Samples 
were prioritised for viral load quantification in technical triplicates (section 2.2.5), 
then for measuring total and rotavirus-specific copro-IgA in duplicate (2.2.7) and for 
NGS measuring in triplicate from the faecal suspension stage (2.2.6).  
 
Table 2.13. Faecal sample collection. Individuals B-M. Number of days with at 
least one available sample pre-vaccination, after dose 1 and after dose 2. Total 
number of samples indicated in parentheses. See Appendix I for more detailed 
information about the cohort and faecal sample collection. (): Total samples, 
considering some recruits provided several samples from the same day. *Samples not 
provided for a period when collection not possible.  
 
 
2.2 Methods 
2.2.1 Faecal sample aliquoting 
Each sample was thawed, weighed and aliquoted into 200 mg to 1 g of faecal 
matter (Appendix I, Tables 8.1.1 to 8.1.12) before being snap-frozen in an ethanol 
and dry ice bath and then stored at -80°C until used. Inevitably, owing to the nature 
of collection and amount of material, several timepoints yielded low weight aliquots, 
which preclude the use of biological replicates for some sections of the study 
(Appendix I). Although homogeneity between aliquots was similar by eye, the 
heterogeneous nature of faecal matter composition represents a caveat of this study.  
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2.2.2 Nucleic acid extraction from vaccine material 
RNA from Rotarix
®
 vaccine material was used as a positive control in cDNA 
synthesis and qPCR assays. RNA from vaccine material was extracted using the 
Trizol/chloroform method further adapted or a published method (Potgieter et al., 
2009) further adapted as follows. Total RNA was extracted from a volume of 200 µL 
of vaccine, mixed with an equal volume of PBS and 1200 µL of TriReagent
® 
(Chomczynski and Sacchi, 1987, 2006). The mixture was vortexed briefly and 
incubated for 15 min at ambient temperature (AT). A 240 µL volume of chloroform 
(CHCl3) was added, the mix vortexed briefly and incubated at AT for 15 min. 
Following centrifugation at 13,200 × g’ and 4ºC for 15 min, the upper phase was 
removed to new sterile microcentrifuge tubes. Glycogen was added to a final 
concentration of 0.05 µg/mL. A 1200 µL volume of ice-cold 2-propanol was added, 
mixed by inversion ten times and incubated for 10 min at AT. Samples were 
centrifuged at 13,200 × g’ for 10 min at 4ºC. The upper phase was discarded, the 
pellet washed with 1.2 mL of 75% ethanol and centrifugation followed at 13,200 × g’ 
and 4ºC for 5 min. The upper phase was discarded and the pellet inverted and 
allowed to air dry for 10 min. The pellet was resuspended in 40 µL of RNAse-free 
water and stored at -80ºC until required. Some additional RNA from vaccine material 
was also extracted as described in section 2.2.3.2. 
PCV1 DNA from vaccine material was extracted using the QIAamp
®
 DNA 
Mini Kit (run in plates testing samples from all infants except individuals C and E 
after dose 1) or the QIAamp
®
 Viral RNA Mini Kit (run in plates testing samples 
from infants C and E after dose 1 and in plates testing samples from all infants after 
dose 2) or and following the manufacturer’s instructions.  
2.2.3 Nucleic acid extraction from stool  
2.2.3.1 Sample preparation for viral load quantification and sequencing  
In order to obtain a homogenous working sample, faecal suspensions were 
prepared from faecal aliquots and used on the same day, to minimise the effects of 
degradation. Surplus from the faecal suspensions was stored at -80°C for potential 
future use (only fresh suspensions were used for experiments in this thesis).  
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A 10% faecal suspension was prepared using 200 mg of faecal sample, 1.5 
mL PBS, 0.5 mL CHCl3 (or proportional amounts) and 1 g of glass beads. The 
samples were homogenised by thorough vortexing and centrifuged at 3,500 × g’ for 
10 min. The upper phase was transferred to new sterile tubes and used to perform 
viral nucleic acid extractions. Chloroform was used in the faecal suspensions for 
nucleic acid extraction in order to inactivate bacteria in faecal matter as adapted by 
Dr Dimitra Klapsa in the poliovirus group at the NIBSC from the WHO Polio 
laboratory manual 4
th
 Ed. (WHO, 2004) section 6.2.1 on ‘Preparation of faecal 
samples for virus isolation’. 
2.2.3.2 Extraction for viral load quantification  
Viral nucleic acids (vNAs) were extracted using the High Pure Viral Nucleic 
Acid column-based kit (Roche) following the method adapted by Dr Dimitra Klapsa 
(NIBSC) as described below. The kit contains polyA RNA as a carrier to increase the 
yield of extracted vNAs and a buffer with ‘inhibitor removal technology’ 
(proprietary) to eliminate contaminants that might inhibit downstream PCR. A 
volume of 200 µL of faecal suspension was mixed thoroughly with 400 µL of 
working solution (1 µL of polyA RNA per 100 µL of binding buffer) and incubated 
for 10 min at AT. The mix was transferred to the columns and centrifuged for 1 min 
at 8,000 × g’. Filter tubes were replaced and 500 µL of inhibitor removal buffer 
added, followed by a centrifugation for 1 min at 8,000 × g’. Filter tubes were 
replaced and 450 µL of wash buffer added, followed by a centrifugation 1 min at 
8,000 × g’. The wash was repeated, followed by an extra centrifugation step for 1 
min at full speed 13,000 × g’. Samples were eluted using 50 µL of elution buffer, 
followed by a centrifugation for 1 min at 8,000 × g’, transferring samples to clean 
tubes and stored at -80ºC. Viral RNA concentration was measured by fluorescence 
using the Qubit
®
 RNA HS Assay Kit according to manufacturer´s instructions.  
2.2.3.3 Extraction for NGS by Nextera
®
  
A number of methods were evaluated: 
TriReagent
®
 and chloroform method. Viral nucleic acids were extracted from 
250 µL of 10% faecal suspension (see 2.2.3.1) by mixing with 750 µL of Tri-
Reagent
® 
(Chomczynski and Sacchi, 1987, 2006), vortexing for 5 s and incubating 
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for 15 min at AT. A volume of 200 µL of CHCl3 (1.492 g/mL at 25ºC) was added 
and the samples were vortexed and incubated for 15 min at AT before being 
centrifuged at 13,200 × g’ for 15 min at 4ºC. The upper phase was transferred to a 
new sterile tube and glycogen was added to a final concentration of 0.05 µg/µL and 
mixed by inverting ten times. A volume of 750 µL of ice-cold 2-propanol (0.785 
g/mL at 25ºC) was added and mixed by inverting ten times. Samples were incubated 
overnight at -20ºC. The following day, samples were centrifuged at 13,200 × g’ for 
10 min at 4ºC. The upper phase was discarded, and the pellet was washed with 1 mL 
of 75% ethanol, by inverting and flicking. Samples were centrifuged at 13,200 × g’ 
for 10 min at 4ºC. The upper phase was removed, and the pellet was allowed to air-
dry for 1 h, at AT and resuspended in 40 µL of RNAse/DNAse-free water. Samples 
were stored at -80ºC.  
Roche nucleic acid kit method. Viral nucleic acids (vNAs) were extracted 
using the High Pure Viral Nucleic Acid adapted as described in section 2.2.3.2.  
Of the methods tested, the latter was the one chosen due to higher RNA 
yields. Following method testing, RNA was freshly extracted again using the Roche 
column-based adapted method. Single faecal matter aliquots generating single faecal 
suspensions, used in triplicate to extract from were used in this work.   
2.2.4 cDNA synthesis and PCR amplification 
The six rotavirus gene segments were amplified by RT-PCR with six sets of 
previously reported primers (Matthijnssens, Ciarlet, Rahman, et al., 2008; Cho et al., 
2013), which were modified as required so that they would span a number of G1P[8] 
serotypes species (Table 2.6).  
Either the SuperScript
TM
 III One-step RT-PCR System with Platimum
TM
 Taq 
High Fidelity (HF) DNA Polymerase kit (one cycle at 60°C for 30 min and 94°C for 
2 min, then 40 cycles at 94°C for 15 s, 45°C for 30 s and 68°C for 4 min, then one 
cycle at 68°C for 5 min, followed by 4°C on hold) for viral segments encoding VP6, 
VP7 and NSP2; or the SuperScript
TM
 III First Strand Synthesis system for RT-PCR 
kit (dNTPs, molecular-grade water and RNA one cycle at 85°C for 2 min, followed 
by 4°C on hold; plus 50°C for 50 min, 85°C for 5 min, followed by 4°C on hold) 
followed by the Phusion Hot Start II HF DNA Polymerase kit (one cycle at 98°C for 
1 min, then 35 cycles at 98°C for 10 s, 61°C [63°C for VP2] for 20 s and 72°C for 90 
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s, then one cycle at 72°C for 5 min, followed by 4°C on hold) for viral segments 
encoding VP3 (Appendix II), VP4 and NSP4 were used to amplify the extracted 
RNA. Three technical replicates were performed from the same vNA extraction.  
The SuperScript
TM
 III First Strand Synthesis system for RT-PCR kit was used 
with random hexamers (provided in the kit) to synthesise cDNA following the 
manufacturer’s instructions prior to pan-rotavirus VP6 qPCR, following the 
manufacturer’s instructions.  
2.2.5 Quantitative PCR 
In order to quantify rotavirus RNA levels in stool, two robust, published 
(Mukhopadhya et al., 2013; Gautam et al., 2014, 2016) and validated standard 
operating procedures used in the Rotavirus Response to Immunisation & 
Transmission Epidemiology (RotaRITE) programme to quantify Rotarix
®
 and all-
rotavirus viral loads in stool were kindly provided by M. Iturriza Gómara’s lab.  
2.2.5.1 Rotarix
®
-specific NPS2 
cDNA synthesis of NPS2 was performed using the modified primers 
mentioned in section 2.1.5 and the SuperScript
TM
 III First Strand Synthesis system 
for RT-PCR kit. cDNA was synthesised in triplicate (technical replicates) from any 
one faecal suspension extract. 
The Rotarix
®
 NSP2 qPCR assay was designed for detection of Rotarix
®
 
vaccine strain due to the difference in sequence of NSP2 gene in vaccine and other 
G1P[8] strains (Gautam et al., 2014, 2016). In the original paper, the assay 
demonstrated 100% sensitivity, 99% specificity and 94% efficiency with a limit of 
detection (LoD) of two copies per reaction (Gautam et al., 2014). Absolute 
quantification of RV cDNA from faecal samples using the Platinum
®
 qPCR 
SuperMix-UDG was performed in triplicate, adapting the Rotarix
®
 NSP2-PCR 
standard operating procedure, kindly provided by M. Iturriza Gómara. A pCR4
TM
-
TOPO
®
-TA plasmid (3956 bp) containing a Rotarix
®
 specific half-length NSP2 
amplicon of 281 bp was a kind gift from C. Bronowski and M. Iturriza Gómara, 
University of Liverpool, and was used to generate the standard curve for 
quantification. The plasmid copy number was calculated as follows:  
Chapter 2  Materials and methods 
74 
 
molecules
 L
 
 concentration  
ng
 L
   6.022         
molecules
mol
  
 length of amplicon        650  
g
mol
   109  
ng
g
  
 
 
Rotarix
®
 NSP2 qPCR specific primers and probe (Table 2.8) were optimised 
(considering the highest Ct value and lower probe concentration) for use at final 300 
nM and 100 nM respectively; adding ROX at 50 nM as recommended by the 
manufacturer. The LoD was determined after ten replicates of two-fold serial 
dilutions of the plasmid in herring sperm DNA (60 µg/mL), ranging from 5 × 10
-1
 to 
7.8125 × 10
-3
 copies/µL. The last dilution at which signal was detected was 0.125 
copies of DNA/µL (equating to 1.25 × 10
3
 copies of DNA/g of stool), indicating the 
LoD.  
Vaccine material concentration was calculated using 
                                                     , where 5 is 
the times mg used to make 1 mL, 8 relates to the 1/8 extraction volume run in the 
reverse-transcription reaction, 5 relates to a 1/5 dilution of the eluate and 10 relates to 
the 1/10 reverse-transcription volume run in the qPCR. Amplification of vaccine 
virus in stool was calculated as i.e.                                    
                , where 10 relates to the 1/10 reverse-transcription volume run 
in the qPCR, the next 10 relates to 1/10 eluate volume run in the reverse-transcription 
reaction, the last 10 relates to the 10% faecal suspension and the 5 relates to the times 
mg used were to make 1 g. As an example: 1.2 × 10
3
 copies in 2 µL [copies in 
reaction volume] × 10 [2 µL out of 20 µL of the RT final product volume are used in 
the qPCR, so 1/10] × 10 [5 µL out of 50 µL of eluate are used for the RT reaction, so 
1/10] × 10 [faecal suspension are prepared with approximately 200 mg of stool in a 2 
mL volume, so 10%] × 1000 mg/225 mg [to calculate amount in one 1 g of stool 
with respect to amount of stool used, hence the “5” as a general approximation in the 
equation above]= 5.35 × 10
6
 copies/g of stool. Neat and 1/10 eluates were previously 
tested for RT and PCR inhibition and neat samples were amplified better than 1/10 
dilutions when visualised by agarose-gel electrophoresis.  
The samples were incubated in an Agilent Mx3005P QPCR System with a 
programme comprising incubation at 50°C for 2 min; followed by one cycle at 95°C 
for 2 min; then, 40 cycles at 95°C for 15 s and 60°C for 1 min; and held at 4°C. For 
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data analysis, triplicates were treated collectively as described in the manual for 
MxPro QPCR Mx3000P and Mx3005P QPCR Systems software version 4.10, 
meaning “fluorescence values for all wells that are identified with the same replicate 
symbol are averaged, so that the results for all wells with the same replicate number 
will be identical”. The threshold fluorescence level (ΔRn), used to derive cycle 
threshold (Ct) values, was manually assigned at 0.1 in logarithmic scale, around the 
middle of the linear phase of exponential amplification, for consistency. Only assays 
with standard curves an R
2
 ≥0.99 and efficiency between 90% and 110% were 
considered valid.  A sample was considered positive if at least two of three replicates 
had a Ct ˂38 (based on Ct value of false positive non-template controls) and a 
standard deviation ≤0.3. Samples with Ct values ˃38 or standard deviations ≥0.3 
were repeated to assess veracity of results. Values for viral loads in the qPCR 
reaction were defined as copies/2 µL of reaction. Estimate values followed by 
copies/g of stool in the original sample. Any value that appeared to deviate from the 
general profile trend (unexpected dips in viral loads) was repeated to confirm viral 
load levels. 
2.2.5.2 Pan-rotavirus VP6 
cDNA synthesis from VP6 RNA was carried out using the modified primers 
mentioned in section 2.1.5, table 2.9, and the SuperScript
TM
 III First Strand Synthesis 
system for RT-PCR kit in section 2.2.5, in triplicate from any one faecal suspension 
yielding three technical replicates.  
The Rotarix
®
 VP6 qPCR assay (Mukhopadhya et al., 2013) was designed for 
the detection of any rotavirus strain in stool samples due to the conserved nature of 
the VP6 gene sequence (Tang et al., 1997). Absolute quantification of cDNA from 
faecal samples was performed as described for the NSP2 assay. A pCR4
TM
-TOPO
®
-
TA plasmid containing a pan-rotavirus VP6 amplicon of 380 bp was a kind gift from 
C. Bronowski and M. Iturriza Gómara, University of Liverpool, and was used to 
generate the standard curve for quantification. The copy number was calculated as 
described for the NSP2 assay.  
Pan-rotavirus VP6 qPCR specific primers and probe (Table 2.9) were 
optimised for use at 400 nM and 100 nM respectively; ROX and reaction conditions 
and analysis were performed as described for the NSP2 assay. The LoD determined 
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after ten replicates of two-fold serial dilutions of the plasmid (from 5 × 10
-1
 to 7.8125 
× 10
-3
 copies/µL) in herring sperm DNA at 60 µg/mL was 0.25 copies of DNA/µL, 
resulting in 2.5 × 10
2
 copies of DNA/g of stool, i.e.                   
                                  , where 5 is the times mg used to make 
1 g, 10 relates to the 10% faecal suspension, another 10 relates to the 1/10 eluate 
volume run in the reverse-transcription reaction and the last 10 relates to the 1/10 
reverse-transcription volume run in the qPCR.  
Vaccine material (Rotarix
®
 final fills) amplification was calculated using 
                                                     , where 5 is 
the times mg used to make 1 mL, 8 relates to the 1/8 extraction volume run in the 
reverse-transcription reaction, 8 relates to the 1/8 eluate volume run in the reverse-
transcription reaction, 5 relates to a 1/5 dilution of the eluate and 10 relates to the 
1/10 reverse-transcription volume run in the qPCR.  
Reaction conditions and data analysis were performed as described in 2.2.5.1. 
2.2.5.3 PCV1-specific qPCR 
Absolute quantification of PCV1 DNA from faecal samples was performed as 
previously described (Gilliland et al., 2012), using the Taqman Universal Master 
Mix II, no UNG, in triplicate (technical triplicates from extract from one faecal 
suspension). A pCR4
TM
-TOPO
®
 plasmid containing 1757 bp full-length PCV1 DNA 
was kindly provided by S. Connaughton and used for generation of the standard 
curve for quantification. The copy number was calculated as previously described for 
the NSP2 assay.  
Specific primers and probe (Table 2.10) were used at 400 nM and 200 nM, 
respectively. Reaction conditions followed manufacturer’s recommendations: 95°C 
for 10 min; then, 40 cycles at 95°C for 15 s and 60°C for 1 min; and held at 4°C. 
Analysis was performed as described for the NSP2 assay The LoD determined after 
ten replicates of two-fold serial dilutions of the plasmid (from 5 × 10
-1
 to 7.8125 × 
10
-3
 copies/µL) in herring sperm DNA at 60 µg/mL was 0.125 copies of DNA/µL, 
resulting in 1.25 × 10
3
 copies of DNA/g of stool, i.e.                   
                             , where 5 is the times mg used to make 1 g, 10 
relates to the 10% faecal suspension and 25 relates to the 1/25 extraction volume run 
in the qPCR.  
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DNA from vaccine material (Rotarix
®
 final fills) amplification was calculated 
using 
      
  
                    
   
  
             or 
                                              where 7.14 or 5 is the 
times mg used to make 1 mL and 30 or 25 relates to the 1/25 eluate volume run in the 
qPCR, respective to the extraction methods (QIAamp
®
 Viral RNA Mini Kit or 
QIAamp
®
 DNA Mini Kit). This material was detected at 10
5
-10
6
 copies/mL.   
Reaction conditions and data analysis were performed as described in 2.2.5.1. 
2.2.6 Next generation sequencing of faecal rotavirus RNA 
Amplicons for sequencing were first visualised by agarose gel electrophoresis 
and ethidium bromide staining (0.5 µg/mL final concentration), pooled in equimolar 
amount based on relative intensity on gel (amplicons encoding VP6 and VP7, 
Chapter 4) (Appendix II, section 8.2.1) or not pooled (amplicons encoding VP4 and 
NSP4, Chapter 4), purified using the Agencourt
®
 AMPure XP system of magnetic 
beads, eluted in 20 µL of RNAse-free water and quantified by Qubit
®
 DNA HS 
Assay (Invitrogen) following the manufacturer’s instructions. Samples were run on 
an Agilent High Sensitivity DNA chip using the Agilent 2100 Bioanalyser and 
Agilent 2100 Expert Software B.02.08 to assess the segments of interest. The 
mixture was then diluted to 0.2 ng/µL in 10 mM Tris-HCl pH 8.0.  
The Nextera
®
 XT DNA Library Preparation kit v2 was used to prepare the 
sequencing libraries as indicated in the manufacturer’s protocol, using at least 1 ng of 
input DNA per sample. Libraries were sequenced on the MiSeq platform using the 
2  251 paired end v2 flow cells.  
2.2.7 Bioinformatic analysis 
The sequencing data generated was analysed by the bioinformatics team at 
the NIBSC. Data was trimmed and adapter sequences removed using Trimmomatic 
(Trimmomatic 0.32) to search for average Phred score below 30 (Phred score cutoff 
≤Q30; accepting an error probability no bigger than 1 in a thousand or 0.001) 
(Andrews, 2010), within 5 bp windows, and trimmed off 3′ sequence from reads 
following the first window failing to pass, and discarding reads trimmed to under 50 
bp (Bolger, Lohse and Usadel, 2014). Data was indexed ready for alignment to 
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vaccine reference standards JX943604-JX943614 by Burrows Wheeler Algorithm 
(BWA) and prepared for processing with SamTools and Picard (BWA mem v0.7.12-
r1039; Samtools v1.2) (Li and Durbin, 2009; Li, 2011; BroadInstitute & GitHub, 
2018). Read pairs and singleton trimming survivors were aligned to the reference 
using BWA, merged, marked for duplicates and indexed using Picard. SamTools was 
used to obtain coverage and pileup information, next converted to a table showing 
bases aligned at positions using a custom script. Coverage was plotted and results 
summarised using an R script. Mutation loci were identified, and a mutation was 
called if there were >100 aligned reads covering that position supporting the 
alternative allele, present at a frequency ≥1% and in at least 2 of 3 or more replicates 
(VcfUtils, BcfTools, Picard). Integrative Genomics Viewer was used for alignment 
visualisation (Robinson, 2012). Custom scripting tools were used for data processing 
and bioinformatic analysis (Perl, R, Bash).  
2.2.8 Sequencing data analysis 
The longitudinal analysis was focused on describing the type of mutation, 
whether it was synonymous, non-synonymous, a reversion to WT or a stop codon. It 
was highlighted whether it had been identified in vaccine material or in stool from 
other infants, if it had been observed alongside the timepoints tested and how the 
frequency fluctuated. Isolated timepoints at low frequencies were not considered. A 
Python script was used to sort sequencing data by project, sample, recruit, viral 
segment, timepoint and repeat; written by Edward T. Mee (Appendix III).  
Relevant SNP loci were annotated in Geneious 10.2.3 and compared to RVA 
WT G1P[8] reference standards JN887809-10, JN887818-19 to highlight the SNP 
and amino acid changes. A search was run using the Basic Local Alignment Search 
Tool (BLAST) in to compare the modified sequences with RVA WT sequences.  
Molecular modelling of amino acid changes common to several infants was 
performed with LigPlot
+
 (Laskowski and Swindells, 2011) and RasMol (Sayle and 
Milner-White, 1995) using the Protein Databank resolved rotavirus structures 
available (detailed in Chapter 4).  
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2.2.9 ELISAs 
To quantify specific anti-RV copro-IgA initially, total copro-IgA was 
measured using a direct sandwich ELISA with a standard for total IgA followed by 
another direct sandwich ELISA measuring specific anti-RV IgA and using the same 
total IgA standard (section 2.2.9.3). This would yield a relative quantification of 
specific anti-RV copro-IgA with respect to total copro-IgA. However, due to 
shortage of the working standard and failure to reproduce its dynamic range with 
other commercial standards (Chapter 5), an indirect competitive commercial ELISA 
was used to quantify total copro-IgA (section 2.2.9.1), followed by specific anti-RV 
copro-IgA quantification using the remainder of the total IgA standard and the direct 
sandwich ELISA for specific anti-RV IgA (section 2.2.9.3), yielding a trend of 
specific anti-RV IgA with respect to total. Samples, standards and controls were 
assayed in duplicate. A strongly positive stool sample was used as a positive control 
along tested plates and a negative sample from pre-vaccination (previously tested as 
negative) was used as a negative control along the tested plates. Total IgA was 
measured in µg/mL using the Salimetrics
®
 Salivary Secretory IgA standard and 
specific IgA was measured in µg/mL (equivalent to µg/g relating to stool, assuming a 
density of 1 g/mL) using the total purified human secretory IgA standard by Bio-Rad 
(PHP133, batch 290415). Specific IgA was expressed initially as units (ng) of RV-
specific IgA with respect to 100 µg of total IgA. However, due final testing of total 
IgA with an indirect competitive kit, specific IgA was expressed as the readout with 
the total IgA standard and therefore a trend with respect to total IgA measured by the 
commercial kit.  
2.2.9.1 Sample preparation 
A 10% faecal suspension (in 1   PBS) from faecal samples of infants 
vaccinated with Rotarix
®
 was centrifuged at 1,500   g’ for 15 min at 4°C on the day 
of the ELISA. The upper phase was used to quantify total and rotavirus-specific 
copro-IgA and the remainder was snap-frozen and stored at -80°C between and after 
assays. Samples were assayed within two days to minimise IgA degradation 
interfering with results. 
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2.2.9.2 Total copro-IgA quantification 
Total IgA in stool was measured using the Salimetrics
®
 Salivary Secretory 
IgA indirect enzyme immunoassay kit, following the manufacturer’s instructions. 
The kit, designed to measure salivary IgA (range 93.2-974.03 µg/mL), has a dynamic 
range from 2.5-600 µg/mL (for samples diluted five-fold, hence from 12.5-3000 
µg/mL; determined by subtracting two standard deviations to the mean of 18 sets of 
duplicates and interpolating at 0 µg/mL, with minimal distinguished concentration 
from 0 being 2.5 µg/mL). Precision was determined from the mean of 10 replicates 
each control (high, medium and low) and from the mean of average duplicates for 
eight separate runs (high and low controls). Although originally designed for salivary 
IgA, this kit also detects secretory IgA from faecal samples in the range 520-2040 
µg/mL.  
Serial 1:3 dilutions of standard material were prepared from a stock of 600 
µg/mL in 1× SIgA Diluent, obtaining 200 µg/mL, 66.7 µg/mL, 22.2 µg/mL, 7.4 
µg/mL and 2.5 µg/mL. 10% faecal suspensions (see 2.2.3.2) were diluted 1:5 in 1× 
SIgA Diluent. A volume of 10 µL of each standard, control (high and low), 1:5 
diluted sample and 1X SIgA Diluent was added to 4 mL of 1× SIgA Diluent, making 
a further 1:400 dilution (a total 1:2000 dilution for faecal suspension samples). A 
1:120 dilution of Antibody Enzyme Conjugate in 1× Diluent was prepared and 50 µL 
were added to each of the previous tubes, making for a further 1:80 dilution of the 
Antibody Enzyme Conjugate. Tubes were incubated at for 90 min. A volume of 50 
µL from each tube was transferred into the SIgA pre-coated microtitre plate, as well 
as 50 µL of 1× Diluent as a non-specific binding control (in duplicate). The plate was 
covered and incubated at AT and 400 rpm and 2 mm motion radius for 90 min. Next, 
it was washed six times with 300 µL of 1× wash buffer and blotted on a paper towel. 
A 50 µL volume of TMB Substrate Solution were added to each well and the plate 
was incubated at AT and 500 rpm and 2 mm motion radius for 5 min. Following 
incubation at AT for 40 min in the dark, a volume of 50 µL of Stop Solution were 
added and the plate was incubated at AT and 500 rpm and 2 mm motion radius for 3 
min. The absorbance was read at 450 nm and a secondary filter correction at 492 nm, 
within 10 min of adding Stop Solution in a FLUOstar
®
 Omega microplate reader 
using Mars software (BMG LABTECH). Data was analysed using the four-
parameter logistic (4PL) curve as described for the direct ELISA for total IgA in 
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MyAssays
®
 Desktop Basic software, including an initial step to calculate percent 
bound with respect to the ‘zero’ (tube containing only goat anti-human IgA:HRP 
conjugate, hence all free antibody binding to the SIgA-coated plate). Graphs were 
plotted using GraphPad Prism 5.  
 
 
Fig. 2.1. Total IgA in stool of infants vaccinated with Rotarix
®
 by indirect 
competitive ELISA. A constant amount of goat anti-human SIgA conjugated to 
HRP was added to tubes containing specific dilutions of standards or faecal 
suspensions. The antibody enzyme conjugate bound to the SIgA in the standard or 
saliva samples. The amount of free antibody enzyme conjugate remaining was 
inversely proportional to the amount of SIgA present in the sample. After incubation 
and mixing, an equal volume of solution from each tube was added in duplicate to 
the microtitre plate coated with human SIgA. The free or unbound antibody enzyme 
conjugate bound to the SIgA on the plate. After incubation, unbound components 
were washed away. Bound SIgA antibody enzyme conjugate was measured by the 
reaction of the HRP enzyme to the substrate TMB. This reaction produced a blue 
colour. A yellow colour was formed after stopping the reaction with an acidic 
solution. The absorbance was read on a standard plate reader at 450 nm. The amount 
of SIgA antibody enzyme conjugate detected was inversely proportional to the 
amount of SIgA present in the sample. Adapted from Salimetrics
®
 Salivary Secretory 
IgA enzyme immunoassay kit manual. 
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2.2.9.3 Specific anti-RV copro-IgA detection 
Total copro-IgA ELISA for standard relative quantification 
A direct sandwich ELISA for total IgA was performed to assay the total IgA 
standard in parallel to the rotavirus-specific IgA ELISA, generating a relative trend 
quantification for specific IgA in stool. Adapted from an ELISA method developed 
by Anna Pulawska-Czub for total IgA in saliva at the University of Liverpool 
(personal communication) and a published method (Bernstein, Ziegler and Ward, 
1986). The LoD of this in-house assays was established by determining the average 
plus 3 standard deviations (SD) of the optical density (OD) of duplicates from 
negative pre-vaccination samples for all recruits (OD=0.503). Corning
®
 1 × 8 
Stripwell
TM
 96 well microtitre plates were coated with rabbit anti-human IgA 1:4000 
overnight at 4°C. The coating solution was removed and the plates washed five times 
with 300 µL of washing buffer. The wells were blocked with 300 µL of blocking 
buffer and incubated for 2 h at 37°C in a moist chamber. The 10% faecal suspensions 
were diluted 1:6000 (after optimization at different dilutions ranging from 1:1500 to 
1:6000) in PBS 1X. Positive control purified human secretory IgA was prepared in 
duplicate in PBS 1× at dilutions 1:500, 1:1000, 1:2000, 1:4000, 1:8000, 1:10000. 
PBS 1× was used as negative control. A volume of 100 µL of sample, positive or 
negative control were added to each well and the plates were incubated for 2 h at 
37°C in a moist chamber. The plates were washed three times with 300 µL of 
washing buffer. Enzyme-conjugated detection antibody goat anti-human IgA:HRP 
(horseradish peroxidase) was diluted 1:6000 in dilution buffer, 100 µL were added 
per well and the plates were incubated for 1 h at 37°C in a moist chamber.  The 
plates were washed five times with 300 µL of washing buffer. A volume of 100 µL 
of 3, 3', 5, 5'-Tetramethylbenzidine (TMB) liquid substrate were added to each well 
and the plates were kept in darkness for 10 min. The reaction was stopped by adding 
50 µL of 1M H2SO4. Absorbance was read at 450 nm in a FLUOstar
®
 Omega 
microplate reader and Mars software (BMG LABTECH). Data was analysed using 
the four-parameter logistic (4PL) curve in MyAssays
®
 Desktop Basic software 
(MyAssays
®
 Analysis Software Solutions). This model is used to calculate 
concentrations from symmetrical sigmoidal calibrators and widely used for ELISAs. 
Graphs were plotted using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, 
USA).  
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Fig. 2.2. Total IgA in stool of infants vaccinated with Rotarix
®
 by direct 
sandwich ELISA. Coating with rabbit anti-human IgA, adding the 10% faecal 
suspension in PBS or purified human IgA as a standard, followed by a primary 
antibody goat anti-human IgA conjugated with HRP. Next, adding the substrate 
TMB and stopping the reaction with H2SO4 to read the signal.  
 
Production of Rotarix
®
 antigen for specific anti-RV copro-IgA detection  
MA104 African green monkey kidney cells (Cell Supply and internal Cell 
Bank, NIBSC; originally from the European Collection of Authenticated Cell 
Cultures (ECACC) in May 1999, catalogue number 85102918) at passage 23 were 
incubated for 3 days at 37ºC and 5% CO2 in T25, T75 and T175 cell culture flasks. 
They were then washed with PBS 1×, trypsinised with 2 mL, 5 mL and 7 mL of 2.5 
mg/mL trypsin respectively for 5 min at 37ºC and trypsin was neutralised by adding 
5mL, 10 mL and 15 mL of growth media containing heat-inactivated foetal bovine 
serum (FBS). Cells were centrifuged at 360 × g’ for 5 min, the supernatant was 
discarded, and the pellet was resuspended in growth media so as to be split in a 1 to 6 
ratio from initial density. This cell culture was repeated until MA104s were used for 
infection at passage 29. Cells were used at 100% confluency. 
For cell culture adaptation of rotavirus, growth media was removed from the 
T25 MA104 flask. After washing with PBS 1×, replacement serum-free media was 
added, and cells were incubated at 37ºC and 5% CO2 for 5 h. Maintenance media 
(replacement media containing 1 µg/mL trypsin) was prepared and Rotarix
®
 cell 
suspension was thawed from -80ºC to AT. Rotarix
®
 was activated by incubating 500 
µL of virus suspension at 37ºC for 20 min with 20 µg/mL trypsin. After activation, 
9.5 mL of replacement media were added to dilute the virus to a final trypsin 
concentration of 1 µg/mL. Replacement media was removed from the T25 flask and 
cells were washed with PBS 1×. The virus suspension in replacement media was 
added to the cells and these were incubated at 37ºC for 1 h. Meanwhile, the T75 and 
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T175 MA104 flasks were split in a 1 to 6 ratio. After infection with Rotarix
®
, the 
T25 MA104 flask was washed with PBS 1× and 12.5 mL of maintenance media were 
added. The flask was incubated at 37ºC and 5% CO2, observing daily for cytopathic 
effect (CPE; rounded up and clumped, detached cells that appear ‘floating’).  
Once CPE was observed (around 3-6 days later), the flask was freeze-thawed 
three times from -80ºC to 37ºC (in water bath) and then centrifuged at 360 × g’ for 
15 min. The supernatant was stored at -80ºC. Once the T75 MA104 flask was 100% 
confluent, it was infected with Rotarix
®
 supernatant from the T25 in the same 
fashion. The infection was repeated with Rotarix
®
 supernatant from the T75 into the 
T175 flask. They were passages 32 and 33 respectively.  
The Rotarix
®
 cell suspension material was used in enzyme-linked 
immunosorbent assays (ELISAs) to detect rotavirus-specific IgA. 
 
Specific anti-RV copro-IgA ELISA 
A direct sandwich ELISA was used for rotavirus-specific IgA detection. A 
10% faecal suspension (see 2.2.3.2) was used to quantify specific IgA in faecal 
samples from infants vaccinated with Rotarix
®
. Adapted from an ELISA method 
developed by Anna Pulawska-Czub for norovirus specific IgA in saliva at the 
University of Liverpool (personal communication) a published method (Bernstein, 
Ziegler and Ward, 1986). Corning
®
 1 × 8 Stripwell
TM
 96 well microtitre plates were 
coated with mouse anti-human rotavirus VP6 1:3000 overnight at 4°C. The coating 
solution was removed, and the plates washed three times with 300 µL of washing 
buffer. The wells were blocked with 300 µL of blocking buffer and incubated for 1 h 
at 37°C in a moist chamber. Rotarix
®
 suspension (section 2.2.8.1) was diluted 1:4 in 
PBS 1× and 100 µL were added to each well (in duplicate). Plates were incubated for 
1.5 h at 37°C in a moist chamber. The coating solution was removed, and the plates 
were washed three times with 300 µL of washing buffer. The 10% faecal suspensions 
were diluted 1:10 (after optimization at different dilutions ranging from 1:2 to 1:400) 
in duplicate in PBS 1×. PBS 1× was used as negative control. A 100 µL volume of 
sample or negative control were added to each well and the plates were incubated for 
1.5 h at 37°C in a moist chamber. The plates were washed three times with 300 µL of 
washing buffer. Enzyme-conjugated detection antibody goat anti-human IgA:HRP 
was diluted 1:6000 in dilution buffer, 100 µL were added per well and the plates 
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were incubated for 1 h at 37°C in a moist chamber.  The plates were washed five 
times with 300 µL of washing buffer. A volume of 100 µL of 3, 3', 5, 5'-
Tetramethylbenzidine (TMB) liquid substrate were added to each well and the plates 
were kept in darkness for 10 min. The reaction was stopped by adding 50 µL of 1M 
H2SO4. Absorbance was read at 450 nm in a FLUOstar
®
 Omega microplate reader 
and Mars software (BMG LABTECH). Data was analysed using the 4PL as 
described for the direct ELISA for total IgA. The readout from the ELISA is 
expressed as µg/mL (in the range of 0.1 to 2 or 2.5 to 600), and specific IgA is 
normalised relative to total IgA concentration in 1g (1mL) of stool. Example: Child 
M, sample 13 (day 21 after dose 1), total IgA 3481 µg/ml, specific IgA 15 µg/ml. 
Therefore, 15/3481= 0.0043 µg of RV IgA per 1 µg of total IgA, equivalent to 4.3 ng 
of RV IgA per 1 µg of total IgA, plus ×10 because of the faecal suspension. 
 
Fig. 2.3. Specific rotavirus IgA in stool of infants vaccinated with Rotarix
®
 by 
direct sandwich ELISA. Coating with mouse anti-human rotavirus VP6, adding 
vaccine virus grown in MA104s, then adding the faecal suspension in PBS 
(containing the IgA), followed by a primary antibody goat anti-human IgA 
conjugated with HRP. Next, adding the substrate TMB and stopping the reaction 
with H2SO4 to read the signal.  
 
2.2.10 Limitations 
This project was designed as an exploratory and descriptive study, with a low 
number of recruits (n=12) but a large number of sequential samples provided by each 
recruit every other day (n=17-45), sometimes with >1 sample from the same day, and 
each sample yielding from one to >30 aliquots of 200 mg to 1g of stool. Despite the 
small cohort, longitudinal samples provided granularity to the study. Logistics varied 
as parents stored samples in their -20°C freezer at home and brought different 
Chapter 2  Materials and methods 
86 
 
numbers of sample vials at different times to the NIBSC to be stored at -80°C. The 
samples from the first infants recruited were stored for longer than those from the 
latest recruits before being aliquoted. Aliquoting was performed comparably but at 
different points in time, with samples from one infant being aliquoted before or after 
samples from other infants. 
Regarding storage, stool samples were kept as aliquoted stool matter at -80°C 
to prevent nucleic acid and/or protein degradation, since faeces contain less liquid 
and lower pH than faecal suspensions. Faecal suspensions, more homogeneous than 
faecal matter, were the working samples prepared on the day of extractions to 
minimise degradation from freeze-thaw impact and used once to extract nucleic acid 
or to test copro-IgA. They were then stored to be used shortly only if any repeats 
were required. Although stool samples were not filtered or treated with UV light, 
chloroform in the faecal suspension for NA extraction was used to inactivate 
bacteria. Both at the stage of aliquoting and at the stage of faecal suspension 
preparation there may have been sampling bias due to the heterogeneous nature of 
the starting material. Results may have originated from a small set of cells or from 
many cells across the gut and differently representative of the whole vaccine 
infection. 
Due to inconsistent stooling patterns in infants, low volume of sample at 
certain timepoints and feasibility of parental collection, it was not possible to collect 
a fully comparable set of samples across infants. The low amounts of stool sample 
available for collection during the vaccination period for most of the infants 
represents a caveat for the study as biological replicates for some timepoints were not 
possible. Therefore, testing of samples was prioritised for Rotarix
®
 viral load 
quantification (three technical replicates from one faecal suspension), NGS of virus 
shed in stool (three biological replicates from three faecal suspensions) and RV-
specific copro-IgA quantification (two technical duplicates from one faecal 
suspension). Although biological replicates were not possible for all the tests, faecal 
suspensions were a more homogeneous working sample than stool and reduced the 
chance of sample bias at that stage. Regarding variability of collection timepoints 
across infants, relevant timepoints (e.g. peak shedding, last day of shedding and 
highest and median viral loads) were selected to implement comparisons.  
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2.2.11 Statistical analysis 
Biological significance was the main analytical focus whenever statistical 
analysis did not add value to the results. The number of replicates is reported in the 
section above and in the Experimental Methodology section in each chapter. Data 
representation and statistical analyses were performed using GraphPad Prism 8. Due 
to a small cohort (n=12), data was considered non-parametric. Tests included 
Wilcoxon matched-pairs signed ranks and Kolmogorov-Smirnov unpaired test for 
comparison of distribution. Statistical tests and reported significance are denoted in 
the figure legends. 
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Chapter 3: Human monovalent G1P[8] 
rotavirus vaccine shedding patterns in a 
cohort of vaccinated infants in the UK  
3.1 Introduction 
In a naturally acquired rotavirus infection, the mature enterocytes of the villi 
are infected and the virus replicates to high levels in the gut, causing mild to severe 
osmotic diarrhoea (Chapter 1, section 1.4). Rotavirus is shed in faeces of infected 
children, with lower amounts of virus shed by asymptomatic children and 
intermittent shedding by both symptomatic and asymptomatic children 
(Mukhopadhya et al., 2013). Moreover, continuous shedders appear to be less 
protected than those who control shedding rapidly (Chapter 1, section 1.5.1) 
(Richardson et al., 1998).  
The design of live-attenuated vaccines is based on mimicking natural 
infection; their attenuation minimises the risk of initiating full symptomatic infection, 
while the active viral replication induces an immune response as close as possible to 
that achieved by the WT pathogen. Vaccine virus is shed in stool and several trials 
have studied the faecal shedding of Rotarix
®
, with a higher proportion of infants 
shedding after dose 1 than after dose 2 likely due to a catch-up effect of the second 
dose (Chapter 1, section 1.14). Moreover, horizontal transmission of the vaccine to 
placebo recipients was reported in some of the trials, which could contribute to herd 
immunity or to RVGE depending on immunocompetency of individuals.  
Replication of Rotarix
®
 in the gut and viral shedding of rotavirus vaccine in 
stool were anticipated (Hsieh et al., 2014) and the measurement of vaccine viral load 
in faecal samples is a useful, non-invasive approach to assess vaccine take (Chapter 
1, section 1.10.2) in an individual. Typically, clinical trials report faecal vaccine 
virus load over short periods following the dosing regimen. Further shedding data 
come from studies in hospital settings and therefore will frequently be a single point 
in time linked to the clinical evaluation. 
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A clear understanding of vaccine virus take would come from a more 
granular investigation of shedding dynamics, studying multiple timepoints 
throughout the vaccination period (from dose 1 to dose 2) and beyond. This would 
help to elucidate the variation in vaccine take between individuals. It would also 
provide an opportunity to study the shed vaccine virus to determine its sequence as a 
surrogate for the genetic stability of vaccine virus in the gut and to determine if 
vaccine virus variability may impact on overall immunity. Coupled with faecal IgA, 
viral load data would provide a non-invasive basis for better understanding immunity 
to rotavirus through vaccination.  
Of note, Rotarix
®
 contains an unintended contaminant DNA virus, PCV1 
(Victoria et al., 2010), which, despite being a porcine virus, is non-pathogenic in pigs 
and has not been reported to cause disease in humans (Chapter 1, section 1.13) 
(Mankertz et al., 2003; Hattermann et al., 2004; Baylis et al., 2011; Kumar et al., 
2012; Mankertz, 2012). However, porcine circoviruses have been detected in human 
faecal matter from adults, possibly as a result of ingesting pork products (Li et al., 
2010). It is unknown whether PCV1 can replicate in the human GI tract or simply 
pass through without amplification. The investigation by GSK and previous studies 
have detected Rotarix
®
 PCV1 DNA in vaccine stocks at 10
7
 copies/mL of dose 
(Howe et al., 2010; McClenahan, Krause and Uhlenhaut, 2011; Hsieh et al., 2014; 
Mijatovic-Rustempasic et al., 2017). The availability of longitudinal samples from a 
cohort vaccinated with Rotarix
®
 enables additional investigation of whether shedding 
of PCV1 DNA can be detected following vaccination. Transient shedding may 
indicate simple pass-through of viral genome whereas prolonged shedding may be 
indicative of replication within the human gut.  
3.2 Aims 
The first aim of the work presented in this chapter was to perform a detailed 
longitudinal analysis of Rotarix
®
 faecal shedding in infants vaccinated with Rotarix
®
 
in the UK to understand the rotavirus vaccine replication kinetics in this population. 
The second aim was to evaluate the quantity of PCV1 DNA shed -and persistence of 
shedding- alongside the vaccine rotavirus.   
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3.3 Experimental methodology 
To address the vaccine virus shedding, a cohort of infants was recruited, and 
a series of samples acquired from each individual typically spanning the pre-
vaccination period through to four weeks after the second dose, and for some infants 
one year after dose 1. Detailed materials and methods are provided in Chapter 2 and 
Appendix I. Faecal samples were processed and stored appropriately until needed for 
analysis (Chapter 2, sections 2.1.9 & 2.2.1). Inevitably, due to the nature of the 
material and the age of the donors, some samples were of low quantity and thus 
experimental design and analysis reflected this. To maximise the information 
obtained from this limited resource, the reproducibility of data was addressed by 
quantifying viral loads across three technical replicates from material extracted from 
a single faecal suspension. Viral load was quantified by RT-qPCR as it has been 
shown to be a sensitive assay for rotavirus detection (Pang et al., 2004; Hsieh et al., 
2014). It was important to distinguish vaccine virus from naturally-circulating 
rotaviruses, thus for the samples collected prior to vaccination, on day of vaccination 
(before or after vaccine administration), and after one year, a VP6 pan-rotavirus RT-
qPCR assay was employed (Chapter 2, section 2.2.5.2), with a view to identifying 
any pre-existing infection with naturally-circulating rotavirus. Samples collected 
from all timepoints pre-, during and post- vaccination regimen were subjected to a 
Rotarix
®
-NSP2-specific RT-qPCR (Chapter 2, section 2.2.5.1) to determine the 
amount of shed vaccine virus. Viral loads for PCV1 DNA (Chapter 2, section 
2.2.5.3) were evaluated by qPCR on a subset of timepoints. Nucleic acid extracted 
from vials of Rotarix
®
 vaccine served as positive controls and were used as spiking 
material to establish limits of detection of virus from stool (Chapter 2, section 2.1.8).  
3.4 Results 
3.4.1 Sample set 
It was not possible to obtain samples from equivalent timepoints from all 
infants due to stooling patterns and feasibility of collection. Where low volumes of 
material were available, priority was assigned to testing Rotarix
®
 faecal shedding 
throughout the two to three-month vaccination period. Similarly, PCV1 was 
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quantified in pre-vaccination sample and from three to ten timepoints after dose 1 
and dose 2, where samples were available. 
3.4.2 Rotavirus vaccine RNA faecal shedding after Rotarix
®
 vaccination  
Shedding was considered if infants presented detectable and sustained viral 
loads after either dose of vaccine.  
 
Rotarix
®
 vaccine material 
Rotarix
®
 in the vaccine vial was detected in the range of 2.46 × 10
8
 to 2.21 × 
10
9
 copies/mL due to variability in extraction methodology (Chapter 2, section 
2.2.2), which is one log10 higher than a previous report (Mijatovic-Rustempasic et 
al., 2017). The vaccine potency reported by the manufacturer is 10
6
 CCID50/mL of 
dose. Viral loads from vaccine material are expressed in molecules/mL, equivalent to 
molecules/g in VLs from stool, assuming a density of 1 g per mL. 
 
Rotarix
®
 RNA detection in faecal suspensions 
The sensitivity of vaccine virus detection on a background of nucleic acid 
extracted from faecal matter was determined using pre-vaccination samples spiked 
with 10-fold dilutions of Rotarix
®
 vaccine material (from expected 10
8
 to 10
1
 
copies/mL) and amplified using the vaccine-specific NPS2 RT-qPCR (Fig. 3.1). The 
LoD was determined as 10
3
 copies/mL. 
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Fig. 3.1. Determination of the limit of detection of Rotarix
®
 RNA from faecal-
derived samples. Quantitation of rotavirus vaccine genome copy numbers by RT-
qPCR: The X axis shows a serial 10-fold dilution of stool suspension spiked with 
Rotarix
®
 vaccine material as well as negative controls (stool suspension and PBS). 
NSP2 gene copy numbers are shown in the Y axis.  
 
Rotarix
®
 faecal shedding in infants 
None of the infants’ pre-vaccination samples (n=12) revealed shed Rotarix® 
or WT RV. Similarly, none of the infants from whom a sample was available one 
year after vaccination (n=8) shed Rotarix
®
 or WT RV. The pattern of shedding 
varied across the cohort. Following dose 1, shed vaccine virus was detected in all 
infants and following dose 2, viral shedding was identified in 11 of the 12 infants. 
Out of 12 infants, four (33%) controlled Rotarix
®
 VLs to below the LoD after dose 1 
and before dose 2, nine (75%) controlled VLs after dose 2 and before the end of the 
observation period and five (42%) controlled VLs during both periods. Rotarix
®
 viral 
loads ranged between 10
3
-10
9
 copies/g of faeces with sustained shedding (Tables 3.1. 
A & B).  
The day of peak of shedding after dose 1 ranged from day 2 to day 15, with a 
median of day 8 (Fig. 3.2 A). Out of 12 infants, six (50%) presented highest shedding 
between days 2-5 after dose 1 and six (50%) between days 6-15 after dose 1. After 
dose 2, the day of peak shedding was between days 1-3 after dose 2 for 10 infants 
(91%), and for one infant (9%) it was at day 7 after dose 2. The day of peak shedding 
occurred significantly later after dose 1 than after dose 2. Regarding the last day of 
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shedding, after dose 1 it varied from day 12 to day 34, with the median at day 27 
(Fig. 3.2 B). After dose 2, the last day of shedding varied from day 1 to day 25, with 
an outlier at day 41, the median at day 8 and the majority of infants ceasing to shed 
virus by day 20. The duration of shedding was significantly longer after dose 1 than 
after dose 2.  
The highest viral load after dose 1 ranged from 10
6
 to 10
9
 copies/g of stool 
across the cohort, with a median peak VL of 1.58 × 10
8
 copies/g of stool (Fig. 3.3. 
A), comparable to the copy number range quantified within vaccine material. After 
dose 2, the highest VL ranged from 10
5
 to 10
7
 copies/g of stool, with a median 
highest VL of 1.35 × 10
6
 copies/g of stool. The highest VL after dose 1 was 
significantly higher than after dose 2. The median viral load after dose 1 ranged from 
10
4
 to 10
7
, with a median at 10
6
 copies/g of stool (Fig. 3.3. B). After dose 2, the 
median VL ranged from 10
4
 to 10
6
 copies/g of stool, with a median of 10
5
 copies/g of 
stool. The median viral load was significantly higher after dose 1 than after dose 2.  
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Table 3.1. Rotavirus RNA viral loads of individuals B-M after A) dose 1 and B) 
dose 2. Individuals, detectable range of shedding after dose 1 and dose 2 or day of 
dose 2 (D2), shedding period, day of peak shedding, last day of shedding, highest 
viral load and median viral load. Days with respect to dose 1 in (). NA, not 
applicable. 
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Fig. 3.2. A) Day of peak faecal Rotarix
®
 shedding and B) last day of faecal 
Rotarix
®
 shedding after dose 1 (D1) and dose 2 (D2). Statistical differences were 
assessed using a Wilcoxon matched pairs signed rank test (*p < 0.05; **p < 0.01; 
***p < 0.001).  
 
 
 
Fig. 3.3. A) Highest and B) median faecal Rotarix
®
 shedding after dose 1 (D1) 
and dose 2 (D2). Quantitation of rotavirus vaccine genome copy numbers by RT-
qPCR. Rotarix
®
 copy number range in vaccine material delimited by dotted lines. 
Statistical differences were assessed using a Wilcoxon matched pairs signed rank test 
(*p < 0.05; **p < 0.01; ***p < 0.001).  
 
 
Patterns of Rotarix
®
 faecal shedding in infants 
Amongst the 12 infants there were four clear patterns of shedding.  
Profile 1 was defined by a single infant (I) who yielded a profile reflecting 
efficient control of viral shedding after dose 1 (Fig. 3.4 A). Initial high levels of virus 
reduced gradually to non-detectable levels by day 20. Although sample was not 
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available on day 28 (one day after dose 2), there was no detectable vaccine virus 
after dose 2 in the following days.   
Profile 2 was defined by three infants (H, K, L) who yielded profiles whereby 
vaccine virus was shed following dose 1 and dropped to undetectable levels prior to 
dose 2 (Fig 3.4 B). Fewer samples were available from individual L immediately 
around the period of first vaccination. On receipt of the second dose, each individual 
shed vaccine virus but to levels approximating (H) or several logs lower (K, L) than 
those detected following dose 1. The duration of shedding in all three infants was no 
longer than 10-23 days after dose 1 and 2-7 days after dose 2. Longer shedding after 
dose 1 by individual L may be due to illness around the time of first vaccination. 
Interestingly, in individual K, the day before dose 2 was positive for vaccine virus, 
one log lower than VLs one day after dose 2. No vaccine or vaccine-derived variants 
were detected at frequency ≥1% at that timepoint (Chapter 4). 
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Fig. 3.4. Faecal shedding of Rotarix
®
 and WT RV in A) individual I; B) 
individuals H, K and L; C) individuals B, E, D, G and M; and D) individuals C, 
F and J. Quantitation of RV vaccine genome copy number by NSP2-specific RT-
qPCR and of pan-RV genome copy number by VP6-specific RT-qPCR: the X axis 
shows days with respect to dose 1 and the Y axis shows Rotarix
®
 copy number. 
Black dots, vaccine VLs (molecules/g) throughout the two to three-month 
vaccination period; blue empty squares, WT VLs (molecules/g) at specific timepoints 
(pre-vaccination, on day of dose 1, six days after dose 1 or after-a-year). Black 
dashed line, LoD for vaccine virus assay (1.25 × 10
3
 copies/g; negative values below 
this line and of unknown value); blue dashed line, LoD for WT virus assay (2.25 × 
10
3
 copies/g; negative values below this line and of unknown value). Day 0: Day of 
dose 1. Arrow: Day of dose 2.  
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Profile 3 was defined by five infants (B, D, E, G, M) who yielded profiles 
whereby vaccine virus was shed after dose 1 and while typically waning, remained 
detectable at the point when dose 2 was administered (Fig. 3.4 C). Upon receiving 
dose 2, each infant shed virus for varying time ranging from day 1 to day 21 after 
dose 2, at lower amounts than after dose 1. However, shed virus was not detectable 
thereafter and the infants appeared to have ceased viral shedding. For individual E, a 
sample point at day 13 contained no detectable virus. The sample was retested to 
confirm this profile as accurate.  
Profile 4 was defined by three infants (C, F, J) who presented continuous 
shedding after dose 1 until and following dose 2 (Fig 3.4 D). Initial shedding was 
amongst the highest in the cohort from days 1-13, followed by a three to four-log 
decrease in VLs that decreased again after dose 2.  
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Rotarix
®
 RNA detection in faecal suspensions from particular infants 
On occasion, samples appeared to yield data that were contrary to the general 
trend of the shedding profile. In these instances, the samples were re-extracted where 
material remained, and re-examined by RT-qPCR. Another series of spiking 
experiments were performed with Rotarix
®
 final fills at a specific dilution for each of 
the infants’ pre-vaccination samples tested (Table. 3.2). In most cases, the original 
viral load was confirmed (although pre-vaccination samples may yield different 
results, they are the closest samples to a stool negative control). On the sample from 
individual C spiked with vaccine material at 10
5
 copies/mL, more copies at 10
6
 were 
detected, probably due to assay variability or a dilution error in vaccine material. On 
the profile of individual H, there was a sharp dip on day six after dose 1, followed by 
an increase in shedding up to day 12, almost as high as the initial peak at day four 
after dose 1. This dip may be due to mild diarrhoea followed by increased replication 
until immune response controlled the infection. Individual L at timepoint 22 was on 
the limit of viral detection. Viral load quantification of stool suspensions spiked with 
vaccine material proved detection of low Rotarix
®
 vaccine material
 
viral loads spiked 
into stool and suggested the dips observed in profiles may be genuine based on pre-
vaccination samples as the closest sample to a negative control (Fig. 3.5).  
 
Table 3.2. Testing of specific timepoints with unexpected viral loads from 
several infants. Individuals and timepoints with dip or limit in VL from stool and 
vaccine material spiked into faecal suspensions to test detection.   
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Fig. 3.5. Determination of the positivity of Rotarix
®
 RNA from faecal-derived 
samples in different infants. Quantitation of rotavirus vaccine genome copy 
numbers by RT-qPCR. The X axis shows stool suspensions from several infants (C, 
G, H, J, L, M) spiked with Rotarix
®
 vaccine material at different dilutions as well as 
negative controls (stool suspension and PBS). NSP2 gene copy numbers are shown 
in the Y axis.  
 
3.4.3 Rotavirus WT RNA faecal shedding after Rotarix
®
 vaccination 
It was important to determine whether the infants had had a prior exposure to 
naturally circulating rotavirus before vaccination, as this could have implications for 
determining the effect of the vaccine. Similarly, detection of such ‘wild-type’ 
rotavirus at timepoints after vaccination would be suggestive of ineffective or failed 
immunisation.  
The pre-vaccination status was determined by applying a VP6-pan-rotavirus 
RT-qPCR to samples where available. The sample set comprised 12 samples 
collected before day of first vaccination and six samples which were obtained on the 
day of vaccination (one before vaccine administration, infant C; and five after 
vaccine administration, infants D, E, F, H, K; time of vaccination provided 
retrospectively). None of the 12 pre-vaccination day samples yielded detectable 
rotavirus sequence (Fig. 3.4.).  
All three positive samples from day of dose 1 (D, H, K) presented VL levels 
detected using the pan-RV assay that were not different from those achieved by the 
Rotarix
®
-specific assays. One of the infants tested on day of dose 1 with negative 
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results for WT RV (C) was also tested at day 6 after dose 1 and presented pan-RV 
VLs at non-significant levels with respect to those of vaccine. From the cohort, 
samples were available from eight infants at a year post-dose 1 and none yielded 
detectable rotavirus sequence (Fig. 3.4).  
 
3.4.4 Breastfeeding and rotavirus vaccine RNA faecal shedding
 
The amounts of highest shedding after dose 1 and after dose 2 did not appear 
to be significantly lower in breastfed infants (n=6 - D, E, F, G, H, L after both doses) 
versus mixed-fed (n=5 - B, I, J, K, M after dose 1; n=4 – B, J, K, M after dose 2) 
infants (Fig. 3.6). The only infant fed with formula (C) presented high amounts of 
shedding after both doses.  
 
 
Fig. 3.6. Highest viral load in breastfed versus mixed-fed infants A) after dose 1 
and B) after dose 2. Quantitation of rotavirus vaccine genome copy numbers by RT-
qPCR. Rotarix
®
 copy number range in vaccine material delimited by dotted lines. 
Statistical differences were assessed using the Kolmogorov-Smirnov test (*p < 0.05; 
**p < 0.01; ***p < 0.001). VL, viral load.  
 
3.4.5 PCV1 DNA faecal shedding in infants after Rotarix
®
 vaccination
 
Detection of PCV1 in the infant cohort was assessed by DNA qPCR and 
shedding defined as being detectable at similar or higher levels than in vaccine 
material and in a sustained manner after either dose of vaccine.  
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Rotarix
®
 vaccine material 
The viral load of PCV1 in Rotarix
®
 vaccine was determined to be between 
1.03 × 10
5
 to 1.41 × 10
5
 copies/mL of vaccine for DNA extracted using the 
QIAamp
®
 DNA Mini Kit and between 1.83 × 10
6
 to 5.47 × 10
6
 copies/mL of vaccine 
for DNA extracted using the Viral RNA Mini Kit (Chapter 2, section 2.2.2), similar 
amounts to those measured in a recent study in the USA (Mijatovic-Rustempasic et 
al., 2017). Viral loads from vaccine material are expressed in molecules/mL, 
equivalent to molecules/g in VLs from stool, assuming a density of 1 g per mL. This 
material was used as a control in the assessment of the faecal sample collection.  
 
PCV1 faecal viral loads in infants 
PCV1 in stool of vaccinees was detected in the range of 10
3
-10
4 
copies/g 
(Tables 3.3 A & B), similarly to a recent report (Mijatovic-Rustempasic et al., 2017). 
None of the infants had detectable PCV1 prior to vaccination (n=12). One infant (G) 
had no evidence of PCV1 shed in faeces at any of the 14 timepoints tested which 
spanned the administration of doses 1 and 2. Viral DNA was detected in nine of the 
12 infants after dose 1 although to levels not exceeding the PCV1 content of the 
vaccine dose (Fig. 3.7 A & C). While eight of the 12 infants shed PCV1 after dose 2, 
levels did not exceed the VLs quantified in vaccine material and were eliminated 
within three days (Fig. 3.7 B & C). The virus was not detected in stool after the third 
day after dose 1 or the second day after dose 2. The median highest VL was 1.16 × 
10
4
 copies/g of stool for dose 1 and 8.88 × 10
3
 copies/g for dose 2. None of the 
infants were tested for PCV1 viral loads post one year.  
 
 
 
 
 
 
 
 
 
Chapter 3    Rotarix
®
 shedding patterns in vaccinees in the UK 
 
104 
 
Table 3.3. PCV1 DNA viral loads of individuals B-M after A) dose 1 and B) dose 
2. Individuals, nothing or day of dose 2 (D2), detectable range of shedding, shedding 
period, day of peak shedding, last day of shedding, highest viral load and median 
viral load. Days with respect to dose 1 in (). NA, not applicable. 
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Fig. 3.7. Faecal shedding of PCV1 in A) individuals E, I and M; B) individuals B 
and L; and C) individuals C, D, F, H, J and K. Quantitation of PCV1 genome 
copy number by PCV1-specific qPCR: The X axis shows days with respect to dose 1 
and the Y axis shows PCV1 copy number. Black dots, PCV1 VLs (molecules/g) at 
pre-vaccination and throughout the first three to ten timepoints after dose 1 and dose 
2 (depending on sample availability). Black dashed line, LoD for PCV1 virus assay 
(6.25 × 10
2
 copies/g; negative values below this line and of unknown value). Day 0: 
Day of dose 1. Arrow: Day of dose 2.  
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3.4.6 Rotavirus vaccine RNA and PCV1 DNA faecal shedding 
 
On equivalent timepoints, Rotarix
®
 viral loads were detected at two to three 
logs higher than PCV1 viral loads, as expected from the difference in viral loads in 
vaccine material. Of the three infants who had detectable PCV1 VLs only after dose 
1, one shed Rotarix
®
 only after dose 1 (I), another one mostly after dose 1 and after 
dose 2 for a day (M), and another one after both doses, and of the two infants who 
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shed PCV1 only after dose 2, both shed Rotarix
®
 after the two doses (B, L), 
suggesting PCV1 detection is independent of Rotarix
®
 detection.  
In individual L, the pattern of PCV1 detection coincides with the pattern of 
Rotarix
®
 detection in that viral loads at day 35 are slightly higher than those detected 
at day 34 for quantification of both viruses. Of the six infants who presented 
detectable PCV1 viral loads after both doses, four presented a similar decrease in 
viral load after dose 1 (C) and dose 2 (D, H, F) to that of Rotarix
®
 VLs. Individual F 
also presented detectable PCV1 viral loads on day of dose 1 while no Rotarix
®
 viral 
loads were detected on that day, suggesting again that detection of both viruses is 
unrelated. Individual J maintained Rotarix
®
 VLs at days 29 and 30 after dose 2 while 
PCV1 viral loads decreased one log between those days.  
3.5 Discussion 
Pre-licensure and later studies have quantified Rotarix
®
 shedding after 
vaccination using ELISAs (Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 
2004; Dennehy et al., 2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et 
al., 2007; Hsieh et al., 2014). They have also assessed a limited number of 
timepoints at vaccination, one week after dose 1, one week after dose 2 and extra 
timepoints in cases who developed any GE symptoms during the two-month period 
following vaccination (Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 2004; 
Dennehy et al., 2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et al., 
2007). Sequential timepoints have been assessed during the month after vaccination 
until two consecutive negative samples were detected or during the first week after 
each dose (Hsieh et al., 2014; Mijatovic-Rustempasic et al., 2017), as well as at pre-
vaccination, post dose 1 days 2-10 plus post dose 2 day of vaccination and days 2-10 
plus post dose 2 week 2 (Pollock, 2018). Timepoints from within the first and second 
week after vaccination from vaccine recipients have been tested for horizontal 
transmission within the household (Bennett et al., 2019). Regarding quantification 
methodology, molecular methods have proven to be more sensitive than ELISAs in 
rotavirus detection (Pang et al., 2004; Hsieh et al., 2014) and have been used in 
recent studies (Hsieh et al., 2014; Mijatovic-Rustempasic et al., 2017; Bennett et al., 
2019; Parker, 2019; Pollock, 2019). This study aimed at counteracting the previous 
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sampling limitations by using a small cohort to test multiple sequential samples 
following Rotarix
®
 vaccination for one month after each dose using RT-qPCR to 
better define the kinetics of replication in vaccine recipients.  
Infants usually encounter rotavirus at a young age thus vaccination is 
scheduled early in life to minimise the risk of infection with a WT strain and to 
generate better protection against severe disease (Bhan et al., 1993; Bines et al., 
2015, 2018; Vesikari, 2015; Cowley et al., 2017). In this cohort, no vaccine or pan-
rotavirus viral loads were detected at pre-vaccination, suggesting infants had not 
encountered rotavirus before vaccination. The absence of either vaccine or pan-
rotavirus viral loads in the after-a-year samples indicated infants had not encountered 
rotavirus following vaccination (unlikely) or they had (likely) and were protected 
against it. Previous studies have observed Rotarix
®
 shedding in a greater proportion 
of infants after dose 1 (30-80%) than after dose 2 (11-35%) (Bernstein, 1998; 
Vesikari, Karvonen, Korhonen, et al., 2004; Dennehy et al., 2005; Phua et al., 2005; 
Salinas et al., 2005; Ruiz-Palacios et al., 2007; Hsieh et al., 2014; Mijatovic-
Rustempasic et al., 2017) (Chapter 1, section 1.14, Table 1.3) or similarly (30%) 
after both doses in Malawi (Pollock, 2018; Bennett et al., 2019). A recent multicentre 
study that measured Rotarix
®
 vaccine shedding in the UK observed 90% of 
vaccinated infants shedding vaccine virus after dose 1 and 60% after dose 2 (Parker, 
2019). In this cohort vaccine virus was also detected in more infants after dose 1 
(100%) than after dose 2 (91.7%), although not in the same proportion, which may 
be due to a small cohort.  
While Rotarix
® 
is reported to contain 10
6
 CCID50/mL, we quantified stocks as 
2-3 log10 higher, suggesting the vaccine contains more RNA copies than infectious 
particles. Rotarix
®
 viral loads in this UK cohort ranged between 10
3
-10
9
 copies/g of 
faeces with sustained shedding for >3 days after vaccination, suggesting detected 
viral loads were not attributable to inoculum. Since the transit time through the gut in 
Western infants is around 24 hours (Jayanthi et al., 1989; Mihatsch, Hoegel and 
Pohlandt, 2006), a long period of shedding is less likely to be caused by slow 
clearance of inoculum, and more likely to be caused by prolonged viral replication. 
These levels were comparable to copy numbers quantified within vaccine material 
(10
8
 to 10
9
 copies/mL) and to those reported previously in USA-based (1.2 × 10
2
 to 
1.3 × 10
10
 copies/mL of stool) (Mijatovic-Rustempasic et al., 2017) and China-based 
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studies (10
4 
to 10
7
 copies/g of stool) (Hsieh et al., 2014). Rotarix
®
 faecal viral loads 
were two logs lower than those reported in WT infection by others (10
5
 to 10
11 
copies/g of stool) (Kang et al., 2004; Kaplon et al., 2015), as expected for a live-
attenuated virus. Although live virus was not assayed, high and persistent viral loads 
for days after vaccination as well as the actual amount of virus in the gut being much 
higher, were strongly suggestive of active replication. 
In previous studies, peak shedding occurred within the first week after dose 1 
around day 7 (Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 2004; Dennehy 
et al., 2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et al., 2007; Hsieh 
et al., 2014; Mijatovic-Rustempasic et al., 2017) for all or >40% of infants. In this 
cohort shedding also occurred early after dose 1, although within the first week for 
half of the infants or within the second week for the other half, an observation 
facilitated by the comprehensive and longitudinal nature of the sampling. Most of the 
infants with early peak shedding ceased shedding early although not all (individuals 
G, M) and most of the infants with protracted shedding presented late peak shedding, 
with exceptions (individual L).      
In early studies, shedding occurred as early as one or three days after 
vaccination and as late as 28 or 45 days after dose 1 (Bernstein, 1998; De Vos et al., 
2004; Dennehy et al., 2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et 
al., 2007; Hsieh et al., 2014; Mijatovic-Rustempasic et al., 2017; Pollock, 2018). 
Similarly, in this cohort, median longest shedding duration after dose 1 was day 27, 
which suggested that Rotarix
®
 persists in the gut for approximately a month before it 
becomes undetectable in stool. By contrast, shedding was detected beyond 45 days 
after dose 1 in several infants, with the longest shedding detected at more than 70 
days after dose 1 in one of them. These results highlight the possibility that shorter 
shedding detected in previous studies may have been due to a shorter follow up 
period, the lack of continuous sampling or insufficient sampling or recruits; and that 
shedding duration may depend on the recipient’s susceptibility to infection and 
immune response.  
In this cohort, significantly higher viral loads were detected after dose 1 
compared to after dose 2 at both highest and median viral loads, indicating vaccine 
take after dose 1 and a catch-up effect after dose 2. Previous studies in developed 
countries have also quantified higher viral loads after dose 1 with respect to dose 2 
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(Hsieh et al., 2014; Mijatovic-Rustempasic et al., 2017), as opposed to those in a 
LIMC such as Malawi, with similar peak viral loads after both doses (Pollock, 2018; 
Bennett et al., 2019). Moreover, the highest viral loads of breastfed infants were 
lower than those of mixed-fed infants after dose 1 and dose 2 (although non-
significantly), as previously observed in a larger cohort where reduced Rotarix
®
 
shedding was detected in breastfed infants (Bautista-Marquez et al., 2016).  
Regarding shedding patterns, in this cohort of 12 infants, it was clear that 
vaccine virus shedding occurred in all. Profile 1 showed apparent effective control of 
virus shedding after one dose from the 2-dose regimen: high initial viral loads 
decreasing within two weeks and suggesting replication followed by rapid control of 
virus shedding after the first dose, with an absence of shedding after the second dose. 
The other early responders (Profile 2) who controlled vaccine virus after the first 
dose with low shedding after the second dose also appeared to present a robust 
immune response through a prime-boost effect following the two doses. In each 
infant there was a window during which vaccine virus was not detected, suggesting 
effective control of viral shedding. A positive sample on the day before dose 2 for 
one individual (K) may be due to a sample labelling mistake or to sample bias with 
virus still replicating at that stage. Of relevance to these profiles, it has been 
previously found that individuals with a non-secretor or FUT2
-/-
 phenotype are 
resistant to severe RVGE by G1P[8] strains (Imbert-Marcille et al., 2014). Given that 
the proportion of individuals with that phenotype in the Caucasian population is 
approximately 20% (Marionneau et al., 2001), these early responders who ceased 
shedding after dose 1 within 15 days (I, H, K; 25%) may be non-secretors. Similarly, 
results in recent studies in Nicaragua (Bucardo et al., 2018) and Malawi  (Pollock et 
al., 2018) have highlighted that “non-secretors” presented reduced Rotarix® 
shedding. Vaccinated infants in Malawi presented Rotarix
®
 shedding patterns 
identified in this cohort (early and late responders and continuous shedders) and a 
large proportion of “low-shedders” who appear to present poor vaccine take 
(Pollock, 2018, 2019). Likewise in another system, Rotarix
®
 replication was found to 
be attenuated in a human intestinal enteroid developed from a non-secretor patient 
(Saxena et al., 2016). However, in the case of this cohort, this is a conjecture since 
no genetic data was available and ethical approval to obtain genetic information on 
these infants is unlikely to be obtained in the future due to the design of the study. 
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Therefore, future studies in a similar cohort would have to be performed to confirm 
this.   
Other infants (Profile 3) did not clear vaccine virus between the doses, 
suggesting they were not able to mount an immune response capable of controlling 
the initial vaccine virus in the one-month period, but they were capable of 
eliminating the virus effectively on receipt of the booster dose. The second dose 
might have had little effect in some of them who were decreasing shedding (D, G) 
and some catch-up effect on those who presented higher viral loads before dose 2 (B, 
E, M). For individual E, the increase in VL from day 14 may be due to a minority 
variant replicating at higher frequency than previously (Chapter 4). A correlation 
between viral loads and Vesikari’s GE severity score was previously observed in WT 
infection (Kang et al., 2004). Hence, the dip in viral loads at day 13 may also be due 
to mild diarrhoea at a previous timepoint of high shedding (>10
6
 copies/g of stool) 
and insufficient replication of the virus around day 13. For individual G, shedding 
after dose 1 might have been fully controlled if there had not been a second dose. It 
was previously observed that children who do not continuously shed rotavirus 
vaccine appear to be protected against severe disease better than extended shedders, 
and to a level similar to that afforded by natural immunity following infection with 
WT rotavirus (Richardson et al., 1998). Protection for infants in this profile may be 
lower than in those who control infection rapidly, although the slow immunity built 
in these infants may be stronger and more mature.   
A fourth profile (Profile 4) was similar to Profile 3 in that vaccine virus was 
shed between doses. However, owing to the reduced timespan of the samples 
available from individual C and to the lack of further samples from individuals F and 
J, it was not possible to obtain a sufficient number of data points to conclusively 
prove clearance of vaccine virus following dose 2. Nevertheless, the absence of 
vaccine/WT virus at the one-year-after-vaccination timepoint suggested elimination 
of vaccine virus in that period. Higher levels of Rotarix
®
 shedding than those 
observed in this cohort have only been reported in infants with severe-combined 
immunodeficiency, with Rotarix
®
 detected at >10
11
 copies/mL at nine days before 
haematopoietic stem cell transplantation and up to 10
6
 copies/mL at six months after 
transplantation  (Rosenfeld et al., 2017) or with Rotarix
®
 detected at >10
12
 
copies/mL before gene therapy dropping to undetectable 270 days after first infusion 
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(N. C. Patel et al., 2012). Infants in this cohort may have developed a less rapid 
vaccine response in Profile 4, possibly as a result of a low mucosal immune 
response. This variability in vaccine uptake and shedding duration points towards a 
difference in susceptibility to infection by G1P[8] RV strain as well as to differences 
in immune response among the cohort in this study.  
All infants and especially the continuous shedders described above may act as 
virus reservoirs if selection of variants in the presence of NAbs takes place as the 
vaccine virus replicates (Richardson et al., 1998). Examples of horizontal 
transmission have been described for RotaTeq
®
 in Australia, the USA and Finland, 
where transmission of vaccine and vaccine-derived strains was observed within two 
weeks of vaccination in healthy and immunodeficient contacts, in some cases 
causing RVGE (Payne et al., 2010; Yen, Jakob, et al., 2011; Bowen and Payne, 
2012; Donato et al., 2012; Hemming and Vesikari, 2012; Wikswo et al., 2019). In 
the case of Rotarix
®
, there are a number of reports on potential, occasional and 
asymptomatic horizontal transmission of vaccine derived virus from vaccinated to 
unvaccinated twins (Dennehy et al., 2005) and from vaccinated infants to 
unvaccinated infants -vaccine strain confirmed in this study- in the clinical setting or 
community (Phua et al., 2005). Another study reported detection of vaccine strains in 
unvaccinated infants who presented GE symptoms and needed treatment (Boom et 
al., 2012). A study in the Dominican Republic assessed horizontal transmission of 
Rotarix
®
 where contacts acquired the vaccine strain without developing RVGE 
symptoms, indicating Rotarix
®
 may provide indirect protection to unvaccinated 
individuals (Rivera et al., 2011). In another study in Taiwan, Rotarix
®
 shedding was 
found to be significantly higher than that of RotaTeq
®
 probably due to Rotarix
®
 
containing a RVA G1P[8] human strain which may replicate better in the intestine, 
and suggesting horizontal transmission may be more likely in infants vaccinated with 
Rotarix
® 
(Hsieh et al., 2014). A study in Japan reported suspected horizontal 
transmission of Rotarix
®
 in infants with AGE and other enteric pathogens detected 
apart from vaccine-derived and WT rotavirus strains (Kaneko et al., 2017). Another 
study in Japan detected low transmission of Rotarix
®
 within a foster home without 
detection of the vaccine strain in symptomatic unvaccinated individuals (Miura et al., 
2017) and another study in Malawi also detected low transmission of Rotarix
®
 within 
the household with probably very little effect to contacts (Bennett et al., 2019).  
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Another group in Japan studied the possibility of rotavirus vaccine virus 
dissemination among neonates in the intensive care unit under contact precautions: 
Rotarix
®
 vaccinees presented different shedding patterns with longer shedding after 
first dose and no unvaccinated infants shedding detectable vaccine virus (Hiramatsu 
et al., 2018). In the UK, rotavirus vaccination is recommended in the neonatal 
intensive care unit despite a risk of horizontal transmission since the benefits of 
protection against RVGE and other derived conditions such as necrotizing 
enterocolitis are larger than the risk of vaccination in stable neonates (Jaques et al., 
2014, 2015; Ladhani and Ramsay, 2014). In contrast, although the risk of 
transmission of a vaccine or vaccine-derived variant is lower than that of WT RV 
due to lower levels and shorter periods of replication, the immunocompromised are 
advised to avoid vaccination and contact with vaccinees especially after the first dose 
(Anderson, 2008). Cases of acute RVGE and/or continuous shedding have been 
described in immunocompromised individuals after rotavirus vaccination (N. C. 
Patel et al., 2012; Kaplon et al., 2015; Rosenfeld et al., 2017). Therefore, any 
potential horizontal transmission from the cohort of infants studied in this work may 
result in herd immunity or may pose a health risk to susceptible or 
immunocompromised individuals. Moreover, if vaccine-derived variants with 
pathogenic potential arise either in early responders or in continuous shedders they 
may also pose a health risk to healthy individuals. The use of NGS will help 
elucidate minority variants that increase throughout the shedding period following 
vaccination.  
Finally, the study of PCV1 in stool of vaccine recipients highlighted that it 
only transiently passes through the gut of vaccinated infants. It was detected in the 
range of 10
3
-10
4 
copies/g, similarly to a previous report detecting PCV1 DNA in 
stool of Rotarix
®
-vaccinated infants in the USA (Mijatovic-Rustempasic et al., 
2017). Mijatovic-Rustempasic and colleagues detected very little PCV1 and there 
was no overt evidence of virus replication: lower VLs of PCV1 in stool with respect 
to the vaccine stock and a short-lived pulse of VL followed by a rapid drop to levels 
below the limit of detection suggested that PCV1 did not replicate in the gut of 
vaccine recipients following vaccination. Similarly in this cohort, although the 
possibility of low-level replication below the detection limit of the assay or in 
another organ could not be ruled out and live virus was not assayed, the lack of 
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persistent virus detection in stool also suggested that PCV1 did not replicate, 
transiently passed through the gastrointestinal tract of infants and was cleared after 
both doses. Although we have not studied whether PCV1 may enhance Rotarix
®
 
replication (which would require cell culture co-infectivity studies), it appeared that 
PCV1 infection or replication were not enhanced by rotavirus vaccine.   
Studies on genetic diversity of PCV1 from pigs in Hungary and in the UK 
have found very low diversity in strains sequenced two decades apart. This suggests 
that genetic stability of porcine circoviruses may mean PCV1 is at an advanced state 
of evolution (Tombácz et al., 2014) and it may explain the differential non-
pathogenic adaptation of PCV1 in pigs (Cortey and Segalés, 2012). Moreover, since 
Rotarix
®
 is not the only source of PCV1, which can also be found in pork products 
and in human faeces (Li et al., 2010), infants may be exposed to it regardless of 
rotavirus vaccination as suggested by a study in 2017 in which 0.3% infants who 
received placebo were seropositive for PCV1 compared to 1% seropositive Rotarix
®
 
vaccine recipients (Han et al., 2017). Further studies would be needed to elucidate 
whether PCV1 enhances Rotarix
®
 replication (cell culture co-infectivity studies), as 
well as being needed to elucidate whether transient PCV1 may be horizontally 
transmitted to contacts. 
A few caveats considered in the design of this study may have impacted on 
results. Stool samples were divided into small working aliquots of 200 mg to 1 g, 
therefore potentially having an effect on quantified copy numbers due to sampling 
bias and stool being heterogeneous. The faecal suspensions used to extract nucleic 
acid were prepared on the day of extraction from faecal material to prevent any extra 
degradation occurring during storage of faecal suspensions. Due to low sample 
availability and to ensure enough sufficient samples were available for subsequent 
analyses, VLs were tested as technical replicates from single faecal suspensions, a 
more homogeneous sample than faecal matter. The timepoints available from each 
infant were not identical, so comparisons were made between the most relevant 
events during the vaccination period: Days of peak shedding (early from days 2-6 
and late from days 7-15), last day of shedding, highest and median viral loads. 
Despite the small cohort, given the large number of samples available from each 
infant, the granularity of data allowed for effective viral shedding profiling and 
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comparison between infants. Regarding low PCV1 VLs, at specific days for which 
samples were not provided, we may have missed highest VLs.  
This is the first study to undertake a comprehensive assessment of 
longitudinal faecal shedding of Rotarix
®
 in a cohort of vaccinated infants. The viral 
shedding data profiling point to variation in the immune response and control of 
vaccine virus shedding. Furthermore, having confirmed the veracity of apparent 
outlier data points of VL profiles, the immune pressure on the vaccine virus can be 
considered through genetic variation. The opportunity for the vaccine virus to mutate 
or adapt in the context of a developing immune response is addressed through next 
generation sequence analysis of virus at selected timepoints from the cohort infants 
vaccinated with Rotarix
®
 (Chapter 4). 
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Chapter 4: Genetic stability of faecal 
rotavirus RNA in a cohort of infants 
vaccinated with Rotarix
®
 in the UK 
4.1 Introduction  
The fact that some live-attenuated vaccines have been found to present 
mutations that pose a risk to vaccine efficacy and/or safety (e.g. Cann et al., 1984; 
Victoria et al., 2010) has highlighted the importance of monitoring genetic 
consistency of vaccines in use. Although some studies had assessed the genetic 
stability of WT RV strains in cell culture and others have pointed at certain sequence 
or amino acid changes that could be associated with attenuation (Flores, Sears, et al., 
1988; Tsugawa and Tsutsumi, 2016), the genetic changes conferring attenuation to 
Rotarix
®
 have not been well characterised (Chapter 1, section 1.15). Recently, a viral 
RNA in-house sequence of Rotarix
®
 vaccine stocks was established at the NIBSC 
(Mitchell, Lui, et al., unpublished): In Rotarix
®
 vaccine material, 25 SNP loci were 
identified at consistent frequencies across independent bulks and fills. Eighteen of 
these were present in both virus harvest bulks and final fills and spanned six genes 
(VP1, VP3, VP4, VP6, VP7 and NSP1). Thirteen SNP loci were identified in VP4 
and one of them was the same as WT with a mean frequency greater than 50% 
(nucleotide position 1103). Genes encoding for VP1, VP3, VP6 and VP7 and NSP1 
contained one mutation each. For most SNP loci (except two positions in the VP4 
gene) the variant frequency was <17%. There were 23 non-synonymous amino acid 
substitutions identified in the 25 SNPs detected, 20 of them resulting in a residue 
different to that seen in WT strains and vaccine virus, two of them resulting in the 
residue observed in WT and one of them coding for a residue seen in both WT and 
vaccine virus. Most of the changes were identified in VP4, suggesting that mutation 
of the outer capsid protease-sensitive protein was key for cell culture adaptation of 
the vaccine virus during manufacture, as well as mutation of the glycoprotein (VP7) 
and inner capsid protein (VP6), viral polymerase complex and interferon antagonist 
(VP1+VP3 and NSP1). Changes in these proteins are likely to be crucial for cell 
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culture adaptation, although they may have occurred earlier in the generation of a 
candidate vaccine virus and be maintained during manufacture. These data showed a 
very high nucleotide identity between virus harvest bulks and final fills, suggesting a 
consistent vaccine manufacturing process (Mitchell, Lui, et al., unpublished).  
As described earlier (Chapter 3) and in previous studies (Hsieh et al., 2014; 
Mijatovic-Rustempasic et al., 2017), Rotarix
®
 is shed throughout after both doses at 
viral loads similar to or lower than vaccine inoculum and shedding patterns can vary 
from a few days to weeks. Sustained replication of vaccine inoculum in vaccine 
recipients is likely to lead to the establishment of minority variants that may persist 
and confer an advantage on the virus as vaccine-derived variants, as observed 
previously (Chapter 1, section 1.8).  
4.2 Aims 
The aim of the work presented in this chapter was to assess the genetic 
stability of Rotarix
®
 during replication in vaccinees by identifying and quantifying 
SNPs differing from the published Rotarix
®
 reference sequence (GenBank ref. nos. 
JX943604- JX943614) (Gautam et al., 2014) and from the NIBSC-generated 
Rotarix
®
 sequence (Mitchell, Lui, et al., unpublished) at relevant timepoints for each 
viral load profile (section 4.4.1). A second aim was to determine the relationship 
between Rotarix
®
 faecal shedding and vaccine and vaccine-derived variants in this 
population.   
4.3 Experimental methodology  
To address the vaccine genetic stability, faecal material was available as 
described (Chapter 3). Detailed materials and methods are described in Chapter 2 and 
Appendix I. Faecal samples were processed and stored until used (Chapter 2, 
sections 2.1.9 and 2.2.1). Some samples were of low quantity owing to stooling 
patterns and the analysis reflected this. To maximise the information obtained from 
this limited resource, the reproducibility of data in this chapter was addressed by 
sequencing relevant timepoints along the viral load profile of each infant in triplicate 
from independent faecal suspensions. Rotarix
®
 and/or rotavirus from stool of 
vaccinees was extracted following the methods in Chapter 2, section 2.2.3.3. Next, 
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cDNA synthesis and PCR amplification were performed on extracted RNA (Chapter 
2, section 2.2.4) and purified and sequenced using the Nextera
®
 XT DNA Library 
Preparation kit v2 following the methods in Chapter 2, section 2.2.6. Bioinformatic 
analysis (Chapter 2, section 2.2.7) and further data analysis (Chapter 2, section 2.2.8) 
were performed in collaboration with the NIBSC NGS core facility. Criteria were set 
to validate data for SNP calling as having a quality score of at least Q30, coverage of 
≥100 mean reads for each studied position and a mean frequency of ≥1% observed in 
≥2 of 3 replicates. The longitudinal analysis of SNPs focused on describing the type 
of mutation, whether it had been identified in vaccine or stool material, whether it 
had been detected in several timepoints and the fluctuation of its frequency over the 
timepoints tested. Molecular modelling of selected amino acid changes was 
performed with LigPlot
+
 (Laskowski and Swindells, 2011) and RasMol (Sayle and 
Milner-White, 1995) using the Protein Databank resolved rotavirus structures 
available.  
4.4 Results  
4.4.1 Sample set 
Timepoints provided were not equivalent between infants due to stooling 
patterns and parental collection. Where low amounts of stool were available, priority 
was assigned to Rotarix
®
 faecal shedding quantification throughout the sample 
collection, followed by NGS of relevant timepoints from each infant, based on their 
shedding profiles: Timepoints of peak shedding, timepoints just before a large 
decrease in shedding and timepoints during sustained shedding. All the timepoints 
chosen presented viral loads of ≥104 viral copies/mL (Chapter 3). From one to five 
timepoints from each infant were sampled and assayed throughout the two-month 
vaccination period.  
Due to the complexity of amplifying all 11 RV segments from limited faecal 
material (Appendix II, section 8.2.1.3, subsection ‘sample set’), genetic 
characterization was performed on genes encoding VP4, VP7, VP6 and NSP4. These 
segments were chosen on the basis of reported selection pressure in cell culture 
(VP4, VP7, NSP4) (Tsugawa and Tsutsumi, 2016) and number of mutations during 
manufacture (VP4, VP6, VP7) (Mitchell, Lui, et al., unpublished). Moreover, VP4 
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and VP7 were identified as targets of neutralizing heterotypic protection in humans 
(Nair et al., 2017) and VP6 as the target of neutralizing protection in vivo (Burns et 
al., 1996; Feng et al., 2002; Corthésy et al., 2006). NSP4 was also chosen on the 
basis that it may induce immunogenicity as a viral enterotoxin (Ball et al., 1996). 
The data presented below were generated using Nextera
®
 kit libraries as previously 
described.  
4.4.2 Genetic stability of rotavirus faecal RNA in infants after Rotarix
®
 
vaccination  
In this cohort of 12 infants, SNP profiles were generated for each of the 
vaccine recipients in gene segments encoding VP4, VP7, VP6 and NSP4 and from 
one to five timepoints during the vaccination period (Table 4.1). These SNPs were 
compared to the vaccine reference sequence and in-house sequence, assessed against 
WT RVA human G1P[8] (GenBank reference numbers JN887809, JN887818, 
JN887819, JN887814) and compared to human WT consensus by BLAST in 
Geneious (>92% identity) in order to identify potential WT reversion mutations. The 
SNP frequency was quantified as the percentage of sequencing reads in which a SNP 
was detected along the genome. It indicated differences between SNP profiles and 
vaccine material and, therefore, between viral quasispecies as Rotarix
®
 replicated in 
each infant. Each mutation was identified at a different frequency at each timepoint, 
viral segment and infant. For some of the genes at some timepoints for some infants, 
there were no SNPs identified due to the sequence not differing from the reference 
sequence or due to low amounts of DNA following extraction and RT-PCR (tested 
on Bioanalyzer chip after RT-PCR and agarose-gel electrophoresis). The SNPs 
identified were described based on the nucleotide position from A in first codon 
encoding the first methionine for each gene segment: a 12 nucleotide shift (from 
original ref. no. JX943612) when aligned to WT GenBank reference JN887809 for 
gene segment 4 (encoding VP4); the original nucleotide position (in ref. no. 
JX943614) when aligned to WT GenBank reference JN887818 for gene segment 9 
(encoding VP7); the original nucleotide position (in ref. no. JX943613) when aligned 
to WT GenBank reference JN887819 for gene segment 6 (encoding VP6); and a 41 
nucleotide shift (from original ref. no. JX943607) when aligned to WT GenBank 
reference JN887814 for gene segment 10 (encoding NSP4).  
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The SNP genetic profile of Rotarix
®
 vaccine material was validated at the 
NIBSC (Mitchell, Lui, et al., unpublished). The sequence was similar to the 
previously published Rotarix
®
 sequence (GenBank ref. nos. JX943604- JX943614) 
(Gautam et al., 2014), but it presented low level SNPs (Mitchell, Lui, et al., 
unpublished). Within the four gene segments 4, 9, 6 and 10 across infants, timepoints 
and at a varying number of repeats (one to three repeats), 270 SNP loci were 
identified (Table 4.2). Following the criteria described in section 4.3, a total of 81 
SNP loci were identified within the four genes encoding VP4, VP7, VP6 and NSP4 
(Figs. 4.1, 4.5, 4.9 & 4.13), an increase with respect to the 25 SNPs identified in 
vaccine material (Mitchell, Lui, et al., unpublished). In vaccine material, 23 of the 25 
SNPs appear at frequency ≤17%, while in stool mutations were detected at similar or 
higher frequencies than in vaccine. No SNPs were identified under the criteria 
described in section 4.3 in stool from one of the 12 infants in this cohort (individual 
G) for any of the four gene segments studied (Table 4.1). Single nucleotide 
polymorphism loci were identified in eight infants for gene segment 4, in four infants 
for gene segment 9, in two infants for gene segment 6 and in 10 infants for gene 
segment 10. One infant (individual G) yielded low amounts of RNA that resulted in 
low coverage and mapping to RVA for all repeats for gene segment 4, and all but one 
repeat for gene segments 9 and 6. Low level SNPs (<15%) were identified in single 
replicates for gene segment 10 in stool from this infant. 
 
Table 4. 1. Timepoints tested by next generation sequencing in individuals B-M 
for viral segments encoding VP4, VP7, VP6 and NSP4. Individual, timepoints 
tested after dose 1 and after dose 2 (with respect to dose 1) and timepoints where 
enough material was available for sequencing and which were positive for reads 
mapping to rotavirus following the criteria in section 5.3.  
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Table 4. 2. Summary of SNPs identified in genes encoding VP4, VP7, VP6 and NSP4. Individuals, number of SNPs, classification of 
mutation, number identified previously in vaccine material, SNP frequencies and SNPs identified in several children. Individ., individual; SNP, 
single nucleotide polymorphism; S, synonymous; NS, non-synonymous; WTrev, reversion to WT human RVA G1P[8] (GenBank reference 
numbers JN887809, JN887818, JN887819, JN887814,); V, previously identified in vaccine material (Mitchell, Lui, et al., unpublished); common 
SNPs, SNPs common to several infants; comments, days when SNPs identified. White, full 3 repeats or 2 repeats for most; darkest grey, some 3 
repeats some 2 repeats some 1 repeat; middle dark grey, some 2 repeats some 1 repeat; lightest grey, only 1 repeat for most.  
 
Encoded 
protein 
Individ. 
SNP 
No. 
S NS WTrev 
Stop 
codon 
V SNP frequency (%) Common SNPs 
VP4 
B 14 5 8 1   3 
2.2-100.0; 10 SNPs <14% (4 S, 6 NS), 1 SNP at 70-73% (1 
NS), 2 SNPs at >50-100% (1 S, 1 NS), 1 SNP at 92-100% 
(1 WTrev) 
5 1 S; 3 NS; 1 WTrev 
C 9 2 5 2   3 
2.4-100.0; 4 SNPs <4% (2 S, 2 NS), 1 SNP 53-55% (1 NS), 
1 SNP 65-66% (1 NS), 1 SNP 35-95% (1NS), 1 SNP 97-
99% (1 WTrev), 1 SNP 97-100% (1 WTrev) 
6 4 NS; 2 WTrev 
D 27 5 20 2   10 
1.3-100.0; 25 SNPs <34%, 1 SNP >50% (1 NS), 1 SNP 
>50-100% (1 WTrev) 
14 1 S; 11 NS; 2 WTrev  
E 9 1 6 2   6 
1.2-100.0; 5 SNPs <16% (5 NS), 1 SNP 4-95% (1 NS), 1 
SNP 98-100% (1 WTrev), 2 SNPs 100% (1 S, 1 WTrev) 
9 1 S; 6 NS; 2 WTrev 
F 17 2 13 2   9 
1.2-100.0; 14 SNPs <22%, 2 SNPs >50% (1 NS, 1 WTrev), 
1 SNP >50-100% (1 WTrev) 
12 10 NS; 2 WTrev 
G                   
H 13   12 1   11 
1.3-65.0; 12 SNPs at <19% (12 NS), 1 SNP at 57-65% (1 
WTrev) 
12 11 NS; 1 WTrev 
I 15 4 9 2   8 1.3.99.5; 14 SNPs at <35%, 1 SNP at 97-99% (WTrev) 11 2 S; 8 NS; 2 WTrev 
J 41 12 28 1   8 
1.0-100.0; 35 SNPs at <50%, 4 SNPs >50% (4 NS), 1 SNP 
>50-96% (1 NS), 1 SNP 90-100% (1 WTrev) 
13 2 S; 10 NS; 1 WTrev 
K 11 2 8 1   8 
1.2-91.7; 10 SNPs <19% (2 S, 8 NS), 1 SNP 89-92% (1 
WTrev) 
9 1 S; 7 NS; 1 WTrev 
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L 12 2 8 2   7 
1.7-100.0; 9 SNPs <20% (2 S, 7 NS), 1 SNP 57-100% (1 
WTrev), 2 SNPs >95% (1 NS, 1 WTrev) 
8 6 NS; 2 WTrev 
M 13   11 2   8 
1.2-98.7; 11 SNPs <50%, 1 SNP 68-72% (1 NS), 1 SNP 94-
99% (1 WTrev) 
11 9 NS; 2 WTrev 
 
 
 
Encoded 
protein 
Individ. SNP No. S NS 
Rev. to 
WT 
Stop 
codon 
V SNP frequency (%) Common SNPs 
VP7 
B 4 2 1   1   
4.2-99.9; 1 SNP <5% (1 S), 2 SNPs < 27% (1 S, 1 
STOP), 1 SNP at 99.9% (1 NS) 
1 1NS 
C 6 1 4 1   1 2.0-17.3 1 1 WTrev 
D                   
E 2   2       8-30.6     
F 3 2 1       
9.9-89.8; 2 SNPs <12% (1 S, 1 NS), 1 SNP at 
89.9% 
    
G 1 1         7.3   1 S 
H 2 2         3.6-6.0     
I                   
J 8 4 3 1   1 
3.4-32.5; 6 SNPs <32% (3 S, 3 NS), 1 SNP 6-34% 
(1 S), 1 SNP 6-33% (1 WTrev) 
1 1  WTrev 
K                   
L 3   3       5.5-47.8     
M 9 4 3 1 1 1 
4.7-99.9; 8 SNPs <50%, 1 SNP up to 99.9% (1 
WTrev) 
1 1  WTrev 
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Encoded 
protein 
Individ. SNP No. S NS 
Rev. to 
WT 
Stop 
codon 
V SNP frequency (%) Common SNPs 
VP6 
B 9 3 6       
1.2-31.9; 5 SNPs <4.7% (2 S, 3 NS), 4 SNPs 16-
32% (1 S, 3 NS) 
1 1 NS 
C 5 2 3       1.4-6.2 1 1S 
D 1   1       4.1     
E 9 4 5       
1.1-99.9; 8 SNPs <10.7% (4 S, 4 NS), 1 SNP at 
99.9% (1 NS) 
2 2 NS 
F 4 2 2       1.7-34.0     
G 2 1 1     1 4.1-51.9 1 1 S 
H 4 1 3       
1.3-17.3; 3 SNPs <3.6% (1 S, 2 NS), 1 SNP at 
17.3% (1 NS) 
1 1 NS 
I 2   2       
1.7-8.7; 1 SNP at 8.7% (1 NS), 1 SNP at 1.7% (1 
NS) 
    
J 13 6 7     1 1.0-16.6; 12 SNPs <8.7%, 1 SNP 12-16% (1 S) 6 2 S; 4 NS 
K 9 4 5       
1.1-18.47; SNPs <3.9% (3 S, 4 NS), 2 SNPs 15.-
19% (1 S, 1 NS) 
3 1 S; 2 NS 
L 6 4 2       1.0-17.7     
M 10 3 7     1 1.0-5.7 1 1 S 
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Encoded 
protein 
Individ. SNP No. S NS 
Rev. to 
WT 
Stop 
codon 
V SNP frequency (%) Common SNPs 
NSP4 
B 
10 1 9       
1.0-100.0; 8 SNPs <4.4% (1 S, 7 NS), 1 SNP up to 
63% (1 NS), 1 SNP 18-92-100% (1 NS) 
5 5 NS 
C 
8 1 6 1     
1.5-85.4; 7 SNPs <15% (1 S, 5 NS, 1 WTrev), 1 
SNP 83-86% (1 NS) 
6 
1 S; 6 NS; 1 
Wtrev 
D 9 2 5 1 1   1.1-37.5; 8 SNPs <4.1%, 1 SNP 35-37% (1 NS) 3 2 NS; 1 WTrev 
E 
4   3 1     
1.1-100.0; 3 SNPs <5.3% (2 NS, 1 WTrev), 1 SNP 
at 100% (1 NS) 
3 2 NS; 1 WTrev 
F 
6 2 3 1     
1.6-71.9; 4 SNPs <50%, 1 SNP >50% (1 NS), 1 
SNP >50-72% (1 NS) 
3 2 NS, 1 WTrev 
G 
5 3 1   1   1.1-13.9 
    
H 7 1 6       1.0-7.8 1 1 NS 
I 
5 1 4       
1.2-12.9; 3 SNPs <3.7% (3 SN), 1 SNP at 10.8% 
(1 S), 1 SNP 7.9-12.9% (1 NS) 
2 2 NS 
J 
25 6 17 2     
1.1-80.7; 23 SNPs at <50%, 1 SNP 50-61% (1 
NS), 1 SNP 50-81% (1 NS) 
8 7 NS; 2 WTrev 
K 5 3 2       1.1-2.6     
L 
12 1 10 1     
D1 2.4-36.4; D2 1.3-2.9; 11 SNPs <23% (1 S, 9 
NS, 1 WTrev), 1 SNP 35-36% (1 NS) 
7 6 NS; 1 Wtrev 
M 7   6 1     1.2-41.5; 7 SNPs <15%, 1 SNP 39-42% (1 NS) 6 5 NS; 1 WTrev 
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Gene segment 4, encoding VP4 
In total, 39 SNP loci were found in gene segment 4, encoding VP4: 13 
synonymous and 26 non-synonymous, with two reversions to WT identified (Table 
4.3, Fig. 4.1). The number of non-synonymous SNPs more than doubled with respect 
to vaccine material: 13 SNPs (Mitchell, Lui, et al., unpublished). Three pairs of 
contiguous SNP loci affecting an amino acid each were identified in one and nine 
infants: nucleotide positions 1087 and 1088, leading to amino acid change N363G in 
infant I; and nucleotide positions 1090 and 1092, leading to amino acid change 
M364V in infants J, I, D, F, M, H, K, L, and E, respectively. Of all the SNP loci 
identified in VP4, 11 were detected previously in vaccine material (Mitchell, Lui, et 
al., unpublished) appearing at similar or higher frequencies in stool of vaccine 
recipients. Twenty-seven SNP loci were novel in stool, appearing at varying 
frequencies from 1-100%.  
All the SNP loci previously identified in vaccine material were non-
synonymous. Ten of them diverged from virus in vaccine material, human WT 
G1P[8] sequence (GenBank reference JN887809) and human WT consensus. 
Mutation case A1090G plus G1092A leading to amino acid substitution M364V also 
diverged from virus in vaccine material, human WT G1P[8] sequence (GenBank 
reference JN887809) and human WT consensus. Mutation A1103G leading to amino 
acid substitution K368R diverged from virus in vaccine material, converging towards 
human WT G1P[8] sequence (GenBank reference JN887809) and human WT 
consensus. Mutation, T1153C leading to amino acid substitution Y385H, diverged 
from virus in vaccine material and did not converge towards human WT G1P[8] 
sequence (GenBank reference JN887809) or human WT consensus.  
From the novel SNP loci, 17 were non-synonymous. Of those, 14 diverged 
from virus in vaccine material, human WT G1P[8] sequence (GenBank reference 
JN887809) and human WT consensus. Mutation cases T796A plus A797G leading to 
amino acid substitution Y2666S and A1087G plus A1088G leading to amino acid 
substitution N363G also diverged from virus in vaccine material, human WT G1P[8] 
sequence (GenBank reference JN887809) and human WT consensus. Mutation 
T761C leading to amino acid substitution I254T diverged from virus in vaccine 
material and human WT consensus and converged towards human WT G1P[8] 
sequence (GenBank reference JN887809). Mutation G1338T leading to amino acid 
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substitution L446F diverged from virus in vaccine material and human WT 
consensus.  
A triallelic SNP locus at nucleotide position 797, mutation A>C, leading to a 
non-conservative amino acid substitution Y266S was previously detected in vaccine 
material at 0.8-3.5% frequency (Mitchell, Lui, et al., unpublished). This SNP locus 
was not detected in stool of the cohort studied, although the other allele (nucleotide 
substitution A>G, amino acid substitution Y>C) was detected in stool of individual 
H, at day 3 after dose 1 and frequency of 5%. 
Out of the 39 SNP loci found in VP4, 24 were present in faecal matter from 
one infant. Most of these SNP loci appear transiently at low frequency (<30%). Other 
SNP loci present frequencies that are initially low and increase by the latest 
timepoint. To focus the data analysis, SNP loci identified in ≥3 infants were further 
investigated. Out of these 12 SNP loci, nine had been detected in vaccine material 
previously (Mitchell, Lui, et al., unpublished) and three were novel with respect to 
vaccine in-house sequence (Table 4.3), and some had also been previously identified 
in stool within this project (segments encoding VP4, VP7 and VP6; Appendix II, 
Preliminary data).  
Of those nine SNP loci previously identified in Rotarix
®
, the locus at 
nucleotide position 754, mutation G>A, led to non-conservative amino acid 
substitution D252N in the VP8* subunit (Fig. 4.3). In Rotarix
®
, D252N was found at 
frequencies from 13.8-16.6% (Mitchell, Lui, et al., unpublished) while in stool it was 
found at either early or late single timepoints in four infants (individuals D, H, K, L) 
at similar frequencies <20% (Table 4.3, Fig. 4.2). Molecular modelling of VP4 at this 
position was performed using LigPlot
+
 and RasMol (Fig. 4.4 C) and the Protein 
Databank Rhesus rotavirus VP4 structure (PDB entry 4V7Q). This analysis predicted 
that phenylalanine (F) 252 formed hydrogen bonds with aspartic acid (D) 249 and 
with asparagine (N) 253. A negatively charged amino acid like aspartic acid (D) (in 
vaccine material) and a polar uncharged amino acid with a similar structure such as 
asparagine (N) (in stool) would likely present different interactions than hydrophobic 
phenylalanine (F).  
A cluster of SNP loci in the VP5* subunit between nucleotides 1088 and 
1162, corresponding to amino acids 363 to 388, was detected at high frequency 
variation (>50% to >90%). These are near and within the putative fusion domain of 
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the virus: amino acids 384 to 401 (Mackow et al., 1988; Dormitzer et al., 2004; 
Trask et al., 2010). The changes observed in the proposed hotspot were already 
present in vaccine material at a range of frequencies from 1.1-59.3% (Mitchell, Lui, 
et al., unpublished). In stool, the frequencies were either similar or higher than those 
in vaccine material (Table 4.3).  
Within the variation hotspot in VP5*, there were SNP loci affecting amino 
acids N363S and M364V/I (Fig. 4.3). In Rotarix
®
, N363S was found at 1.1-1.8% 
frequency, M364V at 6.2-9.6% frequency and M364I at 4.1-5.9% frequency 
(Mitchell, Lui, et al., unpublished). In stool, they were identified in seven, nine and 
ten individuals respectively, at similar frequencies as in vaccine material and high 
(>50%) and very high (>90%) for some infants by the latest timepoints (Table 4.3, 
Fig. 4.2). Their increase or decrease in frequency goes parallel to the increase or 
decrease in viral loads in stool. They were molecularly modelled (Fig. 4.4 D), 
showing that glutamic acid (E) 363 was predicted to form hydrophobic contacts with 
isoleucine (I) 360 and threonine (T) 399, and T364 with aspartic acid (D) 400. The 
polar or hydrophobic changes are likely to maintain similar interactions.  
Of interest, the locus at nucleotide position 1103, mutation A>G, leading to a 
conservative amino acid substitution K368R (Fig. 4.3) was found in vaccine material 
at approximately 50-60% (Mitchell, Lui, et al., unpublished), while in stool of 
vaccine recipients it appeared at >50% up to 99-100% in several infants after both 
doses (individuals B, C, D, F, J, L) and in several other infants after dose 1 
(individuals E, H, I, K, M) (Table 4.3, Fig. 4.2). Those infants where this mutation 
was identified after both doses are continuous shedders or shed between doses and 
those where the mutation was identified only after dose 1 control shedding after dose 
1 (except individual L, who presented this mutation after dose 2 after viral load 
control after dose 1). Depending on timepoints of measurement, SNP frequency 
increased or decreased in parallel with viral loads. Individual J stands out as a 
continuous shedder in whose stool this mutation was maintained along the 
vaccination period at very high frequencies. This amino acid substitution K368R was 
molecularly modelled (Fig. 4.4 D), showing that threonine (T) 368 was predicted to 
form hydrophobic interactions with other atoms within the polypeptide chain and 
with T582. A positively charged amino acid such as tyrosine (Y) or arginine (R) will 
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likely establish other molecular interactions different to a hydrophobic amino acid 
such as T.  
Within the variation hotspot region in VP5*, two more variant SNP loci at 
nucleotide positions and mutations T1153C and A1162C, corresponding to amino 
acid substitutions Y385H and I388L fall within the limits of the virus fusion domain 
(amino acids 384 to 404) (Fig. 4.3). In Rotarix
®
, Y385H was identified at 12.1-
19.2% frequency (Mitchell, Lui, et al., unpublished). In stool, it was identified in 
eight vaccinees (individuals, J, D, F, M, B, H, K, L) at similar frequencies as in 
vaccine material (Table 4.3, Fig. 4.2), except for individual J, whose detected SNP 
frequency increased from after dose 1 until before dose 2 up to 80% and then 
decreased down to 50% by the latest timepoint tested. Molecular modelling of VP4 
(Fig 4.10 E) showed that alanine (A) 385 was predicted to form a hydrogen bond 
with threonine (T) 381 and some hydrophobic contact with methionine (M) 392. This 
hydrogen bond is likely to be similar in Rotarix
®
 presenting a tyrosine (Y) at amino 
acid 385 and in stool of vaccine recipients presenting a histidine (H) since it is 
formed through the amine group. However, the hydrophobic nature of the alanine 
(A) would be disrupted with the aromatic ring of the tyrosine (Y) and the aromatic 
and positive charge of the histidine (H), which may disrupt the protein structure. 
The conservative substitution at amino acid I388L is located in epitope region 
5-1 (Zeller et al., 2012) (Fig. 4.3). In Rotarix
®
, it was found at 2.7-4.8% frequency 
(Mitchell, Lui, et al., unpublished). In stool, it was identified in nine infants 
(individuals J, I, D, F, M, H, K, E, C) at similar frequencies as in vaccine material 
and high frequencies (>50%) in individual C after dose 1, although it decreased to 
low frequencies similar to vaccine after dose 2 (Table 4.3, Fig. 4.2). Molecular 
modelling of VP4 (Fig 4.10 E) showed that the side chain hydroxyl group in serine 
(S) 388 was predicted to form some hydrophobic contact with threonine (T) 322, 
likely a hydrogen bond since side chains of serine and threonine are hydrophilic. In 
the case of I388L, one hydrophobic amino acid would be substituted by another 
hydrophobic one, potentially with a less significant effect than if the change was 
non-conservative.  
After the variation hotspot, another locus was identified at nucleotide position 
1409 in VP5*, mutation T>C, leading to non-conservative amino acid substitution 
I470T, at the base of the β-barrel (Fig. 4.3). In Rotarix®, I470T was detected at 
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frequencies 6.3-10.4% (Mitchell, Lui, et al., unpublished). In stool, it was detected in 
seven vaccine recipients (individuals J, I,  F, M, H, K, E) at similar frequencies to 
vaccine material (<11%) or <20%, except for individual F after dose 1 whose 
frequency was identified at just over 50% and then decreased to levels similar to 
vaccine material after dose 2 (Table 4.3, Fig. 4.2). Molecular modelling of VP4 (Fig. 
4.4 F) showed that asparagine (N) 470 was predicted to form hydrogen bonds with 
phenylalanine (F) 466 and glutamine (Q) 467, as well as some hydrophobic contacts 
with further amino acids such as alanine (A) 509. These contacts are likely to differ 
in Rotarix
®
, which presented a hydrophobic amino acid as isoleucine (I) 470. 
However, threonine (T) 470 in stool of vaccine recipients is likely to present similar 
interactions as a polar uncharged amino acid.  
Another locus identified at nucleotide position 1435 in VP5*, mutation T>C, 
led to non-conservative amino acid substitution Y479H at the base of the β-barrel 
(Fig. 4.3). In Rotarix
®
, Y479H was identified at 2.4-5.2% (Mitchell, Lui, et al., 
unpublished). In stool, it was detected in four infants (individuals J, D, M, H) at 
similar frequencies to vaccine material (<7%) at early timepoints for all individuals 
except for individual D (day 39) (Table 4.3, Fig. 4.2). Molecular modelling of VP4 
showed that glutamine (Q) 479 presented some atoms affected by hydrophobic 
contacts with neighbouring amino acids (Fig. 4.4 F). A hydrophobic amino acid such 
as tyrosine (Y) at that residue position in Rotarix
®
 would likely form different 
interactions, and so would a histidine (H) as a positively charged amino acid detected 
in stool of vaccinees.  
Two novel SNP loci were in the VP8* subunit and another one in the VP5* 
subunit. A locus at nucleotide position 340, mutation C>A, led to non-conservative 
amino acid substitution P114T located in epitope region 8-3 (Zeller et al., 2012) (Fig. 
4.3). In stool, P114T was detected in two infants (individuals C and M) at three and 
13 days after dose 1 and frequencies of <55% and <71% and in one infant 
(individual J) after both doses at frequencies from 40% to 19% after dose 1 and from 
30% to 48% after dose 2 (Table 4.3, Fig. 4.2). Molecular modelling of VP4 (Fig. 4.4 
A) showed that glutamic acid (E) 114 was predicted to form no amino acid contacts 
outside the amino acid primary sequence and no hydrophobic contacts (Fig. 4.4 A). 
Contacts are likely to differ with the proline (P) present in Rotarix
®
 due to its cyclical 
inflexible nature and more similar with the threonine (T) detected in stool of vaccine 
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recipients, due to its polar nature. The absence of that proline (P) in virus from stool 
may result in a less tight conformation.  
Another novel locus at nucleotide position 499, mutation T>C, led to 
conservative amino acid substitution F167L located in the VP8* subunit (Zeller et 
al., 2012) (Fig. 4.3). In stool of this cohort, F167L was detected in five infants 
(individuals C, F, M, L, E) at varying frequencies (Table 4.3, Fig. 4.2). After dose 1, 
it was detected at low (individual M), 50% frequency (individual F) and high 
frequency (individual L), after dose 2 at high frequency (individual E) and at high 
frequency after both doses (individual C). Molecular modelling of VP4 (Fig 4.4 B) 
showed that leucine (L) 167, within a hydrophobic region, was predicted to form a 
hydrogen bond with arginine (R) 163, two hydrogen bonds with glutamic acid (E) 
164, one hydrogen bond with asparagine (N) 168 and two hydrogen bonds with 
leucine (L) 169. Contacts are likely to be similar in Rotarix
®
 presenting 
phenylalanine (F) 167 since the hydrogen bonds are formed with the leucine (L) 
backbone and the hydrophobic head of phenylalanine (F) would be buried in the 
adjacent hydrophobic pocket (threonine 154, leucine 155, methionine 686), and more 
similar in stool from the five vaccine recipients who also presented a leucine (L) at 
amino acid position 167.  
Of the three novel SNP loci, the locus in the VP5* subunit presented a 
mutation A>G at nucleotide position 1430, leading to a non-conservative amino acid 
substitution D477G located at the base of the β-barrel (Fig. 4.3). In stool, D477G was 
detected in three infants (individuals J, M, E) at early timepoints and frequencies 
<16% (Table 4.3, Fig. 4.2). Molecular modelling of VP4 (Fig. 4.4 F) showed that 
asparagine (N) 477 was involved in hydrophobic contact with threonine (T) 68. This 
contact is likely to differ in Rotarix
®
 presenting a negatively charged aspartic acid 
(D), and in stool of three vaccine recipients who presented a glycine (G) at that 
position. 
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Table 4. 3. Single nucleotide polymorphism loci identified in stool of individuals B-M for viral segment encoding VP4. Nucleotide (nt) 
original, nucleotide position in GenBank reference JX943612. Nucleotide+12, nucleotide position from A in first codon encoding the first 
methionine (12 nucleotide shift when aligned to WT GenBank reference JN887809). Nucleotide change. Amino acid (aa) change. Vaccine 
frequency (%), frequency of SNP in Rotarix
®
 previously (Mitchell, Lui, et al., unpublished). Vaccine recently, if SNP loci identified in Rotarix
®
 
control within these sequencing runs. Individuals, individuals in whose stool the SNP has been identified. Timepoints, timepoints where SNP has 
been identified. Faecal frequency (%), frequency range in which the SNP has been identified. Underlined nucleotides, consensus identity. 
Nucleotides or amino acids in red, found in WT G1P[8] (GenBank reference JN887809). Amino acids in black bold, amino acid change. Amino 
acids in red bold, possible reversion to WT strain. 
1
 Identified in vaccine material at the NIBSC (Mitchell, Lui, et al., unpublished). Shaded in 
blue, loci present in ≥2 infants. Marked in purple, loci present in ≥3 infants.  
 
 
nt 
original 
nt+12 
nt 
change 
aa 
change 
Individuals Timepoints Faecal frequency (%) 
  74 86 A>G K29R J 1(day38) 10 
  162 174 G>A S58S D 1(day8) 8.2-12 
  241 253 A>G N85D B 1(day19) 9.9-13.2 
  328 340 C>A P114T J, M, C 4(day13, 27, 38, 67) //1(day13)//1(day34) 18.6-57.1//68.4-72.2//53.2-55.6 
  431 443 A>G Q148R B 1(day19) 2.9-3.2 
  
487 499 T>C F167L F, M, L, E, C 1(day7)//2(day5, day13)//1(day15) 
//1(day35)//2(day9, 34) 
53.8-58.1//3.5-17.8//98.7-99.2 
//100.0//97.0-99.9 
 
513 525 A>G T175T I, E 1(day9)//1(day35) 1.8-2.8//100.0 
 
535 547 G>A A183T J 2(day38, day67) 3.4-64.7 
 
555 567 T>C S189S J 1(day67) 30.0-34.4 
  
742 754 G>A D252N¹ D, H, K, L 1(day39)//1(day3)//1(day4)//1(day35) 16.2-17.4//10.9-18.6//14.5-16.5 
//15.3-19.6 
 
749 761 T>C I254T D 1(day8) 15.3-21.0 
 
785 797 A>G Y266C¹ H 1(day3) 4.9-6.6 
 
834 846 G>A K282K J 1(day67) 27.5-33.0 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
132 
 
 
895 907 A>G N303D J 1(day670 9.8-16.1 
 
987 999 C>T P333P J 1(day67) 23.2-55.4 
 
1007 1019 G>A R340K I 1(day9) 7.3-10.0 
 
1075 1087 A>G N363D I, B 1(day9)//2 (day19, 32) 8.7-10.6//3.4-73.4 
  
1076 1088 A>G N363S¹ J, I, D, F, M, 
C 
1(day3)//1(day9)//2(day8, 39)//1(day7)// 
1(day5)//2(day9, 34) 
2.2-3.2//2.0-3.7//5.1-50.7//3.8-
4.9//5.0-5.1//35.1-95.2 
 
1075&10
76 
1087&
1088 
A>G & 
A>G 
N363G I   
  
1078 1090 A>G M364V¹ J, I, D, M, H, 
K, L, E 
5(days3, 14, 27, 38, 67)//1(day9)//2(day8, 
39)//1(day5)//1(day3)//1(day4)//1(day35)// 
1(day6) 
13.5-58.1//3.4-6.8//1.4-17.1//8.5-
9.2//8.0-15.2//10.1-13.1//9.5-
20.8//4.8-5.0 
  
1080 1092 G>A M364I¹ J, I, D, F, M, 
B, H, K, E 
2(day3, 13)//1(day9)//2(day8, 39) 
//1(day7)//2(day5, 13)//3(days19, 32, 
44)//1(day3)//1(day4)// 1(day6) 
12.8-18.6//26.3-34.9//3.5-14.3//11.8-
13.5//18.1-26.7//19.1-99.9//3.0-
5.4//13.1-14.7//12.7-15.2 
 
1078 & 
1080 
1090 & 
1092 
A>G & 
G>A 
M364V¹ J, I, D, F, M, 
H, K, L, E 
  
  
1091 1103 A>G K368R¹ J, I, D, F, M, 
B, H, K, L, E, 
C 
5(days3, 14, 27, 38, 67)//1(day9)//2(days8, 
39)//2(day7, 30)//2(day5, 13)//3(day19, 32, 
44)//1(day3)//1(day4)//2(day15, 35) 
//2(day6, 35)//2(day9, 34) 
90.5-100.0//97.9-99.5//52.1-
100.0//31.5-100.0//94.8-98.7//92.6-
100.0//57.2-65.0//89.3-91.7//57.8-
100.0//98.7-100.00//97.1-.100.0 
  
1141 1153 T>C 
(consen
sus G) 
Y385H¹ J, D, F, M, B, 
H, K, L 
5(days3, 14, 27, 38, 67)//1(day39)//1(day7) 
//2(day5, 13)//1(day32)//1(day3)//1(day4) 
//1(day35) 
4.3-96.4//7.1-33.2//3.9-4.6//1.8-4.5 
//2.2-2.3//10.1-15.4//4.8-5.9//6.9-17.6 
  
1150 1162 A>C I388L¹ J, I, D, F, M, 
H, K, E, C 
2 (days3, 13)//1(day9)//1(day39)//1(day7) 
//2(day5, 13)//1(day3)//1(day4)//1(day6) 
//2(day9, 34) 
4.5-12.7//5.9-8.4//1.6-4.2//6.2-6.9 
//13.4-45.4//2.9-3.1//6.2-7.4//9.5-11.2 
//2.8-66.7 
 
1150 1162 A>T I388L J 1(day 3) 1.2-3.6 
 
1171 1183 G>A V395I L 1(day15) 1.7-2.1 
 
1269 1281 T>C F427F B 3(days19, 32, 44) 16.5-100.0 
 
1311 1323 A>G T441T K 1(day4) 1.7-3.2 
 
1326 1338 G>T L446F D 1(day8) 1.2-2.7 
 
1350 1362 A>C P454P J 1(day38) 6.0-13.6 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
133 
 
  
1397 1409 T>C I470T¹ J, I, D, F, M, 
H, K, L, E 
1(day3)//1(day9)//1(day39)//2(day7, 
day30)//1(day5)//1(day3)//1(day4) 
//1(day15) //1(day6) 
6.1-13.0//2.6-5.6//1.3-14.3//13.9-51.6 
//6.4-7.1//3.5-7.9//9.1-12.4//1.7-2.1 
//1.7-2.3 
 
1413 1425 T>C T475T K 1(day4) 1.5-3.7 
  1415 1427 A>C N476T¹ H 1(day3) 1.3-6.7 
 
1418 1430 A>G D477G J, M, E 1(day3)//2(days5, 13)//1(day6) 1.0-1.8//8.5-15.3//1.4-2.5 
  
1423 1435 T>C Y479H¹ J, D, M, H, K 1(day3)//1(day39)///1(day5)//1(day3) 
//1(day4) 
1.4-1.8//1.3-6.4//1.4-1.9//2.7-3.2 
//1.2-1.8 
 
1470 1482 G>A E494E J 1(day67) 16.9-32.4 
 
1682 1694 A>G N565S M 1(day5) 2.7-3.1 
 1830 1842 T>C I614I J 1(day67) 8.5-13.1 
  1881 1893 C>T S631S J 1(day13) 33.7-5.3 
  2040 2052 T>C N684N I 1(day9) 3.2-4.0 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
134 
 
 
 
 
 F
ig
. 
4
.1
. 
F
r
eq
u
en
cy
 o
f 
S
N
P
 l
o
ci
 o
v
e
r 
ro
ta
v
ir
u
s 
g
en
o
m
e 
se
g
m
en
t 
4
 (
V
P
4
) 
in
 s
to
o
l 
fr
o
m
 A
) 
in
fa
n
ts
 B
-F
, 
H
; 
a
n
d
 B
) 
in
fa
n
ts
 I
-M
. 
P
er
ce
n
ta
g
e 
o
f 
re
ad
s 
co
n
ta
in
in
g
 e
ac
h
 S
N
P
 f
o
r 
ea
ch
 n
u
cl
eo
ti
d
e 
p
o
si
ti
o
n
 a
t 
se
v
er
al
 t
im
ep
o
in
ts
 a
ft
er
 d
o
se
 1
 (
b
lu
e 
tr
ia
n
g
le
s)
 a
n
d
 d
o
se
 2
 
(p
in
k
 s
q
u
ar
es
);
 e
rr
o
r 
b
ar
s 
fo
r 
tr
ip
li
ca
te
s 
sh
o
w
n
. 
A
ll
 d
ay
s 
in
 r
ef
er
en
ce
 t
o
 d
o
se
 1
. 
N
u
cl
eo
ti
d
e 
p
o
si
ti
o
n
 r
ef
er
s 
to
 f
u
ll
 l
en
g
th
 c
o
d
in
g
 
se
q
u
en
ce
 (
JN
8
8
7
8
0
9
).
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
135 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
136 
 
 
 
 
 
 
 
 
 
F
ig
. 
4
.2
. 
F
re
q
u
en
cy
 o
f 
S
N
P
 l
o
ci
 i
d
en
ti
fi
ed
 i
n
 r
o
ta
v
ir
u
s 
g
en
o
m
e 
se
g
m
en
t 
4
 (
V
P
4
) 
o
v
er
 t
im
ep
o
in
ts
 t
es
te
d
 i
n
 s
to
o
l 
fr
o
m
 A
) 
in
fa
n
ts
 B
-
F
, 
H
; 
a
n
d
 B
) 
in
fa
n
ts
 I
-M
. 
V
ac
ci
n
e 
g
en
o
m
e 
co
p
y
 n
u
m
b
er
 i
n
d
ic
at
ed
 o
n
 t
h
e 
le
ft
 Y
 a
x
is
 f
o
r 
re
fe
re
n
ce
 a
n
d
 i
n
 g
re
y
 o
n
 t
h
e 
g
ra
p
h
s.
 F
re
q
u
en
cy
 
o
f 
S
N
P
 l
o
ci
 i
n
d
ic
at
ed
 i
n
 r
ig
h
t 
Y
 a
x
is
. 
S
N
P
 l
o
ci
 i
d
en
ti
fi
ed
 i
n
 s
to
o
l 
fr
o
m
 e
ac
h
 i
n
fa
n
t 
d
es
cr
ib
ed
 i
n
 k
ey
; 
er
ro
r 
b
ar
s 
fo
r 
tr
ip
li
ca
te
s 
sh
o
w
n
. 
D
o
tt
ed
 l
in
es
: 
U
p
p
er
 l
im
it
 o
f 
S
N
P
 f
re
q
u
en
cy
 i
n
 v
ac
ci
n
e 
m
at
er
ia
l 
fo
r 
a 
p
ar
ti
cu
la
r 
S
N
P
 (
k
ey
).
 D
ay
: 
D
ay
 o
f 
d
o
se
 1
. 
D
ay
 b
y
 b
la
ck
 a
rr
o
w
: 
D
ay
 
o
f 
d
o
se
 2
. 
A
ll
 d
ay
s 
in
 r
ef
er
en
ce
 t
o
 d
o
se
 1
. 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
137 
 
 
 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
. 
4
.3
. 
A
) 
S
ch
em
a
ti
c
 
o
f 
V
P
4
 
p
ri
m
a
ry
 
a
m
in
o
 
a
ci
d
 
se
q
u
en
ce
 
a
n
d
 
B
) 
A
to
m
ic
 
m
o
d
el
 
o
f 
th
e 
V
P
4
 
sp
ik
e,
 
h
ig
h
li
g
h
ti
n
g
 
th
e 
n
o
n
-
sy
n
o
n
y
m
o
u
s 
a
m
in
o
 a
ci
d
 s
u
b
st
it
u
ti
o
n
s 
o
ri
g
in
a
ti
n
g
 f
ro
m
 S
N
P
 l
o
ci
 i
d
en
ti
fi
ed
 i
n
 s
to
o
l 
o
f 
≥
3
 i
n
fa
n
ts
 (
B
-M
).
 A
) 
N
u
m
b
er
s 
in
d
ic
at
e 
am
in
o
 
ac
id
 p
o
si
ti
o
n
. 
T
h
e 
V
P
8
*
 s
u
b
u
n
it
 i
s 
in
d
ic
at
ed
 i
n
 p
u
rp
le
 (
le
ct
in
) 
an
d
 t
h
e 
V
P
5
*
 s
u
b
u
n
it
 i
s 
in
d
ic
at
ed
 i
n
 r
ed
 (
th
e 
β
-b
ar
re
l,
 b
o
d
y
 a
n
d
 s
ta
lk
, 
an
ti
g
en
 
d
o
m
ai
n
s)
 a
n
d
 g
re
en
 (
th
e 
C
-t
er
m
in
al
, 
fo
o
t 
d
o
m
ai
n
) 
(S
et
te
m
b
re
 e
t 
a
l.
, 
2
0
1
1
).
 T
ry
p
si
n
 c
le
av
ag
e 
si
te
s 
ar
e 
in
d
ic
at
ed
 b
y
 s
m
al
l 
b
la
ck
 u
p
w
ar
d
-
p
o
in
ti
n
g
 a
rr
o
w
s 
(A
ri
as
 e
t 
a
l.
, 
1
9
9
6
; 
C
ra
w
fo
rd
 e
t 
a
l.
, 
2
0
0
1
).
 T
h
e 
h
em
ag
g
lu
ti
n
in
 b
in
d
in
g
 d
o
m
ai
n
 i
s 
in
d
ic
at
ed
 i
n
 l
ig
h
t 
p
u
rp
le
 (
W
ei
n
er
 e
t 
a
l.
, 
1
9
7
8
; 
Y
eu
n
g
 e
t 
a
l.
, 
1
9
8
7
; 
L
ó
p
ez
 a
n
d
 A
ri
as
, 
2
0
0
4
) 
an
d
 t
h
e 
ce
ll
 f
u
si
o
n
 d
o
m
ai
n
 i
n
 l
ig
h
t 
re
d
 (
M
ac
k
o
w
 e
t 
a
l.
, 
1
9
8
8
; 
D
o
rm
it
ze
r 
et
 a
l.
, 
2
0
0
4
; 
T
ra
sk
 e
t 
a
l.
, 
2
0
1
0
).
 A
n
ti
g
en
ic
 r
eg
io
n
s 
in
 V
P
8
*
 a
n
d
 V
P
5
*
 a
re
 i
n
d
ic
at
ed
 b
y
 h
o
ri
zo
n
ta
l 
d
o
u
b
le
-d
ir
ec
ti
o
n
 a
rr
o
w
s 
(D
o
rm
it
ze
r 
et
 a
l.
, 
2
0
0
4
; 
M
o
n
n
ie
r 
et
 a
l.
, 
2
0
0
6
; 
Z
el
le
r 
et
 a
l.
, 
2
0
1
2
).
 A
ff
ec
te
d
 r
es
id
u
es
 a
re
 i
n
d
ic
at
ed
 i
n
 y
el
lo
w
 s
p
h
er
es
. 
B
) 
R
ib
b
o
n
 r
ep
re
se
n
ta
ti
o
n
 o
f 
th
e 
V
P
8
*
 s
u
b
u
n
it
 i
n
 
p
u
rp
le
 (
th
e 
le
ct
in
, 
h
ea
d
) 
an
d
 o
ra
n
g
e 
(t
h
e 
α
),
 V
P
5
*
 s
u
b
u
n
it
 i
n
 r
ed
 (
th
e 
β
-b
ar
re
l,
 b
o
d
y
 a
n
d
 s
ta
lk
, 
an
ti
g
en
 d
o
m
ai
n
s)
 a
n
d
 g
re
en
 a
n
d
 (
th
e 
C
-
te
rm
in
al
, 
fo
o
t 
d
o
m
ai
n
),
 a
n
d
 r
es
id
u
es
 a
ff
ec
te
d
 a
s 
y
el
lo
w
 s
p
h
er
es
. 
F
ro
m
 P
ro
te
in
 D
at
a 
B
an
k
 (
P
D
B
) 
en
tr
y
 4
V
7
Q
 (
S
et
te
m
b
re
 e
t 
a
l.
, 
2
0
1
1
).
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
139 
 
 
 
 F
ig
. 
4
.4
. 
M
o
le
cu
la
r 
sc
h
em
a
ti
c
 o
f 
re
si
d
u
es
 i
n
 V
P
4
 t
h
a
t 
in
te
ra
ct
 w
it
h
 A
) 
a
m
in
o
 a
ci
d
 1
1
4
; 
B
) 
a
m
in
o
 a
ci
d
 1
6
7
; 
C
) 
a
m
in
o
 a
ci
d
 
2
5
2
; 
D
) 
a
m
in
o
 a
ci
d
s 
3
6
3
, 
3
6
4
 a
n
d
 3
6
8
; 
E
) 
a
m
in
o
 a
ci
d
s 
3
8
5
 a
n
d
 3
8
8
; 
a
n
d
 F
) 
a
m
in
o
 a
ci
d
s 
4
7
0
, 
4
7
7
 a
n
d
 4
7
9
. 
C
h
ai
n
 s
tr
u
ct
u
re
 a
n
d
 
3
D
 s
tr
u
ct
u
re
 s
h
o
w
n
: 
A
m
in
o
 a
ci
d
 (
s)
 c
ir
cl
ed
 i
n
 b
la
ck
 a
n
d
 g
re
y
 r
es
p
ec
ti
v
el
y
. 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
140 
 
 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
141 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
142 
 
 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
143 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
144 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
145 
 
Gene segment 9, encoding VP7 
In the gene encoding VP7, six SNP loci were identified: two synonymous and 
four non-synonymous, with one reversion to WT (Table 4.4, Fig. 4.5). The number 
of non-synonymous SNPs increased from one in vaccine material (Mitchell, Lui, et 
al., unpublished) to four in stool. One of the SNP loci identified in vaccine material 
in gene segment 9 was not identified in stool of this cohort: SNP locus at nucleotide 
position and mutation T771C, leading to silent amino acid substitution N257N, at 
0.1-3.4% frequency in Rotarix
®
 (Mitchell, Lui, et al., unpublished). One SNP locus 
was previously identified in vaccine material and five were novel, particular to one 
infant each and detected at one timepoint from one week to two weeks after dose 1 at 
frequencies <50% (Table 4.4).  
The SNP locus previously identified in vaccine material was non-
synonymous and diverged from virus in vaccine material and consensus, converging 
towards virus in human WT G1P[8] sequence (GenBank reference JN887818). From 
the novel SNP loci, three were non-synonymous and diverged from virus in vaccine 
material, human WT G1P[8] sequence (GenBank reference JN887818) and human 
WT consensus.  
No SNP loci were observed in ≥3 infants. Therefore, to focus data analysis, 
SNP loci common to ≥2 infants were further investigated. Of the SNP loci in VP7, 
nucleotide position 368, mutation G>A, led to conservative amino acid substitution 
S123N located in known epitope region 7-1a (Zeller et al., 2012) (Fig. 4.7). Amino 
acid substitution S123N was previously detected in vaccine material at the NIBSC at 
frequencies 3-17% (Mitchell, Lui, et al., unpublished). In stool of two infants it was 
detected at similar frequency at day 13 for individual J, and at similar frequency at 
day 5 and frequency of >50% at day 13 for individual M (Table 4.4, Fig. 4.6). 
Modelling of VP7 (Fig. 4.8) was performed following the Protein Data Bank Rhesus 
VP7 structure (PDB entry 3FMG). This analysis showed that asparagine (N) 123 was 
predicted to form hydrogen bonds with alanine (A) 125, serine (S) 126 and 
phenylalanine (F) 127, A125 part of epitope region 7-1a. There are likely to be 
similar interactions in Rotarix
®
 presenting serine (S) 123 due a similar polar amino 
acid with an uncharged side chain and in stool of two infants presenting asparagine 
(N) 123.  
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Table 4. 4. Single nucleotide polymorphism loci identified in stool of individuals B-M for viral segment encoding VP7. Nucleotide (nt) 
original, nucleotide position in GenBank reference JX943614. Nucleotide change. Amino acid (aa) change. Vaccine frequency (%), frequency of 
SNP in Rotarix
®
 previously (Mitchell, Lui, et al., unpublished). Vaccine recently, if SNP loci identified in Rotarix
®
 control within these 
sequencing runs. Individuals, individuals in whose stool the SNP has been identified. Timepoints, timepoints where SNP has been identified. 
Faecal frequency (%), frequency range in which the SNP has been identified. Underlined nucleotides, consensus identity. Nucleotides or amino 
acids in red, found in WT G1P[8] (GenBank reference JN887818). Amino acids in black bold, amino acid change. Amino acids in red bold, 
possible reversion to WT strain. 
1
 Identified in vaccine material at the NIBSC (Mitchell, Lui, et al., unpublished). Shaded in blue, loci present in 
≥2 infants. Marked in purple, loci present in ≥2 infants.  
 
 
nt 
original 
nt 
change 
aa 
change 
Individuals Timepoints 
Faecal frequency 
(%) 
 
118 A>G I40V L 1(day15) 13.7-31.1 
 
133 T>C F45L L 1(day15) 5.5-47.8 
 
162 G>A G54G J 1(day13) 5.8-34.0 
  368 G>A S123N¹ J, M 1(day13)//2(day5, 13) 6.3-32.5//9.1-99.9 
 
585 G>A V195V C 1(day9) 5.1-10.7 
 
689 T>C V230A C 1(day9) 1.6-2.0 
 
 
 
 
 
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
147 
 
 
Fig. 4.5. Frequency of SNP loci over rotavirus genome segment 9 (VP7) in stool 
from infants C, J, L, M. Percentage of reads containing each SNP for each 
nucleotide position at several timepoints after dose 1 (blue triangles); error bars for 
triplicates shown. All days in reference to dose 1. Nucleotide position refers to full 
length coding sequence (JN887818).  
 
 
 
 
 
Fig. 4.6. Frequency of SNP loci identified in rotavirus genome segment 9 (VP7) 
over timepoints tested in stool from infants J, M. Vaccine genome copy number 
indicated on the left Y axis for reference and in grey on the graphs. Frequency of 
SNP loci indicated in right Y axis. SNP loci identified in stool from each infant 
described in key; error bars for triplicates shown. Dotted lines: Upper limit of SNP 
frequency in vaccine material for a particular SNP (key). Day: Day of dose 1. Day by 
black arrow: Day of dose 2. All days in reference to dose 1.  
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Gene segment 6, encoding VP6 
In gene segment 6, one synonymous mutation G>A at nucleotide position 654 
led to a silent amino acid substitution L218L (Table 4.5, Fig. 4.9) located in the β-
roll region of VP6 domain H (Fig. 4.11). It was the same synonymous mutation 
previously identified in vaccine material (Mitchell, Lui, et al., unpublished) and in 
stool it was common to two infants. No non-synonymous SNPs were identified in 
gene segment 6 in vaccine material or virus from stool. The silent amino acid 
substitution L218L was previously detected in vaccine material at frequencies up to 
15% (Mitchell, Lui, et al., unpublished). In stool, it was detected at similar frequency 
within the second week after dose 1 (individual J) and at lower frequency within the 
first week (individual M) (Table 4.5, Fig. 4.10). Molecular modelling of VP6 (Fig. 
4.12) was performed following the Protein Data Bank Bos VP6 structure (PDB entry 
1QHD). This analysis showed that leucine (L) 218 was predicted to form two 
hydrogen bonds with phenylalanine (F) 285 and one with valine (V) 330, the first 
one near a VP4 interaction site and the second one within the H domain. These 
interactions will be maintained in Rotarix
®
 and in stool of two vaccine recipients as 
they presented the same amino acid change L218L.  
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Table 4. 5. Single nucleotide polymorphism loci identified in stool of individuals B-M for viral segment encoding VP6. Nucleotide (nt) 
original, nucleotide position in GenBank reference JX943613. Nucleotide change. Amino acid (aa) change. Vaccine frequency (%), frequency of 
SNP in Rotarix
®
 previously (Mitchell, Lui, et al., unpublished). Vaccine recently, if SNP loci identified in Rotarix
®
 control within these 
sequencing runs. Individuals, individuals in whose stool the SNP has been identified. Timepoints, timepoints where SNP has been identified. 
Faecal frequency (%), frequency range in which the SNP has been identified. Underlined nucleotides, consensus identity. Nucleotides or amino 
acids in red, found in WT G1P[8] (GenBank reference JN887819). Amino acids in black bold, amino acid change. Amino acids in red bold, 
possible reversion to WT strain. 
1
 Identified in vaccine material at the NIBSC (Mitchell, Lui, et al., unpublished). Shaded in blue, loci present in 
≥2 infants. Marked in purple, loci present in ≥2 infants.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 nt 
original 
nt 
change 
aa 
change 
Individuals Timepoints Faecal frequency (%) 
 654 G>A L218L¹ J, M 1(day13)//1(day5) 12.7-16.6//5.4-5.7 
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Fig. 4.9. Frequency of SNP loci over rotavirus genome segment 6 (VP6) in stool 
from infants J, M. Percentage of reads containing each SNP for each nucleotide 
position at several timepoints after dose 1 (blue triangles); error bars for triplicates 
shown. All days in reference to dose 1. Nucleotide position refers to full length 
coding sequence (JN887819).  
 
 
 
 
 
Fig. 4.10. Frequency of SNP loci identified in rotavirus genome segment 6 (VP6) 
over timepoints tested in stool from infants J, M. Vaccine genome copy number 
indicated on the left Y axis for reference and in grey on the graphs. Frequency of 
SNP loci indicated in right Y axis. SNP loci identified in stool from each infant 
described in key; error bars for triplicates shown. Dotted lines: Upper limit of SNP 
frequency in vaccine material for a particular SNP (key). Day: Day of dose 1. Day by 
black arrow: Day of dose 2. All days in reference to dose 1.  
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
153 
 
   
F
ig
. 
4
.1
1
. 
A
) 
S
ch
em
a
ti
c
 o
f 
V
P
6
 p
ri
m
a
ry
 a
m
in
o
 a
ci
d
 s
eq
u
en
ce
 a
n
d
 B
) 
A
to
m
ic
 m
o
d
el
 o
f 
th
e 
V
P
6
 i
n
n
er
 c
a
p
si
d
 p
ro
te
in
, 
h
ig
h
li
g
h
ti
n
g
 
th
e 
n
o
n
-s
y
n
o
n
y
m
o
u
s 
a
m
in
o
 a
ci
d
 s
u
b
st
it
u
ti
o
n
 o
ri
g
in
a
ti
n
g
 f
ro
m
 S
N
P
 l
o
ci
 i
d
en
ti
fi
ed
 i
n
 s
to
o
l 
o
f 
≥
2
 i
n
fa
n
ts
 (
J
, 
M
).
 A
) 
N
u
m
b
er
s 
in
d
ic
at
e 
am
in
o
 a
ci
d
 p
o
si
ti
o
n
. 
A
 s
in
g
le
 s
u
b
u
n
it
 B
 d
o
m
ai
n
, 
ei
g
h
t 
α
-h
el
ic
es
, 
is
 i
n
d
ic
at
ed
 i
n
 d
ar
k
 b
lu
e 
an
d
 t
h
e 
H
 d
o
m
ai
n
, 
β
-b
ar
re
l 
sa
n
d
w
ic
h
 o
r 
β
-r
o
ll
, 
is
 i
n
d
ic
at
ed
 i
n
 r
ed
 (
M
at
h
ie
u
 e
t 
a
l.
, 
2
0
0
1
).
 R
eg
io
n
s 
in
te
ra
ct
in
g
 w
it
h
 V
P
4
, 
V
P
7
 a
n
d
 V
P
2
 a
re
 i
n
d
ic
at
ed
 (
M
at
h
ie
u
 e
t 
a
l.
, 
2
0
0
1
; 
M
cC
la
in
 e
t 
a
l.
, 
2
0
1
0
).
 A
n
ti
g
en
ic
 r
eg
io
n
s 
in
 V
P
6
 a
re
 i
n
d
ic
at
ed
 i
n
 g
re
en
 f
o
r 
su
b
g
ro
u
p
 I
 a
n
d
 p
u
rp
le
 f
o
r 
su
b
g
ro
u
p
 I
I 
(M
at
h
ie
u
 e
t 
a
l.
, 
2
0
0
1
).
 Q
u
at
er
n
ar
y
 
an
ti
g
en
ic
 r
eg
io
n
s 
fo
r 
V
P
6
-s
p
ec
if
ic
 N
A
b
s 
ar
e 
in
d
ic
at
ed
 i
n
 p
in
k
 (
A
iy
eg
b
o
 e
t 
a
l.
, 
2
0
1
3
, 
2
0
1
4
).
 A
ff
ec
te
d
 r
es
id
u
e 
is
 i
n
d
ic
at
ed
 i
n
 y
el
lo
w
 
sp
h
er
e.
 B
) 
R
ib
b
o
n
 r
ep
re
se
n
ta
ti
o
n
 o
f 
a 
V
P
6
 s
in
g
le
 s
u
b
u
n
it
 i
n
 d
ar
k
 b
lu
e 
an
d
 o
ra
n
g
e 
(d
o
m
ai
n
 B
, 
α
-h
el
ic
es
) 
an
d
 r
ed
 (
d
o
m
ai
n
 H
, 
β
-s
an
d
w
ic
h
) 
an
d
 r
es
id
u
e 
af
fe
ct
ed
 a
s 
a 
y
el
lo
w
 s
p
h
er
e.
 F
ro
m
 P
D
B
 e
n
tr
y
 1
Q
H
D
 (
M
at
h
ie
u
 e
t 
a
l.
, 
2
0
0
1
).
  
 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
154 
 
 
 
 
F
ig
. 
4
.1
2
. 
M
o
le
cu
la
r 
sc
h
em
a
ti
c 
o
f 
re
si
d
u
es
 i
n
 V
P
6
 t
h
a
t 
in
te
ra
ct
 w
it
h
 a
m
in
o
 a
ci
d
 2
1
8
. 
C
h
ai
n
 s
tr
u
ct
u
re
 a
n
d
 3
D
 s
tr
u
ct
u
re
 
sh
o
w
n
: 
A
m
in
o
 a
ci
d
 c
ir
cl
ed
 i
n
 b
la
ck
 a
n
d
 g
re
y
 r
es
p
ec
ti
v
el
y
. 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
155 
 
Gene segment 10, encoding NSP4 
In the gene encoding NSP4, a total of 34 SNP loci were identified: 8 
synonymous and 27 non-synonymous, with one reversion to WT (Table 4.6, Fig. 
4.13). None of them was observed in vaccine material at the NIBSC (Mitchell, Lui, 
et al., unpublished) or when tested in Rotarix
®
 vaccine material used as control for 
this project. From the 27 non-synonymous novel SNP loci, 21 diverged from virus in 
vaccine material, human WT G1P[8] sequence (GenBank reference JN887818) and 
human WT consensus.  
Mutation G150T leading to amino acid substitution A37-S and mutation 
T546C leading to amino acid substitution S169P diverged from virus in vaccine 
material and human WT consensus. Mutation T175C leading to amino acid 
substitution I45T diverged from virus in vaccine material and converged towards 
virus in human WT G1P[8] sequence (GenBank reference JN887818) and human 
WT consensus. One pair of contiguous SNP loci affecting amino acids 45 (T175C 
and A176G leading to I45T) was identified in six infants. 
Twenty-four SNP loci were particular to one infant each. Of those, several 
non-synonymous mutations were identified in the viroporin domain of NSP4 (Fig. 
4.15 A): mutations leading to amino acid changes H47P (non-conservative, 
positively charged to aromatic), I68S (non-conservative, hydrophobic to polar 
uncharged) and T74M (non-conservative, polar uncharged to hydrophobic). They 
were identified in continuous shedders or shedders between doses and at frequencies 
<20% in early or late timepoints. Nucleotide position 445 and mutation T>C led to 
non-conservative amino acid substitution I135T in the enterotoxin domain (Fig. 4.15, 
B) in individual I at low frequency (<2%) over a week after dose 1 (day 9). 
Molecular modelling of NSP4 at this position (Fig. 4.16) was performed following 
the Protein Data Bank human NSP4 structure (PDB entry 3MIW). This analysis 
showed that isoleucine (I) 135 was predicted to form an intramolecular hydrogen 
bond. Some of its atoms also present hydrophobic contacts with other atoms in 
nearby residues within the chain (leucine 134, threonine 136 or histidine 131). 
Nucleotide position 453 and mutation C>A, led to non-conservative amino acid 
substitution P138T, a hypervariable region in the amphipathic α-helix coiled coil 
domain, in individual J at low frequency (<6%) after dose 2 (day 27). Four SNP loci 
were common to two infants, such as locus at nucleotide position 183, mutation 
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A>G, leading to non-conservative amino acid substitution K48E in individuals J and 
I within two weeks of dose 1 at low frequencies (<15%). Mutation at nucleotide 
position 195, mutation C>T, led to non-conservative amino acid substitution P52S in 
individuals J and C at low frequencies (<10%) in early timepoints. Amino acid 
change K163R was identified in two infants from low to high frequencies (>50%) at 
early and late timepoints.  
To focus data analysis, SNP loci common to ≥3 infants were considered: they 
were located within the hydrophobic H2 domain of the protein (Fig. 4.15 A). 
Because the complete structure of NPS4 is not resolved yet, these molecular 
interactions were not modelled for NSP4. Nucleotide position 139, mutation T>C, 
leading to non-conservative amino acid substitution F33S, was detected at low 
frequency in one infant (individual M) and frequencies higher after dose 2 than after 
dose 1 in two infants (individuals B, J) (Table 4.6 Fig. 4.14). This change from a 
hydrophobic to a polar amino acid might disturb the hydrophobicity and stability of 
NSP4 anchoring in the membrane. Nucleotide position 150, mutation G>A, leading 
to non-conservative amino acid substitution A37T, or mutation G>T, leading to non-
conservative amino acid substitution A37S was detected at low frequencies (<16%) 
in stool from two infants (individuals C, M) after both doses and after dose 1. 
Nucleotide position 153, mutation T>C, leading to non-conservative amino acid 
substitution S38P, was detected stool from five infants at low frequency (individuals 
J, L), 50% (individual M) and very high frequency (individual E) after dose 1 and in 
stool from individual B from >60% after dose 1 to low frequency after dose 2.   
Nucleotide position 175, mutation T>C, leading to non-conservative amino 
acid substitution I45T, was detected in stool of seven infants (Table 4.6 Fig. 4.14): at 
low frequency after dose 1 (individuals C, D, E, L, M), from low after dose 1 to 31% 
after dose 2 (individual F), and from 35% to low after dose 1 (individual J). 
Nucleotide position 176, mutation A>G, leading to conservative amino acid 
substitution I45M, was detected in five infants at low frequency (individuals B, D, 
M), 35% (individual L), low to >60% after dose 2 (individual F) and >84% after 
dose 2 (individual C). Positions 175 and 176 mutating as described above, led to 
non-conservative amino acid substitution I45T, which has been detected in five 
infants (C, D, F, L, M) along their vaccination period at the frequencies described 
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above. Nucleotide position 178, mutation T>C, leading to non-conservative amino 
acid substitution L46S, was detected at low frequencies in individuals C, L, and M.  
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Table 4. 6. Single nucleotide polymorphism loci identified in stool of individuals B-M for viral segment encoding NSP4. Nucleotide (nt) 
original, nucleotide position in GenBank reference JX943607. Nucleotide+12, nucleotide position from A in first codon encoding the first 
methionine (41 nucleotide shift when aligned to WT GenBank reference JN887809). Nucleotide change. Amino acid (aa) change. Vaccine 
frequency (%), frequency of SNP in Rotarix
®
 previously (Mitchell, Lui, et al., unpublished). Vaccine recently, if SNP loci identified in Rotarix
®
 
control within these sequencing runs. Individuals, individuals in whose stool the SNP has been identified. Timepoints, timepoints where SNP has 
been identified. Faecal frequency (%), frequency range in which the SNP has been identified. Underlined nucleotides, consensus identity. 
Nucleotides or amino acids in red, found in WT G1P[8] (GenBank reference JN887814). Amino acids in black bold, amino acid change. Amino 
acids in red bold, possible reversion to WT strain. Shaded in blue, loci present in ≥2 infants. Marked in purple, loci present in ≥3 infants.   
 
nt 
original 
nt+41 nt change 
aa 
change 
Individuals Timepoints Faecal frequency (%) 
 
55 96 G>A D19N C 1(day34) 2.3-4.0 
 
59 100 C>T T20I D 1(day8) 35.1-37.5 
 
83 124 C>A P28H B 2(days32, 44) 1.5-4.3 
  98 139 T>C F33S J, M, B 4(days13, 27, 38, 67)//1(day13)//3(days19, 32, 44) 7.9-61.8//10.4-11.4//18.3-100.0 
 
103 144 T>G Y35D J 4(days13, 17, 38, 67) 5.0-80.7 
  109 150 G>A A37T C 2(days9, 34) 4.7-15.6 
 109 150 G>T A37S M 1(day13) 3.0-4.1 
  
112 153 T>C S38P J, M, B, L, E 1(day13)//1(day13)//2(days19, 32)//1(day15)//1(day35) 4.4-5.4//39.8-41.5//3.4-62.8//14.3-15.3 
//100.0-100.0 
 
117 158 T>C V39V B 2(days32, 44) 1.0-3.7 
 
119 160 T>A L40Q D 1(day8) 2.2-2.6 
 
121 162 A>G T41A K 1(day4) 1.6-2.6 
 
131 172 T>G F44C M, L 1(day13)//1(day15) 4.9-5.5//11.9-12.2 
  
134 175 T>C I45T J, D, F, M, L, E, C 2(days13, 27)//1(day8)//2(day7, 41) 
//1(day13)//1(day15)//1(day6)//2(days9, 34) 
4.6-36.1//2.3-2.8//8.1-38.6//1.2-
11.9//19.3-22.0//4.5-5.3//1.1-4.9 
  
135 176 A>G I45M D, F, M, B, L, C 1(day8)//3(day7, 30, 41)//1(day13) 
//1(day19)//1(day15)//2(days9, 34) 
4.0-4.1//1.2-71.9//2.7-3.6//2.8-3.8 
//35.0-36.4//1.3-85.4 
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134 & 
135 
175 & 
176 
T>C & 
A>G 
I45T D, F, M, L, C     
  137 178 T>C L46S M, L, C 1(day13)//1(day15)//2(days9, 34) 13.2-14.8//7.1-7.4//5.6-10.5 
 
140 181 A>C H47P J 2(days13, 27) 1.4-4.7 
 
142 183 A>G K48E J, I 1(day13)//1(day9) 3.5-4.1//7.9-12.9 
 
154 195 C>T P52S J, C 1(day13)//1(day9) 8.9-8.9//8.6-9.0 
 
203 244 T>G I68S C 1(day9) 2.7-3.0 
 
213 254 T>C C71C J 2(days13, 38) 1.0-12.9 
 
221 262 C>T T74M B 1(day32) 1.1-1.5 
 
222 263 G>A T74T J 2(days38, 67) 2.1-17.4 
 
279 320 C>T D93D J 1(day13) 1.8-2.0 
 
354 395 T>C T118T J 1(day67) 8.0-17.1 
 
404 445 T>C I135T I 1(day9) 1.2-2.0 
 
412 453 C>A P138T J 1(day27) 3.1-5.8 
 
462 503 A>G K154K J 2(days27, 38) 7.5-48.3 
 
480 521 G>A E160E J 1(day67) 3.1-4.1 
 
488 529 A>G K163R J, F 1(day27)//2(day7, 41) 3.5-9.1//27.5-55.1 
 
505 546 T>C S169P J 1(day67) 1.1-4.2 
 
507 548 A>G S169S B 1(day44) 1.1-4.4 
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Concluding remarks 
Mutations identified in all four segments did not directly increase with time. 
The majority increased after dose 1 (and some also after dose 2) and later decreased 
or were not detected by the end of the vaccination period. Others, particularly in gene 
segments 4 and 10 of individual J, were dominant or fixed by the end of the 
vaccination period. Most of the mutations identified in stool of vaccine recipients 
diverged from the WT consensus. However, in one mutation in VP4 (leading to 
K368R) and another one in NSP4 (leading to I45T) the dominant sequence 
converged towards the WT consensus.  
4.5 Discussion 
The combined viral load and sequencing data on rotavirus indicate that 
vaccine virus can be detected in stool samples and that it is shed throughout the 
vaccination period (Chapter 3), supporting the hypothesis that vaccine-derived 
variants arise as a result of replication following vaccination. Previous studies 
assessed RV genetic stability in naturally infected infants by Sanger sequencing 
(Flores, Sears, et al., 1988) and in cell culture (Tsugawa and Tsutsumi, 2016). 
Genetic stability of porcine RVs in pigs (Blackhall, Fuentes and Magnusson, 1996) 
and murine RVs in mice (Tsugawa, Tatsumi and Tsutsumi, 2014) have also been 
studied. A recent study at the NIBSC assessed the genetic stability of Rotarix
®
 
during manufacture (Mitchell, Lui, et al., unpublished). This study uses a unique set 
of samples to elucidate the genetic variants arising as vaccine virus replicated in the 
gut of vaccine recipients as a measure of genetic stability in the population and is the 
first of its kind. The study of SNPs throughout replication in the host in comparison 
to vaccine material allows to study the genetic changes that may have contributed to 
attenuation and to further adaptation in the host.   
In previous vaccine stability studies (Mitchell, Lui, et al., unpublished), SNP 
loci were detected in all structural proteins and in one non-structural protein, NSP1. 
One triallelic mutation that was previously observed in vaccine material in gene 
segment 4 at low frequency was not detected in stool: nucleotide position 797, 
mutation A>C, leading to non-conservative amino acid substitution Y266S. The 
other allele (nucleotide substitution A>G, leading to amino acid substitution Y>C) 
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was detected in stool of individual H at an early timepoint and low frequency. The 
A>C allele may have been present at a frequency <1% detection threshold.  
In stool from the 12 infants of this cohort, variants previously observed in 
vaccine material (Mitchell, Lui, et al., unpublished) increased in frequency after 
replication in the gut, some of them achieving transient dominance or fixation by the 
latest timepoints studied. Novel variants arose as a result of replication in the gut, 
usually at low frequencies but some increasing to transient dominance or fixation as 
well. The gene segments characterised encoded proteins VP4, VP7, VP6 and NSP4, 
due to their importance in viral entry, immunogenicity and virulence. Single 
nucleotide polymorphism loci resulted in both synonymous and non-synonymous 
mutations leading to silent, conservative or non-conservative amino acid changes. To 
focus data analysis, only SNP loci common to ≥3 (gene segments 4 and 10) or ≥2 
(gene segments 9 and 6) infants have been considered. Mapping of sequence changes 
to known or predicted amino acid structure and immune dominant domains was 
performed where possible.  
Gene segment 4, encoding VP4 
Mutations detected in VP4 that were previously observed in vaccine material 
(Mitchell, Lui, et al., unpublished) were non-synonymous and appeared at similar or 
higher frequency in stool. One of them appeared in the hemagglutinin VP8* domain: 
amino acid substitution D252N. VP8* can act as a viral hemagglutinin (Weiner et 
al., 1978; Yeung et al., 1987; López and Arias, 2004) and the cleavage sites for 
trypsin are in the linker region, targeting mono-basic arginine (R) at amino acid 
positions 231, 241 and 247 (Arias et al., 1996; Crawford et al., 2001). The 
conformation stabilising effect of the salt bridges formed between D252 and 
neighbouring positively charged residues (arginines) will be lost as the D252N 
substitution abrogates the existing negative charge. The D252N substitution was 
detected at similar frequencies in vaccine material, and its location nearby the linker 
region implies a selective preference for conformational flexibility in this region.  
A cluster of mutations was detected in the VP5* subunit between amino acids 
363 and 388, pointing towards there being a hotspot region for variation at the start 
of the putative fusion domain of the virus (amino acids 384 to 401), which is a 
hydrophobic region (Mackow et al., 1988; Dormitzer et al., 2004; Trask et al., 2010). 
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Changes in amino acids N363S and M364V/I were previously detected in the USA in 
WT isolates passaged in MA104 and Vero cell culture (Esona et al., 2010). As 
conservative substitutions of polar uncharged and hydrophobic amino acids 
respectively, they may improve the ability to penetrate the cell since frequencies 
were higher than in vaccine early after dose 1 and in one continuous shedder 
(individual J) the mutation persists at frequencies up to 50% by the end of the 
vaccination period.  
Mutation at amino acid 368 from K>R is present in a known WT RV G1P[8] 
strain (GenBank reference number JN887809), which suggests that a consistent and 
very high frequency in stool with respect to vaccine material comprise a complete 
reversion to WT sequence (e.g. individual J). Sanger sequencing that generated the 
original Rotarix
®
 sequence (GenBank reference numbers JX943604-JX943614) 
(Gautam et al., 2014) may have not detected the G allele if it was approximately 
30%, but as it was 50-60%, it was unlikely it was undetected. In the case of other 
continuous shedders and shedders between doses, the frequency of this mutation 
after dose 2 appears to be proportionally equivalent to after dose 1, except for 
individual B, who maintained a very high frequency. It appears as if the immune 
response of individuals B and J, who presented low RV-specific copro-IgA (Chapter 
5), was not strong enough to prevent the vaccine virus from replicating and 
generating this variant, suggesting it may be relevant for rotavirus vaccine 
persistence in the GI tract. In the case of early responders (who controlled virus 
between doses), only one infant (individual L) showed this mutation after dose 2 
(when its RV-specific copro-IgA levels are medium). This amino acid change has 
also been identified in an immunocompromised infant in Germany (Andreas Mas 
Marques, personal communication, 2019). It appears as if the infection advantage 
gained in cell culture is maintained in vivo, especially in those individuals with a less 
robust or later immune response.  
Changes in amino acids 385 and 388 are known to be related to neutralisation 
and attenuation of the virus (Kapikian, Hoshino and Chanock, 2001; Tsugawa and 
Tsutsumi, 2016). The non-conservative substitution at amino acid 385 (Y>H) is 
located between amino acids 384 and 386 of epitope region 5-1 (Zeller et al., 2012) 
(Fig 4.9). In stool of this cohort, it was found at low frequencies similar to vaccine 
except in individual J, a continuous shedder in whose stool this mutation was 
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identified at high frequency (>80%) late after dose 1 but was decreased to 50% by 
the end of the vaccination period. Changes at this residue have previously been 
identified in several studies: in un-passaged 89-12 Rotarix
®
 precursor, WTs and 
consensus as asparagine (N) and in Rotarix
®
 candidate passaged 33 times as tyrosine 
(Y) in the USA (Ward et al., 2006); in natural human strains passaged in cell culture 
MA104 and Vero cells in the USA (Esona et al., 2010), in a mouse RV strain 
passaged in mice, changing from glutamic acid (E) to lysine (K) in Japan (Tsugawa, 
Tatsumi and Tsutsumi, 2014); in AGMK cells passaged with WT RVA G1P[8] as 
D385H/N  in Japan (Tsugawa and Tsutsumi, 2016); and in an immunocompromised 
infant in Germany as Y385D (Andreas Mas Marques, personal communication, 
2019). This non-conservative Y385H substitution could affect the fusion domain and 
attenuation of the virus and further affect epitope region 5-1, and it appears as if the 
change may be relevant in children with a weak/delayed immune response. 
The conservative substitution at amino acid I388L is located in epitope region 
5-1 (Zeller et al., 2012) (Fig. 4.3). It was found at low frequency in the cohort except 
for individual C, who presented this change at >60% frequency early after dose 1 and 
individual M who presented >4% within the second week after dose 1. This amino 
acid change at 388 was previously identified in the USA in WT isolates passaged in 
cell culture MA104 and Vero cells (Esona et al., 2010) and in an 
immunocompromised infant in Germany (Andreas Mas Marques, personal 
communication, 2019). Due to its conservative nature, it appears as if this amino acid 
substitution may not have a large impact on protein structure or immunogenicity.  
The hyper-variation hotspot at amino acids 363 to 388 may alter the fusion 
capabilities of the virus (Mackow et al., 1988; Gorziglia, Larralde and Ward, 1990; 
Burke, Bridger and Desselberger, 1994). It appears as if this cluster was generated in 
vitro when passaging the Rotarix
®
 vaccine candidate in Vero cells and was 
maintained in vivo despite higher selection pressure as it provided an advantage to 
cell penetration and therefore infection. Areas of high mutability such as the 
proposed hotspot do not significantly modify protein structure and function and this 
region may be a result of the genetic robustness (Lauring, Frydman and Andino, 
2013) by which rotavirus generates genetic diversity, leading to a not very different 
but potentially more advantageous phenotype in vivo.  
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Other mutations previously observed in vaccine material were I470T and 
Y479H. The change from a hydrophobic to a polar or to a positively charged amino 
acid might have effects in protein structure and the ability to fold and penetrate the 
cell. These changes appear at low frequency, except for I470T in individual F with 
high frequency after dose 1 but decreasing to low frequency after dose 2. A 
substitution at amino acid 470 was previously identified in mouse RV passaged in 
cell culture (Tsugawa, Tatsumi and Tsutsumi, 2014) and it appears less relevant than 
other mutations in the previous cluster.  
Three novel mutations were identified in VP4 that were common to at least 
three infants: two in the VP8* subunit and one in the VP5* domains. Mutation 
leading to P114T in epitope region 8-3 (Zeller et al., 2012) was detected at 
approximately 70% in individual M after dose 1, at >50% in individual C after dose 
2 and fluctuating from 20% to 50% in individual J from after dose 1 through to after 
dose 2. Substitution P114T was previously identified in surveillance of clinical 
samples as vaccine-derived variant at Public Health England (PHE) by David J. 
Allen (Desselberger, 2017a) and at the NIBSC within this project (Preliminary data 
in Appendix II). First detection within the second week after dose 1 followed by high 
or consistent frequencies throughout the vaccination period suggest P114T might 
provide an advantage potentially in terms of evasion of the host immune response in 
individuals with high viral loads and low RV-specific copro-IgA levels. 
Substitution F167L, located in the VP8* subunit, was detected in five 
individuals, in most of them at high or very high frequency after each dose or both. 
While the hydrophobicity of the amino acid is maintained, the leucine interactions 
may be key to binding sialic acids and the hemagglutinin function of the VP8* 
region. The leucine allele is present in a known human WT RVA G1P[8] strain 
(GenBank reference number JN887809) and may constitute a reversion to WT 
phenotype. This change was previously identified in several studies: in the USA as 
mentioned previously (Ward et al., 2006; Esona et al., 2010), in circulating RV 
strains from Belgian infants (Zeller et al., 2017), in infants with suspected Rotarix
®
-
derived severe gastroenteritis in Japan (Sakon, Miyamoto and Komano, 2017) and in 
an immunocompromised infant in Germany (Andreas Mas Marques, personal 
communication, 2019). High frequencies in infants with low RV-specific copro-IgA 
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suggest this revertant to wild type variant may potentially infect naïve and 
immunocompromised individuals.  
Non-conservative amino acid substitution D477G in the VP5* subunit was 
identified at low frequencies in vaccine recipients. Conservative amino acid 
substitution N477S was previously observed in an isolate that could be cultured in 
the absence of trypsin, with slower proteolysis kinetics, but maintaining replication 
(Trask et al., 2013). The change from an aspartic acid (D) at 477 in Rotarix
®
 and 
consensus to a glycine (G) in vaccinees does not seem to provide a structural change 
favouring replication kinetics in vivo.  
Gene segment 9, encoding VP7 
One mutation detected in stool of two infants in VP7 was previously 
observed in vaccine material (Mitchell, Lui, et al., unpublished): conservative S123N 
in epitope region 7-1a (Zeller et al., 2012), an immunodominant region believed to 
be a target for NAbs (Aoki et al., 2009). Moreover, it was previously found in stool 
from infected infants in Malawi (Jere et al., 2018). In stool, it was detected at similar 
and higher frequencies than in vaccine material. Targeting of certain epitopes by the 
host immune system may drive mutation that favours immune escape of the virus. 
Alterations in this epitope region may affect the ability to evade antibodies, as 
reported previously for VP7 (Iturriza-Gómara et al., 2001).  
Gene segment 6, encoding VP6 
One SNP locus was identified in stool of two infants in VP6 and previously 
detected in vaccine material: silent substitution L218L in the β-roll region of VP6 
domain H. Its location in the protein is unrelated to VP2, VP7 or VP4 interaction and 
it is not located in a known antigenic region (Mathieu et al., 2001; McClain et al., 
2010) nor within the quaternary epitope region in the transcriptional pore against 
which VP6-specific intracellular NAbs are directed (Aiyegbo et al., 2013, 2014). 
This substitution may impact trimerization as it is located in the β-roll region of 
domain H (López et al., 1994; Affranchino and González, 1997), although because it 
is silent, it suggests maintenance of a hydrophobic residue in a hydrophobic, 
conserved region (Mathieu et al., 2001).   
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Gene segment 10, encoding NSP4 
None of the mutations detected in NSP4 were previously observed in vaccine 
material and most of them were particular to one or two infants. Some SNP loci were 
located in the viroporin domain (amino acids 47 to 90) (Hyser et al., 2010). Amino 
acid substitution K48E located in the penta-lysine domain (Hyser et al., 2010) may 
affect transmembrane insertion and viroporin activity. It was previously observed in 
mice as K48I: the isoleucine was present in a limited-virulence tissue culture-
attenuated murine RV strain (Angel et al., 1998). NSP4 functions as enterotoxin 
(Estes and Kapikian, 2007; Rajasekaran et al., 2008) and one of the SNP loci 
identified, leading to non-conservative amino acid substitution I135T, was located 
within its diarrhoea-mediating domain (amino acids 114 to 135 of NSP4) (Ball et al., 
1996; Ousingsawat et al., 2011). Although the complete crystal structure of NSP4 
has not been resolved yet, the oligomerisation domains (containing the enterotoxin 
domain) have been described (Bowman et al., 2000; Chacko et al., 2012; Kumar et 
al., 2018). Modelling of amino acid 135 has shown a change from a hydrophobic 
(isoleucine) to a polar uncharged (threonine) amino acid, potentially affecting 
structure and enterotoxin function. Another mutation led to P138T, located within 
amino acids 131 to 140 which are considered a hypervariable region related to 
altered pathogenesis in cell culture of porcine RVs (Zhang et al., 1998) and murine 
RVs (Angel et al., 1998). Amino acid substitution P138T was previously observed in 
a porcine OSU RV mutant as P138S, losing ability to induce diarrhoea in neonatal 
mice (Zhang et al., 1998). This change from an aromatic to a polar amino acid, as in 
the porcine study, might lead to an effect the ability to mobilise intracellular calcium. 
Amino acid change K163R in the DLP-binding domain was observed before in 
wildtype E2 genotypes of NPS4 (Srivastava et al., 2015) with respect to DS-1 strain 
E2 genotype. The C-terminal region is relevant for multimerization (Rajasekaran et 
al., 2008) and this change may provide an advantage in vivo as it was detected at 
>50% frequency late in the vaccination period in one of the continuous shedders 
(individual F).  
Mutation leading to amino acid change F33S increased to >50% in a 
continuous shedder (individual J) and to fixation in another infant (individual B) who 
shed between doses and after dose 2. This change potentially disturbing the 
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
 
173 
 
hydrophobicity and stability of NSP4 anchoring in the membrane may provide an 
infection advantage in certain vaccine recipients.  
Those SNP loci identified in at least three infants were non-synonymous 
mutations located in the H2 hydrophobic domain, located traversing the endoplasmic 
reticulum (ER) membrane and functioning as a signal sequence (Hu et al., 2012), 
with residues 1-23 within the ER lumen and residues 44 to 715 in the cytoplasm 
(Parr et al., 2006). Although identified at low frequency in stool of two infants only 
(individuals C, M), amino acid substitution at site 37 was previously observed in 
mice as a change from valine (V) to alanine (A), considered key for enterotoxin 
activity in vivo in mice (Tsugawa, Tatsumi and Tsutsumi, 2014). It was also 
identified in circulating RV strains in Belgium (Zeller et al., 2017) and detected as 
A37S in a vaccine-derived RV in Japan (Sakon, Miyamoto and Komano, 2017). This 
change from a hydrophobic to a polar amino acid might affect the stability of the H2 
domain and virulence in vivo as it appeared to have increased frequency late in stool 
from individual C.  
Change S38P was identified at low frequency in some infants and at >40% 
and >60% in two individuals within the second week after dose 2. A substitution at 
amino acid 38 was previously detected in MA104 cell culture as a change from a 
serine (S) to phenylalanine (F) (polar to hydrophobic) (Tsugawa, Tatsumi and 
Tsutsumi, 2014) and in a tissue culture-attenuated mice strain as amino acid 
substitution S38F (polar to hydrophobic) (Angel et al., 1998). This change S38P 
from a polar to a cyclical amino acid might affect protein structure, signal sequence 
and exposure of that residue, although it appears not to persist.  
Substitution I45T was identified at low frequency except for two infants (F, 
J): although both are continuous shedders, in individual F it increased from <10% 
within the first week after dose 1 to approximately 30% ten days after dose 2, and in 
individual J it decreased 40% to <10% after dose 1. An amino acid change at 
position 45 was previously observed in the Rotarix
®
 vaccine candidate 89-12 as a 
change from T45A in symptomatic and asymptomatic patients (Ward, Mason, et al., 
1997), as T45A in AGMK cells passaged with WT G1P[8] (Tsugawa and Tsutsumi, 
2016) and in murine strains as T45M (Angel et al., 1998). The change I45T from a 
hydrophobic to a polar amino acid might affect stability of NSP4 cytoplasmic 
domain and it appeared to be selected in one of the infants at a late timepoint.   
Chapter 4  Genetic stability of faecal rotavirus RNA in Rotarix
® 
vaccinees in the UK 
 
174 
 
Mutation leading to substitution I45M was identified at low frequency except 
for three infants (individuals L, C, F). The very high frequencies in stool of 
individuals C and F after dose 2 suggest this mutation is selected in some hosts 
where replication is prolonged and immune response low. This amino acid change 
was previously detected in murine strains (Angel et al., 1998) and in an 
immunocompromised child (Andreas Mas Marques, personal communication, 2019). 
This maintenance of a hydrophobic amino acid might have affected stability of the 
cytoplasmic domain and provide an advantage to infection/spread within susceptible 
hosts.  
Amino acid change L46S was identified at low frequency in vaccine 
recipients and it was observed previously detected in circulating RV strains in 
Belgium (Zeller et al., 2017). This change from a hydrophobic to a polar amino acid 
might have contributed to stabilising the cytoplasmic domain.  
Concluding remarks 
As an RNA virus vaccine, Rotarix
®
 exists as a quasispecies: a heterogeneous 
viral population. When a human monovalent G1P[8] strain was passaged in vitro, 
pressure to balance viral fitness and adapt to cells arose, resulting in accumulation of 
mutations and potential gain of attenuation in the original host. When administered at 
high dose in the original host, it replicated in vivo existing as a viral quasispecies 
now under increased selection pressure. The viable quasispecies continued to 
replicate and positively selected previous and/or novel variants resulting in structural 
or functional phenotypic changes that may have allowed improved infection, 
replication or escape from host immunity. These changes were selected at the 
quasispecies level and were not necessarily present in the same virion, so different 
virions may result in different phenotypes. Molecular evolution of a quasispecies can 
lead to transient dominance or fixation of alleles in the viral population, although 
population fitness takes priority over variants of high fitness and the quasispecies can 
supress those variants if they may disturb the mutation-selection balance (Andino 
and Domingo, 2015). Therefore, it was key to identify the genomic loci prone to 
mutation in the host and compare them to the ones previously identified in vaccine 
material, highly stable across independent bulks and fills (Mitchell, Lui, et al., 
unpublished).  
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Changes in the outer capsid proteins VP7 and VP4 may result in functional 
differences in viral entry affecting receptor binding, trypsin cleavage sites and the 
fusion domain, as well as regions key for neutralisation. From the changes resulting 
from potential cell culture adaptation of the vaccine with increased frequency in 
vaccinees, a reversion to WT phenotype in the fusion domain is selected to very high 
frequency, suggesting it facilitates infection in vivo. The novel changes in the spike 
protein resulting from replication in the host appeared at high and very high 
frequency and may comprise variants with pathogenic capability. If they are 
immunodominant epitopes, they may lead to escape mutants. The inner capsid 
protein, VP6, has been found to maintain a silent mutation in an area unrelated to 
intracellular neutralization at similar levels to vaccine material in vaccine recipients, 
highlighting the importance of its structural conservation. Since no SNP loci were 
identified in NSP4 in vaccine material, it appears that NSP4 is stable and not crucial 
for in vitro viral adaptation. However, NSP4 appears to be potentially relevant for 
infection and further replication in infants. 
Although synonymous mutations that are innocuous in vitro may have a large 
impact on the ability to infect and replicate in vivo —they may affect viral RNA 
secondary structure and/or codon-pair usage, increase immunomodulatory RNA 
regions and/or lead to codons that following a single nt substitution may result in 
stop codons, all of these potentially affecting viral fitness (Klitting et al., 2018)—, 
the synonymous mutation leading to silent amino acid substitution L218L in VP6 
appears not to affect quasispecies viability. Most of the common SNPs identified in 
this cohort were non-synonymous in genes encoding VP4, VP7 and NSP4. Genes 
encoding viral surface epitopes, flexible within the protein structure, tend to present 
non-synonymous mutations that allow for diversity that results in a neutral effect in a 
competent host but may be advantageous in an immunocompromised host (Lauring, 
Frydman and Andino, 2013). This antigenic variation in VP4 and VP7 may be 
unrelated to immune selection (Sánchez et al., 2003) and it may represent mutational 
robustness (Lauring, Frydman and Andino, 2013). The variants previously observed 
in vaccine material (Mitchell, Lui, et al., unpublished) identified at higher frequency 
in stool of vaccine recipients appear to have been a dominant minority in cell culture 
that was re-selected in the original host as a strategy to override the initial low fitness 
in infants. However, as the vaccine virus adapted in infants, only a few of them were 
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still selected. Revertant mutations might have been selected as a means of 
compensating the low fitness provided by attenuating mutations when replicating in 
the original host. Novel mutations appear to be a result of virus-host adaptation 
throughout replication in infants. All these mutations, whether in structural or non-
structural proteins, may have an effect on cell tropism and host range (Domingo, 
Sheldon and Perales, 2012).  
Data showed that SNPs previously identified in vaccine material were 
detected at similar or higher frequencies in vaccine recipients and that novel SNPs 
were introduced during viral replication. Some mutations identified at high frequency 
immediately after vaccination decreased their frequency later after dose 1, with 
immune pressure potentially forcing their disappearance or negative selection of 
those mutations being replaced by others providing better viral fitness. SNP loci 
maintained at a low frequency may represent minority variants that are emerging. 
Other SNPs appearing after a certain time at low frequency and then becoming 
undetectable in the population, potentially represent a minor variant that emerges and 
is then not selected within the viral population. SNPs emerging before dose 2 and 
staying at a similar frequency after could be driven by immune pressure to persist 
and suggested relevance in immunogenicity or pathogenesis. The changes that 
increased in frequency over time and those that appeared at very high frequency by 
the end of the vaccination period were detected in profiles where vaccine virus had 
not been cleared after first dose, infants with a low RV-specific copro-IgA response 
(Chapter 5). Most of the mutations that appear to be fixed by the end of the 
vaccination period were those previously observed in vaccine material, as well as 
two novel mutations, suggesting that the vaccine virus may acquire lasting changes 
while transiting the GI tract of certain infants.  
In this cohort, the SNPs identified did not increase in number as the vaccine 
virus replicated in infants who controlled shedding early. In continuous shedders or 
shedders between doses, the quasispecies diversity increased by late timepoints 
presenting some novel variants signifying adaptation and further evolution within the 
host. However, except in three infants, viral loads were undetectable by the latest 
timepoints tested. In infants shedding vaccine virus by the latest timepoints, these 
vaccine-derived variants may pose a risk if transmitted horizontally in the 
population, as observed previously in several studies for rotavirus (Payne et al., 
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2010; Rivera et al., 2011; Kaneko et al., 2017; Miura et al., 2017; Sakon, Miyamoto 
and Komano, 2017) and rabies (Faber et al., 2005). Herd immunity as well as the 
opportunity to evolve molecularly and become pathogenic both stem from this 
horizontal transmission.  
No health-related data on vaccine recipients or susceptible contacts was 
provided in this study, so it was assumed they were asymptomatic shedders of 
vaccine virus. It appears then that attenuation was maintained in the original host and 
the virus was stable within the population of vaccinees. Novel variants may have 
arisen due to adaptation to human cells or, since they have been detected late in the 
vaccination period and previously observed in passaged vaccine virus (Ward et al., 
2006; Esona et al., 2010), WT strain clinical surveillance (Desselberger, 2017a; 
Zeller et al., 2017), vaccine-derived (Sakon, Miyamoto and Komano, 2017) and 
immunocompromised infants (Andreas Mas Marques, personal communication, 
2019), may have appeared as immune escape mutants or receptor binding enhancer 
mutations.  
To understand whether the replicating virus containing novel variants may be 
virulent, further studies engineering these variants into rotavirus would have to be 
performed in an animal model such as mice. Alternatively, since heterogeneity of 
rotavirus replication has previously been observed in human intestinal enteroids 
(HIEs) from different patients (Saxena et al., 2016), these HIEs may be an 
appropriate model to test these mutations. A series of individual and combined 
variant tests would be required to study multifactorial pathogenesis: individual 
variants at low frequency may be sufficient to have a pathogenic effect (Bull, 2015), 
and so may be several variants in infection complementation. Since the establishment 
in 2017 of a helper-virus-free reverse genetics system to study rotavirus (Kanai et al., 
2017), the mutations that led to relevant amino acid changes in VP4, VP7 and NSP4 
could be engineered singly or in combination to study pathogenicity in vivo. Of 
interest, novel mutations resulting in substitutions P114T, F167L and D477G and 
strong revertant K368R in VP4, mutation leading to substitution S123N in VP7 and 
mutations leading to substitutions K48E, I35T and P138T, as well as F33S, A37T, 
S38P, I45T, I45M and L46S in NSP4. If any of these variants alone or in 
combination increase virulence/pathogenicity, methods for their control should be 
developed, maybe by increasing vaccine production yields to relieve vaccine virus 
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pressure. If they favour attenuation, they may be incorporated in vaccine candidates 
by genetic engineering as previously tested for a live rabies vaccine (Nakagawa et 
al., 2017).  
Although sampling bias and limit of detection may have influenced the 
variants detected, particularly those present at lower frequencies, the longitudinal 
nature of the study allowed observation of trends, increased knowledge about variant 
regions of the virus and about behaviour of vaccine virus in transit through the gut. 
Biological and technical replicates added confidence to the results. Overall, SNP 
frequency data from triplicates was consistent. A few exceptions of inconsistent 
frequency for some SNPs were detected, probably due to sampling bias and 
increased difficulty in efficient amplification of the longest gene segments. A 
limitation of this study was the low success obtaining amplicons for some of the 
genes at some timepoints, especially VP6 and VP7 at late timepoints (Table 4.1). 
This may be due to VP7 and VP6 being gene segments difficult to amplify at 
timepoints of low viral load, but in the case of high viral load timepoints, variability 
of primer binding regions and potential SNPs in them may have been responsible for 
low-intensity RT-PCR bands.   
The results on vaccine virus sequence variation while replicating in the host 
suggest that variants previously detected in vaccine material (Mitchell, Lui, et al., 
unpublished) were generated in cell culture and then either lost or selected and 
maintained in infants. Vaccine-derived novel variants arising as a result of adaptation 
to the host, together with vaccine variants maintained at high frequency by the end of 
the vaccination period may pose a risk to immunocompromised infants or 
immunocompromised contacts of vaccine recipients. As the antibody at site of 
infection, faecally-derived IgA (copro-IgA) may also reveal information on the 
ability of an infant to control a rotavirus infection. With the detailed profiling from 
this cohort, an association of copro-IgA with shed virus may now be possible 
(Chapter 5). 
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Chapter 5: Antibody-mediated mucosal 
immunogenicity to human monovalent 
G1P[8] RV vaccine in a cohort of 
vaccinated infants in the UK 
5.1 Introduction  
The immune response in rotavirus-infected individuals triggers interferons 
and an ‘antiviral state’ in a primary infection (Chapter, 1 section 1.6.1). In a 
secondary infection, the immune response is mediated mainly via secretory IgA in 
the duodenum, either by neutralising anti-VP4 or anti-VP7 antibodies (heterotypic 
immunity) or by non-neutralising anti-VP6 intracellular antibodies that block viral 
transcription (Chapter 1, section 1.6.2). Increases of >1:200 and >1:800 in RV-
specific IgA and IgG titres in serum respectively, and increases of ≥20 arbitrary units 
(U)/mL as performed by Bernstein (Bernstein, 1998) or ≥4-fold in RV-specific 
serum IgA titre have been considered to provide protective immunity against 
infection and disease in natural rotavirus infection (Coulson et al., 1992; Matson et 
al., 1993; O’Ryan et al., 1994; Velázquez et al., 1996, 2000; Cheuvart et al., 2014). 
While serum IgA appears to be a long-lasting marker of protection, copro-IgA 
appears to be a more accurate marker in the short-term at high levels in the 
population (Coulson et al., 1990, 1992; Matson et al., 1993; Clarke and 
Desselberger, 2015). Animal studies in mice indicate that copro-IgA, a good 
surrogate marker of duodenal IgA, is the most accurate marker of protection (Feng et 
al., 1994; Burns et al., 1995), likely due to its direct proximity to the site of viral 
replication. 
Studies on correlates of protection after rotavirus vaccination have indicated 
that seroconversion rate correlated with efficacy at a population level and was 
associated with a decrease in RV disease (Chapter 1, section 1.16). Apart from 
homotypic protection, neutralising anti-VP7 and anti-VP4 serum antibodies may also 
provide heterotypic protection (Johansen and Svensson, 1997; Angel, Franco and 
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Greenberg, 2012; Clarke and Desselberger, 2015) and further heterotypic protection 
may be generated after vaccination due to non-neutralising, protective anti-VP6 
antibodies. Transcytosed secretory anti-VP6 IgA might be responsible for viral 
“expulsion” and inhibition of transcription in rotavirus infection (Thouvenin et al., 
2001; Feng et al., 2002; Aiyegbo et al., 2013, 2014).  
Rotavirus-specific copro-IgA shedding is expected in stool of Rotarix
®
 
vaccine recipients, as it has been detected in previous studies (Chapter 1, section 
1.16). Clinical trials have assessed immunogenicity by RV-specific IgA 
seroconversion, RV-specific IgG seroconversion and by vaccine-specific NAbs 
(O’Ryan, 2007). These studies assessed a timepoint after dose 1 and another 
timepoint two months after dose 2. Later studies have used a similar approach or a 
small number of timepoints expanding the first two years after vaccination for 
clinical evaluation (Chapter 1, section 1.16). However, none covered multiple 
timepoints following vaccination and testing IgA at the site of infection.  
In studies regarding the mode of feeding and immunogenicity, breastfed 
children were found to present lower IgA levels in stool following Rotarix
®
 
vaccination (Bautista-Marquez et al., 2016). IgA acquired through breastmilk may 
interfere with infection by the vaccine virus, lowering replication and impairing 
mounting an immune response as robust as in non-breastfed infants, who present 
higher shedding after Rotarix
®
 vaccination.  
In the absence of serum material, which can only be retrieved by invasive 
approaches, a discrete study on faecal RV-specific copro-IgA levels in vaccine 
recipients would inform on the levels of RV-specific IgA in the duodenum, the most 
relevant site for virus neutralisation in the lumen and for intracellular “expulsion”. 
This study, expanding from dose 1 to dose 2 and after, would help to elucidate 
differences in short-term mucosal response between individuals. This type of study 
would also contribute to better understand the relationship between virus shedding 
load and duration in relation to IgA-mediated mucosal immunity. 
5.2 Aims 
The first aim of the work presented in this chapter was to produce a detailed 
longitudinal pattern of anti-RV copro-IgA from infants vaccinated with Rotarix
®
 in 
this UK cohort to understand the anti-RV mucosal immune response. The second aim 
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was to determine the relationship between Rotarix
®
 faecal shedding and anti-RV 
copro-IgA.  
5.3 Experimental methodology  
To address anti-RV copro-IgA, the same cohort of infants described in 
Chapter 3 was sampled, using stool material from the pre-vaccination period through 
to approximately a month after dose 2 and, for some, after-a-year. Materials and 
methods are detailed in Chapter 2 and Appendix I. Faecal samples were processed 
and stored until used (Chapter 2, sections 2.1.9 & 2.2.1). Some samples were of low 
volume due to stooling patterns and this was reflected in the analysis. To maximise 
the information obtained from this limited resource, and to allow for the study in 
Chapter 4, the reproducibility of data in this chapter was addressed by quantifying 
total and specific anti-RV copro-IgA levels across technical duplicates from material 
extracted from a single faecal suspension. Relative quantification of anti-RV copro-
IgA has been reported previously (Macartney and Offit, 2000). Total IgA was 
measured with a commercial kit and specific IgA was quantified as a trend and 
measured using a total IgA standard. Samples collected at times pre-, during and 
post-vaccination regimen were tested in an assay to measure total copro-IgA and 
another assay to measure specific anti-RV copro-IgA (Chapter 2, section 2.2.9).  
5.4 Results 
5.4.1 Sample set 
Obtaining samples from equivalent timepoints across the cohort was not 
possible due to the nature and collection of the material. Where low amounts of stool 
were available, priority was assigned to Rotarix
®
 faecal shedding quantification 
throughout the sample collection and to NGS of specific timepoints from each infant, 
based on their shedding profiles. Therefore, for IgA testing, samples from 11 infants 
were assayed at pre-vaccination, samples from 12 infants after dose 1 and dose 2 and 
samples from eight infants after a year. For one individual, the sample available at 
pre-vaccination was only sufficient to quantify shedding.  
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5.4.2 Preliminary data  
Preliminary data was obtained using the total IgA in-house assay followed by 
the specific anti-RV IgA in-house assay using the original total purified human 
secretory IgA standard (Bio-Rad, PHP133, batch 290415) (Chapter 2, section 
2.2.9.3). Sample from one individual was tested to evaluate the conditions of the 
assay parameters: Blocking concentration, dilution buffer concentration, 
concentrations of coating and detection antibodies, standard dynamic range and stool 
dilutions for total and specific IgA.  
Data from one infant (M) (Fig. 5.1) throughout the vaccination period showed 
fluctuation in specific IgA from day 11, increasing until day 18, followed by lower 
levels. Total IgA was high at day 12, maintained by day 18 and decreasing after. This 
profile suggested IgA levels peaked around day 18, when viral loads (Fig. 5.1) are 
still high but beginning to drop (Chapter 3, Fig. 3.4 C).  
 
 
Fig. 5.1. Preliminary total and specific anti-RV copro-IgA concentration in one 
infant (M). Quantitation of total and specific IgA by direct sandwich ELISA shown 
in the left and right Y axes respectively. The X axis shows days with respect to dose 
1. Day 0: Day of dose 1. Black arrow: Day of dose 2. Blue dots: Total IgA. Green 
dots: Specific IgA. Days shown in blue and green (slightly separated to avoid 
superimposed dots): 11, 12, 14, 18, 21 and 29. Day shown in blue only: 27. 
 
The readout from the sandwich ELISA for total IgA was in µg/mL (or µg/g 
when related to stool; the range of the original standard being from 2 to 0.05 µg/mL), 
with specific IgA normalised to total IgA concentration in 1g (1mL) of stool. As an 
example: Individual M, on day 21 after dose 1, presented a total IgA level of 3481 
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µg/mL and a RV-specific IgA amount of 15 µg/mL. Therefore, 15/3481= 0.0043 µg 
of RV-specific IgA per 1 µg of total IgA, or 430 ng of RV-specific IgA per 100 µg of 
total IgA.  
 
5.4.3 Optimisation of different batches of human secretory IgA 
The total and specific IgA assays worked with the purified human IgA 
standard (Bio-Rad product PHP133, batch 290415) in the range of 2-0.1 µg/mL (Fig. 
5.2. A). The stool suspensions were tested in dilutions 1/7500 for total IgA and 1/100 
for RV-specific IgA. When these conditions were performed with a new batch of the 
standard (batch 020615), no dynamic range could be obtained, with the OD saturated 
at high amounts (OD>2.3) for all dilutions of the standard, despite low background 
(OD≤0.1) (Fig 5.2. B).    
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Fig. 5.2. A) Total human secretory IgA standard and stool samples from 
individual M, using the standard from Bio-Rad PHP133 batch 290415 and B) 
batch 060215. Dynamic range of the standard squared in green (batch 290415) or 
red (060215) box. Yellow highlighting indicates samples outside the range. 
 
 
A series of modifications were performed to identify the cause of the poor 
dynamic range (Table 5.1). Washing buffer was changed to a stronger concentration; 
manual washing rather than a plate washer was introduced to ensure thorough 
washing; and the blocking agent was changed such that it contained 3% BSA to 
reduce the background. The dilution buffer was also changed to 3% BSA in PBS for 
consistency. The originally adapted protocol worked well, as the only changes 
implemented were BSA in the blocking and dilution buffers. The issue was most 
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likely related to the human secretory IgA standard. Two different and new batches 
from Bio-Rad (batches 020615 and 170516), one from Sigma (product I1010, batch 
SLBP7516V) and one from Invivogen (product ctrl-ga, batch GAC-36-01) were 
tested. None of these standards resulted in a dynamic range modelling the first batch 
(290415). In order to elucidate if the issue was related to the dilutions or the material 
itself, more material of the original batch (kindly provided by M. Iturriza Gómara 
and A. Pulawska-Czub) was tested and the dynamic range modelled that previously 
observed for batch 290415. The manufacturer was contacted: they explained that the 
source of human secretory IgA (which is purified from human colostrum by size-
exclusion fractionation and ion-exchange chromatography; Bio-Rad PHP133 
datasheet) from which they generated the original batch was exhausted, so the 
material would not be identical. Therefore, the original batch was kept for future 
quantification of specific anti-RV copro-IgA levels.  
 
Table 5.1. Materials and reagents tested and modified to optimise the total IgA 
sandwich ELISA. , worked; , did not work.  
 
 
 
To test total IgA, four kits were considered: ThermoFisher Scientific IgA 
human uncoated ELISA kit (product 88-50600-22, range 1.6-100 ng/mL), an Abcam 
kit (product ab196263, range 0.78-50 ng/mL), Sigma SIgA ELISA (product SE 
120114, range 0-200 µg/dL) and Salimetrics
®
 Salivary Secretory IgA indirect 
enzyme immunoassay (product 1-1602-5, range 12.5-3000 µg/mL). The Salimetrics
®
 
Salivary Secretory IgA indirect enzyme immunoassay kit was selected as it had 
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previously worked well with stool samples (Miren Iturriza Gómara, personal 
communication). This kit provided a salivary secretory IgA (sIgA) standard with 
specific sensitivity of 12.5 µg/mL. The expected range of sIgA in saliva (93.2-974.03 
µg/mL) is lower than in stool (520-2040 µg/mL). The Salimetrics
®
 standard was 
tested using the direct sandwich ELISA and the original working standard was tested 
using the Salimetrics
®
 competitive ELISA to establish assay comparability. The total 
copro-IgA levels would be measured using the competitive ELISA and RV-specific 
copro-IgA using the sandwich ELISA together with the original total working 
standard. The Salimetrics
®
 assay detected stool samples for the dilutions indicated in 
the protocol and yielded a final standard dynamic range from 12.5-3000 µg/mL, as 
expected from the manufacturer’s specifications. However, the original working 
standard tested in the Salimetrics
®
 assay did not work due to the differences in 
protocol. The same was true for the standard from the Salimetrics
®
 kit when tested in 
the sandwich ELISA for total IgA: they were not comparable.  
In summary, the Salimetrics
®
 kit was used to measure total IgA in the range 
of 12.5-3000 µg/mL and specific anti-RV IgA was measured using the in-house 
specific sandwich assay and quantifying with the original working standard for total 
IgA in the range of 2.5 to 0.1 µg/mL, with a LoD of 0.503 OD (no samples with 
OD>0.503 were plotted). The relative abundance is indicated as a ratio or trend of 
specific to total IgA. 
5.4.4 Total copro-IgA 
Total copro-IgA levels in this cohort were detected in the range of 173.5-
16,250 µg/g of stool, a wider range than previously observed (Martin, 2000; 
Scholtens et al., 2008). Although the pattern of total IgA detection varied across the 
cohort, all infants presented detectable levels throughout the timepoints tested from 
pre-vaccination to after dose 1 and 2 (Figs. 5.3. A & B). Highest total IgA levels 
usually followed a decrease in vaccine virus shedding after each vaccine dose (Figs. 
3.4. A-D), with levels fluctuating during the rest of the period.  
All 12 infants presented detectable total copro-IgA levels after dose 1, with 
three recruits (25%) presenting highest levels at days 2-9, five recruits (41.6%) at 
days 12-16 and four recruits (33.3%) at days 20-29, and a median day of highest total 
IgA of day 14. Although the pattern of total IgA detection varied across the cohort, 
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all infants presented detectable levels throughout the timepoints tested after dose 1 
and 2. Interestingly, individuals E and C presented timepoints with very low total 
IgA levels immediately after dose 1. After dose 2, seven recruits (58.3%) presented 
highest IgA at days 30-38, two recruits (16.7%) at days 41-47 and three recruits 
(25%) at days 54-57. Individual H presented some timepoints with very low total 
IgA levels after dose 2. All the eight recruits for whom an after-a-year sample was 
available presented detectable total IgA levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 RV-specific copro-IgA response in Rotarix
® 
vaccinees in the UK 
188 
 
 
 
 
 
 
 
F
ig
. 
5
.3
. 
T
o
ta
l 
a
n
d
 s
p
ec
if
ic
 a
n
ti
-R
V
 c
o
p
ro
-I
g
A
 c
o
n
ce
n
tr
a
ti
o
n
 i
n
 A
) 
in
d
iv
id
u
a
ls
 K
, 
L
, 
G
, 
M
, 
D
 a
n
d
 I
 a
n
d
 B
) 
in
d
iv
id
u
a
ls
 H
, 
B
, 
E
, 
C
, 
J
 a
n
d
 F
. 
Q
u
an
ti
ta
ti
o
n
 o
f 
to
ta
l 
an
d
 s
p
ec
if
ic
 I
g
A
 b
y
 i
n
d
ir
ec
t 
co
m
p
et
it
iv
e 
an
d
 d
ir
ec
t 
E
L
IS
A
 s
h
o
w
n
 i
n
 l
ef
t 
(l
im
it
 o
f 
d
et
ec
ti
o
n
 
(L
o
D
)=
1
2
.5
 µ
g
/m
L
 o
r 
µ
g
/g
) 
an
d
 r
ig
h
t 
(L
o
D
=
0
.5
0
3
 O
D
) 
Y
 a
x
es
 r
es
p
ec
ti
v
el
y
. 
T
h
e 
X
 a
x
is
 s
h
o
w
s 
d
ay
s 
w
it
h
 r
es
p
ec
t 
to
 d
o
se
 1
. 
D
ay
 0
: 
D
ay
 o
f 
d
o
se
 1
. 
B
la
ck
 a
rr
o
w
: 
D
ay
 o
f 
d
o
se
 2
. 
B
lu
e 
d
at
ap
o
in
ts
: 
T
o
ta
l 
Ig
A
. 
G
re
en
 d
at
ap
o
in
ts
: 
S
p
ec
if
ic
 I
g
A
. 
T
im
ep
o
in
ts
 a
t 
w
h
ic
h
 
sa
m
p
le
s 
w
h
ic
h
 w
er
e 
te
st
ed
 b
u
t 
w
h
o
se
 l
ev
el
s 
w
er
e 
b
el
o
w
 t
h
e 
L
o
D
 a
re
 s
h
o
w
n
 a
s 
cr
o
ss
es
. 
 Chapter 5 RV-specific copro-IgA response in Rotarix
® 
vaccinees in the UK 
189 
 
 
 
 
 
 
 
 Chapter 5 RV-specific copro-IgA response in Rotarix
® 
vaccinees in the UK 
190 
 
5.4.5 Specific anti-RV copro-IgA  
Specific anti-RV copro-IgA levels in this cohort were detected in the range of 
67.17-3420.18 µg/g as readout using the total IgA standard (Figs. 5.3. A & B). Only 
positives based on the limit of detection established in the assay were considered. 
Furthermore, as a relative trend of specific IgA with respect to total IgA, detectable 
RV-specific copro-IgA levels ranged from 100 ng of RV-specific IgA per µg of total 
IgA to nearly 10,000 ng of RV-specific IgA per µg of total IgA (Figs. 5.4. A-C).  
At pre-vaccination, three of 11 infants tested (D, G, L) were positive for anti-
RV cIgA and all three of them had been breastfed. The other three breastfed infants 
(E, F, H) were negative for anti-RV cIgA at pre-vaccination. After dose 1, seven of 
the 12 infants tested (D, G, H, I, K, L, M) were positive for anti-RV cIgA and after 
dose 2, four of the 12 were positive (B, G, L, K). A year later, three of the 8 infants 
tested (B, C, E) were positive for anti-RV cIgA. By the period(s) where RV-specific 
copro-IgA was detected, one infant (D) was positive at pre-vaccination and after dose 
1, two infants (G, L) were positive at pre-vaccination and after both doses, one infant 
(K) was positive after both doses, three infants (H, I, M) were positive only after 
dose 1, one infant (B) was positive only after dose 2, two infants (C, E) were positive 
after a year and two infants (F, J) presented no IgA.  
Throughout the two to three months after dose 1, two infants presented spread 
RV- specific copro-IgA levels (K, L), three infants presented three to six curtailed 
(D, M) or protracted (G) RV- specific copro-IgA levels, another three infants (B, H, 
I) presented early (individual H), expected (individual I) or late (individual B) copro-
IgA detection at a single timepoint, and four infants  presented undetectable specific 
copro-IgA levels (C, E, F, J).  
Individuals K and L presented a sustained RV-specific copro-IgA response 
after dose 1 and dose 2, with undetectable shedding after each dose (Fig. 5.4 A). 
They were mix-fed and breastfed respectively, and individual L provided no samples 
around the period of first vaccination (Chapter 2, Table 2.13), and presented highest 
detectable RV-specific IgA levels after dose 2. One infant (G) presented their highest 
RV-specific IgA levels at day 28 pre-vaccination (pre-vaccination sample tested) 
(Fig. 5.4. B). Just before dose 1, RV-specific IgA levels were still high, followed by 
lower RV-specific IgA levels that increased after dose 2.  
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Three infants presented their highest RV-specific IgA levels after dose 1 at 
days 2-10 (D, H, M) (Fig. 5.4 B). Individual D presented high RV-specific IgA levels 
pre-vaccination and very high levels immediately after dose 1, with undetectable 
levels thereafter. Individual H presented high RV-specific IgA levels following dose 
1 immediately before shedding became undetectable. Individual M presented high 
(up to 1000 ng RV-specific IgA per 100 µg total IgA) and very high (>1000 ng RV-
specific IgA per 100 µg total IgA) RV-specific IgA levels after dose 1. Another 
infant (I), for whom no shed virus was detectable after dose 1, presented highest RV-
specific IgA levels after dose 1 at day 23, a week after viral loads were no longer 
detected (Fig 5.4 B; overimposed dots on this graph is a coincidence of the axes used 
across this set of data). Individual B presented their highest RV-specific IgA levels 
right after dose 2, with undetectable viral loads 25 days after dose 2 (Fig. 5.4 B) and 
positive RV-specific IgA levels a year after vaccination.  
Two infants (C, E) presented their highest RV-specific IgA levels a year after 
vaccination without any RV-specific IgA levels having been detected previously (Fig 
5.4. C). Individual C presented detectable viral loads for the number of samples 
provided and no shedding a year after vaccination. Individual E, however, presented 
undetectable viral loads around day 13 after dose 1 without any RV-specific IgA 
levels detected in that period and low total IgA levels throughout (Fig. 5.3. B), only 
increasing late after dose 2, when viral loads were undetectable. Another two infants 
(F, J) presented no RV-specific IgA levels at all, and their vaccine virus shedding 
was continuous and not controlled for the period of observation (Fig 5.4. C), 
including an after-a-year sample for individual F. Total IgA levels for these infants 
were higher than those of individuals C and E (Fig. 5.3. B). Individual F may have 
controlled infection at a few timepoints later than the last samples provided. 
Individual J, however, failed to control infection by the end of the vaccination 
period, since viral loads were not fully controlled after 70 days from dose 1.  
Specific anti-RV copro-IgA data showed that children who presented 
sustained detectable levels of RV-specific copro-IgA shed vaccine virus for short 
periods of time with viral loads plummeting after peak RV-specific copro-IgA (K, L, 
H, I). In contrast, the other children who presented undetectable RV-specific copro-
IgA had sustained shedding after both doses (C, E, F, J).  
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Fig. 5.4. Rotavirus vaccine RNA viral loads and anti-RV copro-IgA trend in A) 
individuals K and L; B) individuals B, D, G, H, I and M; and C) individuals C, 
E, F and J. Quantitation of rotavirus vaccine genome copy numbers by RT-qPCR: 
NSP2 gene copy numbers are shown in the left Y axis, limit of detection (LoD)= 
1.25 × 10
3
 copies/g; black dotted line. Trend of specific IgA expressed as ng of RV-
specific IgA per 100 µg of total IgA: Shown in the right Y axis (LoD=0.503 OD). 
The X axis shows days with respect to dose 1. Day 0: Day of dose 1. Black arrow: 
Day of dose 2. Black dots and lines: Rotavirus RNA (only positives shown). Purple 
dots: Specific IgA trend (only positives shown). Green dots: Specific IgA (as µg/g of 
stool). 
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5.4.6 Rotarix
®
 RNA faecal shedding and specific anti-RV copro-IgA  
All the infants presented different profiles of shedding with respect to copro-
IgA responses. High levels of RV-specific copro-IgA (>900 ng of RV-specific 
copro-IgA with respect to 100 µg of total copro-IgA) were detected among infants 
who controlled shedding rapidly (n=3; I, K, L; Fig. 5.4 A & B), as well as among 
shedders between doses (n=4; B, D, G, M; Fig. 5.4 B) and in the after-a-year sample 
of those who presented poor response after vaccination (n=2; C, E; Fig. 5.4 C). It 
was also observed that levels of RV-specific copro-IgA were poor or undetectable 
after vaccination among infants with high and/or protracted viral loads (n=5; C, D, E, 
F and J; Figs. 5.4 B & C).  
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5.4.7 Rotarix
®
 RNA faecal shedding, specific anti-RV copro-IgA and vaccine and 
vaccine-derived variants in stool 
Data on viral shedding and RV-specific copro-IgA was assessed against 
genetic stability data to identify any variants that may have had an impact on viral 
replication and the immune response against Rotarix
®
. Regarding gene segment 4 
(encoding the rotavirus spike protein VP4), individuals K and L, who presented 
highest levels of copro-IgA and rapidly stopped shedding after both doses, presented 
a vaccine variant at high frequency (leading to amino acid change K368R) that was 
undetectable or present at lower frequency after dose 2. Individual L also presented a 
novel variant (leading to amino acid change F167L) at very high frequency after dose 
1 that was not detected after dose 2.  
Individual D, with undetectable RV-specific IgA from a few days after dose 1 
and with protracted shedding until after dose 2 presented the same vaccine variant 
(resulting in K368R) and another (resulting in N363S) at high frequency after dose 1 
but at lower frequency after dose 2. Individuals H, M and I, with a strong immune 
response and lack of shedding after dose 1 or soon after dose 2, presented the same 
variant (resulting in K368R) again at high frequency after dose 1 but undetectable 
after dose 2. Individual M also presented a novel variant (leading to P114T) at high 
frequency after dose 1.  
Individual B, however, with a strong response but shedding between doses, 
presented that vaccine variant resulting in K368R at high frequency still after dose 2 
and another vaccine variant (resulting in M364I) that increased from dose 1 to after 
dose 2. Individual E appeared to suppress the variant resulting in K368R after dose 2 
but a novel variant (resulting in F167L) was present at high frequency after dose 2, 
suggesting it may have been responsible for the increase in viral loads. Similarly, 
individual C, with a poor response and high amounts of shedding, presented the 
variant resulting in K368R and the novel variant resulting in F167L at high 
frequency after both doses, in addition to two other vaccine variants that decreased 
(resulting in I388L) and increased (resulting in N363S) and another novel variant 
(leading to P114T) in common with individual M and detected after dose 2.  
Individual F, continuous shedder with undetectable RV-specific copro-IgA 
response, presented the vaccine variant resulting in K368R and another vaccine 
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variant leading to I470T decreasing in frequency from after dose 1 to after dose 2 and 
the previously mentioned novel variant leading to F167L after dose 1, but 
undetectable after dose 2. Individual J presented the vaccine variant most common 
among infants (leading to K368R) at very high frequencies after dose 1 and dose 2 
plus several other vaccine variants that fluctuated in frequency and were around 50% 
after dose 2 (leading to Y385H and M364V) and a novel variant that also fluctuated 
and was around the same frequency late after dose 2 (leading to P114T).  
Variants detected in genes 9 and 6 (encoding VP7 and VP6 respectively) 
were detected early at low and 50% frequency in two infants, and early at low 
frequency in two infants, respectively. Regarding gene segment 10 (encoding the 
rotavirus enterotoxin NSP4), only variants resulting in F33S, S38P and I45M were 
detected at high frequency after the second dose in a continuous shedder and late 
responder (individuals J and B), in a late responder (individual E) and in continuous 
shedders (individuals C and J), respectively.  
5.5 Discussion 
In previous studies, RV-specific copro-IgA did not correlate with infection or 
illness in challenged adults (Ward et al., 1989). However, copro-conversion had been 
detected in newborns, infants vaccinated with RotaShield
®
 and adults fed filtrated 
stool (Bernstein, Ziegler and Ward, 1986; Losonsky et al., 1988; Losonsky and 
Reymann, 1990). RV-specific copro-IgA was detected in approximately 77% of 
symptomatic infants (Hoshino et al., 1985; Hjelt et al., 1986; Grimwood et al., 
1988). Moreover, RV-specific copro-IgA was found to be predictive of duodenal 
RV-specific IgA one and four months after infection (although the four month 
detection may have been due to reinfection) (Grimwood et al., 1988; Coulson et al., 
1992) and of neutralizing copro-antibodies in infants (Coulson 1992). Regardless of 
their shedding status (shedders or non-shedders), infected infants presented a ≥4-fold 
increase in RV-specific copro-IgA one month after infection (Matson et al., 1993). 
There was an inverse correlation with infection rate when RV-specific copro-IgA 
was ≥80 U/mL and with disease when it was ≥20 U/mL (Matson et al., 1993). A high 
proportion of infants (>90%) were found to be re-infected (Coulson et al., 1992; 
Matson et al., 1993), with 38% of them showing persistent increases in copro-IgA 
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levels defined as “plateaus” of neutralising activity (Coulson et al., 1992). These 
“plateaus” were associated with higher infection although asymptomatic and usually 
occurred in infants with younger sibling or who attended nursery. The RV-specific 
copro-IgA response in asymptomatic individuals and non-shedders was found to be 
intermittent (Coulson et al., 1990, 1992). Coulson and colleagues suggested that 
frequent infection generated an anamnestic duodenal IgA plateau (Coulson et al., 
1992). Fluctuations previously observed were also related to transient diarrhoea (in 
the presence or absence of shedding) (Grimwood et al., 1988). Later, extended 
excretion was associated with intermittent RV-specific copro-IgA (Richardson et al., 
1998).  
The peak of RV-specific copro-IgA was found to be at days 11-21 or between 
two and four weeks after infection in adults and infants (Grimwood et al., 1988; 
Bernstein, McNeal, et al., 1989; Richardson et al., 1998). RV-specific copro-IgA 
declined or was found to be stable from two to seven months after infection (Hjelt et 
al., 1986; Grimwood et al., 1988; Matson et al., 1993) and was detectable up to 9-12 
months after infection and at 13.5-fold higher than baseline in adults (Bernstein, 
McNeal, et al., 1989). In infants, RV-specific copro-IgA was detectable from up to 
18 and 26 months after infection (Coulson et al., 1990, 1992).  
RV-specific copro-IgA as a predictor of neutralising copro-antibodies in the 
duodenum and copro-conversion were considered the most sensitive measure of 
immune response at the site of infection (Grimwood et al., 1988; Coulson and 
Masendycz, 1990; Coulson et al., 1990). It was estimated then that there was a 200% 
increased risk of protection prediction underestimation when using RV-specific 
serum IgA (Coulson et al., 1990).  
In some clinical trials, immunogenicity was measured as stool RV-specific 
IgA at pre-immunization and days 4, 7, 14 and 21 post-vaccination and resulted in 
significant increases (Bernstein, 1998). However, in most clinical trials, 
immunogenicity was measured in terms of RV-specific IgA seroconversion after 
dose 1, at two months and one year after vaccination or similarly, taking into account 
a titre increase of ≥20 units/mL or ≥4-fold in >60-90% of infants (depending on 
study settings) after dose 2 (Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 
2004; Dennehy et al., 2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et 
al., 2007). This may be due to the detection consistency of RV-specific serum IgA at 
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days pre-vaccination, 14 and 21 post-vaccination than RV-specific copro-IgA. 
Moreover, until 2015, no other specimens but serum had been identified as correlates 
of protection or considered in regulatory decision-making (Powell et al., 2015). A 
recent study on IgA response to rotavirus in infants vaccinated with Rotarix
®
 in the 
UK observed a 50% seroconversion one week after each dose (Parker, 2019). A 
higher percentage of seroconversion may be detected at the time of peak 
seroconversion, three to four week after each dose. Efficacy was tested in terms of 
prevention of RVGE from after the second dose to two weeks, one year or more than 
a year later compared to placebo group (Dennehy et al., 2005; Phua et al., 2005; 
Ruiz-Palacios et al., 2007) or weekly when a diarrhoea episode occurred and up to a 
year after vaccination (Salinas et al., 2005). 
Some of the original questions about how long RV-specific copro-IgA 
persists, if it correlates with protection against infection or RVGE and the titres 
needed to achieve protection have been answered in the past in natural infections. 
However, no such studies have been performed on infants vaccinated with Rotarix
®
, 
a live-attenuated vaccine that was considered to elicit asymptomatic infection in 
clinical trials. This is the first study to assess longitudinally and in a nearly 
exhaustive and comprehensive manner the levels of RV-specific copro-IgA in infants 
vaccinated with Rotarix
®
 within the first two to three months after vaccination (as 
well as after a year since dose 1, where sample available) to assess the immune 
response at the site of infection. 
In all 12 infants studied in this cohort, total copro-IgA was detected in a 
pattern of fluctuating levels, with total IgA coinciding with the viral shedding profile 
as amounts of total IgA were high when viral loads appeared undetectable in all 
infants overall. The RV-specific IgA response, however, did not present a clear 
correspondence or correlation. In some infants (individuals I, H, M), dose 1 appeared 
to be enough to generate a response that would eventually result in viral elimination 
from stool. In the profile of individual H, although no RV-specific IgA levels were 
detected after dose 2, shedding rapidly stopped (Chapter 3, Fig. 3.4 B), suggesting 
immunity generated after dose 1 was enough to impair lasting replication of the 
vaccine virus. For individual M, the high and very high RV-specific IgA levels after 
dose 1 signified a strong or very strong immune response that was potentially enough 
to eliminate viral shedding after dose 2. In the case of individual I, it appears that 
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immunity generated after dose 1 was sufficient to impair shedding after dose 2.  
Similarly, in individual D, a strong specific copro-IgA response after dose 1 
appeared enough to eventually eliminate virus in stool. It appears as if maternal IgA 
from breastfeeding did not interfere with infection and replication, and no strong 
immune response was generated afterwards as infection lasted from dose 1 through 
to dose 2 and beyond. However, shedding data, despite being protracted after dose 1, 
indicated shedding decrease to undetectable levels after dose 2 (Chapter 3, Fig. 3.4 
C). Hence, it is possible that RV-specific IgA levels were below the assay’s limit of 
detection or that sample storage might have caused non uniform degradation across 
samples. 
Interestingly, in those infants who presented a sustained and upward trend of 
RV-specific IgA response throughout the vaccination period (individuals K, L, G), 
dose 2 appeared to exert a booster effect as expected, allowing fast elimination of 
vaccine virus. If individual L experienced any illness, it did not appear to impair 
replication of vaccine virus and specific local immune response to it. In individual 
G’s profile, although maternal IgA might have partly neutralised vaccine virus, it 
appears as if this infant was infected and Rotarix
®
 replicated after dose 1 and dose 2, 
generating an immune response that allowed detectable levels after dose 1 and 
increased levels after dose 2, with an overall good immune response. By contrast, in 
another infant, dose 2 appeared necessary to generate a strong specific copro-IgA 
response (individual B). Although shedding increased from late after dose 1 to 
immediately after dose 2, it appears as if immunity after dose 2 was required to stop 
shedding after dose 2. Their detectable RV-specific IgA levels one year after 
vaccination suggested that if they came across a WT rotavirus there was no shedding 
and a specific response was mounted.  
In two infants (individuals C, E), although the two doses did not appear to 
eliminate shedding or to generate a strong immune response, infants were protected 
against rotavirus infection in the long-term (a year later). In the case of individual C, 
although the number of samples provided were not enough to draw a firm 
conclusion, the clear downward trend in viral loads suggests that eventually control 
of infection after dose 2 would have been observed if sample collection had 
continued. A very high specific response was detected a year later in the absence of 
shedding, suggesting immunity against rotavirus was elicited after vaccination, 
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probably at levels below the assay’s limit of detection during the period studied 
and/or at higher levels after collection stopped. For individual E, It is possible that a 
vaccine-derived variant arose around day 13 (such as that leading to amino acid 
change F167L; Chapter 4) and was responsible for the continued shedding during the 
latest days after dose 1 and before dose 2, with dose 2 acting as a booster that helped 
eliminate shedding. Their (individual E) low total IgA levels suggested RV-specific 
IgA levels may have been low and undetectable for the two-month period after 
vaccinations. Total IgA was only high after viral loads were undetectable and 
although no RV-specific IgA was detected then, it may have been low but enough to 
have stopped viral replication. The after-a-year sample being positive and high for 
RV-specific IgA levels in the absence of shedding suggests this individual acquired 
immunity against rotavirus after vaccination. This may be due to recovery from a 
potential IgA deficiency, to a subclinical recent re-infection stimulating their 
response or to the development of an immune response following continuous 
replication of vaccine virus at low levels (below the limit of detection of the assay).  
In another two infants (F, J), however, vaccination clearly did not prevent 
long-term shedding nor generate a strong immune response in the first months after 
vaccination. The continuous and slowly decreasing shedding suggested there may 
have been an underlying immunodeficiency that prevented rapid clearing of the virus 
in stool. If they generated an immune response, they may be late responders and 
vaccine and vaccine-derived variants at high frequency throughout their vaccination 
periods may have influenced the delay in mounting an immune response (Chapter 4). 
They may also have controlled the disease by compensation mechanisms such as IgG 
(Istrate et al., 2008), of slower generation than IgA.  
The small number of individuals and inconsistent positive timepoints for RV-
specific IgA in this cohort did not allow the comparison of RV-specific IgA levels in 
breastfed (n=6) versus mixed-fed (n=5) infants from a population point of view. 
Individuals who presented detectable strong and sustained RV-specific IgA 
responses (K, L) were mixed-fed and breastfed respectively. Similarly, those who 
presented strong responses (individuals B, G, H, I and M) were both mixed-fed and 
breastfed, similar to those individuals who presented poor or undetectable responses 
(D, E, F and J). The only formula-fed infant (individual C) also presented a poor 
immune response throughout the two-month period after vaccination. 
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Although RV-specific copro-IgA and shedding levels were different 
throughout the cohort, it was clear that a RV-specific response was present at 
detectable levels when shedding was undetectable and vice versa, undetectable RV-
specific copro-IgA levels corresponded to lasting shedding. In early studies, although 
symptomatic infection was associated with lower RV-specific copro-IgA levels, it 
was found to be unrelated to viral shedding by electron microscopy or ELISA 
(Coulson et al., 1992). We have considered these infants asymptomatic, although 
they may have experienced diarrhoea where a dip in viral load occurred, and it did 
not appear that low viral loads generated low IgA, since all infants presented high 
viral loads at some point after vaccination. Moreover, although detectable RV-
specific copro-IgA before dose 1 in some infants appeared to be of maternal 
breastmilk origin (individuals G, D) and may have had an impact on the infants’ 
mucosal IgA responses, breastfeeding did not appear to prevent vaccine virus 
shedding or influence the timepoints or amounts of RV-specific IgA detection, unlike 
previously reported in a larger cohort (Bautista-Marquez et al., 2016). 
Individuals who could eliminate shedding and presented a strong response 
also presented fewer variants and at lower frequency than those who shed 
continuously and presented an undetectable or poor immune response. These results 
suggested the local IgA response of infants with sustained shedding and poor or 
absent RV-specific copro-IgA levels was not fast enough to prevent the vaccine virus 
from reaching the replication stage at which variants have become transiently 
dominant or fixed.  
These results illustrate the differences in immunogenicity at the level of RV-
specific copro-IgA generated by the vaccine in different infants and suggest that, 
except in those with a poor or delayed immune response, Rotarix
®
 generates a 
mucosal response sufficient to elicit a fast and effective response in the long-term 
(within the two-month vaccination period and a year later), in some cases already 
after one dose. No comments can be made regarding protection against severe 
diarrhoea as no data was provided on health status in the first months after 
vaccination or a year later. However, since Rotarix
®
 is known to have a high 
protective efficacy against severe RVGE in developed settings, it appears that most 
of these infants (excluding the continuous shedders without information on the after-
a-year response) would be protected against rotavirus diarrhoea. The continuous 
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shedders with low total IgA and low or absent RV-specific IgA may be protected 
through compensation mechanisms by IgG (Istrate et al., 2008). Multiple intestinal 
host factors may be responsible for these differences in RV-specific copro-IgA 
fluctuating patterns.  
The horizontal transmission of these vaccine viruses from the infants who 
eliminated shedding and presented a RV-specific copro-IgA response would likely 
contribute to herd immunity in the general population. However, transmission of 
variants that provide an advantage to infection, replication, pathogenicity, virulence 
or immune escape, mostly present and/or maintained at high frequency in continuous 
shedders, may pose a risk of vaccine-derived gastroenteritis if transmitted to 
susceptible contacts.  
Despite the lack of direct quantitative comparability between total and RV-
specific IgA, the relative proportion was maintained and indicated the trends in poor 
or strong RV-specific copro-IgA responses in this cohort. The generation of a RV-
specific IgA standard (non-existent at present) would enable absolute quantification 
and comparison across laboratories. Moreover, due the nature of faecal samples 
regarding storage (and hence protein degradation) and low homogeneity, together 
with the variable amounts of true RV-specific IgA, positive results were detected at 
differing timepoints across infants. This intrinsic variation and inconsistency of 
detection would complicate the establishment of copro-IgA as an alternative 
correlate of protection to serum IgA. The identification of key predictive timepoints 
and standardised titre cut-off would contribute to further understanding peak time of 
rotavirus incidence and hence vaccine failure and improvement of vaccine 
scheduling across populations in different settings (Bennett et al., 2017), as well as 
serve as an immunogenicity measure in future trials for next generation live-
attenuated or non-replicative rotavirus vaccines.  
This study is the first of its kind and has contributed to the knowledge about 
mucosal immunity against rotavirus in vaccine recipients, with a novel focus relating 
data on the early RV-specific copro-IgA response and viral shedding. The results 
confirm the generation of immunity against rotavirus in immunocompetent infants 
after two vaccine doses and provide finer detail on the different shedding profiles and 
the variety of immune responses. Faecal collection has proven to yield useful data 
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showing that detection of RV-specific IgA appears to be associated with elimination 
of shedding at an individual level.  
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Chapter 6: Conclusions 
The overall findings in this thesis assessing vaccine virus shedding and 
genetic stability as well as RV-specific copro-IgA levels in this cohort constitute a 
novel and unique set of data that has contributed to a better understanding of the 
individual responses to vaccination and of vaccine virus evolution during replication 
in the host. The research implications of these results as well future directions are 
discussed here.  
The aim of the work presented in this thesis was to assess the genetic stability 
of Rotarix
® 
vaccine virus following replication in vaccinees in relation to their faecal 
viral loads and RV-specific IgA response. Previous studies have focused on minimal 
and cross-sectional timepoints to assess RV vaccine shedding and copro-conversion 
(Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 2004; Dennehy et al., 2005; 
Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et al., 2007), so little is known 
about the dynamics of infection and immunity at the site of infection around the time 
of vaccinations. Moreover, deemed safe but without knowledge about the mutations 
that confer attenuation and with a potential to alter its virulence through mutation in 
the host, Rotarix
®
 has only been characterised for genetic stability by the 
manufacturer using Sanger sequencing and recently at the NIBSC using NGS 
(Mitchell, Lui, et al., unpublished). Characterisation of Rotarix
®
 genetic stability in 
the population of vaccine recipients had not been performed to date. The introduction 
of Rotarix
®
 in the NIP may generate vaccine variants of high frequency, revertants 
and novel variants while replicating in vaccinated infants and generating an intestinal 
IgA response to infection, and those variants may result in vaccine instability in 
vaccine recipients. The ready access to a cohort of vaccinated infants and a collection 
of longitudinal samples from before vaccination through to beyond the completion of 
the vaccine dose schedule generated data that provided a detailed assessment of the 
three parameters and added considerably to the knowledge of Rotarix
® 
shedding and 
stability in vaccine recipients as well as to their RV-specific faecal IgA response. 
In this detailed longitudinal study of Rotarix
®
 shedding and RV-specific 
copro-IgA response following vaccination, none of the infants in the cohort appeared 
to have encountered rotavirus before vaccination as shown by the absence of vaccine 
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or WT rotavirus shedding —pre-vaccination RV-specific copro-IgA is likely of 
maternal breastmilk origin—, as expected in a high-income country where rotavirus 
is not known to circulate all year round (Kapikian et al., 1976; Cook et al., 1990). 
Overall, high and sustained shedding suggested active replication of Rotarix
®
 in all 
vaccinees and it was clear that infants with detectable RV-specific copro-IgA levels 
controlled viral shedding more rapidly. The viral load range in this cohort was lower 
than in WT infection (Kang et al., 2004; Kaplon et al., 2015), as expected for a live-
attenuated vaccine which would replicate asymptomatically, and similar to 
previously reported viral loads for Rotarix
®
 in stool of vaccine recipients elsewhere 
(Hsieh et al., 2014; Mijatovic-Rustempasic et al., 2017). The detection of shedding 
in all or almost all (11/12) infants after dose 1 and dose 2, in contrast to previous 
studies that detected a higher proportion of infants shedding after dose 1 than after 
dose 2 (Bernstein, 1998; Vesikari, Karvonen, Korhonen, et al., 2004; Dennehy et al., 
2005; Phua et al., 2005; Salinas et al., 2005; Ruiz-Palacios et al., 2007; Hsieh et al., 
2014; Mijatovic-Rustempasic et al., 2017), maybe due to a higher vaccine take in 
this cohort or due to reduced sampling frequency or larger cohorts used in previous 
studies. In accordance with previous studies, shedding was significantly higher after 
dose 1 than after dose 2, confirming vaccine take after dose 1 and a booster effect 
with vaccine take after dose 2. Among the cohort, total IgA was detected at 
fluctuating levels corresponding to shedding profiles, with high levels when viral 
loads were undetectable and vice versa, coinciding with shedding control. The 
granularity of this study allowed further detail regarding peak shedding, detecting 
two windows of peak shedding time: one during the first week and another one 
during the second week after dose 1, with most of the infants presenting early peak 
shedding also controlling shedding earlier than those with peak shedding during the 
second week. Although commencement of shedding was similar to previous reports 
(Bernstein, 1998; De Vos et al., 2004; Dennehy et al., 2005; Phua et al., 2005; 
Salinas et al., 2005; Ruiz-Palacios et al., 2007; Hsieh et al., 2014; Mijatovic-
Rustempasic et al., 2017; Pollock, 2018), duration was longer in three infants (up to 
70 days after dose 1 in one of them), highlighting the valuable data obtained by a 
longitudinal study of this kind and indicating shedding duration depends on host 
immune status and other susceptibility factors.  
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Four distinct profiles of Rotarix
®
 faecal shedding were observed. Those who 
presented shedding control with high RV-specific copro-IgA after the first dose as 
well as those who presented an early response with high RV-specific copro-IgA after 
the first dose, shedding control after dose 1 and low shedding after dose 2 appeared 
to mount an immune response to the two-dose vaccination regime that was robust 
enough to control shedding following dose 1 (those with specific IgA at a few 
timepoints) or with a booster effect by increasing RV-specific copro-IgA following 
dose 2 (those with specific IgA spread across timepoints). Although the assay to 
quantify total copro-IgA was not comparable to the assay used for RV-specific 
copro-IgA quantification, the relation could still be expressed as a trend that showed 
variable RV-specific copro-IgA in each infant. However, the generation of a 
rotavirus-specific IgA standard at the NIBSC would allow for harmonisation of assay 
data. If generated from copro-IgA, stool samples from a large cohort of infected 
and/or vaccinated infants would be collected weekly (Coulson et al., 1990), prepared 
as a faecal suspension and purified for anti-VP4/VP7/VP6 using filtration methods or 
magnetic beads. Units of protection would have to be established in a faecal 
suspension matrix and would need to be commutable. The generation of such a 
standard would contribute to better understanding of vaccine failure, comparison of 
results obtained in different studies and could be used as an immunogenicity measure 
in future rotavirus vaccine trials.  
Regarding the other shedding profiles, late responders did not control 
shedding between doses and only after dose 2 the catch-up effect of the vaccine 
appeared to elicit an immune response, in some cases inferred from cessation of 
shedding as RV-specific copro-IgA was undetectable for most of them following 
dose 2 or both doses. Most of the infants were early or late responders, as expected in 
a high-income country, with infants controlling shedding either after dose 1 or 
immediately after dose 2. The continuous shedders, however, presented a delayed 
immune response based on a lack of viral load detection in the after-a-year samples 
after high viral loads in the absence of shedding control or detectable RV-specific 
copro-IgA following vaccination. The late responders and continuous shedders were 
previously identified in Malawi at lower proportions, where low shedders were most 
abundant (Pollock, 2018) and are expected to be a lower proportion in high-income 
settings. Any vaccinated infants shedding vaccine virus may potentially contribute to 
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horizontal transmission of Rotarix
®
 vaccine or vaccine-derived variants, especially 
the continuous shedders who have vaccine virus replicating for longer. Suspected 
cases of symptomatic horizontal transmission of Rotarix
®
 have been reported since 
2005 but without full confirmation (Chapter 3, Discussion) and a few cases of 
asymptomatic transmission leading to indirect protection were reported in the 
Dominican Republic (Rivera et al., 2011). Profiles of rotavirus vaccine shedding 
would be better understood if more studies were performed in different populations, 
potentially shedding light onto the proportions of types of shedders or non-shedders. 
Studies to clarify the potential for transmission to other strata of the population who 
are healthy but susceptible or immunocompromised would be unethical. Therefore, 
retrospective studies when such cases are reported are key. Parental information and 
awareness on hygiene practices when taking care of an infant vaccinated with a live-
attenuated vaccine that is shed in stool should be encouraged to avoid transmission to 
susceptible contacts.  
The differences observed in vaccine uptake and shedding duration in this 
cohort point towards varying susceptibilities to G1P[8] RV infection and differences 
in the immune responses within the cohort. No health or genetic data was provided, 
hence analysis in those respects was not possible. Similar studies in other cohorts in 
the UK with permission to test secretor status would shed light onto this 
susceptibility factor in this region, as has been assessed in Nicaragua and Malawi 
recently (Bucardo et al., 2018; Pollock et al., 2018). Interestingly, in this cohort, 
breastfeeding did not appear to be an obvious factor influencing shedding duration or 
RV-specific copro-IgA levels in any of the breastfed infants as opposed to a larger 
cohort where a reduction in shedding and RV-specific serum IgA was observed in 
breastfed infants (Bautista-Marquez et al., 2016), probably due to the difference in 
size and the geography of cohorts, and supporting the hypothesis that breastfeeding 
does not reduce immunogenicity at an individual level. Another factor believed to be 
related to rotavirus susceptibility is the microbiome. Correlations between certain 
genera or between microbiota richness and Rotarix
®
 shedding has been observed 
recently in India (Parker, Praharaj, et al., 2018). Studying the microbiome (down to 
genus level) of Rotarix
®
 vaccinees in this small cohort would contribute to better 
understanding this complex susceptibility factor. Samples from this cohort are 
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currently in use for such study at the NIBSC as a collaboration with Dr Gregory C. 
A. Amos in the Bacteriology Department.  
A year after first vaccine dose, the fact that none of the infants presented 
vaccine rotavirus or all-RVA shedding suggested that if they had re-encountered 
rotavirus, very likely during their first year after vaccination, they were able to clear 
it rapidly. This was supported by data from those infants who presented detectable 
RV-specific copro-IgA levels a year after first dose, suggesting that whether they had 
controlled shedding after the two-dose regime or not, they were protected against 
rotavirus infection a year later. The limit of detection of the assays may have 
influenced results for those timepoints where amounts of virus or copro-IgA were 
very low and were considered negative, potentially impairing detection of low 
shedding and/or low RV-specific IgA responses.  
Regarding these, it remains unclear whether the RV-specific IgA antibodies 
(anti-VP4, anti-VP7 and anti-VP6) in stool of infants have neutralising capacity and 
whether human anti-VP6 antibodies in stool of infants are able to block intracellular 
transcription as it has been reported for recombinant antibodies (Aiyegbo et al., 
2013). Anti-VP6 antibodies have also been reported to be protective in mice (Burns 
et al., 1996; Corthésy et al., 2006; Lappalainen et al., 2014, 2015; Maffey et al., 
2016). Testing stool from the infants in this cohort who presented rapid viral load 
control and high pre-vaccination RV-specific copro-IgA, likely maternal from 
breastmilk, would be of highest interest to detect any anti-VP6 copro-IgA that may 
provide protection in humans. Samples from this cohort have been sent to Dr Sarah 
L. Caddy at the MRC in Cambridge and will be assayed using the two following 
working systems. On the one hand, electroporation of MA104 or Vero cells with 
anti-VP6/VP4/VP7 copro-IgA purified from stool (by filtration or using magnetic 
beads) will be used to test neutralisation of intracellular infection with WT G1P[8]. 
On the other hand, DLPs and TLPs of WT and vaccine G1P[8] strain will be 
incubated in vitro with anti-VP6 copro-IgA from stool (crude faecal suspension), 
followed by another incubation with dNTPs and tested by RT-qPCR to study 
whether transcription pockets would be blocked by these antibodies (Aiyegbo et al., 
2013), which could be further assayed to study in vivo protection in mice.  
The work described in this thesis also aimed to assess the genetic stability of 
a rotavirus live-attenuated vaccine in a cohort of vaccine recipients. Whole genome 
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RNA sequencing may have allowed studying all the rotavirus gene segments in an 
economic and time-efficient manner. However, in the case of RNA from vaccine 
recipients in this cohort, low viral loads (≤106 viral copies/g) did not allow such 
approach (Appendix II). Another approach using segment-specific RT-PCR prior to 
DNA library preparation was used instead. Due to limited extraction volumes, 
amplification was only possible from four segments (Appendix II, section 8.2.1.2). 
Characterisation of gene segments encoding VP4, VP7, VP6 and NSP4 was 
prioritised as these viral proteins are involved in viral entry, immunogenicity and 
virulence. Next generation sequencing of Rotarix
®
 genes encoding VP4, VP7, VP6 
and NSP4 generated an extensive set of data and common SNPs were selected for 
analysis. However, SNPs particular to each infant could be investigated further.  
At key timepoints of Rotarix
®
 shedding, variants previously detected at low 
frequency in vaccine material (Mitchell, Lui, et al., unpublished) were detected at 
high frequency in stool, some becoming transiently dominant or fixed by the latest 
timepoints, suggesting low level SNPs in cell culture adaptation of the Rotarix
®
 
vaccine candidate were selected in vivo in the immunised host. Other variants arose 
as a result of Rotarix
®
 replication in vaccine recipients, some increasing to high 
frequencies by the end of the period observed. From the changes identified in the 
VP7 and VP4 encoding genes affecting receptor binding, trypsin cleavage, 
membrane fusion and neutralisation (the latter potentially enabling immune escape), 
the consistency and high frequency of a VP4 vaccine variant revertant to wild type 
that may enhance in vivo replication and of two VP4 vaccine-derived variants with 
immunodominant potential emphasised the relevance of the spike protein in infection 
and immune selection, despite the possibility of mutations being a result of 
mutational robustness and maintenance of fitness in the quasispecies. The 
synonymous mutation identified in VP6 highlighted the importance of its structural 
conservation in vivo. Moreover, mutations identified in the NSP4 encoding gene 
highlighted the importance of this protein in in vivo infection.  
The data in this study suggested that some mutations generated during 
vaccine manufacture were re-selected in vivo if their adaptation resulted in a 
replication advantage, and other appeared to arise as a result of adaptation in the 
host. Although the vaccine virus appeared stable in the cohort with very few 
consistent and high-frequency mutations, changes that appeared fixed by the end of 
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the vaccination period suggested that Rotarix
®
 may acquire lasting changes while 
replicating in some susceptible infants. While vaccine shedding and transmission 
may result in herd immunity of other individuals in contact with vaccine recipients, 
changes detected at the end of the vaccination period, as those observed in some 
continuous shedders, if transmitted horizontally to susceptible healthy individuals or 
to immunocompromised contacts, may contribute to vaccine derived RVGE. The 
mutations that increased in frequency over the vaccination period and those detected 
at very high frequency by the end of the vaccination period were identified in 
profiles where virus shedding had not ceased after dose 1, which corresponded with 
infants with low RV-specific copro-IgA levels. This data suggested that those infants 
who cannot control viral replication fast enough develop a weak RV-specific 
duodenal IgA response and are more prone to shed variants with pathogenic potential 
since they had a longer window of time to evolve within the host and become 
transiently dominant or fixed. In contrast, most infants exhibited a strong RV-
specific copro-IgA response and controlled shedding, and thus appeared less likely to 
transmit vaccine or vaccine-derived variants and more likely to be protected later. 
Although late responders and continuous shedders presented variants at high 
frequency by the end of the vaccination period tested, the number of SNPs did not 
increase with time in infants who controlled shedding early. It appeared that 
attenuation in the infant cohort of asymptomatic shedders and Rotarix
®
 genetic 
stability were maintained, suggesting this rotavirus vaccine is safe and unlikely to 
become pathogenic in vaccine recipients, as has been reported extensively for the 
live attenuated oral poliovirus vaccine (Cann et al., 1984; Minor, 1993; Chumakov, 
1999; Kew et al., 2005; Burns et al., 2014; Famulare et al., 2016) and less so for 
others: e.g. HIV-1, mumps or varicella zoster virus vaccines (Berkhout et al., 1999; 
Morfopoulou et al., 2017; Willis et al., 2017).   
A relevant perspective to address the biological relevance of the genetic 
variants identified in vaccinees and their potential for horizontal transmission would 
be to assess and quantify any infectious vaccine-derived rotavirus in stool of vaccine 
recipients. For this, one approach would consist of performing nuclease digestion to 
destroy any non-encapsidated viral RNA, followed by RT and qPCR after viral RNA 
extraction. Another approach would consist of inoculating susceptible cell lines to 
recover infectious virus. Although technically challenging due to stool containing 
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high bacterial loads and likely other infectious viruses, these methods are used to 
recover enteroviruses such as poliovirus from stool samples and sewage (Majumdar 
et al., 2018). The recovery of infectious rotavirus would shed light on the viability of 
the identified mutations as well as providing information about reversion when 
reintroduced in cell culture.  
Following the identification of SNP loci and their corresponding amino acid 
changes in Rotarix
®
 shed in stool of vaccine recipients, a reverse genetics system 
would be necessary to define the phenotype of these changes individually or in 
combination (Chapter 4, concluding remarks). This work could be performed in 
collaboration with Dr Gabriel I. Parra at the FDA, who has a working reverse 
genetics system kindly available (Dr Nicola J. Rose, personal communication). After 
generation of these engineered viruses as previously described and reviewed 
(Desselberger, 2017b; Kanai et al., 2017), an animal model or human intestinal 
enteroids would be an appropriate system to test their host-restriction (effect of 
secretor status, cell differentiation stages, etc.), pathogenicity, virulence, attenuation 
or immunogenicity (Saxena et al., 2016). Further studying whether specific sequence 
changes in the vaccine virus may elicit a stronger or weaker local IgA response 
would require a large sample size and the use of an animal or gut model. If the 
impact of the changes identified in Chapter 4 is elucidated, they could be used in the 
generation of a novel rotavirus live attenuated vaccine, as seen before for live rabies 
vaccine using one attenuating mutation (Nakagawa et al., 2017) or tried 
unsuccessfully with stabilising mutations for oral poliovirus vaccines (Macadam et 
al., 2006).  
Apart from the effect in genetic variation of a live attenuated vaccine after 
introduction in infants, studying the effect of vaccine introduction in the environment 
would shed light onto emerging strains, as new types might appear that avoid 
immunity directed at the vaccine virus. Differences in circulating RV strains after 
vaccine introduction have been reported, with little evidence of this being caused by 
selective pressure (Leshem et al., 2014; Markkula et al., 2017). An increase in 
G2P[4] after vaccine introduction in countries who used Rotarix
®
 has been reported, 
although G1P[8] was also a prevalent strain (Leshem et al., 2014). Similarly, in 
countries that introduced RotaTeq
®
 (containing G2), G1P[8] and G2P[4] were also 
prevalent, with G1P[8] slightly more prevalent (Leshem et al., 2014). In countries 
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with little rotavirus vaccination, G2P[4] was also a predominant strain in recent years 
(Leshem et al., 2014). In more recent studies in Australia, in areas where Rotarix
®
 
was introduced there was a shift in strains detected in RVGE hospitalised infants 
towards previous or novel circulating types (G3, G9, G12) which were also detected 
in countries with different levels of coverage (Roczo-Farkas et al., 2018). Taken 
together, these differences may be due to natural variation during the seasons, to 
vaccine-induced immune pressure or to low effectiveness cross-protecting against 
certain strains. 
An added perspective to this project would aim to characterise the circulating 
vaccine and WT RV strains using environmental sewage samples from before and 
after implementation of the immunisation programme, from across the UK. A 
collection of already concentrated sewage samples and unconcentrated raw sewage 
are available from the poliovirus group at the NIBSC (Appendix IV, Table 8.4.1). 
The concentrated sewage samples would be used to extract nucleic acids as described 
in Chapter 2 (Roche kit adapted method) and run VP6-pan-rotavirus qPCRs for 
samples before the introduction of rotavirus vaccination in the UK (available from 
2004 and 2011). Samples from after vaccine introduction (available from 2015 and 
2016) would be used to run the NSP2-vaccine-specific qPCR to quantify vaccine 
virus circulating into the environment. In order to assess whether the population 
differs across time periods, standard PCR typing would be performed with specific 
primers for G1-G4, G8, G9, G10 and G12 types; and P[4], P[6] and P[8] types, as 
well as RV-specific NGS using similar methods to those employed in this thesis. 
Raw sewage would be spiked with known amounts of Rotarix
®
 to establish the limit 
of detection for qPCR as well as for genotyping and sequencing. In order to retrieve 
RV viral particles from sewage, a capture assay consisting of magnetic beads coated 
with protein G and anti-rotavirus-VP6 antibody would be performed. This 
(unpublished) protocol was kindly made available by Dr Khuzwayo C. Jere and Prof 
Miren Iturriza Gómara, University of Liverpool and would be used to quantify live 
rotavirus in sewage.   
Finally, regarding the adventitious virus contained in Rotarix
®
, PCV1, 
transient passage through the gastrointestinal tract of vaccinated infants without 
replication was evidenced by the low viral loads detected briefly and at lower 
amounts than in vaccine material after each dose, similarly to a recent report in the 
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USA (Mijatovic-Rustempasic et al., 2017). Following PCV1 viral load testing in this 
small cohort,  sequencing of PCV1 DNA in stool from vaccine recipients was also 
performed at the NIBSC (Mitchell, Botas-Perez, et al., unpublished) and it will 
inform on whether any sequence changes arose throughout the brief period of virus 
passing through the gut of vaccinated infants. Regarding any potential infectivity of 
PCV1, PCV1 from Rotarix
®
 or from stool of vaccinees would be used in a range of 
cell lines to test any productive infection. Vaccine-unrelated purified PCV1 and 
animal cells would be used as controls for known productive infection: African green 
monkey kidney (WHO Vero cells; interferon-deficient (Desmyter, Melnick and 
Rawls, 1968; Chew et al., 2009)), porcine kidney (PK-15 cells; and reported to 
support PCV1 replication (McClenahan, Krause and Uhlenhaut, 2011)) and swine 
testis (ST cells; reported to support PCV1 replication (McClenahan, Krause and 
Uhlenhaut, 2011)). Viral loads would be measured in the previous cell lines and 
potential infectivity assessed. Materials are available at the NIBSC to perform these 
studies.  
In summary, this is the first study to have quantified in detail the longitudinal 
shedding of Rotarix
®
 in vaccine recipients, as well as to assess the genetic stability of 
a rotavirus live-attenuated vaccine in vaccinees and to measure their RV-specific 
copro-IgA response. It has contributed to a more granular understanding of rotavirus 
replication defining clear shedding profiles, identifying shedding control in infants 
with detectable RV-specific copro-IgA response and a higher number of vaccine and 
vaccine-derived variants in infants with shedding of long duration and an absent or 
weak RV-specific copro-IgA response. This study has identified relevant regions in 
VP4, VP7 and NSP4 prone to variation in infants, as well as a region in VP6 key for 
structural conservation. Overall, Rotarix
®
 appeared to be stable within the cohort of 
vaccinees, eliciting a RV-specific copro-IgA response, controlling shedding 
following replication and decreasing frequency of vaccine and vaccine-derived 
variants by the end of the vaccination period. This study has contributed to laying the 
groundwork for future studies to define shedding profiles in different populations of 
vaccinees, to pinpoint the role and RV-specific copro-IgA antibody types, to 
elucidate the phenotype of the vaccine and novel variants identified in vaccinated 
infants and to characterise the attenuating mutations in Rotarix
®
.  
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Appendix I: Faecal sample collection  
Overall collection  
The overall collection consisted of faecal samples from 12 infants born and 
vaccinated in around Hertfordshire, South East England, UK (Chapter 2, Table 2.13). 
Information on gender or health status was not provided. Information on year of birth 
not displayed to maintain anonymity. Infants received the first dose of Rotarix
®
 at 8 
weeks (10 infants) or 9 weeks (2 infants) of age, and the second dose at 12 weeks (9 
infants) or 13 weeks (3 infants), spaced by a month (11 infants) or a month and a 
week (1 infant). Rotarix
®
 batch numbers for dose 1 and dose 2 were not provided.  
Individuals 
Individual B 
Table 8.1.1. Faecal sample aliquot collection for infant B. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual C 
Table 8.1.2. Faecal sample aliquot collection for infant C. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
 
 
 
 
 
Appendix I Faecal sample collection 
262 
 
Individual D 
Table 8.1.3. Faecal sample aliquot collection for infant D. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual E 
Table 8.1.4. Faecal sample aliquot collection for infant E. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual F 
Table 8.1.5. Faecal sample aliquot collection for infant F. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual G 
Table 8.1.6. Faecal sample aliquot collection for infant G. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual H 
Table 8.1.7. Faecal sample aliquot collection for infant H. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual I 
Table 8.1.8. Faecal sample aliquot collection for infant I. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
 
 
 
 
 
 
Appendix I Faecal sample collection 
268 
 
Individual J 
Table 8.1.9. Faecal sample aliquot collection for infant J. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual K 
Table 8.1.10. Faecal sample aliquot collection for infant K. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual L 
Table 8.1.11. Faecal sample aliquot collection for infant L. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Individual M 
Table 8.1.12. Faecal sample aliquot collection for infant M. Number of aliquots 
collected per timepoint available before vaccination, after dose 1, after dose 2 and 
after a year.   
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Appendix II: Preliminary data - 
Genetic stability of faecal rotavirus RNA in 
infants vaccinated with Rotarix
®
  
8.2.1 Sequence-dependent amplification followed by Nextera
®
 library prep 
8.2.1.1 Introduction 
The Nextera
®
 XT DNA kit protocol would be used after specific gene 
segment RT-PCR. The transposomes with adaptors are combined with the DNA 
template, followed by tagmentation to fragment the DNA and addition of adapters 
(Fig. 8.2.1). Limited cycle PCR incorporates the sequencing primers and indices.  
 
  
Fig. 8.2.1. An overview of the procedure for the Nextera
®
 XT DNA Sample 
Preparation Guide. From the Nextera
®
 XT DNA Sample Preparation Guide 
(#15031942, Illumina
®
).  
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Rotavirus vaccine material has been previously sequenced using this method 
(Mitchell, Lui, et al., unpublished). Sequence-dependent amplification of rotavirus 
gene segments is a more time-consuming and expensive method than sequence 
independent amplification due to RT-PCR prior to library preparation. Although it 
may introduce errors from starting PCR and from PCR during library preparation, 
accounting for PCR errors such as marked duplicates, generates reliable and 
consistent data.  
8.2.1.2 Experimental methodology and sample set 
For a first assessment of the genetic stability of Rotarix
®
, we used faecal 
material from two infants (J and F) in the cohort previously described (Chapter 2 and 
Appendix I). Samples were aliquoted and stored until use (Chapter 2, section 2.1.9 
and 2.2.1) and only samples of high quantity were used for this assessment. 
Timepoints of expected high viral loads were tested as three technical replicates from 
one single extract. Viral nucleic acids were extracted following the methods in 
Chapter 2, sections 2.2.3.1 and 2.2.3.3. To prepare for library generation with the 
Nextera
®
 XT DNA kit, cDNA synthesis and PCR amplification were performed on 
extracted RNA (Chapter 2, section 2.2.4), pooled in equimolar amounts and purified 
following the methods in Chapter 2, section 2.2.6. Library preparation by 
fragmentation and tagging with adapters in a single reaction using Nextera
®
 (Chapter 
2, section 2.2.6), bioinformatic analysis (Chapter 2, section 2.2.7) and further data 
analysis (Chapter 2, section 2.2.8) were performed jointly with the NGS team.  
The timepoints tested were equivalent or nearly equivalent in both infants: 
days 4, 9 and 24/25 (J/F) after dose 1 and days 2/3 (J/F) and 4 after dose 2. In order 
to assay three technical replicates, extraction volumes of 50 µl allowed the 
assessment of four gene segments: 12 µl were used in cDNA synthesis for each 
segment, so 48 µl from the extraction volume would be used to test four segments. 
Genetic characterization was performed on genes encoding VP3, VP4, VP6 and VP7 
as these presented non-synonymous SNP loci variants and the highest frequency 
ranges in vaccine material (Mitchell, Lui, et al., unpublished). Moreover, VP3, VP4 
and VP7 were related to virulence in the gnotobiotic piglet (Hoshino et al., 1995) and 
VP4, VP6 and VP7 were reported to undergo selection in cell culture and be targets 
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for neutralizing protective antibodies (Burns et al., 1996; Feng et al., 2002; Corthésy 
et al., 2006; Nair et al., 2017).  
8.2.1.3 Results and short discussion 
Preliminary data from VLs in stool from two infants (J, F) was in the range of 
expected copy number in stool of vaccinated infants of 10
2
-10
10
 copies/mL 
(Mijatovic-Rustempasic et al., 2017). Viral loads were high after dose 1, while lower 
VLs appeared after dose 2. Preliminary data for viral segments VP3, VP4, VP6 and 
VP7 at several timepoints after dose 1 and dose 2 identified SNPs at a frequency of 
≥1% (Table 8.2.1). Both individuals presented the highest number of SNPs against 
reference for gene segment 4 (encoding VP4) and they both presented more non-
synonymous than synonymous SNPs for all four viral segments. All the potential 
reversions to wild type were previously identified in vaccine material (Mitchell, Lui, 
et al., unpublished) except for one in segment 4. Frequencies in stool are similar to 
vaccine material, high (>50%) or very high (>90%).  
 
Table 8.2.1. Single nucleotide polymorphisms identified in stool from two 
infants (J, F) for genes encoding VP3, VP4, VP6 and VP7 by Nextera
®
. Protein 
encoded by gene segment, infant, number of SNPs against reference (JX943611- 
JX943614), type of SNP, frequency and common SNPs. S, synonymous; NS, non-
synonymous; previously identified in vaccine material; Rev. to WT (JN887809-10, 
(JN887818-19), reversion to wild type. 
 
 
 
VP3. One SNP locus found in the VP3 encoding gene for individual J 
coincides with the SNP locus previously identified in vaccine material (Mitchell, Lui, 
et al., unpublished): nucleotide change G1715A affecting amino acid R572K (Table 
8.2.2). Most of the mutations in VP3 were synonymous and there were eight amino 
acid changes, two of them were previously observed in WT RV G1P[8] strain 
Prot. 
gene
Infant
SNPs against 
reference
S NS V
Rev. 
to WT
SNP frequency Common SNPs
VP3
Individual J 39 18 21 1 1 38 SNPs at <26%; 1 SNP at 43% (S)
2
NS; 1 in 
vaccineIndividual F 56 25 31 1 0 All SNPs at <22%
VP4
Individual J 86 30 57 9 1 (V) 80 SNPs at <50%; 6 SNPs at >50%/<97% (2S, 4NS)
13
3 S; 10 NS; 
8 in vaccine 
(NS)Individual F 61 17 44 10 2 (1V) 56 SNPs at <50%; 5 SNPs at >51%/<99% (NS)
VP6
Individual J 62 29 33 1 0 60 SNPs at <17%; 2 SNPs at >40%/>50% (S)
2
2 S; 2 NS; 1 
in vaccine 
(S)Individual F 26 9 17 1 0 All SNPs at <6%
VP7
Individual J 40 17 23 2 3 (V)
38 SNPs at <13%; 1 SNP at >14% (rev. to WT); 1 SNP at 
>55% (NS) 1 NS
Individual F 34 12 22 1 0 All SNPs at <8%
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(GenBank reference number JN887810): nucleotide change A1470G affecting amino 
acid I490M and nucleotide change C1838T affecting amino acid A613V. The viral 
segment encoding VP3 presented low frequency synonymous mutations and isolated 
high frequency mutations. Some SNP loci were consistent, like the first one, amino 
acid D27D, which was detected on day 24 after dose 1 and stayed at a similar 
frequency after the second dose was administered. Other SNP loci appeared after a 
certain time at low frequency and then disappeared after that, such as those affecting 
amino acid N729D. Further points were needed to assess reappearance (Chapter 4). 
Other SNPs increase and then are not detected later, such as amino acid L169L.  
VP6, VP7. For VP6 and VP7, most mutations were synonymous and 
appeared at low frequencies and early timepoints (Table 8.2.3). Individual J 
presented one SNP locus in VP6 previously found in the vaccine material (Mitchell, 
Lui, et al., unpublished) at low frequency: nucleotide change G654A leading to 
amino acid silent substitution L218L. The viral segment encoding VP7 presented 
five low frequency synonymous mutations and four non-synonymous low frequency 
mutations at early timepoints for both infants. There was a SNP locus affecting 
amino acid 123, with the non-synonymous mutation S123N increasing frequency in 
individual J to about 40%, potentially indicating the emergence of a mixed 
population. 
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Table 8.2.2. SNP loci in stool of individuals J and F for viral segment encoding 
VP3. % SNP frequency shown for each nucleotide (nt) and amino acid (aa) position 
at days 4, 9 and 24/25 after dose 1; and days 2/3, 4 and 21/NA after dose 2. aa 
changes in bold and possible reversions to a WT in red. 
1
 identified in vaccine by our 
group. Frequency range of SNPs in vaccine material shown where applicable. 
Shaded in red, loci present in two replicates; shaded in yellow, loci present in three 
replicates; and shaded in green, loci present in four replicates.  
 
 
 
Table 8.2.3. SNP loci in stool of individuals J and F for viral segments VP6 and 
VP7. % SNP frequency shown for each nucleotide (nt) and amino acid (aa) position 
in corresponding viral segment at days 4 and 9 after dose 1. aa changes in bold and 
possible reversions to a WT in red. 
1
 identified in vaccine by our group. Frequency 
range of SNPs in vaccine material shown where applicable. Shaded in red, loci 
present in two replicates; shaded in yellow, loci present in three replicates; and 
shaded in green, loci present in four replicates. 
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VP4. The VP4 encoding gene segment presented most of the SNP loci as 
non-synonymous mutations (Table 8.2.4). Most SNP loci identified in the vaccine 
virus were present in virus shed by both infants (Fig. 8.2.2). Most of the low 
frequency mutations occurred at one point in time and disappeared, not being 
selected or appearing as a minor variant not detected later. There was a non-
synonymous novel mutation, changing amino acid 114 from P to T (P114T), and 
appearing in both infants after first dose first at low frequency and then at consistent 
high frequencies since day 25 after dose 1 (from a frequency of 34% to 78%).  
The region covering nucleotides 1088 - 1409 (aa 363-470) may be a hotspot 
for variation as SNP loci were observed in stool at frequencies higher than in vaccine 
material. A number of the changes seen in the proposed hotspot were already present 
in the vaccine at a range of frequencies (from 1% to almost 60%). Most of these 
changes appeared at a frequency higher than 50% or at a very high frequency (>90%) 
and seemed to become transiently dominant or fixed over the vaccination period 
evaluated. Amino acid change K368R is of interest: it was present at about 50% in 
vaccine material and appeared in the stool at 99% to 100% after both doses in stool 
from both infants. It consists of potential reversion to a known WT RV G1P[8] strain 
(GenBank reference number JN887809) at nucleotide position 1103 and amino acid 
368, that might alter the putative fusion domain of the virus (aa 384-404) (Mackow 
et al., 1988; Dormitzer et al., 2004; Trask et al., 2010).  
Two other variant amino acids, Y385H and I388L fell within the limits of the 
virus fusion domain and are believed to be related to neutralisation and attenuation of 
the virus (Kapikian, Hoshino and Chanock, 2001; Tsugawa and Tsutsumi, 2016), 
potentially affecting the fusion domain and attenuation. Other SNP loci appeared at 
high frequency and seemed fixed, such as nucleotide position C999T (amino acid 
P333P) in individual J, while the remaining SNP loci appeared at frequencies lower 
than 15%. VP4 presented a region prone to variation in both infants and in vaccine, 
as well as specific SNP loci to virus shed by each infant.  
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Table 8.2.4. SNP loci in stool of individuals J and F for viral segment VP4. % 
SNP frequency shown for each nucleotide (nt) and amino acid (aa) position at days 4, 
9 and 24/25 after dose 1; and days 2/3, 4 and 21/NA after dose 2. aa changes in bold 
and possible reversions to a WT in red. 
1
 identified in vaccine by our group. 
Frequency range of SNPs in vaccine material shown where applicable. Shaded in 
blue, loci present in both infants; shaded in red, loci present in two replicates; shaded 
in yellow, loci present in three replicates; and shaded in green, loci present in four 
replicates.  
 
 
In VP4, there was a novel SNP locus identified at nucleotide position 340 
(amino acid P114T; in VP8* epitope region 8-3 (Zeller et al., 2012)) in both infants, 
but not in the in-house vaccine sequence (Fig. 8.2.2). SNP loci in the nucleotide 
region 1088-1409 were identified in both infants at higher frequency than in the in-
house vaccine sequence. Some SNP loci  affecting amino acids I388L and Y385H 
were identified in VP5* epitope region 5-1 (Zeller et al., 2012) and others affecting 
amino acids N363S, M364V/M354I, I470T and K368R in the body of VP5* 
(putative fusion domain) (Fig. 8.2.3). Nucleotide position 1103 (K368R) appeared at 
99-100% in stool and 50% in vaccine material. 
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Fig. 8.2.2. SNP loci individuals J and F for viral segment VP4. SNP frequency 
(%) shown for each nucleotide (nt) position at several timepoints after dose 1 
(blue/pink triangles) and dose 2 (blue/pink squares; day from dose 1 in brackets). 
SNP loci 340 (P114T), 1103 (K368R) and cluster 1088-1409 boxed. 
Nucleotide position refers to full length coding sequence (JN887809).  
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Fig. 8.2.3. Amino acid changes observed at high frequencies in VP4. VP8* 
subunit in purple, VP5* subunit in red (the antigen domains) and green (the foot 
domain), and SNP loci in yellow.  
 
8.2.2 Sequence-independent amplification followed by RNA ScriptSeq
®
 library 
prep 
8.2.2.1 Introduction 
The RNA ScriptSeq
TM
 v2 kit protocol would be used for direct whole 
genome sequencing of all 11 rotavirus gene segments. The protocol starts by 
fragmenting RNA and then using random primers to perform cDNA synthesis, 
tagging the 5' end at the same time (Fig. 8.2.4). Terminal tagging oligonucleotides 
are used to tag the 5' end of the cDNA (now di-tagged), which is amplified by 
limited-cycle PCR using primers complimentary to tagging sequences that add 
adapters necessary to generate clusters. Illumina
®
 indexes replace the reverse primer 
during PCR amplification to barcode samples if several of them are pooled in one 
run.  
Few reports exist on RVA clinical samples sequenced using RNA 
ScriptSeq
TM
 by direct sequencing (after generation of a dsDNA library from RNA 
starting material) of RNA with random hexamers (Jere et al., 2018). RNA 
ScriptSeq
TM
 has been previously used in clinical samples from RVA diarrhoeic 
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infants down to 10
2
 copies/µL of qPCR reaction (Miren Iturriza Gómara and 
Khuzwayo C. Jere, personal communication, 2017).  
Sequence-independent amplification of rotavirus gene segments is a less 
time-consuming method and would allow reducing costs of RT and PCR 
amplification. No errors from pre-library preparation PCR would be carried over to 
library preparation, although errors from the library preparation PCR are still 
possible.  
 
 
Fig. 8.2.4. An overview of the procedure for the ScriptSeq™ v2 RNA-Seq 
Library Preparation Kit. From the ScriptSeq
TM
 v2 RNA-Seq Library Preparation 
Kit* manual (SSV21124, Epicentre
®
, an Illumina
®
 company).  
 
8.2.2.2 Experimental methodology and sample set 
Vaccine material 
Six independent PCV1-free Rotarix
®
 virus harvest bulks were sequenced by 
sequence-dependent amplification by Dr Jane L. Mitchell. Vaccine material was 
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stored at -80ºC and viral RNA was extracted, reverse-transcribed, amplified and 
purified following the manufacturer’s instructions (GSK’s protocol made available to 
Dr Jane L. Mitchell). Library preparation using the Nextera
®
 XT DNA kit (Chapter 
2, section 2.2.6), bioinformatic analysis and further data analysis were performed by 
the NGS team and by Dr Jane L. Mitchell (not shown).  
Six independent Rotarix
®
 final fills were sequenced by sequence-independent 
amplification by Dr Jane L. Mitchell. Vaccine material was stored at 4ºC and viral 
RNA was extracted following the TriReagent
®
 and chloroform method (Chapter 2, 
section 2.2.3.3). To prepare for library generation with the RNA ScriptSeq
TM
 kit, 
extracted RNA was DNAse I-treated, purified using the Agencourt
®
 AMPure XP 
system or Agencourt
®
 RNA Clean XP system, and quantified by NSP2 cDNA 
synthesis (Chapter 2, section 2.2.4) and Rotarix
®
 NSP2-specific qPCR (Chapter 2, 
section 2.2.5.1). Library preparation by unique terminal tagging using RNA 
ScriptSeq
TM
 (see Faecal Samples within this section), bioinformatic analysis and 
further data analysis were performed by the NGS team and by Dr Jane L. Mitchell 
(not shown).   
Faecal samples 
For a sequence-independent assessment of the genetic stability of Rotarix
® 
in 
vaccine recipients, faecal material from individual C in the cohort previously 
described was used (Chapter 2 and Appendix I). Samples were aliquoted and stored 
until use (Chapter 2, sections 2.1.9 and 2.2.1) and samples with sufficient surplus 
material in optimisations were used for this assessment. Viral nucleic acids were 
extracted following the methods in Chapter 2, sections 2.2.3.1 and as follows testing 
several methods:  
Qiagen kit method. A volume of 140 µL of 10% faecal suspension (section 
2.2.3.1) was used to extract total RNA following the modified QIAamp
®
 Viral RNA 
Mini Kit’s instructions. Wash AW1 consisted of 250  L, followed by centrifugation 
at 13,200 × g’ for 1 min. An additional DNase I treatment was performed as 
indicated by the manufacturer (15 min incubation at AT) after the AW1 wash. The 
next AW1 wash consisted again of 250 µL, followed by centrifugation at 13,200 × g’ 
for 1 min. The rest of the method was performed as described by the manufacturer, 
eluting in a volume of 50 µL of RNAse/DNAse-free water and storing samples at -
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80ºC. Quantification was performed using the Qubit
®
 RNA High Sensitivity Assay 
kit following manufacturer instructions, followed by Rotarix
®
 NSP2-specific qPCR 
(section 2.2.6.1). 
Roche RNA kit method. A volume of 200 µL of 10% faecal suspension was 
used to extract total RNA using the High Pure RNA Isolation Kit, eluting in 50 µL 
RNAse-free water and storing samples at -80ºC. Quantification with Qubit
®
 RNA 
High Sensitivity Assay kit was followed by Rotarix
®
 NSP2-specific qPCR. 
Pot ieter’s adapted method  rom  aecal suspension. A volume of 200 µL of 
10% faecal suspension was used to extract total RNA following a published method 
(Potgieter et al., 2009) further adapted as described in section 2.2.1, resuspending in 
50 µL of RNAse-free water and storing samples at -80ºC. Single-stranded RNA 
(ssRNA) and protein impurities were removed following the published method. 
Quantification with Qubit
®
 RNA High Sensitivity Assay kit was followed by 
Rotarix
®
 NSP2-specific qPCR.  
Pot ieter’s adapted method  rom stool. This method was adapted and kindly 
shared by Dr Khuzwayo C. Jere at the University of Liverpool. An amount of 100 
mg of faecal matter was used to extract total RNA as described in the previous 
paragraph but with different starting material, directly the faecal matter. Next, 
lithium chloride 2 M was used to precipitate ssRNA and protein impurities, 
incubating first for 20 min at AT followed by 16 h in an ice and water bath, at 4°C. 
The samples were treated with DNAse I (Sigma-Aldrich) as indicated by the 
manufacturer and purified using the magnetic bead Agencourt
®
 AMPure XP system 
or Agencourt
®
 RNA Clean XP system. Quantification with Qubit
®
 RNA High 
Sensitivity Assay kit was followed by Rotarix
®
 NSP2-specific qPCR.  
Of the four methods tested, Pot ieter’s adapted method  rom  aecal 
suspension was the optimal protocol when tested in vaccine material, spiked vaccine 
material and faecal material from an infant who supplied large amounts of sample, 
due to higher RNA yields. 
To prepare for library generation with the RNA ScriptSeq
TM
 kit, extracted 
RNA was cleaned from ssRNA, DNAse I-treated, purified and quantified (previous 
paragraphs and Chapter 2). The RNA ScriptSeq
TM
 v2 library preparation kit was 
used to prepare the sequencing libraries from 500 pg to 50 ng of dsRNA extracted 
from faecal samples or 10% faecal suspensions and denaturing the dsRNA at 95°C 
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for 5 min before following the manufacturer’s instructions. Library quantification 
was performed using Qubit
®
 dsDNA HS Assay Kit. The size distribution was 
assessed on an Agilent High Sensitivity DNA chip, Agilent 2100 Bioanalyzer and 
Agilent 2100 Expert Software B.02.08 following the manufacturer’s instructions. 
The libraries were sequenced on the MiSeq platform using the 2x 251 paired end v2 
Flow cells. The sequence data generated was analysed by NGS team at the NIBSC. 
A similar workflow as the one described in the Nextera
®
 XT DNA analysis was used 
to analyse the data generated with the RNA ScriptSeq
TM
 v2 kit. The workflow used a 
Phred score cutoff of ≤Q30 and SNP loci were called if there was a mean coverage 
of aligned reads of >100, >50, >20 or >10 for each studied position at a mean 
frequency of >1%,  >2%, >5% and >10% respectively, (frequency threshold selected 
dependent on read depth); and observed in >2 of 3 replicates. Further data analysis 
(Chapter 2, section 2.2.8) were performed by the NGS team and by me. Several 
extraction methods were tested:  
University of Liverpool preliminary data: For samples of expected high 
shedding, Potgieter’s adapted method from stool was used.  
Primary preliminary data: Faecal samples from individual C, at day 7 after 
dose 1 (10
9
 copies/mL of stool), day 7 after dose 2 (or day 38 after dose 1; 10
5
 
copies/mL of stool), day 7 after dose 2 diluted 1/10 (10
4
 copies/mL of stool) and day 
7 after dose 2 diluted 1/100 (10
3
 copies/mL of stool) were extracted with the High 
Pure RNA Isolation Kit from Roche from faecal suspensions, the QIAamp
®
 Viral 
RNA Mini Kit from Qiagen from faecal suspensions and Potgieter’s adapted method 
from faecal suspensions and from stool (Chapter 2, section 2.2.4.3). Timepoints were 
tested as technical duplicates from a single faecal suspension.  
Secondary preliminary data: Faecal samples from individual C, at day 7 after 
dose 1 (10
9
 copies/mL of stool) and dilutions at different concentrations from 10
8
 to 
10
3
 copies/mL of stool, at day 8 after dose 1 (10
9
 copies/mL of stool) and at day 8 
after dose 2 (or day 37 after dose 1; 10
5
 copies/mL of stool) were tested in triplicate 
to pool plus another sample alone. They were extracted with Potgieter’s adapted 
method from faecal suspensions (Chapter 2, section 2.2.4.3). The same was 
performed with the day 7 after dose 1 (10
9
 copies/mL of stool) and dilutions at 
different concentrations from 10
8
 to 10
3
 copies/mL of stool tested in triplicate to pool 
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plus another sample alone cleaned up in parallel with the MinElute
®
 Gel Extraction 
kit to identify the best purification method.  
Tertiary preliminary data: Faecal sample suspensions (previous suspensions 
from -80°C plus suspensions made on the day) from individual C, at days 7, 8 10 and 
15 after dose 1 were tested as three extractions from one single faecal suspension 
with Potgieter’s adapted method from faecal suspensions (Chapter 2, section 2.2.4.3). 
Because RNA extracted from the mentioned faecal suspensions were detected in low 
amounts by Qubit
®
 with respect to the fresh faecal suspensions, as well as by NSP2-
specific qPCR, with 1-2 log10 variability (data not shown), faecal samples from all 
infants and several timepoints were extracted again as three extractions from one 
single faecal suspension, cleaned-up and quantified using the same methods as in the 
previous paragraphs to prepare for RNA ScriptSeq
TM
 library generation (Table 
8.2.5). 
 
Table 8.2.5. List of individuals and timepoints prepared to test by RNA 
ScriptSeq
TM
 library preparation. RNA was extracted using Potgieter’s adapted 
method, cleaned-up with Agencourt
®
 RNA Clean XP system and quantified by 
Qubit
®
 RNA High Sensitivity Assay and Rotarix
®
 NSP2-specific qPCR.  
 
8.2.2.3 Results and short discussion 
Vaccine material 
Rotarix
®
 sequencing of virus harvest bulks by sequence-dependent 
amplification identified 26 SNPs present at frequencies from 5% to over 60% 
frequency (Mitchell et al., unpublished data), similarly to the original vaccine 
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sequence (Mitchell, Lui, et al., unpublished). Most of them were identified in the 
viral segment encoding VP4. Rotarix
®
 sequencing of final fills by RNA ScriptSeq
TM
 
identified a small amount of SNPs present at low frequency (<25%) (Mitchell et al., 
unpublished data) with respect to the original vaccine sequence (Mitchell, Lui, et al., 
unpublished). Only nucleotide position 1103 for segment 4 was detected at >50% 
frequency (Mitchell et al., unpublished data). This mutation appeared in the original 
vaccine sequence at a similar frequency, detected at the NIBSC (Mitchell, Lui, et al., 
unpublished).  
Faecal samples 
In this cohort, Rotarix
®
/rotavirus in stool of vaccinees was detected in the 
range of 10
3
-10
9
 copies/g of stool (Chapter 3), comparable to previous reports in the 
range of 10
2
-10
10
 copies/mL of stool (Mijatovic-Rustempasic et al., 2017).  
University of Liverpool preliminary data: A first attempt to sequence all the 
viral segments was made using RNA ScriptSeq
TM
 library preparation as sequencing 
strategy. When samples from this cohort were tested in parallel to clinical samples at 
the University of Liverpool, they were not detected by AGE and not sent for NGS 
(data now shown). Other attempts were performed at the NIBSC using adapted 
methods.  
Primary preliminary data: The method that yielded consistent viral loads and 
samples detectable by Qubit
®
 was Potgieter’s adapted method from faecal 
suspensions, maintaining glycogen as a carrier (Table 8.2.6). Preliminary data for 
individual C, day 7 after dose 1 presented 10% mapping to Rotarix
®
 and day 7 after 
dose 2 presented 2% mapping to vaccine sequence. Mean coverage was 200-400 per 
bp for sample from day 7 after dose 1 and lower than 100 reads per base for day 7 
after dose 2. Glycogen as a carrier generated less SNPs than no carrier at all (Table 
8.2.7). In total, there were eight SNPs against the reference, one synonymous and 
seven non-synonymous, as well as two reversions to wild type.  
Secondary data: The method that yielded best results was the Agencourt
®
 
RNA Clean XP system, considering Qubit
®
 quantification was very low for the gel 
extraction method. Coverage cut-offs for SNP calling of 10, 20, 50 and 100 reads 
were compared to the qPCR mean copies per 2 µL and it was observed that if those 
mean copies were below 10
2
, there was less SNP calling the more stringent the 
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coverage cut-off was (Figure 8.2.5). Data from individual C at a cut-off of 10 reads 
presented SNPs for VP1, VP3, VP4, VP6, VP7, NSP1, NSP2 and NSP2 gene 
segments (data not shown). At a cut-off of 20 reads, data presented SNPs for VP1, 
VP2, VP3, VP4, VP6, VP7, NSP1, NSP2 and NSP4 segments (data not shown). At a 
cut-off of 50 reads, data presented SNPs for VP1, VP3, VP4, VP6, VP7, NSP1 and 
NSP3 segments (data not shown). At a cut-off of 100 reads, data presented SNPs for 
VP1, VP3, VP4 and NSP1 segments: VP4 presented five non-synonymous SNPs 
across the timepoints studied, four at frequencies >50% and one at a frequency lower 
than 30%. Three of the SNPs were previously detected in the vaccine, while two 
were novel in stool. Two were a mutation to wild type (one seen previously by 
Nextera
®
 in vaccine material and stool from infants and the other one novel in stool 
and previously identified in stool by Nextera
®
). VP1 presented one novel 
synonymous SNP at a frequency lower than 70%. VP3 presented three SNPs, one at 
lower than 7% and two between 8 and 22%, with three amino acid changes and two 
to wild type, none seen before in vaccine material or stool. NSP1 presented another 
novel SNP at frequency lower than 20%. At less stringent cut-offs, most of the SNP 
loci are maintained and other ones arise. SNP loci detected in vaccine final fill 
material by RNA ScriptSeq
TM
 (Mitchell et al., unpublished data) that were also 
detected in stool of infants by the same sequencing method were in NSP2, NSP4, 
VP1, VP2, VP3, VP4 and VP6 (Table 8.2.8). It was decided that a copy number ≤103 
copies/2 µL qPCR reaction, which translated into ≤106 copies/mL of stool, reduced 
the ability to call low frequencies of SNPs (Fig. 8.2.5). 
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Table 8.2.6. Optimisation of extraction methods for downstream RNA 
ScriptSeq
TM
 library preparation. Extraction methods, use of carrier, timepoints of 
samples tested, expected viral loads, viral loads after extraction and after magnetic 
bead purification, as well as Qubit
®
 dsRNA quantification are shown for individual 
C. VL, viral loads.  
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Table 8.2.7. Single nucleotide polymorphisms detected during optimisation for 
downstream RNA ScriptSeq
TM
 library preparation. Frequency of SNPs detected 
in stool of individual C, at day 7 after dose 1, with respect to SNPs previously 
detected in vaccine material. Amino acid change in bold, amino acid change to wild 
type in bold red, 
1
 mutation detected in vaccine bulks and fills (Mitchell, Lui, et al., 
unpublished), * used in previous project (Mitchell, Lui, et al., unpublished), light 
blue background for mutations detected in samples from other infants. aa, amino 
acid; NA, not applicable; nt, nucleotide.   
 
 
 
 
Fig. 8.2.5. Rotarix
®
 copy number in stool of one infant (individual C) and RNA 
ScriptSeq
TM
 next generation sequencing signal comparison. Rotarix
®
 copy 
number is displayed on the Y axis and next generation (NGS) signal at coverage of 
100 mean reads on the X axis. Top panel: Sample from an early timepoint (day 7 
after dose 1) at original viral load plus a range of dilutions. Bottom left panel: 
Sample from an early timepoint (day 8 after dose 1). Bottom right panel: Sample 
from a late timepoint day 37 after dose 1).  
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Table 8.2.8. Single nucleotide polymorphisms detected by RNA ScriptSeq
TM
 and 
Nextera
®
 XT in vaccine material, as well as which of those were detected in stool 
of several infants by RNA ScriptSeq
TM
 and Nextera
®
 XT. Protein encoded by 
gene segment, nucleotide position, nucleotide change, SNPs detected by RNA 
ScriptSeq
TM
 in vaccine material, which of those were detected by Nextera
®
 XT in 
vaccine material, which were detected in stool of one infant (C) by RNA ScriptSeq
TM
  
and which were detected in stool of two infants (J, F) by Nextera
®
 XT.  
 
 
 
Tertiary preliminary data: When two of seven plates were run, there was low 
frequency of successful library generation, low proportion of reads mapping to 
rotavirus and low sequencing depth for all the samples. A small number of samples 
of known high viral loads (individual C, day 8 after dose 1 repeats, with 10
9
 
copies/mL of stool; and individual L, day 15, with 10
8
 copies/mL of stool) aligned to 
rotavirus, showing some level of duplication. It appeared as if other nucleic acid 
outcompeted or inhibited rotavirus, and/or small amounts of molecules participated 
in the sequencing reaction. Therefore, samples were re-cleaned with new LiCl, 
freshly extracted and comparable samples were used in parallel with new LiCl. 
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Faecal suspensions from individual C at 10 days before dose 1 were spiked with 
Rotarix
®
 at 10
9
 to 10
6
 copies/mL of vaccine using previously used LiCl for the 10
9
 
copies/ml one and fresh LiCl for the rest. Read depth was too low to apply a 
threshold for variant calling of 100 reads. Only 0.04% of reads were assigned to 
viruses. No analysis of the bacterial complement was permitted to be performed by 
NIBSC HuMAC. The raw reads did not correlate with the number of reads mapping 
to the reference. The samples that were re-cleaned with LiCl, individual C day 8, 
individual L day 15 and individual D day 8, produced more library than the rest. It 
appeared there was systematic presence of bacterial ribosomal RNA outcompeting 
rotavirus, or a higher virus to contaminant ratio in the samples that produce 
informative library.  
The high amounts of bacterial ssRNA with respect to dsRNA from rotavirus 
might have not been removed with the 2 M LiCl precipitation. The use of a bacterial 
ribosomal RNA removal kit, such as Ribo-Zero
TM
, before RNA ScriptSeq
TM
 library 
preparation might have contributed to obtaining cleaner rotavirus dsRNA for NGS. 
Due to small amounts of RNA extracted from stool, sometimes not detected by 
Qubit
®
 and around the ng/µL concentration scale, far from the 1-5 µg needed for 
Ribo-Zero
TM
 and just below the minimum 10
2
 copies/µL of qPCR reaction needed 
for RNA ScriptSeq
TM
 on clinical samples, this type of kit was not used for 
subsequent samples. This kit was discontinued on November the 2
nd
, 2018.  
8.2.4 Genetic stability of faecal Rotarix
®
 assessed by sequence-dependent vs 
sequence-independent methods 
This preliminary data studying SNP loci in virus shed in stool of two/several 
vaccine recipients suggested that vaccine variants increase in frequency and that 
novel SNPs arise during viral replication in infants. A similar number of SNPs were 
called by RNA ScriptSeq
TM
 and by Nextera
®
 XT in vaccine material (Table 8.2.2.4) 
(Mitchell, Lui, et al., unpublished). In stool, there were more SNPs called by 
Nextera
®
 than by RNA ScriptSeq
TM
 and those detected by RNA ScriptSeq
TM
 were 
not as consistent within repeats and only identified at timepoints with very high viral 
loads (10
6
-10
9
 copies/g of stool), since other timepoints yielded very low RNA 
amounts mapping to RVA. The need to use a consistent method for library 
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preparation, the vaccine material sequencing work having been performed using 
Nextera
®
 XT (Mitchell, Lui, et al., unpublished), as well as the discontinuation of the 
RNA ScriptSeq
TM
 enzyme were factors influencing the decision to perform RT-PCR 
and Nextera
®
 XT library preparation on RNA extracted from stool.  
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Appendix III: Python script 
In order to analyse sequencing data prepared with the Nextera
® 
XT DNA 
Library Preparation kit v2 and processed by the NGS team at the NIBSC (Chapter 2, 
section 2.2.7.3), a Python script was set up (developed by Edward T. Mee) to sort 
output files by date, project, repeat, timepoint, infant and viral segment (script shown 
below), with the possibility of sorting by each parameter.  
 
Input file:  rota.calls.rotarix.together.may17.csv 
Output file:  rota.calls.rotarix.together.may17.csv_output_sorted 
Python version:  2.7.15 (v2.7.15:ca079a3ea3, Apr 30 2018, 16:30:26) [MSC 
v.1500 64 bit (AMD64)] 
Processed with:  filterv5.py written by Ed Mee. 
Script last modified:  24/05/2018 11:06 
Processed by:  lbotaspe 
Processed at:  24/05/2018 14:35 
Number of unique sample identifiers : 110 
Parameters were:  
Minimum coverage:  100 
Maximum reference frequency:  0.99 
 
***************** 
Script: 
#Written by ETM for LBP, May 2018 
 
import csv 
import pprint 
import sys 
import operator 
import os 
import time 
import getpass 
 
# Input files must be in csv format ['sample','chr','pos','ref','cov', 
'R','A','C','G','T','pR','pA','pC','pG','pT'\] 
# For .xlsx files open in Excel and save as .csv 
input_file = sys.argv[1] 
 
# could modify to automatically name the output_file with the input_file + e.g 
_output/ 
output_file = input_file+"_output" 
 
# prompt the user to specify the desired coverage cutoff 
cutoff = int(raw_input("Specify minimum coverage required:")) 
 
#prompt the user to specify the desired reference cutoff 
ref_frequency = float(raw_input("Specify maximum reference value (1 - SNP 
frequency):")) 
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# function to extract unique names to be used as the filenames for the sorted data 
# based on separation of files by specific delimiter in the first column 
# currently set to take the name from the first column and the second field delimited 
by '_' 
def get_filenames(file_to_filter): 
        # Open the sorted combined file 
        with open (file_to_filter, 'r') as combined_file: 
 
            csv2 = csv.reader(combined_file, delimiter = ',') 
            # skip the header row 
            csv2.next() 
 
            # define new list for all (redundant) and unique names 
            redundant = [] 
            unique = [] 
                # read through each line in the file 
            for row in csv2: 
 
                #define the entire first column as the sample 
                sample = row[0] 
 
                #split the sample fullname from the entry based on the delimiter '_' 
                date, fullname, seqnumber, lane = sample.split('_') 
 
                redundant.append(fullname) 
 
            # check each entry in the redundant list.... 
            for entry in redundant: 
 
                #.... against the unique list 
                if entry in unique: 
                    #if it is already in the list then skip 
                    pass 
                #otherwise add it to the list 
                else: 
                    unique.append(entry) 
 
        # return the unique list 
        return unique 
 
 
 
#function to take the final file names, open the results and write specific results to 
final output files. 
def write_unique_to_file(unique_in): 
        final_names = [] 
        templist = [] 
        for i in unique_in: 
 
                final_names.append(i) 
 
        # open the sorted output file 
        with open (output_file+"_sorted.csv", 'r') as sorted_outfile: 
                # define csv3 as the variable 
                csv3 = csv.reader(sorted_outfile, delimiter=',') 
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                # for each row in this file 
                for row in csv3: 
                        # add that entry to templist 
                        templist.append(row) 
 
                # set counter to 0 to read through list of file names 
                k = 0 
                # iterate until the end of the list 
                while k < len(final_names): 
                        # take each entry in final names 
                        final_name = final_names[k] 
 
                        # open a new file with a name corresponding the sample 
                        with open(final_name+".csv", 'wb') as final_file: 
 
                                # read in each line from the sorted_outfile / csv3 IF it contains a 
string matching the final_name 
                                writer=csv.writer(final_file, delimiter=',', quotechar='"') 
                                # write the header row into the output file 
                                
writer.writerow(['sample','chr','pos','ref','cov','R','A','C','G','T','pR','pA','pC','pG','pT']) 
 
                                # set counter j to 0 to interate through the templist, i.e. all sorted 
results 
                                j = 1 
                                # iterate until the end of the list 
                                while j < len(templist): 
 
                                        ############# 
                                        entry = str(templist[j]) 
                                        #print code 
                                        code = entry.split('_')[1] 
                                        #print code 
 
                                        if code == final_name: 
 
                                        # add each entry to the output file 
                                                writer.writerow(templist[j]) 
                                        else: 
                                                pass 
                                        j +=1 
 
                        k += 1 
 
#function to sort the final files by chr and position 
def sort_files (input_file): 
         
        with open (input_file+".csv", 'r') as f_in, open (input_file+"_sorted.csv", 'wb') as 
f_out: 
 
                # read in the unsorted data 
                csv1 = csv.reader(f_in, delimiter=',') 
 
                # skip the first row with the header 
                csv1.next() 
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                #sort the remaining rows by column 3 (position) 
                sort = sorted(csv1, key=lambda x: (str(x[1]), int(x[2]))) 
 
                writer=csv.writer(f_out, delimiter=',', quotechar='"') 
                # write the header row into the output file 
                
writer.writerow(['sample','chr','pos','ref','cov','R','A','C','G','T','pR','pA','pC','pG','pT']) 
                # take each row in the sorted data and write it into the new file 
                for row in sort: 
                    writer.writerow(row)              
 
#function to write metadata including analysis paramaters to a separate file 
def metafile (meta_out): 
 
        # name the output file 
        with open(meta_out+"_meta.tsv", 'w') as metadata: 
                #specify the user-supplied input and output file names 
            print >> metadata, "Input file: " +"\t" + input_file 
            print >> metadata, "Output file: " +"\t" + output_file + "_sorted" 
 
                #record details of the script, when it was modified, when it was run 
            print >> metadata, "Python version: " +"\t" + sys.version 
            print >> metadata, "Processed with: " +"\t" + os.path.basename(__file__) + " 
written by Ed Mee." 
            print >> metadata, "Script last modified: " +"\t" + time.strftime('%d/%m/%Y 
%H:%M', time.gmtime(os.path.getmtime(__file__))) 
            print >> metadata, "Processed by: " +"\t" + str(getpass.getuser()) 
            print >> metadata, "Processed at: " +"\t" + (time.strftime("%d/%m/%Y") 
+"\t" +time.strftime("%H:%M")) 
 
                # record the number of unique samples that were found in the input file and 
the user-supplied parameters. 
            print >> metadata, "Number of unique sample identifiers :" +"\t" + 
str(len(file_names)) 
            print >> metadata, "Parameters were: \nMinimum coverage: " +"\t" + 
str(cutoff) + "\nMaximum reference frequency: " +"\t" + str(ref_frequency) 
            print >> metadata, "\n*****************\nScript:"  
            with open(__file__) as f: 
                    print >> metadata, '\n'.join(f.read().split('\n')[1:]) 
 
#function to delete intermediate files 
def cleanup(tempfiles): 
 
        for tempfile in tempfiles: 
                os.remove(tempfile+".csv") 
 
if __name__== '__main__': 
    try: 
 
        # open the spreadsheet with the raw data. 
        with open (input_file, 'rb') as csvfile: 
 
        # specify that the delimiter is a comman and do not treat commas inside quotes 
as delimiters. 
            reader = csv.reader (csvfile, delimiter = ',', quotechar = '"') 
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            next(reader,None) 
 
            # Define a new array to hold the results. The header row will be same as in 
the input file, but can be altered if a different text is required. 
            results = [['sample','chr','pos','ref','cov','R','A','C','G','T','pR','pA','pC','pG','pT']] 
 
            # read one row at a time 
            for row in reader: 
 
                # skip any rows where the coverage is less than the user specified cutoff. 
Can be fixed if it will always be the same 
 
                if int(row[4])<cutoff: 
                    pass 
 
                # for all rows with coverage greater than the cutoff 
                else: 
                    # check the pR value. If it is less than 0.99 then the result is kept 
                    if float(row[10])<=ref_frequency: 
                        # the entire row is taken as a result 
                        result = row [0:15] 
                        #the row is added to the end of the results array 
                        results.append(result) 
                    # if the pR value is > 0.99 then the row is ignored 
                    else: 
                        pass 
 
            # Create and open a new file with the name specified by the user 
            with open (output_file+".csv", 'wb') as outfile: 
                #define the new file as a csv 
                writer=csv.writer(outfile, delimiter=',', quotechar='"') 
                # for each row in the results array, write the row to the new file 
                for r in results: 
                    writer.writerow(r) 
 
            # Open the results file and create a new file with the suffix _sorted 
            with open (output_file+"_sorted.csv", 'wb') as sorted_outfile, open 
(output_file+".csv", 'r') as unsorted: 
                # read in the unsorted data 
                csv1 = csv.reader(unsorted, delimiter=',') 
 
                # skip the first row with the header 
                csv1.next() 
                #sort the remaining rows by column 3 (position) 
                sort = sorted(csv1, key=lambda x: int(x[2])) 
 
                writer=csv.writer(sorted_outfile, delimiter=',', quotechar='"') 
                # write the header row into the output file 
                
writer.writerow(['sample','chr','pos','ref','cov','R','A','C','G','T','pR','pA','pC','pG','pT']) 
                # take each row in the sorted data and write it into the new file 
                for row in sort: 
                    writer.writerow(row) 
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        #scan the sorted file to determine the unique names that will be used for the 
final sample files 
        file_names = get_filenames(output_file+"_sorted.csv") 
 
        # write each set of entries to a new file corresponding to the sample name 
        write_unique_to_file(file_names) 
 
        for name in file_names: 
                sort_files (name) 
 
        # call the metafile function 
        metafile(output_file) 
 
        cleanup(file_names) 
         
    except IndexError: 
        print "\n\n !! ERROR !! \nScript should contain exactly 3 arguments. \nUsage: 
python " + os.path.basename(__file__) + " input_file.csv output_file" 
 
    except ValueError: 
        print "\n\n !! ERROR !! \n\n Cutoff must be an integer. \n Maximum reference 
value must be 0 - 1" 
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Appendix VI: Sewage collection 
Sewage samples from sewage plants in Beckton (London, Greater London), 
Dalmarnock (Glasgow, Scotland), Dunstable (Luton, Bedfordshire), Severn 
(Worcester) and Sheildhall (Glasgow) from before (2004/2005/2011) and after 
(2015/2016) the introduction of Rotarix
®
 in the vaccination programme, were kindly 
provided by Dr Javier Martin and Dr Manasi Majumdar at the NIBSC (Table 8.4.1). 
These samples were concentrated using the two-phase separation method, following 
the ‘Guidelines for environmental surveillance of poliovirus circulation’ (WHO, 
2003; Harvala et al., 2014; Majumdar et al., 2018). A litre of raw sewage from 
Roundhill (Stourbridge, UK; 16
th
 December 2004) was kindly provided by Dr 
Dimitra Klapsa.  
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Table 8.4.1. Sewage sample collection. Samples collected in years 2004, 2005, 
2011, 2015 and 2016 and several locations. *Beckton: 24h composite (1 sample 
every hour). All other sites: Grab (1 single take). 
 
 
